



# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

JOIN THE CONVERSATION • JOIN THE CONVERSATION • JOIN THE CONVERSATION

- /IASLC
- @IASLC
- iaslungcancer
- IASLC
- IASLC
- IASLC

# WCLC 2024 PROGRAM BOOK

WCLC 2024 PROGRAM BOOK

wclc2024.iaslc.org

# Nuvation Bio

Driven by science  
**FOCUSED ON LIFE**

Learn more at  
**NuvationBio.com**



# TABLE OF CONTENTS

**05**

## **OVERVIEW**

- 7** Welcome Messages
- 9** Important Information
- 11** IASLC Staff and WCLC Committees
- 20** IASLC and Conference Awards
- 32** Program at a Glance

**43**

## **SCIENTIFIC PROGRAM: SATURDAY, SEPTEMBER 7**

**61**

## **SCIENTIFIC PROGRAM: SUNDAY, SEPTEMBER 8**

**87**

## **SCIENTIFIC PROGRAM: MONDAY, SEPTEMBER 9**

**113**

## **SCIENTIFIC PROGRAM: TUESDAY, SEPTEMBER 10**

**135**

## **POSTERS**

- 140** Posters - Sunday, September 8
- 160** Posters - Monday, September 9
- 179** ePosters

**219**

## **GENERAL INFORMATION**

- 221** Exhibit and Supporter Information
- 238** Satellite CME and Industry Sponsored Symposia
- 248** Exhibit Showcases
- 254** Conference Information
- 258** Venue Floor Plans

---

### **CONFERENCE SECRETARIAT**

International Conference  
Services Ltd. (ICS)  
555 Burrard Street (Bentall Center 2)  
Vancouver, BC, Canada, V7X 1M8

Phone: +1 604 681 2153  
[www.icsevents.com](http://www.icsevents.com)



### **GLOBAL OFFICES**

Vancouver, Toronto,  
Vienna, London, Texas,  
Tokyo, Singapore



# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

## Attend the IASLC Business Meeting

Tuesday, September 10  
10:30-11:15 | Room 20A

 **REFRESHMENTS PROVIDED**

IASLC President Welcome & Update

CEO Report

CSO Report

Financial Report

JTO & JTO CRR Report

**CONQUERING LUNG & OTHER THORACIC CANCERS  
WORLDWIDE IN THE 21ST CENTURY**



IASLC 19th World Conference on Lung Cancer Toronto, Canada | #WCLC2018



WCLC 2024 OVERVIEW

# 01 / WCLC 2024 OVERVIEW



WELCOME MESSAGES / WCLC 2024 CONFERENCE CHAIRS

Dear Colleagues from around the World,

On behalf of the International Association for the Study of Lung Cancer (IASLC) it is our great pleasure to welcome you to the IASLC 2024 World Conference on Lung Cancer (#WCLC24) in San Diego, USA.

Over the next four days, WCLC will offer groundbreaking scientific activity bringing together more than 6,000 delegates globally from all fields in basic and clinical sciences to help conquer lung and other thoracic cancers worldwide in the 21st century and to celebrate 50 years of IASLC and lung cancer research and treatment advances. We are proud to have received more than 1,800 abstracts which will be presented in oral, mini-oral, and poster sessions. More than 350 invited lecturers, 150 oral and mini-oral presentations as well as over 1,500 posters and ePosters will contribute to the exchange of new information among delegates.

To facilitate discussions and networking opportunities, we offer a virtual platform available on desktop and mobile devices that will allow delegates to ask questions and chat with other participants during the sessions.

We encourage you to participate actively in the discussions but also take some time to enjoy the beauty of San Diego. This sunny gem quite literally has it all - pristine sandy waterfronts and epic waves, ample natural beauty, world-class museums, and theme parks galore.

We also would like to extend our gratitude and thanks to all supporters and exhibitors for their continued support to WCLC and IASLC. Without them, this Conference would not be possible. Thank you for joining us in San Diego or online. We wish all delegates an enjoyable and productive Conference.


Yours sincerely,



**Narjust Florez**  
Conference Co-Chair  
USA



**Linda Martin**  
Conference Co-Chair  
USA



**Sandip Patel**  
Conference Co-Chair  
USA



**Fabio Ynoe de Moraes**  
Conference Co-Chair  
Canada

## WELCOME MESSAGES / IASLC PRESIDENT AND IASLC CEO

Dear WCLC Participants,

As the President and the CEO of the IASLC, we are thrilled to welcome you to the IASLC 2024 World Conference on Lung Cancer (#WCLC24) in beautiful San Diego. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating, and collaborative meeting.

This year marks the 25th WCLC and the 50th Anniversary of IASLC, serving as a unique moment to pause and reflect on how this meeting and the thoracic oncology field have evolved over the past five decades. During this time, we have seen extraordinary progress in the field of lung cancer diagnosis and treatment, with the discovery of new biomarkers, new screening techniques, and the rise of precision medicine leading to improvements in overall mortality and quality of life for patients. Throughout its long history, the WCLC has played a strong role in facilitating that progress—providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships, connecting established researchers with young investigators, and serving as a foundational meeting for healthcare professionals (representing the full spectrum of the multidisciplinary team), patients and advocates who have dedicated their lives to conquering these challenging diseases.

This enduring importance is illustrated in how the WCLC has evolved over time—growing from a gathering of approximately 100 colleagues in the late-1970s to an expansive conference that regularly attracts nearly 7,000 international participants. Such growth in size, impact, and relevance did not happen by accident. We are grateful to our previous WCLC conference presidents, organizers, and participants. Additionally, we want to honor our past and current board members, as well as former CEOs Heine H. Hansen, Paul A. Bunn Jr. and Fred R. Hirsch for their leadership of the IASLC from its formative years to the present day.

Please join us in celebrating the rich history of these 50 years by attending the Special Plenary Session: Celebrating 50 Years of the IASLC, Legacy of Impact, Future of Promise. Additionally, we hope you will participate in the 50 Year Anniversary Blockparty in the famous Gaslamp Quarter the same evening. Book your ticket and join us for a fun night with great food, games, live music, dancing, and most of all great company. While the story of the WCLC is well-established, we know that we must always be looking to the future if we are to continue making inroads in the treatment of lung and other thoracic cancers. That is why for WCLC 2024, we are proud to announce that the Conference Chairs along with the WCLC 2024 Program Committee have put together an incredible scientific program. We want to thank them for their hard work and we are especially grateful for the dedication and leadership of our Conference Chairs: Drs. Sandip Patel, Linda Martin, Narjust Florez and Fabio Ynoe de Moraes. We have no doubt that you will find WCLC 2024 to be an exceptional educational experience.

Thank you for attending WCLC 2024 and thank you for your engagement with the IASLC. We hope you enjoy the Conference; explore San Diego; find opportunities to develop new relationships and collaborations; and gain novel skills and insights that can be applied to improving the lives of thoracic cancer patients—both in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment, and engagement of those who attend it. In short, your participation is one of the main reasons why the event has remained the world's leading thoracic cancer conference for 50 years.

We appreciate you being a part of our ongoing story.



**Paul Van Schil**  
President, IASLC  
Belgium



**Karen Kelly**  
CEO, IASLC  
USA



## WIFI DETAILS

Please join the network below to access free wifi for the duration of the Conference.

Network Name: **WCLC2024**

Password: **WCLC2024**

## DISCLAIMER

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources.

Although every effort has been made to ensure the accuracy, currency, and reliability of the content, the organizers accept no responsibility in that regard.

# LET'S GET SOCIAL!

Stay connected with the IASLC community and get the latest updates on the IASLC World Conference on Lung Cancer (#WCLC24) through our social media channels!

Follow us to engage with fellow attendees, access exclusive content, and be the first to know about important announcements and highlights from the Conference.



/IASLC



iaslungcancer



@IASLC



IASLC



IASLC



IASLC



Join the Conversation:

**#WCLC24**

## IASLC WCLC 2024 VIRTUAL PLATFORM

All sessions will be audio recorded and made available on the Virtual Platform within 24 hours. The Virtual Platform also includes presentation slides, abstracts and posters.

Log-in details are sent to your registered email. If you need assistance, visit the Virtual Platform Help Desk located outside the Exhibit Hall, or send an email to **wclc2024-registration@icsevents.com**.

WCLC 2024 VIRTUAL PLATFORM:

**MEETINGSAPP.IASLC.ORG/EVENT WCLC2024**



APP STORE



ANDROID

### VIRTUAL PLATFORM FEATURES:

- ✓ Full Scientific Schedule
- ✓ Abstract Book, Program Book
- ✓ Venue and Exhibit Floor Plan
- ✓ Presentation Slides and Recordings (Within 24 Hours)
- ✓ Opportunity to Create Personalized Schedule
- ✓ Networking Features to Connect with Delegates and Faculty
- ✓ Notification Alerts
- ✓ Livestream of Plenary Sessions and IASLC Award Ceremony



## Find WCLC News at **ILCN.org**

Stay informed on the latest from #WCLC24 at [ILCN.org](https://www.ilcn.org) — the official news source of the IASLC, the only global association dedicated to the multidisciplinary study of lung cancer.



### 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

### THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association has grown to serve more than 12,000 members globally from all lung and thoracic cancer disciplines and more than 100 countries.

By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.

#### THE IASLC'S MISSION

Be the multidisciplinary world authority on lung and other thoracic cancers through collaborative science, education, and advocacy in order to ensure optimal prevention and patient care.

#### THE IASLC'S VISION

To Conquer Lung and Other Thoracic Cancers Worldwide in the 21st Century.



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

The IASLC's headquarters are located at the following address:

**1775 N. Sherman Street, Suite 1600,**  
**Denver, CO 80203-4317**  
Phone: **1-855-464-2752**

#### IASLC Board of Directors 2023 - 2025

**President:** Paul Van Schil, Belgium

**Past President:** Heather Wakelee, USA

**President-Elect:** Caicun Zhou, China

**Secretary:** Ming-Sound Tsao, Canada

**Treasurer:** Joachim Aerts, Netherlands

**Chief Executive Officer:** Karen Kelly, USA

#### Board Members

Joe Chang, USA

Carlos Gil Moreira Ferreira, Brazil

Jhanelle Gray, USA

Young Tae Kim, Republic of Korea

Natasha Leighl, Canada

Morten Quist, Denmark

Antoni Rosell, Spain

Lecia Sequist, USA

Benjamin Solomon, Australia

Paula Ugalde, USA

Ignacio Wistuba, USA

Wen-Zhao Zhong, China

#### IASLC Staff

**J. Michael Hoehn**, Chief Operating Officer

**Jennifer C. King**, Chief Science Officer

**John Skadow**, Chief Financial Officer

**Matt Yeingst**, Chief Development Officer

**Andrea Alarcon**, Scientific Project Manager

**Tessa Baxter**, Development Program Manager

**Bernina Bijou**, Executive Assistant

**Becky Bunn**, Director, Strategic Initiatives

**Bailey Creamer**, Editorial Assistant

**Kathy Doherty**, Director, Human Resources

**Wanda Folsom**, Education Manager

**Thalia Giraldo**, Data Analyst

**Javier Gonzalez**, Accountant

**Rory Graham**, Web Content Administrator

**Ken Harrell**, Associate Director, Information Technology

**Kelsey Hecker**, Conference Coordinator

**Kelly Heemsbergen**, Conference Manager

## THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC)/WCLC PROGRAM COMMITTEE

**O’Ryan Jackson**, Development Specialist  
**Kendra Lechtenberg**, Scientific Project Manager  
**Sara Lindsey Patton**, Patient Advocacy Specialist  
**Katie Maher**, Membership Manager  
**Sunhee Malinowski**, Controller  
**Jan Mazotti**, Senior Advisor, Communications  
& Public Relations  
**Kahri Nestingen**, Sponsorship and Exhibits  
Coordinator

**Kelly Nevins**, Associate Director, Education  
**Rodrigo Sagastegui**, Marketing Specialist  
**Savannah Spakes**, Membership Coordinator  
**Alexander Watson**, Business Services Lead  
**Kelsey Wood**, Associate Director, Membership  
**Laura Woodruff**, Education Specialist  
**Murry Wynes**, Senior Advisor, Scientific Affairs  
**Keelan Zius**, Scientific Program Manager

### WCLC 2024 Program Committee

#### Risk Factors, Risk Reduction and Tobacco Control

**Track Chair:** Carolyn Dresler, USA  
**Track Chair:** Laura Mezquita, Spain  
 Marcelo Corassa, Brazil  
 Manfred Neuberger, Austria  
 Tercia Reis, Brazil  
 Biago Ricciuti, Italy  
 Abhishek Shankar, India  
 Randi Williams, USA

#### Tumor Biology - Preclinical Biology

**Track Chair:** Marie-Liesse Asselin Labat, Australia  
**Track Chair:** Andres Cardona, Columbia  
 Upal Basu Roy, USA  
 Lauren Byers, USA  
 Magnus Dillon, UK  
 Mervat El Deftar, Egypt  
 Ivan Gonzalez Espinoza, Mexico  
 Mariam Jamal-Hanjani, UK  
 Triparna Sen, USA

#### Tumor Biology - Translational Biology

**Track Chair:** Jonathan Ostrem, USA  
**Track Chair:** Kate Sutherland, Australia  
 Nicolaus Andratschke, Switzerland  
 Fiona Blackhall, UK  
 Yuchen Han, China  
 Cheryl Ho, Canada  
 Deepali Jain, India  
 Robert Rintoul, UK  
 Fernando Santini, USA

#### Screening and Early Detection

**Track Chair:** Gerard Silvestri, USA  
**Track Chair:** Chi-Fu Yang, USA  
 Milena Cavic, Serbia  
 Long Jiang, China  
 Rachael Murray, UK  
 Coral Olanzagasti, USA  
 Betty Tong, USA  
 Lorraine Tyler, Australia\*

#### Pulmonology and Staging

**Track Chair:** Anne Hsu, Singapore  
**Track Chair:** Jacob Sands, USA  
 Jeremy Erasmus, USA  
 David Feller-Kopman, USA  
 Zeno Gouw, Netherlands  
 Mirella Marino, Italy  
 Takahiro Nakajima, Japan  
 Valerie Rusch, USA

#### Pathology and Biomarkers

**Track Chair:** Wendy Cooper, Australia  
**Track Chair:** Rosalyn Juergens, Canada  
 Sabina Berezowska, Switzerland  
 Guilherme Harada, Brazil  
 Jia Luo, USA  
 Ellen Caroline Nascimento, Brazil  
 Jan Von Der Thusen, Netherlands  
 Yasushi Yatabe, Japan

## Early-Stage Non-small Cell Lung Cancer

**Track Chair:** Jazmin Eckhaus, Australia

**Track Chair:** Pamela Samson, USA

Delphine Antoni, France

Antonio Calles, Spain

Tina Cascone, USA

Yuko Oya, Japan

Martin Reck, Germany

Jonathan Spicer, Canada

Ricardo Terra, Brazil

## Local-Regional Non-small Cell Lung Cancer

**Track Chair:** Jessica Donington, USA

**Track Chair:** Corinne Faivre-Finn, UK

**Track Chair:** Ryan Gentzler, USA

Nasser Altorki, USA

Christine Bestvina, USA

Qian Chu, China

Seamus Cotter, Ireland

Michael MacManus, Australia

Marco Scarci, UK

## Metastatic Non-small Cell Lung Cancer – Local Therapies

**Track Chair:** Elizabeth David, USA

**Track Chair:** Alexander Louie, Canada

Kevin Chua, Singapore

Cassandra Dickens, Australia

Lilian Faroni, Brazil

Matthias Guckenberger, Switzerland

Jii Bum Lee, South Korea

Pablo Munoz Schuffenegger, Chile

## Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

**Track Chair:** Ben Levy, USA

**Track Chair:** Vanita Noronha, India

Charu Aggarwal, USA

Lisa Briggs, Australia

Mauricio Cuello, Uruguay

Gerard Hanna, UK

Kirsty Lee, Hong Kong

Nandini Menon, India

## Metastatic Non-small Cell Lung Cancer - Immunotherapy

**Track Chair:** Tom John, Australia

**Track Chair:** Jarushka Naidoo, Ireland

Clarissa Baldotto, Brazil

Puey Ling Chia, Singapore

Anil Tibdewal, India

Luciana Holtz, Brazil

Misako Nagasaka, USA

Antonio Passaro, Italy

Luis Raez, USA

## Metastatic Non-Small Cell Lung Cancer - Targeted Therapy

**Track Chair:** Prunella Blinman, Australia

**Track Chair:** Stephen Liu, USA

Melissa Culligan, USA

Alessandra Curioni, Switzerland

Ivy Elkins, USA\*

Koichi Goto, Japan

Sewanti Lemaye, India

Victor Marcondes, Brazil

David Planchard, France

Li Yu, China

## Small Cell Lung Cancer and Neuroendocrine Tumors

**Track Chair:** Aaron Tan, Singapore

**Track Chair:** Saiama Waqar, USA

**Track Chair:** Ben Slotman, Netherlands

Lynnette Fernandez-Cuesta, France

Andrea Fung, Canada

Julie George, Germany

Angus Pratt, Canada

Motoko Tachihara, Japan

Abraham Wu, USA

## Mesothelioma, Thymoma, and Other Thoracic Tumors

**Track Chair:** Prasad Adusumilli, USA

**Track Chair:** Sonja Klebe, Australia

John Cho, Canada

Nicolas Girard, France

Aaron Mansfield, USA

Melina Marmarelis, USA

Enrico Ruffini, Italy

Rachel Thomas, UK

Mylene Truong, USA

## Multidisciplinary Care: Nursing, Allied Health and Palliative Care

**Track Chair:** Cristiane Bergerot, Brazil

**Track Chair:** Laura Petrillo, USA

**Track Chair:** Ludmila Svodoba, USA

Megan Daly, USA

Simon Dunne, Ireland

Michael Franco, Australia

Maria Ftanou, Australia

Stephanie McDonald, USA

Lucia Viola, Colombia

## Patient Advocacy

**Track Chair:** Caleb Egwuenu, Nigeria

**Track Chair:** Lillian Leigh, Australia

Oscar Arrieta, Mexico

Stefano Cafarotti, Switzerland

Janet Freeman-Daily, USA

Angeline Low, Australia

Kim Norris, USA

Shani Shilo, Israel

Antoinette Wozniak, USA

## Global Health, Health Services, and Health Economics

**Track Chair:** Pedro Aguiar, Brazil

**Track Chair:** Verna Vanderpuye, Ghana

Fumiko Chino, USA

Jose Corona-Cruz, Mexico

Anne Fraser, New Zealand

Wee Yao Koh, Singapore

Clarissa Mathias, Brazil

Shruti Patel, USA

Noemi Reguart, Spain

Navneet Singh, India

Aaron Mansfield, USA

Melina Marmarelis, USA

## WCLC 2024 International Abstract Review Committee

Prasad Adusumilli, USA  
Joachim Aerts, Netherlands  
Charu Aggarwal, USA  
Pedro Aguiar Jr., Brazil  
Myung-Ju Ahn, Republic of Korea  
Nasser Khaled Altorki, USA  
Valsamo Anagnostou, USA  
Delphine Antoni, France  
Mara Antonoff, USA  
Jose Araujo-Filho, Brazil  
Oscar Arrieta, Mexico  
Fredrick Asirwa, Kenya  
Marie-Liesse Asselin-Labat, Australia  
Lekan Ayo-Yusuf, South Africa  
Houda Bahig, Canada  
Anne-Marie Baird, Ireland  
Thanyanan Baisamut (Reungwetwattana), Thailand  
Clarissa Baldotto, Brazil  
Upal Basu Roy, USA  
Mary Beth Beasley, USA  
Sabina Berezowska, Switzerland  
Cristiane Bergerot, Brazil  
Christine Bestvina, USA  
Prunella Blinman, Australia  
Emi Bossio, Canada  
Timothy Burns, USA  
Lauren Byers, USA  
Terri Byrne, Australia  
Stefano Cafarotti, Switzerland  
Antonio Calles Blanco, Spain  
John Cannings, Australia  
Heloisa Carvalho, Brazil  
Tina Cascone, USA  
Milena Cavic, Serbia  
Joe Chang, USA  
Puey Ling Chia, Singapore  
Fumiko Chino, USA  
Kevin Chua, Singapore  
Esther Conde, Spain  
Teresa Conneran, USA  
Wendy Cooper, Australia  
Marcelo Corassa, Brazil  
Jose Corona-Cruz, Mexico  
Fernando Costa Santini, USA  
Ben Creelan, USA  
Melissa Culligan, USA  
Ibiayi Dagogo-Jack, USA  
Megan Daly, USA  
Elizabeth David, USA  
Talya Dayton, Spain  
Roselle De Guzman, Philippines  
Harry de Koning, Netherlands  
Marc De Perrot, Canada  
Paul Demers, Canada  
Yvonne Diaz, UK  
Cassandra Dickens, Australia  
Magnus Dillon, UK  
Mark Doherty, Ireland  
Dusty Donaldson, USA  
Jessica Donington, USA  
Carolyn Dresler, USA  
Mary Duffy, Australia  
Simon Dunne, Ireland  
Greg Durm, USA  
Grace Dy, USA  
Jazmin Eckhaus, Australia  
Caleb Egwuenu, Nigeria  
Mervat El Deftar, Egypt  
Ivy Elkins, USA\*  
Arielle Elkrief, Canada  
Lawson Eng, Canada  
Nicole Ezer, Canada  
Corinne Faivre-Finn, UK  
Lilian Faroni, Brazil  
Joelle Fathi, USA  
Jill Feldman, USA  
David Feller-Kopman, USA  
Lynnette Fernandez-Cuesta, France  
Narjust Florez, USA  
Martin Forster, UK  
Jesme Fox, UK  
Michael Franco, Australia  
Anne Fraser, New Zealand  
Janet Freeman-Daily, USA  
Maria Ftanou, Australia  
Daichi Fujimoto, Japan  
Andrea Fung, Canada  
Justin Gainor, USA  
Ryan Gentzler, USA  
Carlos Gil Ferreira, Brazil  
Nicolas Girard, France  
Daniel Gomez, USA  
Vinai Gondi, USA

Iván Romarico González-Espinoza, Mexico  
Koichi Goto, Japan  
Zeno Gouw, Netherlands  
Ramaswamy Govindan, USA  
Kevin Haaf, Netherlands  
Yuchen Han, China  
Gerard Hanna, UK  
Guilherme Harada, Brazil  
Merel Hennink, Netherlands  
Cheryl Ho, Canada  
Paul Hofman, France  
Anne Hsu, Singapore  
Satoshi Ikeda, Japan  
Dolores Isla, Spain  
Deepali Jain, India  
Dasantha Jayamanne, Australia  
Hongbin Ji, China  
Long Jiang, China  
Sabita Jiwnani, India  
Tom John, Australia  
Isaac Joseph, Nigeria  
Rosalyn Juergens, Canada  
Ella Kazerooni, USA  
Anna Kerpel-Fronius, Hungary  
Chul Kim, USA  
Bellinda King-Kallimanis, USA  
Noriko Kishi, Japan  
Sonja Klebe, Australia  
Coenraad Koegelenberg, South Africa  
David Kwiatkowski, USA  
Pippa Labuc, Australia  
Stephen Lam, Canada  
Lorenza Landi, Italy  
Sally Lau, USA  
Heather Law, USA  
John Le Quesne, UK  
Jii Bum Lee, Republic of Korea  
Kirsty Lee, Hong Kong  
Percy Lee, USA  
Se-Hoon Lee, Republic of Korea  
Siow Ming Lee, UK  
Lillian Leigh, Australia  
Natasha Leighl, Canada  
Carrie Leong, Singapore  
Tracy Leong, Australia  
Benjamin Levy, USA  
Sun Min Lim, Republic of Korea  
Sewanti Limaye, India  
Mong-Wei Lin, Taiwan

Si-Yang Liu, China  
Stephen Liu, USA  
Billy Loo, USA  
Alexander Louie, Canada  
Jia Luo, USA  
Michael MacManus, Australia  
Milena Mak, Brazil  
Aaron Mansfield, USA  
Mirella Marino, Italy  
Melina Marmarelis, USA  
Edith Marom, Israel  
Claudio Martin, Argentina  
Eldsamira Mascarenhas, Brazil  
Clarissa Mathias, Brazil  
Annette McWilliams, Australia  
Matthew MD, USA  
Nandini Menon, India  
Jane Mensah, Ghana  
Laura Mezquita, Spain  
Yuko Minami, Japan  
John Minna, USA  
Tetsuya Mitsudomi, Japan  
Amy Moore, USA  
Daniel Morgensztern, USA  
Giannis Mountzios, Greece  
Pablo Munoz Schuffenegger, Chile  
Rachael Murray, UK  
Misako Nagasaka, USA  
Jarushka Naidoo, Ireland  
Takahiro Nakajima, Japan  
Ellen Nascimento, Brazil  
Barry Nelson, USA  
Manfred Neuberger, Austria  
Leticia Nogueira, USA  
Kim Norris, USA  
Kenneth O'Byrne, Australia  
Michael Offin, USA  
Coral Olazagasti, USA  
Isabelle Opitz, Switzerland  
Raymond Osarogiagbon, USA  
Yuko Oya, Japan  
Antonio Passaro, Italy  
Shruti Patel, USA  
Matthew Peters, Australia  
René Petersen, Denmark  
Laura Petrilo, USA  
Zofia Piotrowska, USA  
Claudia Poleri, Argentina  
Cecilia Pompili, UK



Angus Pratt, Canada  
Mariano Provencio, Spain  
Morten Quist, Denmark  
Ahmed M. Rabea, Egypt  
Luis Raez, USA  
Suresh Ramalingam, USA  
Nicole Rankin, Australia  
Noemí Reguart, Spain  
Patricia Reis, Brazil  
Tércia Reis, Brazil  
Natasha Rekhman, USA  
Joshua Reuss, USA  
Biagio Ricciuti, USA  
Robert Rintoul, UK  
Fabio Rocha Fernandes Tavora, Brazil  
Delvys Rodriguez-Abreu, Spain  
Felipe Roitberg, Brazil  
Julia Rotow, USA  
Luis Rueda Marulanda, Colombia  
Enrico Ruffini, Italy  
Rossana Ruiz, Peru  
Pamela Samson, USA  
Victor Santos, Brazil  
Marco Scarci, UK  
Kurt Schalper, USA  
Susan Scott, USA  
Triparna Sen, USA  
Suresh Senan, Netherlands  
Priyanka Senthil, USA  
Uchechukwu Shagaya, Nigeria  
Riyaz Shah, UK  
Abhishek Shankar, India  
Aparna Sharma, India  
Shani Shilo, Israel  
Lynette Sholl, USA  
Elaine Shum, USA  
Navneet Singh, India  
Ben Slotman, Netherlands  
Ben Solomon, Australia  
Joshua Sonett, USA  
Brendon Stiles, USA  
Kate Sutherland, Australia  
Kenji Suzuki, Japan  
Motoko Tachihara, Japan  
Marco Tagliamento, Italy  
Aaron Tan, Singapore  
Jennifer Temel, USA  
Ricardo Terra, Brazil  
Anil Tibdewal, India

Betty Tong, USA  
William Travis, USA  
Ming Tsao, Canada  
Masahiro Tsuboi, Japan  
Yasuhiro Tsutani, Japan  
Chih-Yen Tu, Taiwan  
Ilit Turgeman, Israel  
Stefania Vallone, Italy  
Anthonie van der Wekken, Netherlands  
Verna Vanderpuye, Ghana  
Luigi Ventura, UK  
Giulia Veronesi, Italy  
Lucia Viola, Colombia  
Jan von der Thüsen, Netherlands  
Heather Wakelee, USA  
Saïama Waqar, USA  
Jeffrey Ward, USA  
Clare Weeden, UK  
William William Jr., Brazil  
Randi Williams, USA  
Ignacio Wistuba, USA  
Antoinette Wozniak, USA  
Abraham Wu, USA  
Yi-Long Wu, China  
Yosuke Yamada, Japan  
Chi-Fu Jeffrey Yang, USA  
David Yankelevitz, USA  
Yasushi Yatabe, Japan  
Helena Yu, USA  
Wen-Zhao Zhong, China  
Guang-Biao Zhou, China

\*Earlier in 2024 the lung cancer community lost two beloved advocates and committee members Lorraine Tyler and Ivy Elkins.

We are grateful for the impact they made to lung cancer research and advocacy. Their legacy inspires us to push forward in our mission.

*They will be deeply missed.*



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

# IASLC Congratulates the 2024 Cancer Care Team Award Winners!

## ASIA/ROW WINNER

**MAS Clinic & Hospital**

*Tamluk, West Bengal, India*

## EUROPE WINNER

**Erasmus University Medical Center**

*Rotterdam, Netherlands*

## LATIN AMERICA WINNER

**Centro de Tratamiento e Investigación sobre  
Cáncer Luis Carlos Sarmiento Angulo (CTIC)**

*Bogotá, Colombia*

## NORTH AMERICA WINNERS

**Fox Chase Cancer Center &  
Temple University Health System**

*Philadelphia, Pennsylvania, USA*



# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

## Join Us at the IASLC Committee Corner!

**IASLC Member Lounge in the Exhibit Hall**

Engage with IASLC Committee Chairs  
and Members.

### Sunday, September 8

10:00-10:45

Rare Tumors  
Multidisciplinary Clinical Science  
Early Detection and Screening  
Pathology  
Basic and Translational Science  
Global Multidisciplinary Practice Standards  
Tobacco Control and Smoking Cessation

### Monday, September 9

10:00-10:45

Communications  
Membership  
Career Development  
Nurses and Allied Health Professionals  
Patient Advocates  
Education  
Global Policy and Partnerships

**CONQUERING LUNG & OTHER THORACIC CANCERS  
WORLDWIDE IN THE 21ST CENTURY**

## IASLC DISTINGUISHED SERVICE AWARDS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 7 – 18:15 – 20:00.**

The Mary J. Matthews Pathology/Translational Award recognizes an IASLC scientist for lifetime achievement in pathology and translational research of thoracic malignancies. Mary J. Matthews served as a senior investigator and pathologist at the National Cancer Institute. She was a pioneer in defining the histologic subtypes of lung cancer.



### MARY J. MATTHEWS PATHOLOGY / TRANSLATIONAL RESEARCH AWARD

## Erik Thunnissen

Netherlands

**Dr. Erik Thunnissen, MD, PhD,** is retired and currently a research associate at the Department of Pathology, Amsterdam Medical University, VUMC. He obtained his training as a pathologist in 1982 and earned his Ph.D. in 1987 on an early AI topic “avant la lettre”. Dr. Thunnissen furthered his education with a course in clinical epidemiology in Maastricht.

In 1992, Dr. Thunnissen founded both the Dutch Pulmonary Pathology Working Group and the Dutch Molecular Pathology Working Group. He published a significant model on quantitative immunohistochemistry, illustrating the relationship between epitope concentration and staining intensity. He has been instrumental in managing pulmonary molecular external quality assessment programs for the European Society of Pathology and supporting UKNEQAS (UK organization for EQA in tissue sections).

Dr. Thunnissen represented the International Association for the Study of Lung Cancer (IASLC) in crafting the molecular pathology guidelines for patient selection for targeted therapy in both 2013 and 2018. His research emphasizes the detailed morphology of lung cancer, challenging conventional pattern recognition approaches. His work on invasion assessment in pulmonary adenocarcinomas highlighted significant reproducibility issues among pathologists worldwide, leading to a modified classification that demonstrated superior reproducibility and lower variation in pT staging compared to existing WHO classifications. Dr. Thunnissen also initiated a large-scale validation study for this modified classification.

## IASLC DISTINGUISHED SERVICE AWARDS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 7 – 18:15 – 20:00.**

The Paul A. Bunn, Jr. Scientific Award recognizes an IASLC scientist for a lifetime achievement of scientific contributions to thoracic cancer research. The award is named after IASLC's longtime CEO Dr. Paul Bunn, whose studies set worldwide standards for the treatment of lung cancer.



### PAUL A. BUNN, JR. SCIENTIFIC AWARD

## Julie Brahmer

USA

**Dr. Julie R. Brahmer, MD, MSc,** serves as the Director of the Thoracic Oncology Program and Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She is also the Co-Leader of the Cancer Immunology Program and directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus. Dr. Brahmer plays a crucial role as the co-principal investigator of Johns Hopkins' National Clinical Trials Network and oversees all oncology cooperative group activities across the Johns Hopkins campuses.

Dr. Brahmer earned her undergraduate degree in Chemistry and Philosophy from Creighton University in 1989 and her medical degree from the University of Nebraska Medical Center, College of Medicine in 1993. She completed her internship and residency in Internal Medicine at the University of Utah and subsequently served as Chief Medical Resident before moving to Baltimore for her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins.

Her research interests focus on leading early-phase immunotherapy trials, international phase III studies of immunotherapies in lung cancer, and investigator-initiated trials evaluating combination immunotherapies. Dr. Brahmer played a pivotal role in the development and FDA approval of nivolumab for the second-line treatment of advanced NSCLC and pembrolizumab for first-line treatment of PD-L1 high NSCLC. She co-leads toxicity guideline development for national and international organizations such as ASCO, NCCN, and SITC.

Active in professional societies including IASLC, ASCO, AACR, and SITC, Dr. Brahmer serves on scientific advisory boards of lung cancer patient advocacy organizations. She has been a dedicated member of IASLC since 2000, contributing significantly to various committees during her tenure on the board.

## IASLC DISTINGUISHED SERVICE AWARDS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 7 – 18:15 – 20:00.**

The Adi F. Gazdar IASLC Merit Award proudly recognizes Adi Gazdar and honors his lifelong dedication to lung cancer research and his pioneering work in molecular pathology.



### ADI F. GAZDAR IASLC MERIT AWARD

**Kwun Fong**  
Australia

**Dr. Kwun Fong, MBBS, MD, PhD, FRACP**, with a background shaped by supportive mentorship, has leveraged opportunities afforded by his environment and timely circumstances. Born in Malaysia, Dr. Fong received a comprehensive education thanks to his parents' dedication, culminating in his selection for English boarding school and subsequently the University of London Medical School, where he graduated in 1984 with numerous academic honors.

Specialist training and PhD studies in Australia ignited Dr. Fong's passion for lung cancer research. Throughout his career, he has been recognized with several prestigious awards, including the CIG Best Paper Prize in 1992, the Young Investigator Award from the Thoracic Society of Australia and New Zealand (TSANZ) in 1993, and multiple other accolades for his contributions to clinical oncology and research.

Inspired by leaders in the International Association for the Study of Lung Cancer (IASLC) during his early career, Dr. Fong pursued post-doctoral training at UT Southwestern under the mentorship of renowned researchers John Minna and Adi Gazdar. His experience there profoundly influenced his vision to make a meaningful impact in his home country.

In Australia, Dr. Fong contributed significantly to research and clinical practice, receiving numerous grants and awards, including the TW White Prize from the Thoracic Society of Queensland (TSQ) in 1999 and the Queensland Smart State Clinical Research Fellowship in 2005. He served as Clinical Manager of the Pulmonary Malignancy Unit at The Prince Charles Hospital, recognized for its multidisciplinary care approach and excellence in clinical research. Dr. Fong's contributions extended to international collaborations such as the IASLC Staging Project and various genomic research initiatives.

## IASLC DISTINGUISHED SERVICE AWARDS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 7 – 18:15 – 20:00.**

The Joseph W. Cullen Prevention/Early Detection Award recognizes an IASLC scientist for a lifetime achievement in the prevention of thoracic malignancies. Dr. Cullen served as the Deputy Director of the National Cancer Institute, Division of Cancer Prevention and Control. He created the Smoking, Tobacco and Cancer Program at the NCI in 1982.



### JOSEPH W. CULLEN PREVENTION / EARLY DETECTION AWARD

## Claudia Henschke

USA

**Dr. Claudia Henschke, BA, MS, MD, PhD**, joined the Department of Radiology at the Icahn School of Medicine at Mount Sinai in 2010 as Professor of Radiology. She holds a B.A. and M.S. in mathematical statistics from Southern Methodist University, a Ph.D. in computer science and mathematical statistics from the University of Georgia, and an M.D. from Howard University. Dr. Henschke completed her residency and fellowship training at the Peter Bent Brigham Hospital, Harvard Medical School, where she also served as faculty. Before joining Mount Sinai, she was Professor of Radiology at Weill Cornell Medical College.

In 1992, Dr. Henschke initiated the pioneering low-dose CT screening study, the Early Lung Cancer Action Project (ELCAP), which was reported in *The Lancet* on July 9, 1999. Since then, she has led numerous city, state, national, and international projects focusing on lung screening, smoking cessation, and research, resulting in over 400 publications. Dr. Henschke is the founder and head of the International Early Lung Cancer Action Program (I-ELCAP), a global collaborative effort involving experts in lung cancer. I-ELCAP has screened over 90,000 individuals at 82 institutions across 10 countries, significantly advancing early detection technologies and research into cardiovascular and other diseases through CT scans. She also contributed the I-ELCAP's computer management system to be transformed into an open-source system (VAPALS-ELCAP), adopted by the United States Department of Veterans Affairs for lung cancer screening among Veterans. The success of I-ELCAP led to the initiation of another multinational study, The Initiative for Early Lung Cancer Research on Treatment (IELCART), aimed at assessing various early lung cancer treatments within clinical care.

## WCLC 2024 LECTURESHIP AWARDS

The IASLC Lectureship Awards will be presented during the IASLC Lectureship Award Presentations Plenary Session on **Tuesday, September 10 - 08:30 - 10:30**.

**Clifton F. Mountain Lectureship Award for Staging**

**Chi-Fu Yang, USA**

**Daniel C. Ihde Lectureship Award for Medical Oncology**

**Solange Peters, Switzerland**

**Heine H. Hansen Lectureship Award for Small Cell Lung Cancer**

**Luis Paz-Ares, Spain**

**IASLC Lectureship Award for Tobacco Control and Smoking Cessation**

**Babalola Faseru, USA**

**Fred R. Hirsch Lectureship Award for Translational Research**

**Montse Sanchez-Cespedes, Spain**

**Robert J. Ginsberg Lectureship Award for Surgery**

**Leah Backhus, USA**

**Tsuguo Naruke Lectureship Award for Surgery**

**Wentao Fang, China**

**IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)**

**Maria Ftanou, Australia**

**James D. Cox Lectureship Award for Radiation Oncology**

**Andrea Bezjak, Canada**



## WCLC 2024 EDUCATION AWARDS

All WCLC 2024 Education Award Winners will be presented with their award during the IASLC Award Ceremony on **Saturday, September 7 - 17:00 - 18:00.**

## DEVELOPING COUNTRIES EDUCATION AWARDS

**Xiaoting Cai**, China

P3.02G.03: High-dose Ascorbic Acid Sensitizes Immunotherapy in LKB1-Deficient Lung Cancer by Promoting Tumor Cell Pyroptosis

**Enrique Caballe-Perez**, Mexico

EP.06B.20: Prognostic Impact of Nectin-like Molecule-5 (CD155) Expression in Non-Small Cell Lung Cancer

P2.11A.03: Association of LIPI with Patterns of Response, Resistance, and Survival in Patients with Metastatic NSCLC Treated with PD(L)-1 Blockade

**Lina Chen**, China

P3.13D.10: Clinical Outcomes of Transformed Small-Cell Lung Cancer Versus Extensive Primary Small-Cell Lung Cancer

**Haoyue Guo**, China

P1.12A.08: The Mechanism Study on a Novel CD3-EGFR Bispecific Antibody Combo Improves Osimertinib-Resistant NSCLC Tumor Environment

EP.14C.02: Identification and Isolation of Cancer Stem Like Cells in Pulmonary Sarcomatoid Carcinoma

**Shujie Huang**, China

P4.15E.01: Association Between Dynamic Patient-Reported Outcome-Based Symptom Exacerbation and Postoperative Complication in Lung Cancer

**Long Jiang**, China

MA07.12: Unleashing the Potential of the Probiotic *F.prausnitzii* to Optimize PD-1 Inhibitor Efficacy in NSCLC Treatment

P1.08C.04: Delineating the Prognosis Spectrum: Disentangling Primary Tumor and Lymph Node Responses in NSCLC Following Neoadjuvant Immunotherapy

**Warisa Khatoon**, India

P3.06F.06: Spatial Transcriptomic Profiling Reveals Molecular Patterns Associated with Poor Prognosis in ALK-Rearranged NSCLC Patients

**Yi-duo Lin**, China

MA09.09: Genomic Mapping of Evolutionary From Pre-Invasive to Advanced Stage in Lung Adenocarcinoma

**Shama Pandey**, Nepal

MA14.11: Duration of Intervals in the Care-Seeking Pathway of Lung Cancer in Nepal - Unraveling the Delays From Symptom Onset to Treatment Initiation

**Chao Zhang**, China

MA15.11: Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-Mutant NSCLC Followed by Adjuvant Osimertinib or Observation: A Phase II CTONG2104 Trial

**Yanpei Zhang**, China

MA07.09: Genome-Wide CRISPR Screen Identifies SFRP2 as a Novel Stromal Target to Enhance Abscopal Effect of Radioimmunotherapy

**Yuchen Zhang**, China

P1.03D.03: Artemisinin Enhances Anti-Tumor Immunity by Increasing FGL1 Ubiquitination Degradation via Activating TRIM21 in NSCLC

P1.02D.02: Tumor-Derived Exosomal tsRNA 3' tiRNA-AlaCGC Promotes Immune Tolerance by Inducing Fibroblast Senescence in LUAD

## IASLC PATIENT ADVOCATE EDUCATION AWARDS

**Adela Ayensa Alonso**, Mexico**Occhiena Carlotta**, Italy**Lee-Anne Currie**, Australia**Alison Bolton**, Australia**Blessing Erinwusi**, Nigeria**James Hiter**, USA**Patricia Mondragon**, Mexico**Ravi Prakash**, India**Prakaitip Susilparat**, Thailand

WCLC 2024 EDUCATION AWARDS

EARLY CAREER EDUCATION AWARDS

**Elliot Brea, USA**

MA07.03: Systematic Engineering of TROP2 CAR T Cell Therapy to Overcome Resistance Pathways in EGFR Mutant NSCLC

**Chinmay Jani, USA**

MA14.03: Breathing Dangers: Unraveling Particulate Matter and Asbestos-Associated Lung Cancer Trends in the Top Ten Most Populous Countries.

**Harriet Louise Lancaster, Netherlands**

MA02.05: Inter-Reader Agreement of AI Versus Human Readers in Baseline LDCT Lung Nodule Classification; A UKLS Trial Dataset Sub-Study

**Marta Molina-Alejandre, Spain**

P3.08E.01: Perioperative Chemoimmunotherapy Rescue Cold HLA-deficient Tumors Inducing Strong Immune Responses and Long-Term Survival

**Alexandra Potter, USA**

MA18.08: Risk and Timing of Second Primary Lung Cancer Among Young Women With a History of Breast Cancer in the USA; Treatment Patterns and Survival of Screen-Detected Lung Cancer in the Real World Versus the National Lung Screening Trial

MA04.04: Treatment Patterns and Survival of Screen-Detected Lung Cancer in the Real World Versus the National Lung Screening Trial

**Esther Redin, USA**

MA19.03: SMARCA4 Controls State Plasticity in SCLC Through Regulation of Neuroendocrine Transcription Factors and REST Splicing

PI.03G: Lurbinectedin Synergizes with Selinexor by Inhibiting DNA Damage Repair and Enhancing Immune Cell Infiltration in Neuroendocrine Lung Tumors

**Jorge Humberto Rodriguez-Quintero, USA**

MA01.09: Definitive Chemoradiation Followed by Immunotherapy vs. Surgery for cT4N2M0 NSCLC: A Contemporary Nationwide Analysis.

**Chang (Chloe) Su, USA**

OA17.06: Impact of Using Smoking Duration in Place of Pack-Years as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities

**Anna Walstra, Netherlands**

MA02.07: AI as Primary Reader in European 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Analyzing False Negatives Against Radiologists

**Shan Xiong, China**

OA03.05: Deep Multiple Instance Learning-Enabled Gene Mutation Prediction of Lung Cancer From Histopathology Images

NURSE OR ALLIED HEALTH PROFESSIONAL AWARDS (NAHP)

**Sabrina Moffat, USA**

MA18.11: The Evolution of The Lung Screening Network: Uniting to Strengthen Community and Share Best Practices Among Navigators

NAHP EARLY CAREER RESEARCHER

**Gisele Farias, Brazil**

EP15B.02: Real-World Data From Advanced Practice Nurse Care in Lung Cancer in a Private Clinic in Brazil

NAHP DEVELOPING COUNTRIES

**Vanessa Brunelli, Australia**

EP.01D.04: Impacts of Household Tobacco Smoke on Life-Long Non-Smoking Adults: An Internet-Based Population Survey in India

EP.04A.01: Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation

EARLY CAREER IN TOBACCO CONTROL AND SMOKING CESSATION AWARD

**Sun Choi, Canada**

P1.01C.02: Tobacco Control and Smoking Cessation-Related Content in Oncology Meetings: A Scoping Review

JEN BROCK MEMORIAL AWARD

**Dinh Thi Lan Anh, Vietnam**

## INTERNATIONAL MENTORSHIP PROGRAM

**Hemavathi Baskarane**, India

**Mentor:** Tianhong Li, USA

P1.12A.12: Liquid Biopsy Based Risk Stratification and Intensification of Treatment in EGFR Mutant Advanced NSCLC (L-BRITE) Preliminary Analysis

**Jia-Yi Deng**, China

**Mentor:** Karen Reckamp, USA

EP.11A.04: Patterns of Failure and Subsequent Treatment After Progression on First-line Immunotherapy Monotherapy in Advanced NSCLC

**Chinmay Harida**, India

**Mentors:** David Jablons, USA & Natalie Lui, USA

EP.07D.06: Characteristics of and Long-term Outcomes of Non-Small-cell Lung Cancer Diagnosed Among Young Adults in the USA

**Ming Li**, China

**Mentor:** Hari Keshava, USA

MA09.08: The Mechanical Change and Metastasis Promoting in Lung Adenocarcinoma Progression: From AIS, MIA to IAC

**Qing Liang**, China

**Mentor:** Hari Keshava, USA

EP.04C.06: Investigation on the Incidence and Risk Factors of Lung Cancer Among Chinese Hospital Employees

**Si-Cong Ma**, China

**Mentor:** Misako Nagasaka, USA

P1.06B.09: Noninvasive Blood Biopsy of CRTAM-Type 3 Immune Axis Enables Dynamic Monitoring of irAEs Over the Course of Immunotherapy in Lung Cancer

EP.04E.03: Enzymomics of Bodily Fluids Captures CD38-Orchestrated Immunometabolic Disorder for Early Detection of Immunotherapy Toxicity

**Carlos Picon**, Argentina

**Mentor:** Edward Kim, USA

EP.11A.23: REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC - A Multicenter Cohort Study in Argentina

P1.03G.01: NSCLC Immune Hemogram Index (NIHX) A Predictive Score for Immunotherapy Response in PD-L1 Negative Advanced NSCLC

**Zhen-Bin Qiu**, China

**Mentors:** David Jablons, USA & Natalie Lui, USA & Julien Sage, USA

P2.07C.03: Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting

**Thanaporn Thamrongjirapat**, Thailand

**Mentor:** Joel Neal, USA

EP.12A.14: Multicentered Real-World Evidence of Osimertinib Treatment in EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) in Thailand

**Hongcheng Zhu**, China

**Mentor:** Drew Moghanaki, USA

P4.17D.02: Global Trends in Lung Cancer Survival by Morphology: Analysis From 61 Countries During 2000-2014 (CONCORD-3)

# Nuvation Bio

Driven by science  
**FOCUSED ON LIFE**

---

We are a late-stage, global oncology company focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.

Learn more at  
**NuvationBio.com**





NOW ENROLLING

SOHO 02  
CLINICAL STUDY



**SOHO-02** A Phase 3 open-label, randomized, multicenter trial to evaluate efficacy and safety of oral BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic **NSCLC with HER2-activating mutations**

For complete information please visit:  
<http://www.clinicaltrials.gov> (NCT06452277)


© 2024 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer.

MA-PFM-ONC-US-0402-1  
06/24

# CyPath<sup>®</sup> Lung

Noninvasive early detection of lung cancer

**EARLY  
DETECTION  
OF LUNG  
CANCER  
SAVES  
LIVES.**



\*In individuals with pulmonary nodules less than 20mm

Visit us at Booth 409

# The Journal of Thoracic Oncology 2023 Impact Factor is

# 21.0

# up from 20.4!

THE  
HIGHEST  
YET!




**#2** OF 100 JOURNALS IN  
RESPIRATORY SYSTEM

**#13** OF 322 JOURNALS  
IN ONCOLOGY

# SATURDAY

## September 7, 2024



LABORATIVE NETWORKING EMPOWERING INTERNATIONAL TRANSFORMATIVE INNOVATIVE CUTTING-EDGE INSPIRATIONAL IMPACTFUL EDUCATIONAL MULTIDISCIPLINARY COLLABORATIVE NETWORKING GLOBAL

- LIVESTREAMED
- ACCME ACCREDITED BY IASLC
- BREAKFAST / LUNCH / REFRESHMENTS PROVIDED



# SUNDAY

## September 8, 2024

07:30	<b>Concurrent Meet the Expert (MTE) Sessions</b> <i>(Limited Capacity)</i>				07:30
08:00	07:30 - 08:15				08:00
08:30	<b>Presidential Symposium 1</b>				08:30
09:00	08:30 - 10:00				09:00
09:30					09:30
10:00	<b>Coffee Break</b>		<b>Press Conference</b>		10:00
10:30	10:00 - 10:45		10:05 - 11:05		10:30
11:00	<b>Concurrent Oral Abstract Sessions</b>	<b>Concurrent Mini Oral Abstract Sessions</b>	<b>Concurrent Education Sessions</b>		11:00
11:30	10:45 - 12:00	10:45 - 12:00	10:45 - 12:00		11:30
12:00					12:00
12:30	<b>Poster Viewing Lunch with Presenters in Attendance</b> (P1 Posters)		<b>Gender Equity in Thoracic Oncology</b>	<b>Concurrent Industry Symposia</b>	12:30
13:00	12:00 - 14:00		12:30 - 13:30	12:30 - 13:30	13:00
13:30					13:30
14:00	<b>Concurrent Oral Abstract Sessions</b>	<b>Concurrent Mini Oral Abstract Sessions</b>	<b>Concurrent Education Sessions</b>		14:00
14:30	14:00 - 15:15	14:00 - 15:15	14:00 - 15:15		14:30
15:00					15:00
15:30	<b>Concurrent Oral Abstract Sessions</b>		<b>Concurrent Mini Oral Abstract Sessions</b>	<b>Concurrent Education Sessions</b>	15:30
16:00	15:30 - 16:45		15:30 - 16:45	15:30 - 16:45	16:00
16:30	<b>JTO/JTO CRR Editorial Reception</b> <i>(By Invitation Only)</i>				16:30
17:00	16:00 - 17:00				17:00
17:30	<b>Special Plenary Session: 50 Years of IASLC: Advances in Thoracic Oncology Treatment &amp; Research: Legacy of Impact, Future of Promise</b>				17:30
18:00	17:00 - 18:15				18:00
18:30	<b>Poster Viewing Networking Reception with Presenters in Attendance</b> (P2 Posters)		<b>Poster Tours 1 - 9</b>	<b>Industry Symposium</b>	18:30
19:00	18:15 - 19:45		18:30 - 19:15	18:30 - 19:30	19:00
19:30					19:30
20:00	<b>IASLC 50th Anniversary Celebration</b>				20:00
20:30	<i>(Ticketed Event)</i>				20:30
21:00	20:00 - 23:00				21:00
21:30					21:30
22:00					22:00
22:30	<b>Dress to Impress in Your Favorite Outfit from the Last 50 Years!</b>				22:30
23:00					23:00

LIVESTREAMED

ACCME ACCREDITED BY IASLC

BREAKFAST / LUNCH / REFRESHMENTS PROVIDED

WORKING INFORMATIVE MULTIDISCIPLINARY IMPACTFUL EDUCATIONAL CUTTING-EDGE INSPIRATIONAL INFORMATIVE INSPIRATIONAL COLLABORATIVE NETWORKING EMPOWERING INTERNATIONAL FORMATIVE INNOVATIVE COLLABORATIVE NETWORKING CUTTING-EDGE INSPIRATIONAL IMPACTFUL EDUCATIONAL INFORMATIVE INSPIRATIONAL COLLABORATIVE NETWORKING EMPOWERING INTERNATIONAL

**MONDAY**  
September 9, 2024

07:30	<b>Concurrent Meet the Expert (MTE) Sessions</b> <i>(Limited Capacity)</i>				07:30
08:00	07:30 - 08:15				08:00
08:30	<b>Presidential Symposium 2</b>				08:30
09:00	08:30 - 10:00				09:00
09:30					09:30
10:00	Coffee Break 10:00 - 10:45		Press Conference 10:05 - 11:05		10:00
10:30					10:30
11:00	Concurrent Oral Abstract Sessions 10:45 - 12:00	Concurrent Mini Oral Abstract Sessions 10:45 - 12:00	Concurrent Education Sessions 10:45 - 12:00		11:00
11:30					11:30
12:00	Poster Viewing Lunch with Presenters in Attendance (P3 Posters) 12:00 - 14:00		Navigating the Emotional Aftermath of Challenging Patient Outcomes 12:30 - 13:30	Concurrent Industry Symposia 12:30 - 13:30	12:00
12:30					12:30
13:00					13:00
13:30					13:30
14:00	Concurrent Oral Abstract Sessions 14:00 - 15:15	Concurrent Mini Oral Abstract Sessions 14:00 - 15:15	Concurrent Education Sessions 14:00 - 15:15	Meet the Editors 14:00 - 15:00	14:00
14:30					14:30
15:00					15:00
15:30	Concurrent Oral Abstract Sessions 15:30 - 16:45	Concurrent Mini Oral Abstract Sessions 15:30 - 16:45	Concurrent Education Sessions 15:30 - 16:45		15:30
16:00					16:00
16:30					16:30
17:00	<b>Plenary Session: Unmasking Lung Cancer: Exploring the Rising Influence of Non-Tobacco Factors</b>				17:00
17:30	17:00 - 18:30				17:30
18:00					18:00
18:30	Poster Viewing Networking Reception with Presenters in Attendance (P4 Posters) 18:30 - 20:00	Poster Tours 10 - 17 18:45 - 19:30	Industry Symposium 18:45 - 19:45		18:30
19:00					19:00
19:30					19:30
20:00					20:00
20:30	<b>Faculty Dinner</b> <i>(By Invitation Only)</i>				20:30
21:00	20:30 - 22:30				21:00
21:30					21:30
22:00					22:00
22:30					22:30

LIVESTREAMED

ACCME ACCREDITED BY IASLC

BREAKFAST / LUNCH / REFRESHMENTS PROVIDED

**TUESDAY**  
September 10, 2024

07:30	<b>Concurrent Meet the Expert (MTE) Sessions</b> <i>(Limited Capacity)</i> 07:30 - 08:15			07:30
08:00				08:00
08:30	<b>IASLC Lectureship Award Presentations</b> 08:30 - 10:30			08:30
09:00				09:00
09:30				09:30
10:00				10:00
10:30				10:30
11:00	Coffee Break 10:30 - 11:15	IASLC Business Meeting 10:30 - 11:15	Press Conference 10:35 - 11:35	11:00
11:30	<b>Concurrent Oral Abstract Sessions</b> 11:15 - 12:30	<b>Concurrent Mini Oral Abstract Sessions</b> 11:15 - 12:30	<b>Concurrent Education Sessions</b> 11:15 - 12:30	11:30
12:00				12:00
12:30	Lunch Break 12:30 - 13:30		<b>Beyond Equity: Creating Understanding in Thoracic Oncology</b> 12:30 - 13:30	12:30
13:00				13:00
13:30	<b>Concurrent Oral Abstract Sessions</b> 13:30 - 14:45	<b>Concurrent Mini Oral Abstract Sessions</b> 13:30 - 14:45	<b>Concurrent Education Sessions</b> 13:30 - 14:45	13:30
14:00				14:00
14:30				14:30
15:00	<b>Concurrent Oral Abstract Sessions</b> 15:00 - 16:15	<b>Concurrent Mini Oral Abstract Sessions</b> 15:00 - 16:15	<b>Concurrent Education Sessions</b> 15:00 - 16:15	15:00
15:30				15:30
16:00				16:00
16:30	<b>Closing Plenary Session: Breaking Barriers, Building Bridges: Advancing Patient Advocacy Worldwide</b> 16:30 - 17:30			16:30
17:00				17:00
17:30				17:30

LIVESTREAMED

ACCME ACCREDITED BY IASLC

BREAKFAST / LUNCH / REFRESHMENTS PROVIDED

## Saturday, September 7, 2024

12:00 - 13:00

IS01: Industry Sponsored Symposium by Johnson & Johnson: An Innovative First-Line Treatment Option in EGFR+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer

 LUNCH PROVIDED  NOT FOR CME CREDIT

IS02: Industry Sponsored Symposium by Amgen: Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

 LUNCH PROVIDED  NOT FOR CME CREDIT

13:15 - 14:15

IS04: Industry Sponsored Symposium by Merck & Co., Inc.: A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)

 LUNCH PROVIDED  NOT FOR CME CREDIT

15:45 - 16:45

IS07: Industry Sponsored Symposium by Boehringer Ingelheim: Emerging Therapies in Clinical Practice: What Are the Patient Perspectives on the Future of Lung Cancer Treatment?

 NOT FOR CME CREDIT

IS08: Industry Sponsored Symposium by Daiichi Sankyo and AstraZeneca: New Treatment Approach for HER2+ (IHC3+) Metastatic Solid Tumors After Prior Systemic Treatment

 LIVESTREAMED  
 REFRESHMENTS PROVIDED  NOT FOR CME CREDIT

## Sunday, September 8, 2024

12:30 - 13:30

IS10: Industry Sponsored Symposium by Pfizer Oncology: LORBRENA® (lorlatinib): Overview of CROWN Trial Efficacy and Safety Data

 LUNCH PROVIDED  LIVESTREAMED  NOT FOR CME CREDIT

IS11: Industry Sponsored Symposium by Abbvie: Un-Met Needs in NSCLC: The Emerging Potential Role of ADCs Targeting c-Met

 LUNCH PROVIDED  LIVESTREAMED  NOT FOR CME CREDIT

18:30 - 19:30

IS13: Industry Sponsored Symposium by Thermo Fisher Scientific: Accelerating Treatment Initiation with Next-Day NGS: Insights from a Multidisciplinary Collaboration Program in Precision

 REFRESHMENTS PROVIDED  NOT FOR CME CREDIT

## Monday, September 9, 2024

12:30 - 13:30

IS16: Industry Sponsored Symposium by Roche Diagnostics: Actionable Biomarkers in Early-Stage NSCLC

 LUNCH PROVIDED  LIVESTREAMED  NOT FOR CME CREDIT

## Saturday, September 7, 2024

14:30 - 15:30

IS05: Satellite CME Symposium by PeerView Supported by Janssen: Navigating Rapid Changes in First- and Later-Line Treatment of *EGFR*-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management

LUNCH PROVIDED

ACCME ACCREDITED BY OTHER PROVIDER

IS06: Satellite CME Symposium by Physicians' Education Resource Supported by AstraZeneca: Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real World Settings, What's Next for Emerging Novel Strategies

LUNCH PROVIDED

ACCME ACCREDITED BY OTHER PROVIDER

LIVESTREAMED

15:45 - 16:45

IS09: Satellite CME Symposium by PeerView Supported by AstraZeneca: Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and *EGFR*-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

LUNCH PROVIDED

ACCME ACCREDITED BY OTHER PROVIDER

## Sunday, September 8, 2024

12:30 - 13:30

IS12: Satellite CME Symposium by Physicians' Education Resource Supported by AstraZeneca: What's Next for HER2- and Trop2-Directed ADCs in Lung Cancer: How Emerging Trial Data Will Impact Our Clinics Today and Tomorrow...

LUNCH PROVIDED

ACCME ACCREDITED BY OTHER PROVIDER

LIVESTREAMED

## Monday, September 9, 2024

12:30 - 13:30

IS14: Satellite CME Symposium by PeerView Supported by AstraZeneca: Elevating Care in Resectable Stage I-III NSCLC: Targeted Therapy and Immunotherapy at the Forefront of Multimodal Treatment Strategies

LUNCH PROVIDED

ACCME ACCREDITED BY OTHER PROVIDER

IS15: Satellite CME Symposium by PeerView Supported by Daiichi Sankyo, Inc.: Updating the Lung Cancer Treatment Algorithms with Novel Antibody-Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects

LUNCH PROVIDED

ACCME ACCREDITED BY OTHER PROVIDER

18:45 - 19:45

IS17: Satellite CME Symposium by Physicians' Education Resource Supported by Novartis Pharmaceuticals Corporation: Lung Cancer Tumor Board<sup>®</sup>: Enhancing Precision Medicine Through Advancements in Molecular Testing and Optimal Therapy Selection in MET, RET, and KRAS-altered NSCLC

REFRESHMENTS PROVIDED

ACCME ACCREDITED BY OTHER PROVIDER

LIVESTREAMED

IASLC



2025 HOT TOPIC IN BASIC &  
TRANSLATIONAL SCIENCE

SMALL CELL  
LUNG CANCER

SPRING 2025 | NEW YORK, NY

**Save  
the  
Date!**

*Spring 2025*

# 9th Edition of the TNM Classifications of Thoracic Malignancies **NOW AVAILABLE**

- **TNM Staging Classification Recommendations**
- **Staging Cards**

**IASLC  
Members –  
Copies available  
at the IASLC  
Booth!**



**Scan the QR code  
for more information**

# STARS



IASLC Supportive Training for Advocates on Research & Science

## IASLC Proudly Recognizes the STARS 2023-2024 Mentors



Anne-Marie Baird  
*Ireland*



Andrew Ciupek  
*USA*



Jill Feldman  
*USA*



Lillian Leigh  
*Australia*



Upal Basu Roy  
*USA/India*



1974-2024

Conquering Lung & Thoracic Cancers  
Worldwide in the 21st Century

Heartfelt thanks to our Sponsors!

2024 Gold Sponsors: Genentech | Gilead | Johnson & Johnson

2024 Sponsors: Bristol Myers Squibb | Bayer | Lilly Oncology  
Novartis | Takeda



# STARS



IASLC Supportive Training for Advocates on Research & Science

## IASLC is Proud to Support the 2024 STARS PRA Program Participants

Denise Cutlip | USA

Graham Hall | Australia

Hanin Hussain | Singapore

Sofia Jubany | Argentina

Matthew Koebbe | USA

Yuan Lew | Canada

Angeline Low | Australia

Aurora Lucas | USA

Aditya Manna | India

Lynn Abbott-McCloud | USA

Bev Moir | Canada

Lia Ridout | USA

Peter Spolc | Australia



Conquering Lung & Thoracic Cancers  
Worldwide in the 21st Century

# CHANGE THE FUTURE OF LUNG CANCER



**IASLC**  
FOUNDATION

Lung cancer takes more lives than breast, colon, and prostate cancers combined, but it receives less funding. Your support is crucial.

## 100% of Your Donation Funds Research

Directly support our global Research Grants Programs—empowering experts and advancing innovative lung cancer research, while nurturing future thoracic oncology specialists, improving patient outcomes, and bringing hope worldwide.

Make a Lasting Impact – Donate Today!  
Go to <https://bit.ly/IASLCdonate24>  
or Scan the QR Code to Donate.









2024 HOT TOPIC IN BASIC &  
TRANSLATIONAL SCIENCE:  
**TOLERANCE & RESISTANCE TO  
TARGETED THERAPY IN NSCLC**

DECEMBER 13-15, 2024 | WASHINGTON, DC

#HTTR24

**REGISTER  
NOW!**



[httr2024-iaslc.org/](https://httr2024-iaslc.org/)

<b>DEI</b>	DE&I Session	<b>MTE</b>	Interactive Meet the Expert Session (Breakfast Provided, Limited Capacity)
<b>EP</b>	ePosters	<b>OA</b>	Oral Abstract Session
<b>ES</b>	Education Session	<b>P</b>	Posters
<b>EXH</b>	Exhibit Showcase	<b>PL</b>	Plenary Session
<b>HOD</b>	Highlight of the Day Session	<b>WS</b>	Workshop
<b>IS</b>	Industry Supported or Satellite CME Symposia		
<b>MA</b>	Mini Oral Abstract Session		

## 08:00 - 10:00 WS01 - Pathfinding Clinically Useful Early Diagnostics from Bench to Bedside: A Hands on Workshop

ROOM: 30BC

NOT FOR CME CREDIT

A team of experts from the Early Detection Research Network provide real world experience and insight into biomarker development, validation, regulatory review and metrics of clinical utility for all researchers interested in early cancer detection diagnostics. In this two hour workshop attendees will gain hands on experience and be provided the tools (R scripts) for manipulating data from biomarker development, choosing and measuring diagnostic test accuracy, calibration and generalizability, regulatory requirements of stability, robustness and determination of clinical utility endpoints.

**Workshop Faculty:** Stephen Deppen, USA, Yency Forero, Colombia, Alex Kaizer, USA, Anna Baron, USA, Michael Nolan Kammer, France, Karen Anderson, USA

## 08:00 - 12:00 WS02 - Joint IASLC-CSCO-CAALC Session - Prevention and Evidenced-based Medicine: The Past and Future for Lung Cancer Globally

ROOM: 32AB

BREAKFAST &amp; REFRESHMENTS PROVIDED

NOT FOR CME CREDIT

*Chairs: Chunxue Bai, China, Karen Kelly, USA, Yi-Long Wu, China and Caicun Zhou, China*

### 08:00 Welcome & Introductions

### 08:10 WS02.05 - Lung Cancer Prevention and Biomarker- Guided Treatment in China During the Last Half Century

*Chunxue Bai, China*

### 08:30 WS02.06 - Lung Cancer Targeted Therapy: Insights from the Past to Guide the Future

*Paul Hofman, France*

### 08:50 WS02.07 - Immunotherapy for Lung Cancer: What Is on the Horizon?

*Si-Yang Liu, China*

### 09:10 WS02.08 - Exploring Tomorrow: Advancements in the Prevention and Treatment of Lung Cancer

*Karen Kelly, USA*

### 09:30 Networking and Poster Viewing

### 10:30 WS02.10 - Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIIB Non-Small Cell Lung Cancer (NSCLC)

*Nan Wu, China*

### 10:52 WS02.12 - Interim Analysis of A Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)

*Wen-Zhao Zhong, China*

### 11:04 WS02.13 - Oral Abstract Discussion (WS02.10 – WS02.12)

*Patrick Forde, USA*

**11:19 WS02.14 - Poster Discussion (WS02.15 – WS02.19)***Hai-Yan Tu, China*

- WS02.15 - Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Multicenter Study - Zeliang Ma, China
- WS02.16 - A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC - Yongsheng Wang, China
- WS02.17 - Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFR-Mutant Lung Cancers with SCLC Transformation - Jie Huang, China
- WS02.18 - Updated Event-Free Survival of Tislelizumab Plus Chemotherapy Asneoadjuvant/Adjuvant Therapy for Stage IIB-IIIC NSCLC (LungMark Study) - Yao-Bin Lin, China
- WS02.19 - Clinical Outcomes of Transformed Small-Cell Lung Cancer Versus Extensive Primary Small-Cell Lung Cancer - Lina Chen, China

**11:34 WS02.20 - Poster Discussion (WS02.21 – WS02.24)***Fang Wu, China*

- WS02.21 - Overcoming Immunotherapy Resistance in Non-Small Cell Lung Cancer with a Triple Combination Therapy: Efficacy and Mechanisms - Yaping Xu, China
- WS02.22 - Targeted Therapy or Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFRm Lung Adenocarcinoma: A Study Between Four Cohorts - Fang-Liang Lu, China
- WS02.23 - MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH) - Qing Zhou, China
- WS02.24 - EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy - Lifeng Wang, China

**11:49 WS02.25 - Concluding Remarks****08:00 - 10:00 WS03 - Persuasive Communication****ROOM: 30A****NOT FOR CME CREDIT**

*This workshop will address one of the most pressing issues facing the lung cancer community: how to keep the public focused on a disease that is underreported and still stigmatized. Increased and sustained media coverage will help make screening, awareness, and research funding competitive with other diseases. Press release as a powerful tool: Dr. Castro will introduce the issue with relevant aspects to be consider before the dissemination of scientific information through the community and Annabelle Gurwitch, patient advocate and media maven, will lead a hands-on skill building workshop. During Gurwitch's storied career she's successfully harnessed media attention to causes including housing insecurity, environmental sustainability, and survivorship and inequity issues related to lung cancer treatment. She'll give a tutorial from pitching strategies to publishing which will include the crafting an Op-Ed and optimizing of live/radio/tv appearances. The second half of the workshop will be an interactive q & a. Got ideas? Gurwitch will brainstorm them with you. This is a unique opportunity to hone a skill set useful to patient advocates, researchers, and practitioners*

**Workshop Faculty:** Annabelle Gurwitch, USA and Mónica Castro, Argentina

**08:00 - 11:00**      **WS04 - Radiation Oncology Workshop**  
**(Pre-sign up Required for Case Assignments)**  
**NOTE: DELEGATES ARE REQUIRED TO BRING THEIR LAPTOP**

**ROOM: 20A** NOT FOR CME CREDIT

*Chairs: Kristin Higgins, USA and Fiona Hegi-Johnson, Australia*

- 08:00**      **Welcome & Introduction**  
*Kristin Higgins, USA and Fiona Hegi-Johnson, Australia*
- 08:02**      **WS04.03 - MR Linac Applications in NSCLC**  
*Percy Lee, USA*
- 08:42**      **WS04.04 - When/How to Utilize Adaptive RT Treatment Techniques in NSCLC**  
*Pamela Samson, USA*
- 09:22**      **WS04.05 - SBRT Boost in Locally Advanced NSCLC - LU008 Contouring Guidelines**  
*Charles Simone II, USA*
- 10:02**      **WS04.06 - SBRT for Oligoprogression**  
*Jillian Tsai, Canada*
- 10:42**      **Q&A**

**08:30 - 09:30**      **PC01 - Press Conference**

**ROOM: 26B** NOT FOR CME CREDIT

**08:45 - 12:30**      **WS05 - Early Career Investigator Workshop**

**ROOM: 20D** BREAKFAST & LUNCH PROVIDED NOT FOR CME CREDIT

*Chairs: Narjust Florez, USA and Fabio Ynoe de Moraes, Canada*

- 08:45**      **Welcome & Introduction**  
*Narjust Florez, USA and Fabio Ynoe de Moraes, Canada*
- 08:47**      **WS05.03 - Overcoming Challenges as a Young Investigator**  
*Pablo Munoz Schuffenegger, Chile*
- 08:57**      **WS05.04 - Time Management: Clinical and Research Duties**  
*Sun Min Lim, Republic of Korea*
- 09:07**      **WS05.05 - Career Pathways in Thoracic Oncology**  
*Sada Ikeda, Japan*
- 09:17**      **WS05.06 - Seeking and Preparing a Successful Grant Application**  
*Laura Mezquita, Spain*
- 09:27**      **WS05.07 - How to Become an Elite Educator**  
*Yu Shyr, USA*
- 09:37**      **WS05.08 - Getting your Paper Published**  
*Emily Stone, Australia*
- 09:47**      **WS05.09 - Masterclass on Scientific Presentations**  
*Stephen Liu, USA*
- 09:57**      **WS05.10 - How to Use Social Media to Advance Your Career in Thoracic Oncology**  
*Clarissa Mathias, Brazil*
- 10:07**      **WS05.11 - Joining IASLC as an Early Career Physician/Investigator**  
*Karen Kelly, USA*
- 10:17**      **Q&A**
- 10:45**      **Networking Round #1**



- 11:00**    **Networking Round #2**
- 11:15**    **Networking Round #3**
- 11:30**    **Networking Lunch on the Terrace**

**09:00 - 16:00**    **WS06 - 2024 IASLC CT Screening Symposium**  
 [Ticketed Session – SOLD OUT]

**ROOM: 31ABC**

 **LUNCH & REFRESHMENTS PROVIDED**

 **NOT FOR CME CREDIT**

*Chair: Annette McWilliams, Australia*

- 09:00**    **Chair's Welcome**  
*Annette McWilliams, Australia*

**Topic 1: Implementation of CT Screening Programs: Challenges & Successes**

- 09:10**    **WS06.02 - Welcome**  
*Chi-Fu Jeffrey Yang, USA*
- 09:15**    **WS06.03 - Country 1: British Columbia**  
*Stephen Lam, Canada*
- 09:25**    **WS06.04 - Country 2: Japan**  
*Kazuto Ashizawa, Japan*
- 09:35**    **WS06.05 - Country 3: Summary from Eastern & Nordic Europe**  
*Witold Rzyman, Poland*
- 09:45**    **WS06.06 - Country 4: US**  
*Ella Kazerooni, USA*
- 09:55**    **Panel Discussion & Q&A**
- 10:30**    **Conclusion**  
*Douglas Wood, USA*
- 10:35**    **Break**

**Topic 2: Integration of Mobile CT Screening**

- 10:50**    **Welcome**  
*David Chi-Leung Lam, Hong Kong*
- 10:55**    **WS06.11 - Nuts + Bolts of Mobile CT Screening (Overview)**  
*Melissa Wheeler, USA*
- 11:05**    **WS06.12 - Mobile CT in Urban Areas - UK**  
*Haval Balata, UK*
- 11:15**    **WS06.13 - Mobile CT in Regional Areas - Brazil**  
*Ricardo Sales Santos, Brazil*
- 11:25**    **WS06.14 - Mobile CT in Remote Areas - Australia**  
*Catherine Jones, Australia*
- 11:35**    **Panel Discussion + Q&A**
- 12:00**    **Conclusion**  
*Mary Reid, USA*
- 12:05**    **Lunch Break**

**Topic 3: Equity in CT Screening**

- 13:05**    **Welcome**  
*Witold Rzyman, Poland*
- 13:10**    **WS06.19 - First Nations People**  
*Sue Crengle, New Zealand*

- 13:20**    **WS06.20 - LGBTQI Populations**  
*Shannon Kozlovich, USA*
- 13:30**    **WS06.21 - Community Outreach and Engagement**  
*Efren J. Flores, USA*
- 13:40**    **WS06.22 - Co-design - Equity in Lung Cancer Screening Policy**  
*Helena Wilcox, UK*
- 13:50**    **Panel Discussion + Q&A**
- 14:05**    **Conclusion**  
*Ray Osarogiagbon, USA*
- 14:10**    **Break**

**Topic 4: Future Directions & Emerging Technologies**

- 14:25**    **Welcome**  
*Ella Kazerooni, USA*
- 14:30**    **WS06.27 - IASLC Quality Indicators Project**  
*Martin Tammemagi, Canada*
- 14:40**    **WS06.28 - AI with Chest X-Ray: A Low Cost Alternative to CT Screening in LMIC**  
*Pyng Lee, Singapore*
- 14:50**    **WS06.29 - CT Based Biomarkers**  
*Florian Fintelmann, USA*
- 15:00**    **WS06.30 - Biomarkers in Lung Cancer Screening (Non Imaging)**  
*Peter Mazzone, USA*
- 15:10**    **Panel Discussion + Q&A**
- 15:30**    **Conclusion**  
*David Yankelevitz, USA*
- 15:35**    **WS06.33 - Workshop Summary/Conclusion**  
*John Field, UK*

**10:30 - 12:30**    **WS07 - The Multi-Disciplinary Team and Challenging Real-World Treatment Decisions for Patients with Locally Advanced NSCLC**

**ROOM: 22**

 **NOT FOR CME CREDIT**

*Chairs: Brendon Stiles, USA and Balazs Halmos, USA*

- 10:30**    **Welcome & Introduction**  
*Brendon Stiles, USA and Balazs Halmos, USA*
- 10:35**    **WS07.03 Surgical Considerations**  
*Isabelle Opitz, Switzerland*
- 10:47**    **WS07.04 - Radiation Oncology Considerations**  
*Nitin Ohri, USA*
- 10:59**    **WS07.05 - Medical Oncology Considerations**  
*Benjamin Levy, USA*
- 11:11**    **WS07.06 - Patient Considerations**  
*Teresa D. Conneran, USA*
- 11:16**    **Questions and Panel Discussion**
- 11:25**    **WS07.08 - Interactive Tumor Board with Case Presentations**  
*Andreas Rimner, Germany, Joachim Aerts, Netherlands, Cecilia Pompili, UK, Alessandro Mariani, Brazil, Peter B. Illei, USA*

**10:30 - 12:30****WS08 - Model-Assisted Designs: Make Bayesian Adaptive Clinical Trials Easy and Accessible****ROOM: 26B** **NOT FOR CME CREDIT**

- 10:30** **WS08.01 - Overview of Bayesian Methods, Adaptive Designs, and Model-Assisted Designs**  
*J. Jack Lee, USA*
- 10:45** **WS08.02 - Phase I Model-Assisted Designs - BOIN Suite for Single Agents, Combination Agents, Late-onset Toxicities**  
*Eunji Choi, USA*
- 11:30** **WS08.03 - Phase II Model-Assisted Designs - BOP2 Suite for Single-arm Trials, Randomized Trials with Efficacy and Toxicity Monitoring**  
*J. Jack Lee, USA*
- 12:05** **WS08.04 - Master Protocol Bayesian Adaptive Designs - Basket Trials, Multi-Arm Multi-Stage Adaptive Platform Trials, Adaptive Randomization, Early Stopping for Futility, Toxicity, and/or Efficacy**  
*J. Jack Lee, USA*
- 12:20** **Q&A**

**11:30 - 14:30****WS09 - IASLC/iMig Workshop****ROOM: 30BC** **NOT FOR CME CREDIT***Chairs: Aaron Mansfield, USA and Nobukazu Fujimoto, Japan*

- 11:30** **Welcome**  
*Aaron Mansfield, USA and Nobukazu Fujimoto, Japan*
- 11:34** **WS09.03 - Introduction to Mesothelioma**  
*Arnaud Scherpereel, France*
- 11:44** **WS09.04 - Updates to the Mesothelioma Staging Classification**  
*Valerie Rusch, USA*
- 11:54** **WS09.05 - Updates to the Pathologic Classification for Mesothelioma**  
*Sonja Klebe, Australia*
- 12:04** **WS09.06 - Young Investigator: Heterogeneity of Pleural Mesothelioma**  
*Lise Mangiante, France*
- 12:14** **WS09.07 Mesotheliomas Developing in Carriers of Pathogenic Germline BAP1, BARD1 and BLM Mutations**  
*Michele Carbone, USA*
- 12:24** **Discussion**
- 12:39** **WS09.09 - Is Personalized Medicine Ready in Mesothelioma?**  
*Dean Fennell, UK*
- 12:59** **WS09.10 - IO Resistance in Mesothelioma: Mechanisms and How to Overcome It?**  
*Alessandra Curioni, Switzerland*
- 13:19** **WS09.11 - Pro/Con of Surgery for Mesothelioma: MARS2 Trial and Beyond [Pro]**  
*Andrea Wolf, USA*
- 13:29** **WS09.12 - Pro/Con of Surgery for Mesothelioma: MARS2 Trial and Beyond [Con]**  
*Paul Baas, Netherlands*
- 13:39** **WS09.13 - Case Discussions**  
*Arnaud Scherpereel, France*
- 13:54** **WS09.14 - Case Discussions**  
*Joseph Friedberg, USA*
- 14:09** **Q&A**

**12:00 - 17:00      WS10 - Nurse & AHP + ITONF Workshop****ROOM: 30A****LUNCH PROVIDED****NOT FOR CME CREDIT****12:00      ITONF AGM for ITONF Members***Caitlin Broderick, Australia and Mary Duffy, Australia***12:30      Lunch, Networking****13:00      WS10.04 - Welcome to IASLC NAHP & ITONF Collaborative Workshop***Caitlin Broderick, Australia and Michelle Turner, USA***Session 1: Treatments Beyond the Bedside****13:05      WS10.06 - Introduction***Whitney Lewis, USA***13:10      WS10.07 - Systemic Cancer Treatment Interactions Including Co-morbidities: An Update***Whitney Lewis, USA***13:25      WS10.08 - Opioid Use in Thoracic Oncology - Busting Myths***Katherine Kuhns, USA***13:40      WS10.09 - Alternative Pain Management Strategies in Thoracic Oncology***Dianne Zawisza, Canada***13:55      WS10.10 - Panel Discussion: Lung Cancer Care Around the World***Whitney Lewis, USA***14:20      WS10.12 - Panel Discussion: Lung Cancer Care Around the World***Andreja Sajnic, Croatia, Magda Louis-Juste, USA, Caitlin Broderick, Australia, Gisele Fraga Moreira, Brazil***14:20      Break****Session 2: Multidisciplinary Approach to Optimizing Quality of Life****14:25      Introduction***Michelle Turner, USA***14:30      WS10.17 - Holistic Supportive Care in Thoracic Oncology***Bukola Azeez, USA***14:50      WS10.18 - Palliative & Psychosocial Care: Optimizing Quality of Life Before, During and After Treatment***Michelle Turner, USA***15:10      Q&A****15:20      Break****Session 3: Nursing & Allied Health Professionals Qualitative Research in Thoracic Oncology: A Boot Camp Introduction****15:45      WS10.21 - Introduction***Melissa Culligan, USA and Maria Ftanou, Australia***15:50      WS10.23 - The Importance of Qualitative Research in Thoracic Oncology***Melissa Culligan, USA***15:55      WS10.24 - Qualitative Research Design: Asking & Answering Important Research Questions?***Malene Missel, Denmark***16:05      WS10.25 - Conducting Qualitative Research Studies: Lessons Learned Along the Way - The Brazilian Microbiome Project***Gisele Fraga Moreira, Brazil***16:15      WS10.26 - Conducting Qualitative Research Studies: Lessons Learned Along the Way - Mentoring Nurse PhD Students in Africa***Vanessa Brunelli, Australia*

**16:25** **WS10.27 - Empowering Nurses & Allied Health Professionals to Support, Lead and Deliver Research**

*Maria Ftanou, Australia*

**16:40** **Panel Discussion - Q&A**

*Maria Ftanou, Australia*

**12:00 – 13:00** **Concurrent Industry Sponsored Symposia**

See page 240 for more information.

**13:00 - 14:30** **WS11 - Successful IASLC Grant Application**

**ROOM: 22**

**NOT FOR CME CREDIT**

*Chair: Lei Deng, USA*

**13:00** **Welcome & Introduction**

*Lei Deng, USA*

**13:03** **WS11.02 - Overview of IASLC Grant Programs and Review Process**

*Tindara Franchina, Italy*

**13:03** **WS11.03 - Insights Into Developing an IASLC Grant Application**

*Rachael Helen Dodd, Australia*

**13:23** **WS11.04 - Group Discussion**

*Tindara Franchina, Italy, Rachael Helen Dodd, Australia, Balazs Halmos, USA, Jose Carlos Benítez, France, Abdul Rafeh Naqash, USA, Qing Zhou, China, Masaoki Ito, Japan, Triparna Sen, USA, Lyudmila Bazhenova, USA, Luiz Henrique de Lima Araújo, USA, Kenneth John O'Byrne, Australia, Christina Baik, USA*

**14:05** **WS11.06 - Group Learning and Q&A**

*Tindara Franchina, Italy, Rachael Helen Dodd, Australia, Balazs Halmos, USA, Jose Carlos Benítez, France, Abdul Rafeh Naqash, USA, Qing Zhou, China, Masaoki Ito, Japan, Triparna Sen, USA, Lyudmila Bazhenova, USA, Luiz Henrique de Lima Araújo, USA, Kenneth John O'Byrne, Australia, Christina Baik, USA*

**13:00 - 14:30** **WS12 - Understanding and Managing Compassion Fatigue in Medical Practice**

**ROOM: 32AB**

**NOT FOR CME CREDIT**

*In this workshop, participants will explore the critical topic of compassion fatigue—a common challenge faced by professionals in the field of oncology. We will discuss the reasons for having compassion fatigue, how it is connected to being an HCP and to our character, how to recognize if you suffer from it and how to manage and overcome it. Under the challenges of the past years with work overload, survivorship and complex patient journeys, taking care of ourselves is fundamental for the wellbeing of HCP.*

**Workshop Faculty:** Nir Peled, Israel, Shani Shilo, Israel, Jhanelle Gray, USA, Jennifer Bickel, USA, Fernanda Montana, Argentina

**13:00 - 14:30** **WS13 - Joint IASLC – ASCO Session: Art & Science of Cancer Care: Optimizing Whole-Person Care for Early-Stage Lung Cancer**

**ROOM: 30DE**

**NOT FOR CME CREDIT**

*Chairs: Hidetoshi Hayashi, Japan and Enriqueta Felip, Spain*

**13:00** **Welcome & Introduction**

*Hidetoshi Hayashi, Japan and Enriqueta Felip, Spain*

- 13:04**    **WS13.03 - The Brave New World of Early Stage Lung Cancer: What Does Cure Look Like for the World's Deadliest Cancer?**  
*Rosalyn Juergens, Canada*
- 13:19**    **WS13.04 - Living Through and Beyond Early-Stage Lung Cancer**  
*Ellen Barlow, USA*
- 13:29**    **WS13.05 - Lung Cancer Patients on the Move: Optimizing Physical Health**  
*S. Nicole Culos-Reed, Canada*
- 13:39**    **WS13.06 - Taking Lung Cancer Care to Heart: Cardiovascular Health of People with Lung Cancer**  
*Ana Barac, USA*
- 13:49**    **WS13.07 - Survivorship in Lung Cancer: Creating a New Path**  
*Jarushka Naidoo, Ireland*
- 13:59**    **WS13.08 - The Cost of Living Long-Term with Early-Stage Lung Cancer**  
*Yasushi Goto, Japan*
- 14:09**    **Q&A**

**13:15 – 14:15    Industry Sponsored Symposium**

See page 238 for more information.

**14:30 - 16:30    WS14 - Social Media & Communications Workshop**

**ROOM: 26B**

 **REFRESHMENTS PROVIDED**

 **NOT FOR CME CREDIT**

Chair: Matthew Smeltzer, USA

- 14:30**    **WS14.01 - Welcome: Lifting Your Science Communications Game with the Comms Committee**  
*Matthew Smeltzer, USA*
- 14:35**    **WS14.02 - Essentials for Early Career Investigator in Science Communications**  
*Aakash Desai, USA*
- 14:45**    **WS14.03 - Conquering Stage Fright: Mastering the Art of Confident Presentations**  
*Estelamari Rodriguez, USA*
- 14:55**    **WS14.04 - Crafting Compelling Abstracts and Scientific Content**  
*Karen Reckamp, USA*
- 15:05**    **WS14.05 - Demystifying the Data: Creating Clarity from the Complex**  
*Matthew Smeltzer, USA*
- 15:15**    **WS14.06 - Mastering the Media: Scientific Interview and Engagement Skills**  
*Noemi Reguart, Spain*
- 15:25**    **WS14.07 - How to Reach a Broad Audience: Bringing Diverse Voices into the Lung Cancer Conversation**  
*Ana Velazquez Manana, USA*
- 15:35**    **WS14.08 - Engaging the Power of Patient Advocacy**  
*Dusty Donaldson, USA*
- 15:45**    **WS14.09 - Beyond Likes: How to Become a Social Media Guru**  
*Charu Aggarwal, USA*
- 15:55**    **Panel Discussion**

**14:30 – 15:30    Concurrent Satellite CME Symposia**

See page 240 for more information.

**15:00 - 17:00****WS15 - Genomics for Oncologists: An Interactive Workshop****NOTE: DELEGATES ARE REQUIRED TO BRING THEIR LAPTOP****ROOM: 30BC** **NOT FOR CME CREDIT**

*The workshop, through an interactive small group format, will enable participants to better integrate genomic testing into patient care. Using a interactive small-group format, workshop participants will learn principles related to the selection of different test methods and interpretation of results. There will be case-based hands-on instruction using online genomic oncology tools and review of actual patient genomic testing reports. The workshop has been developed by a national committee made up of oncologists, genetics professionals, and experts in medical education.*

Co-Chairs: Ramaswamy Govindan, USA and Richard Haspel, USA

Panelists: Saiama Naheed Waqar, USA, Lynette Sholl, USA, Aparna Sharma, India

**15:00 - 17:00****WS16 - AABIP-IASLC Session on Peripheral Lung Cancer Therapeutics****ROOM: 28D** **NOT FOR CME CREDIT***Chairs: George Cheng, USA, Septimiu Murgu, USA and Antoni Rosell, Spain***15:00 WS16.03 - Bronchoscopic Therapy for Early-Stage Lung Cancer***Antoni Rosell, Spain***15:10 WS16.04 - Image-Guided Ablation Therapy for Early-Stage Lung Cancer***Robert Suh, USA***15:20 WS16.05 - Radiation Therapy for Early-Stage Lung Cancer***James Urbanic, USA***15:30 WS16.06 - Surgical Advancements for Early-Stage Lung Cancer***Junichi Soh, Japan***15:40 WS16.07 - Emerging Data on Early Systemic Therapeutics in Lung Cancer***Marina Chiara Garassino, USA***15:50 WS16.08 - Problem Based Learning***George Cheng, USA, Septimiu Murgu, USA and Antoni Rosell, Spain***16:20 WS16.09 - Simulation***George Cheng, USA, Septimiu Murgu, USA, Antoni Rosell, Spain and Kerian Van Nostrand, USA***15:30 - 17:00****WS17 - LATAM Workshop: Challenges and Future of Lung Cancer in Latin America****ROOM: 32AB** **NOT FOR CME CREDIT***Chair: Carlos Gil Ferreira, Brazil and Rossana Ruiz, Peru***15:30 WS17.01 - Welcome & Introduction***Carlos Gil Ferreira, Brazil and Rossana Ruiz, Peru***15:32 WS17.03 - Access and Opportunities to Minimally Invasive Surgery in LATAM***Luis Rueda Marulanda, Colombia***15:42 WS17.04 - Biomarker Testing in LATAM: Present and Future***Luis Raez, USA***15:52 WS17.05 - Solutions to Addressing the Challenges of Radiation Oncology in LATAM***Lilian Faroni, Brazil***16:02 WS17.06 - Access to Targeted Therapy and Immunotherapy***Clarissa Baldotto, Brazil*

- 16:12**    **WS17.07 - Where to Start? Creating a Research Team in Your Practice**  
*Gustavo Schvartsman, Brazil*
- 16:22**    **WS17.08 - Argentine Lung Cancer Screening Programs Collaborative Registry: The LuCaS.Ar Project**  
*Iris Boyeras Navarro, Argentina*
- 16:27**    **WS17.09 - Intensified Chemo-Immuno-Radiotherapy with Durvalumab for Stage III NSCLCs: A Single Arm Phase II Study - PACIFIC BRAZIL**  
*William William Jr., Brazil*
- 16:32**    **WS17.10 - Stratifying Risk in Oligoprogressive EGFR-Mutated Non-Small Cell Lung Cancer: The Role of ctDNA**  
*Alberto Guijosa, Mexico*
- 16:37**    **WS17.11 - Abstract Discussion (WS17.08 – WS17.10)**  
*Claudio Martín, Argentina*
- 16:47**    **Q&A**

**15:45 – 16:45      Satellite CME Symposia**

See page 240 for more information.

**15:45 – 16:45      Industry Sponsored Symposium**

See page 238 for more information.

**17:00 - 18:00      IASLC Award Ceremony**

**ROOM: 33ABC**
 **LIVESTREAMED**
 **REFRESHMENTS PROVIDED**
 **NOT FOR CME CREDIT**

Join us as we celebrate the WCLC 2024 and IASLC Award Winners.

**18:15 - 20:00      PL01 - Opening Plenary Session with Distinguished Service Award Presentations**

**PLENARY HALL**
 **LIVESTREAMED**
 **NOT FOR CME CREDIT**

Chairs: Sandip Patel, USA and Narjust Florez, USA

- 18:15**    **Welcome Remarks**  
*Sandip Patel, USA, Narjust Florez, USA, Linda Martin, USA, Fabio Ynoe de Moraes, Canada, Karen Kelly, USA and Paul Van Schil, Belgium*
- 18:30**    **PL01.08 - IASLC - A Community Helping Patients**  
*Tomas Ramirez, Dominican Republic*
- 18:40**    **IASLC Distinguished Service Award Presentations**
- 19:00**    **PL01.10 - Global Excellence in Lung Cancer Care: A Vision from North American National Cancer Leaders**  
*Douglas Lowy, USA*
- 19:15**    **PL01.11 - Global Excellence in Lung Cancer Care: A Vision from North American National Cancer Leaders**  
*Oscar Arrieta, Mexico*
- 19:30**    **PL01.12 - Patient Navigation to Improve Lung Cancer Care in Diverse Population**  
*Robert Winn, USA*
- 19:45**    **PL01.13 - Panel Discussion with Robert Winn, Oscar Arrieta and Douglas Lowy**  
*Moderated by Karen Kelly, IASLC CEO*

**20:00 - 21:30      Welcome Reception**

**EXHIBIT HALL**
 **REFRESHMENTS PROVIDED**



# RENEW YOUR MEMBERSHIP TODAY!



EXPERIENCE  
collaboration with  
global thoracic  
oncology thought  
leaders across  
all disciplines.



EXPERIENCE  
access to the  
*Journal of Thoracic  
Oncology* and  
discount publication  
fees to the  
*JTO Clinical and  
Research Reports*  
(JTO CRR).



EXPERIENCE  
discounts to  
meetings and the  
annual IASLC  
World Conference  
on Lung Cancer.



JOIN THE CONVERSATION • JOIN THE CONVERSATION • JOIN THE CONVERSATION

-  /IASLC
-  @IASLC
-  iaslungcancer
-  IASLC
-  IASLC
-  IASLC



<https://bit.ly/IASLCmembership>

# 2024 IASLC ACADEMY



Rami Manochakian  
Academy Chair | USA



Christian Rolfo  
Academy Chair | USA



Lyudmila Bazhenova  
USA



Frederico Cappuzzo  
Italy



Marina Garassino  
USA



Pilar Garrido  
Spain



Balazs Haimos  
USA



Jessica Lin  
USA



Helena Linardou  
Greece



Pranshu Mohindra  
USA



Amy Moore  
USA



Jyoti Patel  
USA



Zofia Piotrowska  
USA



Luis Raez  
USA



Triparna Sen  
USA



Jonathan Spicer  
Canada



Anne Tsao  
USA



Antoinette Wozniak  
USA



Alona Zer  
Israel



Pamela Abdayem | France  
Fawzi Abu Ross | USA

Lorenzo Belluomini | Italy  
Lauren Brown | Australia

David Dai-Wei Lee | Malaysia  
Aakash Desai | USA

Sora Ely | USA

Isabella Favato Barcelos | Brazil

Maria Gemelli | Italy

Robert Hsu | USA

Long Jiang | China

Sally Lau | USA

Matthew Lee | USA

Rita Leporati | Italy

Yufei Liu | USA

Laura Moliner Jimenez | Spain

Ivy Ng Weishan | Singapore

Eziafa Oduah | USA

Jayson Paragas | Philippines

Kaushal Parikh | USA

Evangelos Sarris | Greece

Ramila Shiipakar | Nepal

Eric Singhi | USA

Marco Tagliamento | France

Sofia Vidaurre Mendes | Brazil

Alison Wallace | Canada

Duo Xu | China

Soo-Ryum (Stewart) Yang | USA

Mei-Mei Zheng | China

Lodovica Zullo | France



# 50 Years of World-Class Research & Education

*IASLC is at the forefront of global science, education and trends for the prevention, treatment and eventual cure for lung and thoracic cancers. Members of IASLC benefit from access to many educational sources.*

**▶▶▶ JOURNALS** Discover cutting-edge research on thoracic malignancies in *JTO* and *JTO CRR*, with *JTO* emphasizing a multidisciplinary approach, and *JTO CRR* offering open-access publication and indexing in PubMed Central and Web of Science.

**▶▶▶ INTERNATIONAL LUNG CANCER NEWS (ILCN)** Stay informed with the latest developments in lung cancer research and treatment through the bimonthly publication *ILCN*, offering comprehensive coverage by international experts across various fields.

**▶▶▶ LUNG CANCER CONSIDERED PODCAST** Join us for engaging conversations with researchers, healthcare professionals, patients, and advocates shaping thoracic cancer treatment, exploring topics like translating research into practice and addressing critical issues such as gender disparities, career barriers, and so much more!

**▶▶▶ PUBLICATIONS** Delve into IASLC's extensive collection of publications, resources, and guidelines, providing vital educational materials and tools for healthcare providers, meticulously crafted to enhance the standard of care for lung cancer patients.

**▶▶▶ LUNG CANCER 360** Discover IASLC's online Education Center and your comprehensive hub for multidisciplinary education, offering CME-accredited and non-CME resources such as conference slides, webinar recordings, podcasts, *JTO* and *JTO CRR* articles, interactive courses, virtual simulations, microlearning modules, and patient advocacy.



To gain access to these resources, and learn more about what the IASLC is doing to conquer lung cancer in the 21st Century, scan the QR code or visit <https://bit.ly/R-Ed>.



# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

THE OFFICIAL DIGITAL NEWSPAPER OF THE  
**IASLC 2024 WORLD CONFERENCE  
ON LUNG CANCER**

# WCLC MEETING NEWS



#WCLC24





SCIENTIFIC PROGRAM **SUNDAY, SEPTEMBER 8**

<b>DEI</b> DE&I Session	<b>MTE</b> Interactive Meet the Expert Session (Breakfast Provided, Limited Capacity)
<b>EP</b> ePosters	<b>OA</b> Oral Abstract Session
<b>ES</b> Education Session	<b>P</b> Posters
<b>EXH</b> Exhibit Showcase	<b>PL</b> Plenary Session
<b>HOD</b> Highlight of the Day Session	<b>WS</b> Workshop
<b>IS</b> Industry Supported or Satellite CME Symposia	
<b>MA</b> Mini Oral Abstract Session	

**07:30 - 08:15 MTE01 - Is There a Role for Surgery in Pleural Mesothelioma?**

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

**ROOM: 30BC**

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

**07:30 MTE01.01 - There Is a Role for Surgery in Pleural Mesothelioma**

*Marc DePerrot, Canada*

**07:45 MTE01.02 - There Is No Role for Surgery in Pleural Mesothelioma**

*Kenneth O'Byrne, Australia*

**08:00 Q&A**

**07:30 - 08:15 MTE02 - Balancing the Risks and Benefits of Lung Cancer Screening When Selecting Individuals for Screening: Case-based Scenarios**

Track: Screening and Early Detection

**ROOM: 32AB**

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

**07:30 MTE02.01 - Screening High-risk Individuals with Comorbidities: When Do the Risks Outweigh the Benefits?**

*Gerard Silvestri, USA*

**07:45 MTE02.02 - Considering Life Expectancy in the Selection of Individuals for Lung Cancer Screening**

*Kevin Ten Haaf, Netherlands*

**08:00 Q&A**

**07:30 - 08:15 MTE03 - Digital Health for Supportive Care Delivery**

Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care

**ROOM: 30A**

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

**07:30 MTE03.01 - Translating Supportive Care to Health App**

*Jennifer Temel, USA*

**07:45 MTE03.02 - Using Community Health Workers to Improve Supportive Care Delivery**

*Cristiane Decat Bergerot, Brazil*

**08:00 Q&A**

**07:30 - 08:15 MTE04 - A Marathon or a Sprint? Defining the Duration of Immunotherapy**

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

**ROOM: 31ABC**

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

**07:30 MTE04.01 - Marathon: A Year or More of Immunotherapy Is Optimal in NSCLC**

*Lecia Sequist, USA*

**07:45 MTE04.02 - Sprint: Less Than a Year of Immunotherapy is Sufficient in NSCLC**  
*Heather Wakelee, USA*

**08:00 Q&A**

**07:30 - 08:15 MTE05 - Advances in Cell Therapy in Lung Cancer (Adoptive T Cell Transfer, CAR T Cells). The Perspective of a Scientist and a Patient Advocate**

Track: Tumor Biology – Preclinical Biology

**ROOM: 30DE**

 **BREAKFAST PROVIDED**

 **ACCME ACCREDITED BY IASLC**

**07:30 MTE05.01 - T Cell/CAR-T Therapies in Lung Cancer (SCLC and NSCLC)**  
*Martin Forster, UK*

**07:45 MTE05.02 - Patient Perspectives on Novel T Cell Therapies and Future Promise**  
*Amy Moore, USA*

**08:00 Q&A**

**07:30 - 08:15 MTE06 - Role for Thoracic RT in ES-SCLC in the Era of Immunotherapy**

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

**ROOM: 33ABC**

 **BREAKFAST PROVIDED**

 **ACCME ACCREDITED BY IASLC**

**07:30 MTE06.01 - There Is No Current Role for Thoracic Radiotherapy in Patients With ES-SCLC**  
*Daniel Morgensztern, USA*

**07:45 MTE06.02 - Thoracic Radiotherapy Should Still be Given to all Patients with ES-SCLC**  
*Yolande Lievens, Belgium*

**08:00 Q&A**

**08:30 - 10:00 Presidential Symposium 1**

**PLENARY HALL**

 **LIVESTREAMED**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Paul Van Schil, Belgium and Karen Kelly, USA*

**08:30 PL02.03 - President's Address**  
*Paul Van Schil, Belgium*

**08:35 PL02.04 - Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: Primary Analysis of HARMONI-2**  
*Caicun Zhou, China*

**08:42 PL02.05 - Discussant**  
*John Heymach, USA*

**08:49 Q&A**

**08:54 PL02.07 - Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC**  
*Tina Cascone, USA*

**09:01 PL02.08 - Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816**  
*Patrick Forde, USA*

**09:08 PL02.09 - Discussant**  
*Nan Wu, China*

**09:15 Q&A**



**09:20** **PL02.11 - Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01**  
*Marina Garassino, USA*

**09:27** **PL02.12 – Discussant**  
*Sanja Dacic, USA*

**09:34** **Q&A**

**09:39** **PL02.14 - Triaging ILST Screening Participants at Program Entry: Comparative Performance of PanCan versus LungRADsv1.1 Protocol**  
*Annette McWilliams, Australia*

**09:46** **PL02.15 – Discussant**  
*TBC*

**09:53** **Q&A**

**10:00 – 10:45** **Coffee Break**

**EXHIBIT HALL**

**REFRESHMENTS PROVIDED**

*Engage with IASLC Committee Chairs and Members in the Committee Corner in the IASLC Member Lounge in the Exhibit Hall. You can meet the following committees:*

- Rare Tumors
- Multidisciplinary Clinical Science
- Early Detection and Screening
- Pathology
- Basic and Translational Science
- Global Multidisciplinary Practice Standards
- Tobacco Control and Smoking Cessation

**10:05 - 11:05** **Press Conference**

**ROOM: 26B**

**NOT FOR CME CREDIT**

**10:10 - 10:40** **Exhibit Showcase**

**EXHIBIT SHOWCASE THEATER, EXHIBIT HALL**

*See page 248 for more information.*

**10:45 - 12:00** **ES01 - Mesothelioma**

**Track: Mesothelioma, Thymoma, and Other Thoracic Tumors**

**ROOM 303C**

**ACCME ACCREDITED BY IASLC**

*Chairs: Stefan Watzka, Austria and Valerie Rusch, USA*

**10:45** **Welcome & Introduction**  
*Stefan Watzka, Austria and Valerie Rusch, USA*

**10:47** **ES01.03 - Global Incidence and Temporal Trends of Mesothelioma**  
*TBC*

**10:59** **ES01.04 - Molecular Landscape and Histological Terrain of Mesothelioma**  
*Ibiayi Dagogo-Jack, USA*

**11:11** **ES01.05 - Perioperative Chemoimmunotherapy for Mesothelioma**  
*Michael Offin, USA*

**11:23** **ES01.06 - Well-being with Mesothelioma: Requirements for Patients and Their Carers**  
*Stephani Ejegi-Memeh, UK*

**11:35** **Q&A**

**10:45 - 12:00 ES02 - Improving Access to Lung Cancer Screening and Early Detection**

**Track: Screening and Early Detection**

**ROOM: 33ABC**

 ACCME ACCREDITED BY IASLC

*Chairs: Lydia Chelala, USA and Luigi Ventura, UK*

- 10:45 Welcome & Introduction**  
*Lydia Chelala, USA and Luigi Ventura, UK*
- 10:47 ES02.03 - Identifying Optimal and Cost-efficient Recruitment Strategies for Lung Cancer Screening**  
*Harry de Koning, Netherlands*
- 10:59 ES02.04 - Promoting Lung Cancer Screening Using a Centralized Approach in the Veterans Administration Health System**  
*Nichole Tanner, USA*
- 11:11 ES02.05 - Increasing Access to and Awareness of Lung Cancer Screening in Australia**  
*Nicole Rankin, Australia*
- 11:23 ES02.06 - Overcoming Geographic, Socioeconomic, and Racial Disparities in Lung Cancer Screening in the USA**  
*Raymond Osarogiagbon, USA*
- 11:35 Q&A**

**10:45 - 12:00 ES03 - Joint IASLC & GLCC Session**

**ROOM: 30A**

 ACCME ACCREDITED BY IASLC

*Chairs: Matthew Peters, Australia and Graham Hall, Australia*

- 10:45 Welcome & Introduction**  
*Matthew Peters, Australia and Graham Hall, Australia*
- 10:47 ES03.03 - What Should Be Available to Ensure the Emotional Needs of People Affected by Lung Cancer Are Met?**  
*Maureen Rigney, USA*
- 10:59 ES03.04 - The Lorraine Tyler Story – Lessons and Inspiration From her Lung Cancer Advocacy**  
*Nicole Parkinson, Australia*
- 11:11 ES03.05 - Tools to Support Implementation of Lung Cancer Screening**  
*Jesme Fox, UK*
- 11:23 ES03.06 - Empowering Change and Amplifying Impact Through Research Advocacy Activities. Comparative Perspectives on Research Advocacy in Nigeria**  
*Isaac Joseph, Nigeria*
- 11:29 ES03.07 - Empowering Change and Amplifying Impact Through Research Advocacy Activities. Comparative Perspectives on Research Advocacy in Canada**  
*Tim Monds, Canada*
- 11:35 Q&A**

**10:45 - 12:00 ES04 - Challenges and Controversies in Immunotherapy**

**Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy**

**ROOM: 20BC**

 ACCME ACCREDITED BY IASLC

*Chairs: Clarissa Baldotto, Brazil and Misako Nagasaka, USA*

- 10:45 Welcome & Introduction**  
*Clarissa Baldotto, Brazil and Misako Nagasaka, USA*

- 10:47**    **ES04.03 - Controversy: How Should We Integrate Immunotherapy and Radiation in Patients With Brain Metastases?**  
*Anil Tibdewal, India*
- 10:59**    **ES04.04 - Controversy: Defining the Influence of the Gut Microbiota on Immunotherapy Response**  
*Arielle Elkrief, USA*
- 11:11**    **ES04.05 - Challenge: Defining Hyperprogression, Pseudoprogession, and Other Nuances of Immunotherapy Response Kinetics**  
*David R. Gandara, USA*
- 11:23**    **ES04.06 - Challenge: How Should We Treat Special Populations of PTS With Immunotherapy: Poor PS, the Elderly, Prior Transplant and Autoimmunity**  
*Siow Ming Lee, UK*
- 11:35**    **Q&A**

**10:45 - 12:00**    **ES05 - Cancer Evolution and Cancer Heterogeneity**

**Track: Tumor Biology – Preclinical Biology**

**ROOM: 30DE**

*Chairs: Mariam Jamal-Hanjan, UK and Adam Schoenfeld, USA*

- 10:45**    **Welcome & Introduction**  
*Mariam Jamal-Hanjan, UK and Adam Schoenfeld, USA*
- 10:47**    **ES05.03 - Genomic and Proteomic Landscape in Lung Cancer**  
*Ramaswamy Govindan, USA*
- 10:59**    **ES05.04 - Genomic Landscape of SCLC and Its Evolution**  
*Julie George, Germany*
- 11:11**    **ES05.05 - Evolutionary Pressure Against MHC Class II Binding Cancer Mutation**  
*Hannah Carter, USA*
- 11:23**    **ES05.06 - Evolution of Neoepitope Landscape in Human Tumours**  
*Amit Jain, Singapore*
- 11:35**    **Q&A**

**10:45 - 12:00**    **ES06 - Novel Local and Biomarker Driven Therapeutic Options for SCLC**

**Track: Small Cell Lung Cancer and Neuroendocrine Tumors**

**ROOM: 31ABC**



*Chairs: Andrea Fung, Canada and Milena Mak, Brazil*

- 10:45**    **Welcome & Introduction**  
*Andrea Fung, Canada and Milena Mak, Brazil*
- 10:47**    **ES06.03 - Molecular Subtypes of Primary and Transformed SCLC & Future Therapeutic Implications**  
*Hongbin Ji, China*
- 10:59**    **ES06.04 - The Current Role of Brain Radiotherapy for Management of LS-SCLC**  
*Vinai Gondi, USA*
- 11:11**    **ES06.05 - Novel Therapeutic Approaches in Lung Neuroendocrine Tumours (Including ADCs, PARPi & Radiopharmaceuticals)**  
*Lynnette Fernandez-Cuesta, France*
- 11:23**    **ES06.06 - Small Cell Lung Cancer Patient Perspectives and Experiences**  
*Judy Johnson, USA*
- 11:35**    **Q&A**

**10:45 - 12:00 OA01 - Perioperative Strategies 1****Track: Early-Stage Non-small Cell Lung Cancer****ROOM: 20A** ACCME ACCREDITED BY IASLC*Chairs: Jonathan Spicer, Canada and Suresh Senan, Netherlands***10:45 Welcome & Introduction***Jonathan Spicer, Canada and Suresh Senan, Netherlands***10:47 OA01.03 - Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC***David Jones, USA***10:57 OA01-04 - IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIa NSCLC***Enriqueta Felip, Spain***11:07 OA01.05 - Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up***Kristof Cuppens, Belgium***11:17 OA01.06 - A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer***Xiaoliang Zhao, China***11:27 OA01.07 - Discussant***Tina Cascone, USA***11:37 Q&A****10:45 - 12:00 OA02 - Redefining First-Line EGFR Therapy****Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy****ROOM: 20D** ACCME ACCREDITED BY IASLC*Chairs: Xiuning Le, USA and Prunella Blinman, Australia***10:45 Welcome & Introduction***Xiuning Le, USA and Prunella Blinman, Australia***10:47 OA02.03 - Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study***Shirish Gadgeel, USA***10:57 OA02.04 - A Phase III Study of Rilertinib Versus Gefitinib as First-Line Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC***Anwen Xiong, China***11:07 OA02.05 - Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA***Se-Hoon Lee, Republic of Korea***11:17 OA02.06 - Discussant***Marina Garassino, USA***11:27 Q&A****10:45 - 12:00 OA03 - Predicting the Future: Novel Pathology Assessments and Imaging Biomarkers****Track: Pathology and Biomarkers****ROOM: 32AB** ACCME ACCREDITED BY IASLC*Chairs: Jia Luo, USA and Chunwei Xu, China***10:45 Welcome & Introduction***Jia Luo, USA and Chunwei Xu, China*

- 10:47**    **OA03.03 - The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing**  
*Matthew Smeltzer, USA*
- 10:57**    **OA03.04 - Predicting Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced NSCLC with Machine Learning and CT Radiomics**  
*Calum MacAulay, Canada*
- 11:07**    **OA03.05 - Deep Multiple Instance Learning-Enabled Gene Mutation Prediction of Lung Cancer from Histopathology Images**  
*Shan Xiong, China (Early Career Education Award Winner)*
- 11:17**    **OA03.06 - Deciphering Single-Cell Resolved Tumour Microenvironment Profiles Using Spatial Metabolic Mapping**  
*Kenneth O'Byrne, Australia*
- 11:27**    **OA03.07 - Discussant**  
*Teodora Radonic, Netherlands*
- 11:37**    **Q&A**

**12:00 – 14:00**    **Poster Viewing Lunch (Poster Session 1: P1) with Presenters in Attendance**

**EXHIBIT HALL**  **LUNCH PROVIDED**

*Note: All P1 Posters will be on display the entire day on Sunday.*

**12:30 - 13:30**    **DEI01 - Gender Equity in Thoracic Oncology**

**ROOM: 22**  **NOT FOR CME CREDIT**  **LUNCH PROVIDED**

*Chairs: Narjust Florez, USA and Linda Martin, USA*

- 12:30**    **Welcome & Introduction**  
*Narjust Florez, USA and Linda Martin, USA*
- 12:32**    **DEI01.03 - Been There, Done That - Realistic Tips From the Trenches**  
*Enriqueta Felip, Spain*
- 12:42**    **DEI01.05 Should You Have an Exit Strategy? And How?**  
*Jarushka Naidoo, Ireland*
- 12:52**    **DEI01.04 How to Remain Sane? From Work-Life Balance to Work-Life Integration**  
*Prunella Blinman, Australia*
- 13:02**    **DEI01.06 - Addressing Challenging Situations: How and When to Do to It? Case Discussion With Panel**  
*Sabita Jiwnani, India, Celine Mascaux, France, Suresh Ramalingam, USA, Verna Vanderpuye, Ghana, Leticia Lauricella, Brazil*

**12:30 – 13:30**    **Satellite CME Symposium**

*See page 243 for more information.*

**12:30 – 13:30**    **Concurrent Industry Sponsored Symposia**

*See page 242 for more information.*

**12:30 - 13:30**    **Exhibit Showcase**

**EXHIBIT SHOWCASE THEATER, EXHIBIT HALL**

*See page 248 for more information.*

**14:00 - 15:15 ES07 - Risk Factors in Early Stage Lung Cancer**

**Track: Early-Stage Non-small Cell Lung Cancer**

**ROOM: 33ABC**

 ACCME ACCREDITED BY IASLC

*Chairs: Yuko Oya, Japan and Kristin Higgins, USA*

**14:00 Welcome & Introduction**

*Yuko Oya, Japan and Kristin Higgins, USA*

**14:02 ES07.03 - Interstitial Lung Disease and Lung Cancer: How Should We Proceed**

*Satoshi Ikeda, Japan*

**14:14 ES07.04 - The High Risk Patient: Older Adults With Lung Cancer**

*Nicole Ezar, Canada*

**14:26 ES07.05 - The High Risk Operation: Intraoperative Challenges and Solutions**

*Hari Balaji Keshava, USA*

**14:38 ES07.06 - Meeting in the Middle: The Role of the Multi-Disciplinary Meeting for Complex Decision Making**

*Matthew Evison, UK*

**14:50 Q&A**

**14:00 - 15:15 ES08 - Lung Cancer Staging: Updates, Limitations, Approach and Guidelines**

**Track: Pulmonology and Staging**

**ROOM: 30BC**

 ACCME ACCREDITED BY IASLC

*Chairs: Takahiro Nakajima, Japan and Mirella Marino, Italy*

**14:00 Welcome & Introduction**

*Takahiro Nakajima, Japan and Mirella Marino, Italy*

**14:02 ES08.03 - Tobacco Awareness Moment - Tobacco Use and Lung Cancer Staging**

*Lawson Eng, Canada*

**14:05 ES08.04 - Lung Cancer Staging: Controversies and Updates**

*Hisao Asamura, Japan*

**14:17 ES08.05 - Lung Cancer Staging: MRI Overcomes Limitations of Anatomic Imaging**

*Edith Marom, Israel*

**14:29 ES08.06 - Bronchoscopy for Diagnosis and Approach to Mediastinal Staging**

*Lucia Viola, Colombia*

**14:41 ES08.07 - Comparative Effectiveness of Invasive Nodal Staging: The Importance of Guidelines and Test Sequencing on Outcomes**

*George Eapen, USA*

**14:53 Q&A**

**14:00 - 15:15 ES09 - Patient Advocates Role: Overcoming Access Barriers**

**Track: Patient Advocacy**

**ROOM: 30A**

 ACCME ACCREDITED BY IASLC

*Chairs: Upal Basu Roy, USA and Lillian Leigh, Australia*

**14:00 Welcome & Introduction**

*Upal Basu Roy, USA and Lillian Leigh, Australia*

**14:02 ES09.03 - Global Perspective about Biomarker Testing**

*Claudia Poleri, Argentina*

- 14:14 ES09.04 - Resources for Patient Education**  
*Bellinda King-Kallimanis, USA*
- 14:26 ES09.05 - Global Differences and Access to Treatments**  
*Uchechukwu Shagaya, Nigeria*
- 14:38 ES09.06 - Is a Clinical Trial Right For You - Patient Commitment to Trials**  
*Seamus Cotter, Ireland*
- 14:50 Q&A**

**14:00 - 15:15 ES10 - First-Line Treatment of EGFR-Mutant NSCLC: TKI Alone or Combinations - What I Use Today and Why**

**Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy**

**ROOM: 20D**



*Chairs: Melissa Culligan, USA and Roberto Ferrara, Italy*

- 14:00 Welcome & Introduction**  
*Melissa Culligan, USA and Roberto Ferrara, Italy*
- 14:02 ES10.03 - US Perspective**  
*Zofia Piotrowska, USA*
- 14:07 ES10.04 - EU Perspective**  
*Alessandra Curioni, Switzerland*
- 14:12 ES10.05 - South East Asia Perspective**  
*Sewanti Limaye, India*
- 14:17 ES10.06 - East Asia Perspective**  
*Koichi Goto, Japan*
- 14:22 ES10.07 - LATAM Perspective**  
*Victor Marcondes, Brazil*
- 14:27 ES10.08 - Panel Discussion**  
*Zofia Piotrowska, USA, Alessandra Curioni, Switzerland, Sewanti Limaye, India, Koichi Goto, Japan, Victor Marcondes, Brazil*

**14:00 - 15:15 ES11 - “Shining the Light” on Lung Neuroendocrine Neoplasms**

**Track: Tumor Biology – Translational Biology**

**ROOM: 30DE**



*Chairs: Fiona Blackhall, UK and John Minna, USA*

- 14:00 Welcome & Introduction**  
*Fiona Blackhall, UK and John Minna, USA*
- 14:02 ES11.03 - Tobacco Awareness Moment - Smoking and Co-Carcinogens**  
*Laura Mezquita, Spain*
- 14:05 ES11.04 - Diagnostic Challenges in Neuroendocrine Carcinomas**  
*William Travis, USA*
- 14:17 ES11.05 - The LungNENomics Project**  
*Tayla Dalyton, Spain*
- 14:29 ES11.06 - Uncovering the SCLC Surfaceome and the Potential for Novel Antibody-Based Therapies**  
*Taofeek Owonikoko, USA*
- 14:41 ES11.07 - Understanding Mechanisms of Immune Evasion in Neuroendocrine Cancers**  
*See-Hoon Lee, USA*
- 14:53 Q&A**

14:00 - 15:15

## ES12 - Why Attending to Tobacco Matters in Lung Cancer

Track: Risk Factors, Risk Reduction &amp; Tobacco Control

ROOM: 31ABC

ACCME ACCREDITED BY IASLC

Chairs: Carolyn Dresler, USA and Lekan Ayo-Yusef, South Africa

## 14:00 Welcome &amp; Introduction

Carolyn Dresler, USA and Lekan Ayo-Yusef, South Africa

## 14:02 ES12.03 - C-TUQ in Clinical Trials and Electronic Medical Records

Stephanie Land, USA

## 14:14 ES12.04 - Framework Convention Implementational Progress Around the World

Lekan Ayo-Yusuf, South Africa

## 14:26 ES12.05 - Lung Cancer Screening Programs/Guidelines That Do Not Include Cessation Interventions - And, Why

Lizza Hendriks, Netherlands

## 14:38 ES12.06 - Why Including Tobacco Use Status in Staging Is Critical

Lawson Eng, Canada

## 14:50 Q&amp;A

14:00 - 15:15

## MA01 - Advances in Treatment for Stage III NSCLC

Track: Local-Regional Non-small Cell Lung Cancer

ROOM: 20BC

NOT FOR CME CREDIT

Chairs: Christine Bestvina, USA and Carlos Ferreira, Brazil

## 14:00 Welcome &amp; Introduction

Christine Bestvina, USA and Carlos Ferreira, Brazil

## 14:02 MA01.03 - Neoadjuvant Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC: Interim Analysis of ALNEO-GOIRC-01-2020 Phase II Trial

Alessandro Leonetti, Italy

## 14:07 MA01.04 - AFT-46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Linda Martin, USA

## 14:12 MA01.05 - Efficacy and Safety of Neoadjuvant Camrelizumab and Apatinib Combined with Chemotherapy in Stage IIIA (N2) NSCLC: A Single Arm, Phase II Trial

Lilan Zhao, China

## 14:17 Q&amp;A

## 14:25 MA01.07 - Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) +/- Metformin in Locally Advanced NSCLC.

Theodoros Tsakiridis, Canada

## 14:30 MA01.08 - Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial)

Mariano Provencio, Spain

## 14:35 MA01.09 - Definitive Chemoradiation Followed by Immunotherapy vs. Surgery for cT4N2MO NSCLC: A Contemporary Nationwide Analysis.

Jorge Humberto Rodriguez-Quintero, USA (Early Career Education Award Winner)

## 14:40 Q&amp;A

## 14:48 MA01.11 - Unveiling Gene Expression and Immune Contexture in Stage II/III NSCLC Patients Receiving Neoadjuvant Pembrolizumab and Chemotherapy

Yulong Chen, China

## 14:53 MA01.12 - Survival Outcomes and Pathologic Response after Chemo-Immunotherapy in Resectable NSCLC: An Individual Patient Data Meta-Analysis

Daniele Marinelli, Italy



**14:58**    **MA01.13 - Adherence to Treatment Protocol of Patients Submitted to Neoadjuvant (Chemo) Immunotherapy in Resectable NSCLC: Ameta Analysis**  
*Francesco Guerrera, Italy*

**15:03**    **Q&A**

**14:00 - 15:15**    **OA04 - Antibody Drug Conjugates in SCLC**

**Track: Small Cell Lung Cancer and Neuroendocrine Tumors**

**ROOM: 20A**

 ACCME ACCREDITED BY IASLC

*Chairs: Kevin Chua, Singapore and Triparna Sen, USA*

**14:00**    **Welcome & Introduction**

*Kevin Chua, Singapore and Triparna Sen, USA*

**14:02**    **OA04.03 - Ifinotamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01**

*Charles Rudin, USA*

**14:12**    **OA04.04 - Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer**

*Afshin Dowlati, USA*

**14:22**    **OA04.05 - SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate (ADC), in Patients (pts) with Advanced Small-Cell Lung Cancer (SCLC)**

*Jie Wang, China*

**14:32**    **OA04.06 - Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)**

*Jie Wang, China*

**14:42**    **OA04.07 - Discussant**

*Anjali Rohatgi, USA*

**14:52**    **Q&A**

**14:00 - 15:15**    **OA05 - Local Consolidative Therapy for Metastatic NSCLC**

**Track: Metastatic Non-small Cell Lung Cancer – Local Therapies**

**ROOM: 32AB**

 ACCME ACCREDITED BY IASLC

*Chairs: John Cho, Canada and Delphine Antoni, France*

**14:00**    **Welcome & Introduction**

*John Cho, Canada and Delphine Antoni, France*

**14:02**    **OA05.03 - Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial**

*Shuo Yang, China*

**14:12**    **OA05.04 - Radiotherapy Improves Survival in Non-Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study**

*Lauren Brown, Australia*

**14:22**    **OA05.05 - Pre-Local Consolidative Therapy Circulating Circulating Tumor DNA Defines Molecular Oligometastatic Non-Small Cell Lung Cancer**

*Rui Fu, China*

**14:32**    **OA05.06 - Radiotherapy Combined with Enhanced Immunotherapy for NSCLC**

*Chuanwang Miao, China*

**14:42**    **OA05.07 - Discussant**

*Megan Daly, USA*

**14:52**    **Q&A**

## 15:30 - 16:45 ES13 - The Grey Zone for Systemic Therapies in Locally Advanced NSCLC, Defining Practice With Minimal Evidence

Track: Local-Regional Non-small Cell Lung Cancer

ROOM: 32AB

ACCME ACCREDITED BY IASLC

Chairs: Seamus Cotter, Ireland and Ryan Gentzler, USA

### 15:30 Welcome & Introduction

Seamus Cotter, Ireland and Ryan Gentzler, USA

### 15:32 ES13.03 - Optimal Duration of Neoadjuvant And Adjuvant Chemo-IO: When Is Enough?

Greg Durm, USA

### 15:44 ES13.04 - Post-resections Treatment Decisions for Patients Achieving MPR or pCR

Julia Rotow, USA

### 15:56 ES13.05 - Care Considerations with Patients With Locally Advanced Disease and Driver Mutations

Yasuhiro Tsutani, Japan

### 16:08 ES13.06 - How Much Toxicity Can We Tolerate in the Adjuvant and Neoadjuvant Setting?

Enriqueta Felip, Spain

### 16:20 Q&A

## 15:30 - 16:45 ES14 - Combined Pathology-Surgery Session

Track: Pathology and Biomarkers

ROOM: 30DE

ACCME ACCREDITED BY IASLC

Chairs: Ming-Sound Tsao, Canada and Ellen Nascimento, Brazil

### 15:30 Welcome & Introduction

Ming-Sound Tsao, Canada and Ellen Nascimento, Brazil

### 15:32 ES14.03 - Thoracic Surgery for Pathologists- What Pathologists and Other Non-surgeons Need to Know About Different Surgical Resections

Jazmin Eckhaus, Australia

### 15:44 ES14.04 - Pathology for Surgeons - What Surgeons Need to Understand From Pathology

Keith Kerr, UK

### 15:56 ES14.05 - Intraoperative Frozen Sections - Why Do Surgeons Want Them? (Surgeons Perspective)

Nasser Altorki, USA

### 16:08 ES14.06 - Intraoperative Frozen Sections - What Pathologists Can Really Assess and How Reliable Are the Results e.g., Nodes, Pattern, STAS, Margins (Pathologist Perspective)

Natasha Rekhtman, USA

### 16:20 Q&A

## 15:30 - 16:45 ES15 - Global Aspects of Patients Care

Track: Global Health, Health Services, and Health Economics

ROOM: 30A

ACCME ACCREDITED BY IASLC

Chairs: Amy Moore, USA and Navneet Singh, India

### 15:30 Welcome & Introduction

Amy Moore, USA and Navneet Singh, India

- 15:32** **ES15.03 - Burden of Lung Cancer to Patients' Caregivers**  
*Anne-Marie Baird, Ireland*
- 15:44** **ES15.04 - Lung Cancer Patient Advocacy (Experiences)**  
*Jill Feldman, USA*
- 15:56** **ES15.05 - Multi-Disciplinary Approach to Improve Patients Care**  
*Pippa Labuc, Australia*
- 16:08** **ES15.06 - How to Improve Survivors Life (Sexuality, Financial)**  
*Clarissa Mathias, Brazil*
- 16:20** **Q&A**

## 15:30 - 16:45 **ES16 - Chemotherapy in Patients With Driver Mutations**

**Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy**

**ROOM: 20D**

 ACCME ACCREDITED BY IASLC

*Chairs: Roy Herbst, USA and Dolores Isla, Spain*

- 15:30** **Welcome & Introduction**  
*Roy Herbst, USA and Dolores Isla, Spain*
- 15:32** **ES16.03 - Chemotherapy + TKI for Treatment Naive Patients: Evaluating the Data**  
*Solange Peters, Switzerland*
- 15:44** **ES16.04 - Should We Continue TKI Beyond Progression When Starting Chemotherapy?**  
*William William, Brazil*
- 15:56** **ES16.05 - Optimizing Chemotherapy at the Time of Progression on TKI**  
*Delvys Rodriguez-Abreu, Spain*
- 16:08** **ES16.06 - Patient Perspective on Chemotherapy in Patients With EGFR Mutations**  
*Angus Pratt, Canada*
- 16:20** **Q&A**

## 15:30 - 16:45 **ES17 - Metastatic NSCLC as a Chronic Disease - How is Quality of Life Impacted?**

**Track: Metastatic Non-small Cell Lung Cancer – Local Therapies**

**ROOM: 31ABC**

 ACCME ACCREDITED BY IASLC

*Chairs: Daniel Gomez, USA and Andrea Filippi, Italy*

- 15:30** **Welcome & Introduction**  
*Daniel Gomez, USA and Andrea Filippi, Italy*
- 15:32** **ES17.03 - Tobacco Awareness Moment - Persistent Smoking and Treatment Outcomes**  
*Mahdi Sheikh, France*
- 15:35** **ES17.04 - The Impact of Long Term Systemic Treatment on Quality of Life**  
*Ji Bum Lee, USA*
- 15:47** **ES17.05 - The Impact of Surgery on Quality of Life**  
*Cecilia Pompili, UK*
- 15:59** **ES17.06 - The Impact of Radiation Therapy on Quality of Life**  
*Houda Bahig, Canada*
- 16:11** **ES17.07 - Financial Toxicity of Local Treatments for Metastatic Disease**  
*Caitlin Broderick, Australia*
- 16:23** **Q&A**

**15:30 - 16:45**

**ES18 – Debate: Latest and Greatest Multimodality Treatment Options in Early Stage NSCLC**

**Track: Early-Stage Non-small Cell Lung Cancer**

**ROOM: 20A**

 ACCME ACCREDITED BY IASLC

*Debate Moderators: Linda Martin, USA and Mariano Provencio, Spain*

**15:30 Welcome & Introduction**

*Linda Martin, USA and Mariano Provencio, Spain*

**15:32 Let's Start the Debate**

**Neoadjuvant Strategy**

*\*René Horsleben Petersen, Denmark*

*\*Jyoti Patel, USA*

*\*Yasushi Yatabe, Japan*

**Adjuvant Strategy**

*\*Noemí Reguart, Spain*

*\*Tetsuya Mitsudomi, Japan*

*\*Ignacio Wistuba, USA*

**Sandwich Strategy**

*\*Jessica Donington, USA*

*\*Ross Soo, Singapore*

*\*Jan von der Thüsen, Netherlands*

**15:30 - 16:45**

**MA02 - Innovation in Lung Cancer Screening and Early Lung Cancer Detection**

**Track: Screening and Early Detection**

**ROOM: 33ABC**

 NOT FOR CME CREDIT

*Chairs: Ashley Prosper, USA and Nichole Tanner, USA*

**15:30 Welcome & Introduction**

*Ashley Prosper, USA and Nichole Tanner, USA*

**15:32 MA02.03 - Circulating T Cell Receptor Repertoire Analysis Improves Cancer Early Detection**

*Luis Montuenga, Spain*

**15:37 MA02.04 - High Detection Rate of Blood MicroRNA Test in Lung Cancer Screening Eligible Individuals**

*Gabriella Sozzi, Italy*

**15:42 MA02.05 - Inter-Reader Agreement of AI Versus Human Readers in Baseline LDCT Lung Nodule Classification; A UKLS Trial Dataset Sub-Study**

*Harriet Lancaster, Netherland (Early Career Education Award Winner)*

**15:47 Q&A**

**15:55 MA02.07 - AI as Primary Reader in 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Impact on Negative Misclassification and Referral Rate**

*Anna Walstra, Netherland (Early Career Education Award Winner)*

**16:00 MA02.08 - Performance of A Blood-based Protein Biomarker Panel in the National Lung Screening Trial**

*Edwin Ostrin, USA*

**16:05 MA02.09 - An Effective Multimodel Based on Cell-Free DNA Methylation for Risk Stratification of Pulmonary Nodules**

*Jian-Bing Fan, China*

- 16:10 Q&A**
- 16:18 MA02.11 - Validation of the Sybil Deep Learning Lung Cancer Risk Prediction Model in Three Independent Screening Studies**  
*Renzo Phellan Aro, Canada*
- 16:23 MA02.12 - UC Screen California: A Statewide Participatory Informatics Approach to Lung Cancer Screening**  
*Amy Cummings, USA*
- 16:28 MA02.13 - Deep Learning-Based Multiomic Model for Lung Cancer Diagnosis**  
*Mengmeng Zhao, China*
- 16:33 Q&A**

## 15:30 - 16:45 OA06 - Novel Immunotherapy Strategies and Combinations

**ROOM: 20BC**

 ACCME ACCREDITED BY IASLC

*Chairs: Cheryl Ho, Canada and Anil Tibdewal, India*

- 15:30 Welcome & Introduction**  
*Cheryl Ho, Canada and Anil Tibdewal, India*
- 15:32 OA06.03 - SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1**  
*Yi-Long Wu, China*
- 15:42 OA06.04 - Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up**  
*Melina Marmarelis, USA*
- 15:52 OA06.05 - IL15 Superagonist (N-803, Anktiva) + Checkpoint Inhibitor (CPI) Prolongs OS in 2ndline or Greater NSCLC Patients Failing CPI**  
*John Wrangle, USA*
- 16:02 OA06.06 - Discussant**  
*Aaron Tan, Singapore*
- 16:12 Q&A**

## 15:30 - 16:45 OA07 - Opportunities for Optimizing Supportive Care

**Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care**

**ROOM: 30BC**

 ACCME ACCREDITED BY IASLC

*Chairs: Lucia Viola, Colombia and Tomi Kovacevic, Serbia*

- 15:30 Welcome & Introduction**  
*Lucia Viola, Colombia and Tomi Kovacevic, Serbia*
- 15:32 OA07.03 - The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients**  
*Yuan Yuan, China*
- 15:42 OA07.04 - Optimising Care of Older Patients with Lung Cancer - An Innovative Nurse-led Model of Care**  
*Shalini Vinod, Australia*
- 15:52 OA07.05 - Improving Supportive and Social Care in Lung Cancer with the 4R Oncology Model for Patient Care Planning and Delivery**  
*Mary Pasquinelli, USA*
- 16:02 OA07.05 - Phase 3 Study of HR20013 For Prevention of Cisplatin-based Chemotherapy-induced Nausea and Vomiting (PROFIT Study)**  
*Li Zhang, China*

**16:12**    **OA07.07 - Discussant**  
*Darcy Burbage, USA*

**16:22**    **Q&A**

**16:00 – 17:00**    **JTO/JTO CRR Editorial Reception**  
**BY INVITATION ONLY**

**TERRACE OUTSIDE ROOM 29**

 **REFRESHMENTS PROVIDED**

**17:00 - 18:15**    **Special Plenary Session: Celebrating 50 Years of the IASLC,  
 Legacy of Impact, Future of Promise**

**PLENARY HALL**

 **NOT FOR CME CREDIT**

 **LIVESTREAMED**

Join us for a special plenary session commemorating 50 years of IASLC, where we will reflect on past achievements in lung cancer treatment and detection and IASLC's role, celebrate current advancements, and together shape the future of lung cancer research and treatment.

**18:15 – 19:45**    **Poster Viewing Networking Reception (Poster Session 2: P2)  
 with Presenters in Attendance**

**EXHIBIT HALL**

 **REFRESHMENTS PROVIDED**

*Note: All P2 Posters will be on display the entire day on Sunday.*

**18:30 – 19:15**    **Poster Tours**

**EXHIBIT HALL/EPOSTER LOUNGE AND EXHIBIT SHOWCASE THEATER**

**Note:** Each Poster Tour will include 4 – 5 Poster (8min per Poster: 3min presentation by the Poster Presenter, followed by 2min Discussion by the Poster Lead and 3min Audience Q&A).

**Poster Tour 1:** PT01.01 - Risk Factors, Risk Reduction & Tobacco Control

**Tour Lead:** Abhishek Shankar, India

**18:30**    **PT01.01.02 - Real-World Data on 3-Year Survival in Non-Small Cell Lung Cancer  
 (NSCLC): Results from 3 French Nationwide Cohorts from 2000 To 2020**  
*Didier Debieuvre, France*

**18:38**    **PT01.01.03 - Racial Disparities Among Patients Diagnosed with Lung Cancer at a  
 Young Age**  
*Aysswarya Manoharan, USA*

**18:46**    **PT01.01.04 - Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk  
 in Treatment-Naïve Type 2 Diabetes: Potential Impact of Obesity and Gender**  
*Junmin Song, USA*

**18:54**    **PT01.01.05 - Effectiveness of Health Education on Adolescent Tobacco Use  
 Intention: Cluster RCT in Ibadan, Nigeria**  
*Omotayo Fagbule, Nigeria*

**19:02**    **PT01.01.06 - Disparities in Lung Cancer Risk Assessment for People Living with HIV**  
*Savanah Hardcastle, USA*

**Poster Tour 2:** PT01.02 - Tumor Biology - Preclinical Biology

**Tour Lead:** Jianjun Jay Zhang, USA

**18:30**    **PT01.02.01 - ADAR1 Regulates Tumorigenesis and Stem Cell Properties in  
 Non-Small Cell Lung Carcinoma**  
*Manish Patel, USA*

- 18:38** **PT01.02.02 - Long Non-Coding RNA STEAP2-AS1 Promotes Non-Small-Cell Lung Cancer Cells Progression by Interacting with ARNTL2 To Upregulate DARS2**  
*Huan Zhang, China*
- 18:46** **PT01.02.03 - Mirnome Functional Profiling of Non-Small Cell Lung Cancer Identified New Mechanisms of PD-L1 Regulation**  
*Fabrizio Bianchi, Italy*
- 18:54** **PT01.02.04 - High-Dose Ascorbic Acid Sensitizes Immunotherapy in LKB1-Deficient Lung Cancer by Promoting Tumor Cell Pyroptosis**  
*Xiaoting Cai, China*

**Poster Tour 3:** PT01.04 - Screening and Early Detection

**Tour Lead:** Hari Balaji Keshava, USA

- 18:30** **PT01.04.02 - Pixel-Wise Pulmonary Nodule Growth Prediction on Low-Dose Computed Tomography with 3D-ConvLSTM Deep Neural Network**  
*Xing Lu, China*
- 18:38** **PT01.04.03 - Barriers to Maximal Screening Impact in Persons Diagnosed with Lung Cancer in a Prospective Cohort**  
*Osa Ogbeide, USA*
- 18:46** **PT01.04.04 - Community Outreach for Lung Cancer Screening Awareness: Utilizing the 'Cancer Challenge' to Educate the Public**  
*Dusty Donaldson, USA*
- 18:54** **PT01.04.05 - Exhaled VOC Detection in Lung Cancer Screening: A Comprehensive Meta-Analysis**  
*Xianzhe Fan, China*
- 19:02** **PT01.04.06 - Efficiency of the Annual CT Screening Interval for Those at a Lower Risk of Lung Cancer - A CISNET Comparative Modelling Study**  
*Kevin ten Haaf, Netherlands*

**Poster Tour 4:** PT01.07 - Early Stage Non-small Cell Lung Cancer

**Tour Lead:** Delphine Antoni, France

- 18:30** **PT01.07.02 - Clinical Relevance of PD-L1 Expression Levels in Surgically Resected EGFR-Mutant Lung Adenocarcinoma Patients (CREGYT-01 Study)**  
*Fumihiko Kinoshita, Japan*
- 18:38** **PT01.07.03 - A Revised International Association for the Study of Lung Cancer Grading System: The Inclusion of Invasive Mucinous Adenocarcinomas**  
*Hanyue Li, China*
- 18:46** **PT01.07.04 - Neoadjuvant Osimertinib Followed by Radiation And/or Surgery in Stage III EGFR-Mutant NSCLC: An Open-Label, Single-Arm, Phase 2 Study**  
*Nir Peled, Israel*
- 18:54** **PT01.07.05 - Oncological Outcomes after Lobe-Specific Mediastinal Lymph Node Dissection in Thoracoscopic Right Upper Lobectomy for Clinical NO NSCLC**  
*Mingyon Mun, Japan*
- 19:02** **PT01.07.06 - Is Wedge Resection Really Enough for the Treatment of Patient with Stage I Non-Small Cell Lung Cancer? A SEER Database Analysis**  
*Luigi Ventura, UK*

**Poster Tour 5:** PT01.09 - Metastatic Non-small Cell Lung Cancer - Local Therapies

**Tour Lead:** Matthias Guckenberger, Switzerland

- 18:30** **PT01.09.02 -Surgical Reduction at the Peak of Response Before Disease Progression in Patients with Metastatic EGFR-Mutated Lung Cancer**  
*Daniil Stroyakovskiy, Russian Federation*

- 18:38** **PT01.09.03 - The Effectiveness of Split-course Stereotactic Body Radiation Therapy in Treating Large Thoracic Cancer**  
*SiQi Tian, China*
- 18:46** **PT01.09.04 - A Multicenter, Randomized, Phase II Trial of EGFR TKI with Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients**  
*Pei-Hsing Chen, Taiwan*
- 18:54** **PT01.09.05 - Pathologic Tumor Positivity vs Only Necrosis in Clinically Suspected Recurrent Brain Metastasis Post-Radiation**  
*Rupesh Kotecha, USA*
- 19:02** **PT01.09.06 - Double Lung Transplantation in Patients with Metastatic Lung-limited Non-Small Cell Lung Carcinoma (NSCLC)**  
*Young Chae, USA*

**Poster Tour 6:** PT01.11 - Metastatic Non-small Cell Lung Cancer - Immunotherapy  
**Tour Lead:** TBC

- 18:30** **PT01.11.02 - Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy**  
*Roberto Ferrara, Italy*
- 18:38** **PT01.11.03 - Exhaled Breath Biomarkers of Response to Immunotherapy in Advanced Non-Small Lung Cancer**  
*David O Reilly, Ireland*
- 18:46** **PT01.11.04 - Trial in Progress: Phase 1/2 Study of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Solid Tumors**  
*Adam Schoenfeld, USA*
- 18:54** **PT01.11.05 - First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial**  
*Yang-Si Li, China*
- 19:02** **PT01.11.06 - Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade**  
*Biagio Ricciuti, USA*

**Poster Tour 7:** PT01.13 - Small Cell Lung Cancer and Neuroendocrine Tumors  
**Tour Lead:** Aaron Tan, Singapore

- 18:30** **PT01.13.02 DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer**  
*Afshin Dowlati, USA*
- 18:38** **PT01.13.03 - Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial**  
*Maurice Perol, France*
- 18:54** **PT01.13.04 - Clinical Outcomes of Transformed Small-Cell Lung Cancer Versus Extensive Primary Small-Cell Lung Cancer**  
*Lina Chen, China*
- 19:02** **PT01.13.05 - Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (Ifinatamab Deruxtecan) in Extensive Stage SCLC Patients**  
*Narasimha Midde, USA*

**Poster Tour 8:** PT01.15 - Multidisciplinary Care: Nursing, Allied Health and Palliative Care  
**Tour Lead:** Ludmila Svoboda, USA

- 18:30** **PT01.15.02 - Association Between Emotional Distress and Immunotherapy Response in Advanced NSCLC (STRESS-LUNG-1): Biomarkers Exploratory Analyses**  
*Fang Wu, China*



- 18:38**    **PT01.15.03 - The Lung Cancer Stigma Communications Assessment Tool: Supporting Engagement with the Lung Cancer Community**  
*Jamie Studts, USA*
- 18:46**    **PT01.15.04 - Efficacy of Digital Therapeutics for the Perioperative Management in Patients with Lung Cancer: A Randomized Controlled Trial**  
*Jinming Xu, China*
- 18:54**    **PT01.15.05 - Remote Exercise Program for Patients with Lung Cancer on Immune Checkpoint Inhibitors**  
*Paulo Bergerot, Brazil*

**Poster Tour 9:** PT01.17 - Global Health, Health Services, and Health Economics

**Tour Lead:** Pedro Aguiar Jr., Brazil

- 18:30**    **PT01.17.02 - Effective EGFR Testing Rates in Advanced Stage NSCLC Patients Treated in Community Oncology Practices: Impact of a Decision Support Program**  
*Ray Page, USA*
- 18:38**    **PT01.17.03 - Clinical Trial Enrollment at a Thoracic Oncology Program at a Single-Academic Institution Serving Primarily Underrepresented Patients**  
*Frank Weinberg, USA*
- 18:46**    **PT01.17.04 - Treatment Outcomes after Access to Broad Molecular Tests, Targeted Agents and Immunotherapy in NSCLC Patients from Brazil**  
*Filipe Visani, Brazil*
- 18:54**    **PT01.17.05 - The Construction and Application of a Novel Precise Health Management Model for Lung Nodule Population**  
*Dahai Liu, China*
- 19:02**    **PT01.17.06 - Sociodemographic and Clinical Predictors of Diagnosis of Lung Cancer in the Emergency Department in a Large, Integrated Health System**  
*Meera Ragavan, USA*

## **18:30 – 19:30**    **Industry Sponsored Symposium**

*See page 242 for more information.*

## **20:00 - 23:00**    **IASLC 50th Anniversary Celebration** **(Ticketed Event)**

### **GASLAMP QUARTER**

Join us in the heart of San Diego's historic Gaslamp Quarter just minutes away from the Convention Center and all WCLC hotels as we celebrate the 50 Year Anniversary of IASLC with an unforgettable block party! Wander through the streets transformed to represent the five past decades of IASLC's groundbreaking work, indulge in delicious food, groove to live music, partake in lively games and activities, and enjoy time with friends and colleagues from all around the world.

**Dress to impress - join us in your favorite outfit from the 70s, 80s or 90s!**

# STARS



IASLC Supportive Training for Advocates on Research & Science

# IASLC is Proud to Support the 2024 STARS Scholars

Sydney Barned | USA

John Cannings | Australia

Yvonne Diaz | UK

Anita McGrath | Australia

Tim Monds | Canada

James Pantelas | USA

Jane Perlmutter | USA

Emily Venanzi | USA

Christine Wu | Canada



1974-2024

Conquering Lung & Thoracic Cancers  
Worldwide in the 21st Century

# IASLC Strategic Plan 2024-2029

Explore the IASLC Strategic Plan 2024-2029.

Discover our visionary goals, innovative strategies, and transformative initiatives.

**Discover | Collaborate | Transform!**



Scan the QR Code to Learn More.



**2025 Targeted Therapies  
of Lung Cancer Meeting**

**FEBRUARY 19-22, 2025 | HUNTINGTON BEACH, CA**

# **SAVE THE DATE**

*February 19-22, 2025*

**#TTLC25**



# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

# VISIT THE MEMBER LOUNGE

Exhibit Hall Booth #1810



- Complimentary headshots for IASLC members
- Networking
- Committee Corner  
September 8 & 9  
10:00 - 10:45

SEPTEMBER 7-10, 2024 • SAN DIEGO, CALIFORNIA • IASLC 2024 WORLD CONFERENCE ON LUNG CANCER



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

# Join the IASLC Today!



Scan the QR code & enter  
**WCLCNewMember2024**  
to receive half off membership  
dues for your first year.

## Join Now and Start Enjoying These Benefits:

Scientific Expertise • Research & Education • ILCN  
Grant Opportunities • Committees • Podcasts  
Lung Cancer 360 • Membership  
Patient Advocacy • Staging  
Networking • Publications •  
IASLC Meeting Discounts  
IASLC Journals





04 / PROGRAM:  
SEPTEMBER 9

SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM





# Need Funding?



IASLC's Research Grants program funds Fellows, Young Investigators, and Mid-Career Researchers.



<https://bit.ly/IASLCgrantprogram>

# IASLC Education Center: Lung Cancer 360

## YOUR NEW GO-TO DESTINATION FOR ONLINE MULTIDISCIPLINARY EDUCATION

THE IASLC EDUCATION CENTER



**LUNG  
CANCER  
360**

The screenshots illustrate the platform's offerings, including microlearning modules, KOL Knockout™ courses, and conference attendee access. Each interface includes a 'Create Account' button and a 'Login' button.

### NOW ONLINE!



- Online courses and simulations
- Microlearning modules
- IASLC conference materials
- Webinar recordings
- Patient Advocacy resources
- JTO, JTO CRR, & ILCN

# LUNG CANCER CONSIDERED



IS AVAILABLE IN MANY LANGUAGES!

ESPAÑOL FRANÇAIS

ΕΛΛΗΝΙΚΑ עִבְרִית

DEUTSCH NEDERLANDS

MAGYAR 普通話 日本語

한국인 ITALIANO POLSKI

Join us in listening to our award winning content  
on your favorite app.



Find new podcast  
episodes here.



Lung Cancer Considered is  
funded in part by:  
**AstraZeneca,  
Daiichi-Sankyo  
& Takeda**



**04 / Conference Program**

**SCIENTIFIC PROGRAM / MONDAY, SEPTEMBER 9**

<b>DEI</b>	DE&I Session	<b>MTE</b>	Interactive Meet the Expert Session (Breakfast Provided, Limited Capacity)
<b>EP</b>	ePosters	<b>OA</b>	Oral Abstract Session
<b>ES</b>	Education Session	<b>P</b>	Posters
<b>EXH</b>	Exhibit Showcase	<b>PL</b>	Plenary Session
<b>HOD</b>	Highlight of the Day Session	<b>WS</b>	Workshop
<b>IS</b>	Industry Supported or Satellite CME Symposia		
<b>MA</b>	Mini Oral Abstract Session		

**07:30 - 08:15 HOD01 - Highlights of the Day - Sunday Abstracts**

**ROOM: 20A**



**BREAKFAST PROVIDED**



**ACCME ACCREDITED BY IASLC**

- 07:30 HOD01.01 - Cutting-Edge Innovations in mNSCLC: The Latest in Local and Targeted Therapies**  
*Carlos Ferreira, Brazil*
- 07:40 HOD01.02 - Harnessing the Immune System with Therapies for mNSCLC and the Latest Research in SCLC and NET**  
*Christian Rolfo, USA*
- 07:50 HOD01.03 - Moving Therapies to Early and Local-Regional NSCLC: Pioneering Progress in Lung Cancer**  
*Paula Ugalde Figueroa, USA*
- 08:00 HOD01.04 - Transforming Lung Cancer Outcomes: Advances in Screening and Early Detection, Comprehensive Care in Nursing, Allied Health, and Palliative Care, and Decoding Lung Cancer in Pathology and Biomarker Research**  
*Jacob Sands, USA*

**07:30 - 08:15 MTE07 - Putting Evidence Into Practice**

**Track: Early-Stage Non-small Cell Lung Cancer**

**ROOM: 31ABC**



**BREAKFAST PROVIDED**



**ACCME ACCREDITED BY IASLC**

- 07:30 MTE07.01 - Early Stage Lung Cancer will Become the Domain of Medical Oncology**  
*Logan Walsh, Canada*
- 07:45 MTE07.02 - Early Stage Lung Cancer will Always be Dominated by Surgery**  
*Isabelle Opitz, Switzerland*
- 08:00 Q&A**

**07:30 - 08:15 MTE08 - Radiological Challenges in Lung Cancer**

**Track: Pulmonology and Staging**

**ROOM: 30BC**



**BREAKFAST PROVIDED**



**ACCME ACCREDITED BY IASLC**

- 07:30 MTE08.01 - Radiological Challenges in the Uniform Application of TNM Staging of NSCLC**  
*Ioannis Vlahos, USA*
- 07:45 MTE08.02 - AI in Lung Cancer Radiology**  
*Constance de Margerie-Mellon, France*
- 08:00 Q&A**

**07:30 - 08:15 MTE09 - Patient Research Advocates Contributions to Research**

Track: Patient Advocacy

**ROOM: 30A** **BREAKFAST PROVIDED** **ACCME ACCREDITED BY IASLC****07:30 MTE09.01 - Equal Partnership with Patient Research Advocates***Merel Hennink, Netherlands***07:45 MTE09.02 - Patient Involvement for Impactful Research***Anthonie van der Wekken, Netherlands***08:00 Q&A****07:30 - 08:15 MTE10 - Quiz Show: Do You Know Your Targets?**

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

**ROOM: 33ABC** **BREAKFAST PROVIDED** **ACCME ACCREDITED BY IASLC***Host: Stephen Liu, USA**Contestants: Natasha Leighl, Canada and Ben Solomon, Australia***07:30 - 08:15 MTE11 - Drugging the Undruggable - Lessons Learnt from Targeting KRAS Driven Lung Cancers**

Track: Tumor Biology – Translational Biology

**ROOM: 30DE** **BREAKFAST PROVIDED** **ACCME ACCREDITED BY IASLC****07:30 MTE11.01 - Biology of KRAS Driven Cancers, Vulnerabilities, and Resistance***Miriam Molina-Arcas, UK***07:50 MTE11.02 - Too Many Choices? Pan vs Allele Specific KRAS Inhibitors***Piro Lito, USA***08:10 Q&A****07:30 - 08:15 MTE12 - Occupational Exposure & Lung Cancer**

Track: Risk Factors, Risk Reduction &amp; Tobacco Control

**ROOM 32AB** **BREAKFAST PROVIDED** **ACCME ACCREDITED BY IASLC****07:30 MTE12.01 - Occupational Exposure and Lung Cancer - Canada Carex***Paul Demers, Canada***08:30 - 10:00 Presidential Symposium 2****PLENARY HALL** **LIVESTREAMED** **ACCME ACCREDITED BY IASLC***Chairs: Caicun Zhou, China and Heather Wakelee, USA***08:30 Welcome & Introduction***Caicun Zhou, China and Heather Wakelee, USA***08:32 PL04.02 - Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohorts from the Phase I/II SOHO-01 Study***Xiuning Le, USA***08:39 PL04.04 - Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC***Gerrina Ruiter, Netherlands***08:46 PL04.05 - Discussant***Chee Lee, Australia***08:53 Q&A**

**08:58** **PL04.07 - FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations**  
*Jie Wang, China*

**09:05** **PL04.08 - Discussant**  
*Alfredo Addeo, Switzerland*

**09:12** **Q&A**

**09:17** **PL04.10 - Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial**  
*Jinji Yang, China*

**09:24** **PL04.11 - Discussant**  
*Paul Paik, USA*

**09:31** **Q&A**

**09:36** **PL04.13 - Aumolertinib Maintenance after Chemoradiotherapy in stage III Non-Small-Cell Lung Cancer: Interim Results of the phase III study (POLESTAR)**  
*Xiangjiao Meng, China*

**09:43** **PL04.14 - Discussant**  
*Fiona Hegi-Johnson, Australia*

**09:50** **Q&A**

**10:00 – 10:45** **Coffee Break**

**EXHIBIT HALL**

 **REFRESHMENTS PROVIDED**

*Engage with IASLC Committee Chairs and Members in the Committee Corner in the IASLC Member Lounge in the Exhibit Hall. You can meet the following committees:*

- Communications
- Membership
- Career Development
- Nurses and Allied Health Professionals
- Patient Advocates
- Education
- Global Policy and Partnerships

**10:05 - 11:05** **Press Conference**

**ROOM: 26B**

 **NOT FOR CME CREDIT**

**10:45 - 12:00** **ES19 - Mesothelioma, Thymoma, and Other Thoracic Tumors**

**Track: Mesothelioma, Thymoma, and Other Thoracic Tumors**

**ROOM: 30BC**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Prasad Adusumilli, USA and Sonja Klebe, Australia*

**10:45** **Welcome & Introduction**  
*Prasad Adusumilli, USA and Sonja Klebe, Australia*

**10:47** **ES19.03 - Radiation Approaches in Thymic Malignancies**  
*Flavia Gabrielli, Brazil*

**10:59** **ES19.04 - Heterogeneity in Thymoma: Challenges and Pitfalls in Diagnosis**  
*TBC*

**11:11** **ES19.05 - Thymectomy in Myasthenia Gravis**  
*Josh Sonett, USA*

**11:23** **ES19.06 - Self-Learning AI as a Diagnostic and Discovery Tool in Malignant Mesothelioma**  
*John Le Quesne, UK*

**11:35** **Q&A**

**10:45 - 12:00 ES20 - Expanding Eligibility for Lung Cancer Screening****Track: Screening and Early Detection****ROOM: 33ABC** ACCME ACCREDITED BY IASLC*Chairs: Chi-Fu Jeffrey Yang, USA and Annette McWilliams, Australia***10:45 Welcome & Introduction***Chi-Fu Jeffrey Yang, USA and Annette McWilliams, Australia***10:47 ES20.03 - Defining Eligibility for Lung Cancer Screening in Asia***Wenhua Liang, China***10:59 ES20.04 - Expanding Lung Cancer Screening Eligibility to Individuals Who Have Never Smoked in the US***Elaine Shum, USA***11:11 ES20.05 - Lung Cancer Screening Among Individuals with Light Smoking Histories***Anna Kerpel-Fronius, Hungary***11:23 ES20.06 - Tobacco Awareness Moment - Smoking Cessation in Lung Cancer Screening***Randi William, USA***11:26 ES20.07 - Lung Cancer Screening Among Individuals with Occupational Exposure***Erica Warner, USA***11:38 Q&A****10:45 - 12:00 ES21 - Patient Navigation and Social Justice: Case Presentation****Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care****ROOM: 30A** ACCME ACCREDITED BY IASLC*Chairs: Sada Ikeda, Japan and Stephanie McDonald, USA***10:45 Welcome & Introduction***Sada Ikeda, Japan and Stephanie McDonald, USA***10:47 ES21.03 - Increased Access for Clinical Trials for Black Americans and Building Clinical Access Pathways in Historically Marginalized Communities in Boston***Barry Nelson, USA***11:03 ES21.04 - Access to Life-Saving Drugs in LMIC***Magda Louis-Juste, Haiti***11:19 ES21.05 - Building Patient Navigation Programs in Central America***Rachel Allende, USA***11:35 ES21.07 - Navigation and Social Justice Panel***Moderator: Ludmila Svoboda, USA**Panelists: Barry Nelson, USA, Magda Louis-Juste, Haiti, Rachel Allende, USA***10:45 - 12:00 ES22 - Novel Immunotherapeutics: Raising the Bar****Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy****ROOM: 20BC** ACCME ACCREDITED BY IASLC*Chairs: Luis Raez, USA and Delvys Rodriguez-Abreu, Spain***10:45 Welcome & Introduction***Luis Raez, USA and Delvys Rodriguez-Abreu, Spain***10:47 ES22.03 - Cancer Vaccines and Oncolytic Viruses***Charu Aggarwal, USA*

**10:59** **ES22.04 - CAR-T Cells in Metastatic NSCLC**  
*Ben Creelan, USA*

**11:11** **ES22.05 - Novel Immunotherapies**  
*Wen-Zhao Zhong, China*

**11:23** **ES22.06 - Targeting the TME**  
*Alfredo Addeo, Switzerland*

**11:35** **Q&A**

## **10:45 - 12:00** **ES23 - Preclinical Evaluation of Exposure to Air Contaminants**

**Track: Tumor Biology – Preclinical Biology**

**ROOM: 30DE**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Tracy Leong, Australia and Joachim Aerts, Netherlands*

**10:45** **Welcome & Introduction**  
*Tracy Leong, Australia and Joachim Aerts, Netherlands*

**10:47** **ES23.03 - Preclinical Models to Explore Environmental Exposure and Lung Cancer Initiation**  
*Clare Weeden, UK*

**10:59** **ES23.04 - Effect of Air Pollution in Developing Countries and the Role of Molecular Profiling in Detection and Screening**  
*Upal Basu Roy, USA*

**11:11** **ES23.05 - Ancestry, Germline Alterations and Air Pollution in Lung Cancer Evolution**  
*Tikvahk Hayes, USA*

**11:23** **ES23.06 - Molecular Aberrations Induced by Environmental Exposure That Drive Lung Carcinogenesis**  
*Guang-Biao Zhou, China*

**11:35** **Q&A**

## **10:45 - 12:00** **ES24 - Novel Immunotherapy Options for Patients with Neuroendocrine Tumors**

**Track: Small Cell Lung Cancer and Neuroendocrine Tumors**

**ROOM: 32AB**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Lynnette Fernandez-Cuesta, France and Jeffrey Ward, USA*

**10:45** **Welcome & Introduction**  
*Lynnette Fernandez-Cuesta, France and Jeffrey Ward, USA*

**10:47** **ES24.03 - Exploring Biomarkers for Immunotherapy in SCLC/NET**  
*Kate Sutherland, Australia*

**10:59** **ES24.04 - Targeting DLL3 in Lung NETs: BiTEs, ADCs and Beyond**  
*Martin Wermke, Germany*

**11:11** **ES24.05 - Other Novel Immunotherapy Combinations in SCLC**  
*Sally Lau, USA*

**11:23** **ES24.06 - Treatment Considerations for Patients diagnosed with Small Cell Lung Cancer with Pre-existing ILD**  
*Daichi Fujimoto, Japan*

**11:35** **Q&A**



**10:45 - 12:00 MA03 - The Science of Sublobar Resection****Track: Early-Stage Non-small Cell Lung Cancer****ROOM: 31ABC****NOT FOR CME CREDIT***Chairs: Paula Ugalde, USA and Enrico Ruffini, Italy***10:45 Welcome & Introduction***Paula Ugalde, USA and Enrico Ruffini, Italy***10:47 MA03.03 - The Impact of AI-driven 3D Reconstruction on Pulmonary Surgery Planning (AIR-SURGE): A Multi-Center Multi-Reader Multi-Case Study***Xiuyuan Chen, China***10:52 MA03.04 - A Deep Learning Model to Predict Occult Lymphatic Metastasis in Clinical Stage I Non-Small Cell Lung Cancer Based on Chest CT***Yuanyuan Fu, China***10:57 MA03.05 - Intraoperative Visualization of Pulmonary Nodules with Indocyanine Green Inhalation Under Near-Infrared Window I and II***Hao Xu, China***11:02 Q&A****11:10 MA03.07 - Outcomes of Older Patients in CALGB 140503 (Alliance): Lobar vs Sublobar Resection for Peripheral Stage IA Non-Small Cell Lung Cancer***Apar Kishor Ganti, USA***11:15 MA03.08 - Differential Impact of Sublobar Resection on Visceral Pleural Invasion Classification***Sang Jun Lee, Republic of Korea***11:20 Q&A****11:28 MA03.10 - Association of Surgical Margin Distance, Locoregional Recurrence, and Survival Among Patients Undergoing Sublobar Resection in CALGB140503***Linda Marin, USA***11:33 MA03.11 - Postoperative Complications Compromised Disease-Free and Recurrence-Free Survival in CALGB 140503 Trial Patients***Daniel Miller, USA***11:38 Q&A****10:45 - 12:00 OA08 - The New Generation of Cytotoxics****Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy****ROOM: 20A****ACCME ACCREDITED BY IASLC***Chairs: Kirsty Lee, Hong Kong and Aakash Desai, USA***10:45 Welcome & Introduction***Kirsty Lee, Hong Kong and Aakash Desai, USA***10:47 OA08.03 - Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01***Jacob Sands, USA***10:57 OA08.04 - Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial***Trevor Feinstein, USA***11:07 OA08.05 - Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial***Benjamin Besse, France*

- 11:17**    **OA08.06 - Sacituzumab Govitecan with Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)-containing Regimen: EVOKE-01**  
*Marina Garassino, USA*
- 11:27**    **OA08.07 - Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study**  
*Jhanelle Gray, USA*
- 11:37**    **OA08.08 - Discussant**  
*Saiama Waqar, USA*
- 11:47**    **Q&A**

**10:45 - 12:00**    **OA09 - Trailblazing Targets: New Insights**

**ROOM: 20D**  ACCME ACCREDITED BY IASLC

*Chairs: Julie Brahmer, USA and Lorenza Landi, Italy*

- 10:45**    **Welcome & Introduction**  
*Julie Brahmer, USA and Lorenza Landi, Italy*
- 10:47**    **OA09.03 - Randomized, Open-Label, Phase III Study of SAF-189s Versus Crizotinib in First-Line ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)**  
*Anwen Ziong, China*
- 10:57**    **OA09.04 - Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs**  
*Cheryl Ho, Canada*
- 11:07**    **OA09.05 - Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study**  
*Mariam Alexander, USA*
- 11:17**    **OA09.06 - Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12**  
*Enriqueta Felip, Spain*
- 11:27**    **OA09.07 - Discussant**  
*Jessica Lin, USA*
- 11:37**    **Q&A**

**12:00 - 14:00**    **Poster Viewing Lunch (Poster Session 3: P3) with Presenters in Attendance**

**EXHIBIT HALL**  LUNCH PROVIDED

*Note: All P3 Posters will be on display the entire day on Monday.*

**12:30 - 13:30**    **HW01 - Navigating the Emotional Aftermath of Challenging Patient Outcomes**

**ROOM: 22**  LUNCH PROVIDED  NOT FOR CME CREDIT

*Mark Lewis, USA and Micheal Maddaus, USA*

**Special guests will make an appearance at this important session.**

**12:30 - 13:30**    **Concurrent Satellite CME Symposia**

*See page 246 for more information.*

**12:30 – 13:30 Industry Sponsored Symposium**

See page 245 for more information.

**14:00 – 15:00 Meet the Editors****ROOM: 26B**

Join JTO Editor-in-Chief Alex A. Adjei and JTO CRR Editor-in-Chief Emily Stone for a Meet-the-Editors. This session is open to all WCLC attendees.

**14:00 - 15:15 ES25 - Latest and Greatest: Practice Updates in the Management of Early Stage Lung Cancers****Track: Early-Stage Non-small Cell Lung Cancer****ROOM: 31ABC**

Chairs: Eldsamira Mascarenhas, Brazil and Ricardo Terra, Brazil

**14:00 Welcome & Introduction**

Eldsamira Mascarenhas, Brazil and Ricardo Terra, Brazil

**14:02 ES25.03 - Tobacco Awareness Moment - How You Can Help Reduce Smoking in Your Country**

Lekan Ayo-Yusef, South Africa

**14:05 ES25.04 - Medical Oncology in the Early Stage Space: Should There Be a Role**

Lorenza Landi, Italy

**14:17 ES25.05 - Advances in Adaptive Radiotherapy in the Treatment of Early Stage NSCLC**

Suresh Senan, Netherlands

**14:29 ES25.06 - Selecting the Ideal Operation for the Early Stage Patient**

Yasuhiro Tsutani, Japan

**14:41 ES25.07 - How Patients Assess Their Treatment in a Constantly Changing Environment**

Anita McGrath, Australia

**14:53 Q&A****14:00 - 15:15 ES26 - Augmented Techniques for Lung Cancer Diagnosis Prognosis and Predicting Response****Track: Pulmonology and Staging****ROOM: 30BC**

Chairs: Jeremy Erasmus, USA and Jacob Scott, USA

**14:00 Welcome & Introduction**

Jeremy Erasmus, USA and Jacob Scott, USA

**14:02 ES26.03 - Augmented Imaging Techniques for Peripheral Nodules**

Carrie Leong, Singapore

**14:14 ES26.04 - Prognosis of Newly Diagnosed Lung Cancer Beyond Imaging - Textural Analysis and Use of AI**

Ella Kazerooni, USA

**14:26 ES26.05 - Predicting NSCLC Response to Radiotherapy Based on Baseline Metabolism and How to Optimize Radiotherapy Accordingly**

Zeno Gouw, Netherlands

**14:38** ES26.06 - Radiomics in Thoracic Oncology: Challenges and Opportunities  
*Jose Araujo-Filho, Brazil*

**14:50** Q&A

## 14:00 - 15:15 ES27 - Patient Advocates Perspectives: Impact of Care and Connection on Patient Outcomes

Track: Patient Advocacy

**ROOM: 30A**

 ACCME ACCREDITED BY IASLC

*Chairs: Janet Freeman-Daily, USA and Caleb Egwuenu, Nigeria*

**14:00** Welcome & Introduction

*Janet Freeman-Daily, USA and Caleb Egwuenu, Nigeria*

**14:02** ES27.03 - Tobacco Awareness Moment - Why It Is Important to Address Cessation if the Patient Is Still Smoking

*Rachel Murray, UK*

**14:05** ES27.04 - Financial Toxicity on Patient Outcomes

*Kimoni Ikutegbe, Nigeria*

**14:17** ES27.05 - Patient-Provider Disconnection on Patient Outcomes

*Stefania Vallone, Italy*

**14:29** ES27.06 - Impact of Not Including Patient Research Advocates

*Janet Freeman-Daily, USA*

**14:41** ES27.07 - Palliative Care on Quality of Life and Patient Outcomes

*Elad Rubinstein, Israel*

**14:53** Q&A

## 14:00 - 15:15 ES28 - Management of Brain Metastases in Oncogene Driven NSCLC

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

**ROOM: 20D**

 ACCME ACCREDITED BY IASLC

*Chairs: Dasantha Jayamanne, Australia and Li Yu, China*

**14:00** Welcome & Introduction

*Dasantha Jayamanne, Australia and Li Yu, China*

**14:02** ES28.03 - Biology of CNS Metastases

*Timothy Burns, USA*

**14:14** ES28.04 - Radiation & Timing (WBRT and SRS)

*Joe Chang, USA*

**14:26** ES28.05 - Leptomeningeal Disease in Driver-Positive NSCLC

*Myung Ju Ahn, Republic of Korea*

**14:38** ES28.06 - Impact of Brain Metastases: a Patient Perspective

*Terri Conneran, USA*

**14:50** Q&A

## 14:00 - 15:15 ES29 - Immunotherapy: Moving Beyond PD-1/PD-L1 and CTLA4

Track: Tumor Biology – Translational Biology

**ROOM: 30DE**

 ACCME ACCREDITED BY IASLC

*Chairs: Weimin Li, China and Noemi Reguart, Spain*

**14:00** Welcome & Introduction

*Weimin Li, China and Noemi Reguart, Spain*

- 14:02**    **ES29.03 - The Biology of Immune Evasion in NSCLC**  
*Marie-Liesse Asselin-Labat, Australia*
- 14:14**    **ES29.04 - Immune Microenvironment in LUAD Among Patients With no Smoking History**  
*Patricia Reis, Brazil*
- 14:26**    **ES29.05 - Novel Immune Checkpoints and Predicting Response to ICIs**  
*David Kwiatkowski, USA*
- 14:38**    **ES29.06 - Harnessing Innate Immune Cells for Treatment of Lung Cancer**  
*Marco Tagliamento, France*
- 14:50**    **Q&A**

## 14:00 - 15:15    **ES30 - Lung Cancer Beyond Smoking**

Track: Risk Factors, Risk Reduction & Tobacco Control

**ROOM: 22**

 ACCME ACCREDITED BY IASLC

Chairs: *Abhishek Shankar, India and Biagio Ricciuti, USA*

- 14:00**    **Welcome & Introduction**  
*Abhishek Shankar, India and Biagio Ricciuti, USA*
- 14:02**    **ES30.03 - Outdoor Air Pollution and Lung Cancer**  
*Joan Schiller, USA*
- 14:14**    **ES30.04 - Genetics, Ancestry, Germline Alterations in Lung Cancer**  
*Andres Cardona, Colombia*
- 14:26**    **ES30.05 - Radon, Indoor Pollution and Lung Cancer**  
*Laura Mezquita, Spain*
- 14:38**    **ES30.06 - Searching for Success in Lung Cancer Prevention Policies**  
*Isabelle Soerjomataram, France*
- 14:50**    **Q&A**

## 14:00 - 15:15    **MA04 - Real-world Implementation of Early Lung Cancer Detection**

Track: Screening and Early Detection

**ROOM: 33ABC**

 NOT FOR CME CREDIT

Chairs: *Efren Flores, USA and Nagashree Seetharamu, USA*

- 14:00**    **Welcome & Introduction**  
*Efren Flores, USA and Nagashree Seetharamu, USA*
- 14:02**    **MA04.03 - Bringing Equity to the Community: The Dana-Farber Cancer Care Equity Program's Lung Cancer Screening Initiative**  
*Narjust Florez, USA*
- 14:07**    **MA04.04 - Treatment Patterns and Survival of Screen-Detected Lung Cancer in the Real World Versus the National Lung Screening Trial**  
*Alexandra Potter, USA*
- 14:12**    **MA04.05 - An Evolution and Expanding Engagement to Excel in Lung Cancer Screening**  
*Michael Gieske, USA*
- 14:17**    **Q&A**
- 14:25**    **MA04.07 - Low-Dose Computed Tomography Lung Cancer Screening Participants Live Longer Than Matched Controls, A Case-Control Study**  
*Robert Dziedzic, Poland*

- 14:30**    **MA04.08 - High Recruitment Rate and Performance of a National Lung Cancer Screening Network Implementing Web-Based Instruments**  
*Ugo Pastorino, Italy*
- 14:35**    **MA04.09 - An International Qualitative Study of Healthcare Provider Perspectives of the Psychosocial Impacts and Barriers to Lung Cancer Screening**  
*Rachael Dodd, Australia*
- 14:40**    **Q&A**
- 14:48**    **MA04.11 - Women Enrolled in Lung Screening as a Result of Direct Outreach Are More Likely to be Cancer Survivors**  
*Shady Faltaous, USA*
- 14:53**    **MA04.12 - Uncovering Disparities and Trends in Lung Cancer Screening Based on Patient Race and Insurance Status**  
*Emily Zolfaghari, USA*
- 14:58**    **Q&A**

## 14:00 - 15:15    **OA10 - DLL3 Targeting BiTE Therapies in SCLC**

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

**ROOM: 20A**

 ACCME ACCREDITED BY IASLC

Chairs: *Diego Kauffmann-Guerrero, Germany and Motoko Tachihara, Japan*

- 14:00**    **Welcome & Introduction**  
*Diego Kauffmann-Guerrero, Germany and Motoko Tachihara, Japan*
- 14:02**    **OA10.03 - Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up**  
*Jacob Sands, USA*
- 14:12**    **OA10.04 - Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study**  
*Sally Lau, USA*
- 14:22**    **OA10.05 - Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC**  
*Martin Wermke, Germany*
- 14:32**    **OA10.06 - Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer**  
*Noura Choudhury, USA*
- 14:42**    **OA10.07 - Discussant**  
*Ticiana Leal, USA*
- 14:52**    **Q&A**

## 14:00 - 15:15    **OA11 - Shifting the Bar in the Front Line Immunotherapy Setting**

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy

**ROOM: 20BC**

 ACCME ACCREDITED BY IASLC

Chairs: *Thomas Newsom-Davis, UK and Deepti Behl, USA*

- 14:00**    **Welcome & Introduction**  
*Thomas Newsom-Davis, UK and Deepti Behl, USA*
- 14:02**    **OA11.03 - Efficacy and Safety of Rilvegostomig, an Anti-PD-1/TIGIT Bispecific, for CPI-naïve Metastatic NSCLC with PD-L1 1-49% or ≥50%**  
*T. Jeroen N. Hiltermann, Netherlands*
- 14:12**    **OA11.04 - Volrustomig + Platinum Doublet Dchemotherapy (CTx) in First-Line Non-Small Cell Lung Cancer (NSCLC): Phase 1b Trial Update**  
*David Spigel, USA*

- 14:22**    **OA11.05 - Results of a Phase III Trial of Prolgolimab with Chemotherapy as First-Line Therapy for Patients with Advanced Non-Squamous NSCLC: DOMAJOR**  
*Daniil Stroyakovsky, Russian Federation*
- 14:32**    **OA11.06 - Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression  $\geq$ 50%: 5-y Outcomes of EMPOWER-Lung 1**  
*Ana Baramidze, Georgia*
- 14:42**    **OA11.07 - Discussant**  
*Karen Reckamp, USA*
- 14:52**    **Q&A**

**14:00 - 15:15      OA12 - Advancing Multimodal Therapies in Stage III NSCLC**

Track: Local-Regional Non-small Cell Lung Cancer

**ROOM: 32AB**

 ACCME ACCREDITED BY IASLC

Chairs: Feng-Ming Kong, Hong Kong and Erin Gillaspie, USA

- 14:00**    **Welcome & Introduction**  
*Feng-Ming Kong, Hong Kong and Erin Gillaspie, USA*
- 14:02**    **OA12.03 - Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA Study**  
*Terufumi Kato, Japan*
- 14:12**    **OA12.04 - Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L)**  
*Shinichi Toyooka, Japan*
- 14:22**    **OA12.05 - APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC**  
*Mariano Provencio, Spain*
- 14:32**    **OA12. 06 - Intensified Chemo-Immuno-Radiotherapy with Durvalumab for Stage III NSCLCs: A Single Arm Phase II Study - PACIFIC-BRAZIL (LACOG 2218)**  
*William Nassib William Jr., Brazil*
- 14:42**    **OA12.07 - Discussant**  
*Gerard Hanna, Ireland*
- 14:52**    **Q&A**

**15:30 - 16:45      ES31 - Surgical Challenges and Opportunities in Locally Advanced NSCLC**

Track: Local-Regional Non-small Cell Lung Cancer

**ROOM: 31ABC**

 ACCME ACCREDITED BY IASLC

Chairs: Jessica Donington, USA and Young Tae Kim, Republic of Korea

- 15:30**    **Welcome & Introduction**  
*Jessica Donington, USA and Young Tae Kim, Republic of Korea*
- 15:32**    **ES31.03 - Fact or Fiction: Single Station N2 Patients Are Eligible for Resection**  
*Mariano Provencio, Spain*
- 15:44**    **ES31.04 - Does Neoadjuvant I/O Redefine Resectability for Stage III NSCLC?**  
*Brendon Stiles, USA*
- 15:56**    **ES31.05 - Resection After I/O or Targeted Therapies: How Hard Is It?**  
*Mara Antonoff, USA*

**16:08** ES31.06 - The Role of Salvage Surgery for Lung Cancer After CRTT With or Without ICI  
*Kenji Sazuki, Japan*

**16:20** Q&A

## 15:30 - 16:45 ES32 - Biomarkers for Lung Cancer in 2024

Track: Pathology and Biomarkers

**ROOM: 30DE**

 ACCME ACCREDITED BY IASLC

*Chairs: Yasushi Yatabe, Japan and Mary Beth Beasley, USA*

**15:30** Welcome & Introduction

*Yasushi Yatabe, Japan and Mary Beth Beasley, USA*

**15:32** ES32.03 - Emerging Biomarkers for Lung Cancer

*Tricia Cottrell, Canada*

**15:44** ES32.04 - The Role of Liquid Biopsies as a Biomarker for Lung Cancer

*Kurt Schalper, USA*

**15:56** ES32.05 - Interpreting Your Molecular Pathology Report - What Does It All Mean? (How to Interpret Various Commercial and Academic Institution Reports)

*Esther Conde, Spain*

**16:08** ES32.06 - Biomarkers for Small Cell Carcinoma - Ready for Prime Time?

*Matthew Oser, USA*

**16:20** Q&A

## 15:30 - 16:45 ES33 - Global Aspects of Access to Precision Oncology

Track: Global Health, Health Services, and Health Economics

**ROOM: 30A**

 ACCME ACCREDITED BY IASLC

*Chairs: Verna Vanderpuye, Ghana and Pedro Aguiar Jr, Brazil*

**15:30** Welcome & Introduction

*Verna Vanderpuye, Ghana and Pedro Aguiar Jr, Brazil*

**15:32** ES33.03 - Tobacco Awareness Moment - Low and Middle Income Countries: Lung Cancer Screening That Includes Smoking Cessation Interventions

*Abhishek Shankar, India*

**15:35** ES33.04 - (Africa) - Molecular Diagnosis, Access to Innovative Agents, Pricing and “Me Too” Drugs

*Emmanuella Nwachukwu, Nigeria*

**15:45** ES33.05 - (LATAM & North America) - Molecular Diagnosis, Access to Innovative Agents, Pricing and “Me Too” Drugs

*Luiz Araújo, Brazil*

**15:55** ES33.06 - (Asia) - Molecular Diagnosis, Access to Innovative Agents, Pricing and “Me Too” Drugs

*Thanyanan Baisamut, Thailand*

**16:05** ES33.07 - (Europe) - Continental Inequities, Pricing and Licensing

*Riyaz Shah, UK*

**16:15** ES33.08 - Resource-stratified Guidelines (WHO)

*Valeria Denninghoff, Argentina*

**16:25** Q&A



**15:30 - 16:45 ES34 - Antibody Drug Conjugates: Current Evidence**

Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

**ROOM: 20BC**

 ACCME ACCREDITED BY IASLC

Chairs: Sun-min Lim, Republic of Korea and Mauricio Cuello, Uruguay

- 15:30 Welcome & Introduction**  
*Sun-min Lim, Republic of Korea and Mauricio Cuello, Uruguay*
- 15:32 ES34.03 - ADCs: The Basics**  
*Grace Dy, USA*
- 15:44 ES34.04 - HER2 and HER3 Directed ADCs**  
*Antonio Calles, Spain*
- 15:56 ES34.05 - TROP2 ADCs (Existing and Emerging), CEACAM and MET**  
*Joshua Reuss, USA*
- 16:08 ES34.06 - Toxicities of Interest**  
*Aparna Sharma, India*
- 16:20 Q&A**

**15:30 - 16:45 ES35 - Disparities and Timing in the Delivery of Local Therapy for Oligometastatic NSCLC**

Track: Metastatic Non-small Cell Lung Cancer – Local Therapies

**ROOM: 32AB**

 ACCME ACCREDITED BY IASLC

Chairs: Lillian Faroni, Brazil and Bill Loo, USA

- 15:30 Welcome & Introduction**  
*Lillian Faroni, Brazil and Bill Loo, USA*
- 15:32 ES35.03 - The Case for Local Therapy at the Time of Diagnosis for Oligometastatic NSCLC**  
*Kevin Chua, Singapore*
- 15:42 ES35.04 - The Case for Local Therapy at the Time of Progression for Oligometastatic NSCLC**  
*Alexander Louie, Canada*
- 15:52 ES35.05 - Disparities in the Delivery of Surgery for Oligometastatic Disease**  
*Elizabeth David, USA*
- 16:02 ES35.06 - Disparities in the Delivery of Systemic Treatment for Oligometastatic Disease**  
*Mark Doherty, Ireland*
- 16:12 ES35.07 - The Importance of Biomarker Testing for Oligometastatic Lung Cancer: Promoting Inclusion, Personalization, and Better Outcomes**  
*Shani Shilo, Israel*
- 16:22 Q&A**

**15:30 - 16:45 MA05 - Treatment Targets and Monitoring Markers for Mesothelioma and Thymic Tumors**

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

**ROOM: 30BC**

 NOT FOR CME CREDIT

Chairs: Aaron Mansfield, USA and Maria Velez, USA

- 15:30 Welcome & Introduction**  
*Aaron Mansfield, USA and Maria Velez, USA*

- 15:32** **MA05.03 - A Phase II Study of Tislelizumab Combined with Chemotherapy in Patients with Thymic Carcinoma**  
*Lin Wu, China*
- 15:37** **MA05.04 - Targeting TROP-2 In Diffuse Pleural Mesothelioma**  
*Michael Offin, USA*
- 15:42** **MA05.05 - External Validation of Proposed 9th Edition of TNM Classification for Thymic Epithelial Tumours: Institutional Series of 436 Cases**  
*Yu Zhi Zhang, UK*
- 15:47** **Q&A**
- 15:55** **MA05.07 - Pretreatment with Cisplatin or Radiation Therapy Enhances CAR T-Cell Therapy Efficacy**  
*Rebecca Bellis, USA*
- 16:05** **MA05.08 - Follow-Up after First-Line Nivolumab Plus Ipilimumab in Patients with Pleural Mesothelioma: A Real-World Dutch Cohort Study (FLORA-Study)**  
*Cornedine de Gooijer, Netherlands*
- 16:10** **Q&A**
- 16:18** **MA05.10 - Presenting Features and Diagnostic Delays of NUT Carcinoma: A Report from the NUT Carcinoma Registry**  
*Jia Luo, USA*
- 16:23** **MA05.11 - Phase 3 Trial of Pleurodesis for Malignant Pleurisy: Sterile Graded Talc vs. OK-432 WJOG8415L (J-PLEURA)**  
*Hideo Saka, Japan*
- 16:28** **Q&A**

## 15:30 - 16:45 OA13 - Perioperative Strategies 2

Track: Early-Stage Non-small Cell Lung Cancer

**ROOM: 20A**

 ACCME ACCREDITED BY IASLC

*Chairs: Patrick Forde, USA and Jazmin Eckhaus, Australia*

- 15:30** **Welcome & Introduction**  
*Patrick Forde, USA and Jazmin Eckhaus, Australia*
- 15:32** **OA13.03 - Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial**  
*John Heymach, USA*
- 15:42** **OA13.04 - ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)**  
*Hidehito Horinouchi, Japan*
- 15:52** **OA13.05 - I-SABR-SELECT: A Radiomics-Based Model for Personalized Immunotherapy for Early-Stage Non-Small Cell Lung Cancer**  
*Joe Chang, USA*
- 16:02** **OA13.06 - Discussant**  
*Pamela Samson, USA*
- 16:12** **Q&A**

## 15:30 - 16:45 OA14 - New Horizons in Targeting KRAS G12C

**ROOM: 20D**

 ACCME ACCREDITED BY IASLC

*Chairs: Lyudmila Bazhenova, USA and Junko Tanizaki, Japan*

- 15:30** **Welcome & Introduction**  
*Lyudmila Bazhenova, USA and Junko Tanizaki, Japan*

- 15:32**    **OA14.03 - Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study**  
*Ziming Li, China*
- 15:42**    **OA14.04 - Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC**  
*Yutaka Fujiwara, Japan*
- 15:52**    **OA14.05 - KRAS G12C Inhibitor IBI351 in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study**  
*Qing Zhou, China*
- 16:02**    **OA14.06 - Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC**  
*Adrian Sacher, Canada*
- 16:12**    **OA14.08 - Discussant**  
*Caicun Zhou, China*
- 16:22**    **Q&A**

**15:30 - 16:45      OA15 - Profiling the Tumour Microenvironment of Lung Cancer Metastasis**

**Track: Tumor Biology – Translational Biology**

**ROOM: 33ABC**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Venessa Chin, Australia and Joseph Chan, USA*

- 15:30**    **Welcome & Introduction**  
*Venessa Chin, Australia and Joseph Chan, USA*
- 15:32**    **OA15.03 - Clinicogenomic Landscape of Lymph Node Metastases in TRACERx**  
*Takahiro Karasaki, Japan*
- 15:42**    **OA15.04 - Multi-Omic Profiling of Paired Non-Small Cell Lung Cancer and Draining Lymph Nodes Reveals Novel T-Cell Differentiation Patterns**  
*Vivian Gerretsen, Netherlands*
- 15:52**    **OA15.05 - Single-Cell Spatial Architectures of Paratumor Zone Determines the Prognosis of Multiple Lung Cancers**  
*Xiaoqiu Yuan, China*
- 16:02**    **OA15.06 - Spatiotemporal Genomic and Transcriptomic Analysis Reveal Molecular Landscape and Intratumoral Heterogeneity in Non-Smoking Lung Cancer**  
*Wenxiang Wang, China*
- 16:12**    **OA15.07 - Discussant**  
*Ming Tsao, Canada*
- 16:22**    **Q&A**

**17:00 - 18:30      PL05 - Plenary Session: Unmasking Lung Cancer: Exploring the Rising Influence of Non-Tobacco Factors**

**PLENARY HALL**

 **LIVESTREAMED**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Linda Martin, USA and Dave Bjork, USA*

- 17:00**    **Welcome & Introduction**  
*Linda Martin, USA and Dave Bjork, USA*
- 17:02**    **PL05.03 - Fire & Fury: Unmasking the Impact of Climate Change on Lung Cancer Risk**  
*Leticia Nogueira, USA*

- 17:17** **PL05.04 - Clearing the Air: Unmasking Indoor Pollutants and Lung Cancer Risk**  
*Roselle De Guzman, Philippines*
- 17:32** **PL05.05 - Vaping, Marijuana, and Lung Cancer in the Modern Era**  
*Pamela Ling, USA*
- 17:47** **PL05.06 - Air Pollution and Inflammatory Response Induced Never-Smoker Lung Cancer**  
*Mariam Jamal-Hanjani, UK*
- 18:02** **PL05.07 - Airborne Carcinogen Exposure Arising from Military Conflict**  
*Felipe Roitberg, Brazil*
- 18:17** **Q&A**

**18:30 – 20:00** **Poster Viewing Networking Reception (Poster Session 4: P4) with Presenters in Attendance**

**EXHIBIT HALL**



**REFRESHMENTS PROVIDED**

*Note: All P4 Posters will be on display the entire day on Monday.*

**18:45-19:45** **Satellite CME Symposium**

*See page 247 for more information.*

**18:45 – 19:30** **Poster Tours**

**EXHIBIT HALL/EPOSTER LOUNGE AND EXHIBIT SHOWCASE THEATER**

*Note: Each Poster Tour will include 4 – 5 Poster (8min per Poster: 3min presentation by the Poster Presenter, followed by 2min Discussion by the Poster Lead and 3min Audience Q&A).*

**Poster Tour 10:** PT02.03 - Tumor Biology - Translational Biology

**Tour Lead:** Fiona Blackhall, UK

- 18:45** **PT02.03.02 - Genomic and Spatial Characterization of Neoadjuvant Efficacy Differences in Non-Small Cell Lung Cancer**  
*Yue He, China*
- 18:53** **PT02.03.03 - Neoadjuvant Gefitinib in EGFR Mutated NSCLC (a Phase 2 Window-Of-Opportunity Study): Deep Genomic and Transcriptomic Analysis**  
*Aaron Tan, Singapore*
- 19:01** **PT02.03.04 - Lurbinectedin Synergizes with Selinexor by Inhibiting DNA Damage Repair and Enhancing Immune Cell Infiltration in Neuroendocrine Lung Tumors**  
*Esther Redin, USA*
- 19:09** **PT02.03.05 Tumour Educated Platelets Display A Distinct RNA Content Profile Across Metastatic Patterns in NSCLC.**  
*Anne-Marie Baird, Ireland*
- Poster Tour 11:** PT02.05 - Pulmonology and Staging
- Tour Lead:** David J. Feller-Kopman, USA
- 18:45** **PT02.05.02 - How Reliable Is PET/CT in T1A and T1B Non-Small Cell Lung Cancer for Mediastinal Staging?**  
*Akif Turna, Turkey*
- 18:53** **PT02.05.03 - Pathologic Nodal Staging Reporting Quality: A Multi-Center Assessment of NSCLC Trends Over Time & Key Reporting Parameters**  
*Haley Tupper, USA*

- 19:01** **PT02.05.04 - Automated Extraction of Key Entities from Thorax CT Reports Using NER with Prompt Engineering**  
*Ozden Altundag, Turkey*
- 19:09** **PT02.05.05 - Incidence of Pneumonitis in Asian Patients with Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis**  
*Christine Pierce, USA*
- 19:17** **PT02.05.06 - Does the Proposed 9th TNM Offer Improved Prognostic Accuracy after Lung Carcinoma Resection? Preliminary Analysis Results**  
*Piotr Kaluzynski, Poland*

**Poster Tour 12:** PT02.06 - Pathology and Biomarkers

**Tour Lead:** Yasushi Yatabe, Japan

- 18:45** **PT02.06.02 - NSCLC in Patients with CTD-ILD: Apobec-Related Mutagenesis, Frequent TP53 Mutations and Paucity of Targetable Alterations**  
*Igor Odintsov, USA*
- 18:53** **PT02.06.03 - Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Treatment-Naive Patients with Advanced Lung Squamous Cancer**  
*Fei Zhou, China*
- 19:01** **PT02.06.04 - The Impact of Lymphovascular Invasion as Prognostic Factor on Long-Term Survival in More Than 3500 Resected NSCLC Patients**  
*Fabien Doerr, Germany*
- 19:09** **PT02.06.05 - Machine Learning Models Discriminate Independent Primaries with Metastatic in Non-Small-Cell Lung Cancer**  
*Ning Liu, China*
- 19:17** **PT02.06.06 - Assessing Pathologic Response to Neoadjuvant Chemoimmunotherapy for NSCLC: Aligning Current Protocols with Artificial Intelligence**  
*Fernando Lopez-Rios, Spain*

**Poster Tour 13:** PT02.08 - Local-Regional Non-small Cell Lung Cancer

**Tour Lead:** Jessica Scott Donington, USA

- 18:45** **PT02.08.02 - Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival**  
*Marta Molina-Alejandre, Spain*
- 18:53** **PT02.08.03 - TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials**  
*Cristina Martínez-Toledo, Spain*
- 19:01** **PT02.08.04 - Targeted Therapy or Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIb EGFRm Lung Adenocarcinoma: A Study Between Four Cohorts**  
*Fang-Liang Lu, China*
- 19:09** **PT02.08.05 - Revisiting the ACS 3N2 + 1N1 Mandate: Should Old Data Define Today's Standard?**  
*Shubham Gulati, USA*

**Poster Tour 14:** PT02.10 - Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy

**Tour Lead:** Gerard G. Hanna, Ireland

- 18:45** **PT02.10.03 - Cutoff Determination for C-met Protein Overexpression by VENTANA MET (SP44) IHC to Determine Teliso-v Eligibility in NSCLC**  
*Nancy Zhang, USA*
- 18:53** **PT02.10.04 - Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress)**  
*Jonathan Riess, USA*

**Poster Tour 15:** PT02.12 - Metastatic Non-small Cell Lung Cancer - Targeted Therapy**Tour Lead:** Prunella Blinman, Australia**18:45** **PT02.12.02 - Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC***Fangdi Sun, USA***18:53** **PT02.12.03 Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib***Matthew Lee, USA***19:01** **PT02.12.04 - Mechanisms of Resistance to First-Line vs Later-Line Alectinib in ALK Fusion-Positive Non-Small Cell Lung Cancer***Sarah Waliqny, USA***19:09** **PT02.12.05 - Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC***Melissa Johnson, USA***19:17** **PT02.12.06 - Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC***Mihaela Aldea, USA***Poster Tour 16:** PT02.14 - Mesothelioma, Thymoma, and Other Thoracic Tumors**Tour Lead:** Natalie Vokes, USA**18:45** **PT02.14.02 - Clinicopathological Characteristics and Treatment Outcomes of Patients with Advanced SMARCA4-Deficient Non-Small Cell Lung Cancer***Hui Liu, China***18:53** **PT02.14.03 - Prognostic Impact of Tumour Size in Resected Thymic Epithelial Tumours - A Validation Analysis of the 9th TNM Staging System -***Miyuki Abe, Japan***19:01** **PT02.14.04 - Real-World Prognostic & Predictive Implications of EORTC & MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)***Florence Wu, Canada***19:09** **PT02.14.05 - Incidence of Pseudoprogression and Hyperprogression in Patients with Pleural Mesothelioma Treated with Ipilimumab and Nivolumab***Owen Mitchell, USA***Poster Tour 17:** PT02.16 - Patient Advocacy**Tour Lead:** Antoinette Wozniak, USA**18:45** **PT02.16.02 - Development of a Patient-Friendly Lung Cancer Lexicon***Jill Feldman, USA***18:53** **PT02.16.04 - Awareness, Stigma, and Fatalism Towards Cancer Clinical Trials Among Black Individuals Diagnosed with Lung Cancer***Andrew Ciupek, USA***19:01** **PT02.16.05 - LIFE Project: Lung Cancer Patients' Involvement in Research Fostering Their Empowerment***Bernard Gaspar, Spain***19:09** **PT02.16.06 - Attributes that Impact Patient and Physician Preferences for Maintenance Treatment in Advanced/metastatic NSCLC***Umit Tapan, USA***20:30 – 22:30** **Faculty Dinner****(By Invitation Only)**

**Walk, Run, Rest, Repeat!  
Eat, Sleep, Stretch, Repeat!  
Step, Scan, Play, Compete!  
Join #WCLC24Well and  
Move Your Feet!**

IASLC



**#WCLC24Well**



**Register for the IASLC  
2024 Wellness Challenge  
and support lung  
cancer research.**



**IASLC WELLNESS  
CHALLENGE 2024**

**STEP IT UP FOR RESEARCH**

*San Diego*



# Congratulations to the 2024 IASLC Reviewer Workshop Participants

Early- and mid-career researchers will participate in a one-day workshop at WCLC 2024 focused on manuscript review. Attendees will learn from journal editors and cover:

- Building a pool of excellent reviewers for IASLC journals
- Understanding technical aspects of publishing, ethics, and publication guidelines
- Mastering the review process and becoming critical reviewers
- Developing the skills to judge manuscript impact
- Making decisions consistent with the journal's impact factor

## Workshop Director



Alex A. Adjei, MD, PhD, FACP  
*Chairman*  
Taussig Cancer Institute,  
Cleveland Clinic  
Ohio, USA

## Workshop Faculty



Emily Stone, MBBS, PhD, FRACP  
*Conjoint Professor, Faculty of  
Medicine, St Vincent's Hospital,  
Sydney and School of Clinical  
Medicine, UNSW,  
Sydney, Australia*



Karen Reckamp, MD, MS  
*Clinical Professor*  
Department of Medicine,  
Cedars-Sinai Medical Center  
California, USA



Sai-Hong Ignatius Ou, MD, PhD  
*Health Science Clinical Professor*  
Chao Family Comprehensive  
Cancer Center  
California, USA



Yun-Sin Lim, PhD  
*Managing Editor*  
Journal of Thoracic  
Oncology  
Hong Kong

## Workshop Participants

Cynthia Bognar  
Brazil

Zac Coyne  
Canada

So Yeon Kim  
USA

Rajat Thawani  
USA

Iris Boyeras  
Argentina

Lei Deng  
USA

Vanessa Menezes  
Brazil

Kelsie Thu  
Canada

Monica Castro  
Argentina

Andréanne Gagné  
Canada

Rachel Paes de Araujo  
Brazil

Chetan Vakkalagadda  
USA

Yvonne Chao  
USA

Samuel Kareff  
USA

Daniel Przybysz  
Brazil

Iael Weissberg  
Brazil

Tendaï Chihuri  
USA

Sam Khan  
Canada

Ivy Riano  
USA

Julie Wu  
USA





# 05 / PROGRAM: SEPTEMBER 10

NTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM SCIENTIFIC



05 / Conference Program

SCIENTIFIC PROGRAM TUESDAY, SEPTEMBER 10

<b>DEI</b> DE&I Session	<b>MTE</b> Interactive Meet the Expert Session (Breakfast Provided, Limited Capacity)
<b>EP</b> ePosters	<b>OA</b> Oral Abstract Session
<b>ES</b> Education Session	<b>P</b> Posters
<b>EXH</b> Exhibit Showcase	<b>PL</b> Plenary Session
<b>HOD</b> Highlight of the Day Session	<b>WS</b> Workshop
<b>IS</b> Industry Supported or Satellite CME Symposia	
<b>MA</b> Mini Oral Abstract Session	

07:30 - 08:15 HOD02 - Highlights of the Day - Monday Abstracts

ROOM: 20BC

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

- 07:30 **HOD02.01 - Next-Gen Solutions in mNSCLC: Breakthroughs in Cytotoxic Therapy and ADC, Latest Advances in mNSCLC Immunotherapy, Cutting-Edge Targeted Therapies**  
*Brian Henick, USA*
- 07:40 **HOD02.02 - Expanding Horizons: Breakthroughs in mNSCLC Targeted Therapy, Innovative Approaches in SCLC and NET Treatment, Latest Research in Mesothelioma, Thymoma, and Other Thoracic Tumors**  
*Lauren Byers, USA*
- 07:50 **HOD02.03 - Pushing the Boundaries: Transformative Advances in Early and Local-Regional NSCLC**  
*Paul Van Schil, Belgium*
- 08:00 **HOD02.04 - From Bench to Bedside: Cutting-Edge Discoveries in Tumor Biology and Translational Research and Revolutionizing Lung Cancer Outcomes with Screening and Early Detection**  
*Joachim Aerts, Netherlands*

07:30 - 08:15 MTE13 - Biomarkers of Response

Track: Local-Regional Non-small Cell Lung Cancer

ROOM: 31ABC

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

- 07:30 **MTE13.01 - Is There More to Pathologic Response than pathCR?**  
*Wendy Cooper, Australia*
- 07:45 **MTE13.02 - ctDNA and MRD in Locally Advanced Disease: Are We There Yet?**  
*Maximilian Diehn, USA*
- 08:00 **Q&A**

07:30 - 08:15 MTE14 - NGS Testing for Targeted Therapy in Lung Cancer - Combined Pathology-Oncology Session

Track: Pathology and Biomarkers

ROOM: 30DE

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

- 07:30 **MTE14.01 - NGS Testing for Targeted Therapy in Lung Cancer - What the Pathologist Wants You to Know**  
*Lynette Sholl, USA*
- 07:45 **MTE14.02 - NGS Testing for Targeted Therapy in Lung Cancer - What the Oncologist Needs to Know**  
*Tom John, Australia*
- 08:00 **Q&A**

## 07:30 - 08:15 MTE15 - Access to Surgery and Radiotherapy

Track: Global Health, Health Services, and Health Economics

ROOM: 30A

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

**07:30 MTE15.01 - Access Barriers to Surgery for Lung Cancer in Low and Middle Income Countries (Diagnosis, Staging, Molecular)**

*Jose Corona-Cruz, Mexico*

**07:45 MTE15.02 - Access Barriers to Radiotherapy for Lung Cancer in Low and Middle Income Countries**

*Divya Khosla, India*

**08:00 Q&A**

## 07:30 - 08:15 MTE16 - How Well Do You Know Your Antibody Drug Conjugates

Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

ROOM: 30BC

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

Gameshow moderated by Benjamin Levy, USA and Jhanelle Gray, USA

## 07:30 - 08:15 MTE17 - Management of the Primary Tumor in Oligometastatic NSCLC with Isolated Brain Metastases

Track: Metastatic Non-small Cell Lung Cancer – Local Therapies

ROOM: 32AB

BREAKFAST PROVIDED

ACCME ACCREDITED BY IASLC

**07:30 MTE17.01 - Surgery for the Primary Tumor in Oligometastatic NSCLC with Isolated Brain Metastases**

*Jeff Yang, USA*

**07:45 MTE17.02 - Radiation for the Primary Tumor in Oligometastatic NSCLC with Isolated Brain Metastases**

*Matthias Guckenberger, Switzerland*

**08:00 Q&A**

## 08:30 - 10:30 IASLC Lectureship Award Presentations

PLENARY HALL

LIVESTREAMED

ACCME ACCREDITED BY IASLC

Chairs: Fabio Ynoe de Moraes, Canada and Paul Van Schil, Belgium

**08:30 Welcome & Introduction**

*Fabio Ynoe de Moraes, Canada and Paul Van Schil, Belgium*

**08:40 PL06.03 - Robert J. Ginsberg Lectureship Award for Surgery**

*Leah Backhus, USA*

**08:51 PL06.04 - James D. Cox Lectureship Award for Radiation Oncology**

*Andrea Bezzak, Canada*

**09:02 PL06.05 - Tsuguo Naruke Lectureship Award for Surgery**

*Wentao Fang, China*

**09:13 PL06.06 - IASLC Lectureship Award for Tobacco Control and Smoking Cessation**

*Babalola Faseru, USA*

**09:24 PL06.07 - IASLC Lectureship Award for Nurses and Allied Health Professionals (NAHP)**

*Maria Ftanou, Australia*

**09:35 PL06.08 - Heine H. Hansen Lectureship Award for Small Cell Lung Cancer**

*Luis Paz-Ares, Spain*

**09:46** **PL06.09 - Daniel C. Ihde Lectureship Award for Medical Oncology**  
*Solange Peters, Switzerland*

**09:57** **PL06.10 - Fred R. Hirsch Lectureship Award for Translational Research**  
*Montse Sánchez-Céspedes, Spain*

**10:08** **PL06.11 - Clifton F. Mountain Lectureship Award for Staging**  
*Chi-Fu J. Yang, USA*

**10:30 – 11:15 Coffee Break**

**EXHIBIT HALL**

 **REFRESHMENTS PROVIDED**

**10:30 - 11:15 IASLC Business Meeting**

**ROOM: 20A**

 **LIVESTREAMED**

 **NOT FOR CME CREDIT**

 **REFRESHMENTS PROVIDED**

**Welcome from the IASLC President**  
*Paul Van Schil, Belgium*

**CEO Report**  
*Karen Kelly, USA*

**CSO Report**  
*Jennifer King, USA*

**Financial Report**  
*Joachim Aerts, Netherlands*

**JTO & JTO CRR Report**  
*Alex Adjei, USA*

**10:35 - 11:35 Press Conference**

**ROOM: 26B**

 **NOT FOR CME CREDIT**

**11:15 - 12:30 ES36 - Joint IASLC – ESTRO Session**

**ROOM: 31ABC**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Drew Moghanaki, USA and Suresh Senan, Netherlands*

**11:15** **Welcome & Introduction**  
*Drew Moghanaki, USA and Suresh Senan, Netherlands*

**11:17** **ES36.03 – Risk-adapted and Response-adapted Strategies for Stage 3 NSCLC**  
*Andrea R. Filippi, Italy*

**11:29** **ES36.04 – TRationale of Dose De-escalation for Stage 3 NSCLC**  
*Ashley Horne, UK*

**11:41** **ES36.05 – Reducing Radiation-related Toxicity in Stage 3 NSCLC**  
*Dawn Owen, USA*

**11:53** **ES36.06 - Is There a Role for SBRT in Stage 3 NSCLC?**  
*Andreas Rimner, Germany*

**12:05** **Q&A**

**11:15 - 12:30 ES37 - Implementing Lung Cancer Screening Around the World**

**Track: Screening and Early Detection**

**ROOM: 20A**

 **ACCME ACCREDITED BY IASLC**

*Chairs: Mong-Wei Lin, Taiwan and Ella Kazerooni, USA*

**11:15** **Welcome & Introduction**  
*Mong-Wei Lin, Taiwan and Ella Kazerooni, USA*

- 11:17 ES37.03 - Challenges and Opportunities for Implementing Lung Cancer Screening in Latin America**  
*Ricardo Sales dos Santos, Brazil*
- 11:29 ES37.04 - Implementing, Expanding, and Optimizing Lung Cancer Screening in Europe: A New Frontier**  
*Giulia Veronesi, Italy*
- 11:41 ES37.05 - Implementing Lung Cancer Screening in Tuberculosis-endemic Settings**  
*Coenraad Koegeleberg, South Africa*
- 11:53 ES37.06 - Accelerating the Uptake of Lung Cancer Screening Through Community Outreach and Engagement in the US**  
*Priyanka Senthil, USA and Dusty Donaldson, USA*
- 12:05 Q&A**

## 11:15 - 12:30 ES38 - Advanced Cancer Survivorship

**Track: Multidisciplinary Care: Nursing, Allied Health and Palliative Care**

**ROOM: 30BC**

 ACCME ACCREDITED BY IASLC

*Chairs: Mariana Laloni, Brazil and Heather Law, USA*

- 11:15 Welcome & Introduction**  
*Mariana Laloni, Brazil and Heather Law, USA*
- 11:17 ES38.03 - Collaborating with a Multidisciplinary Team to Provide Optimal Lung Cancer Supportive Care**  
*Melinda L. Hsu, USA*
- 11:29 ES38.04 - Sexual Health**  
*Laila Agrawal, USA*
- 11:41 ES38.05 - Palliative Care for Patients with Advanced Lung Cancer**  
*Laura Petrillo, USA*
- 11:53 ES38.06 - Exercise for People with Advanced Cancer**  
*Paulo Bergerot, Brazil*
- 12:05 Q&A**

## 11:15 - 12:30 ES39 - Biomarkers and Beyond

**Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy**

**ROOM: 20BC**

 ACCME ACCREDITED BY IASLC

*Chairs: Puey Ling Chia, Singapore and Maximilian Diehn, USA*

- 11:15 Welcome & Introduction**  
*Puey Ling Chia, Singapore and Maximilian Diehn, USA*
- 11:17 ES39.03 - Optimizing Pathologic Biomarkers of Immunotherapy: The Road Forward**  
*Yosuke Yamada, Japan*
- 11:29 ES39.04 - Circulating Immunotherapy Biomarkers**  
*Valsamo Anagnostou, USA*
- 11:41 ES39.05 - Integrated Biomarkers of IO Response/Resistance**  
*Justin Gainor, USA*
- 11:53 ES39.06 - Biomarkers and Beyond for Immunotherapy Toxicities**  
*Jarushka Naidoo, Ireland*
- 12:05 Q&A**

**11:15 - 12:30 MA06 - New Strategies in ALK, ROS1, NTRK, BRAF, and MET NSCLC**

**Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy**

**ROOM: 20D**

 NOT FOR CME CREDIT

*Chairs: Hossein Borghaei, USA and Tércia Reis, Brazil*

- 11:15**     **Welcome & Introduction**  
*Hossein Borghaei, USA and Tércia Reis, Brazil*
- 11:17**     **MA06.03 - Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study**  
*Geoffrey Liu, Canada*
- 11:22**     **MA06.04 - Unecritinib in Patients with ROS1 Positive Advanced Non-Small Cell Lung Cancer: Updated Results from a Phase II Trial**  
*Ziming Li, China*
- 11:27**     **MA06.05 - A Phase II Study of Lorlatinib in Advanced ROS1+ NSCLC Pre-Treated with Crizotinib and Platinum-Based Chemotherapy**  
*Yi-Long Wu, China*
- 11:32**     **Q&A**
- 11:40**     **MA06.07 - Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC**  
*Tony Mok, China*
- 11:45**     **MA06.08 - Kinetics and Management of Adverse Events Associated with Lorlatinib After 5 Years of Follow-Up in the CROWN Study**  
*Todd Bauer, USA*
- 11:50**     **MA06.09 - Predictors of Long-Term Ensartinib Response from the eXalt3 Trial**  
*Christopher Bulow, USA*
- 11:55**     **Q&A**
- 12:03**     **MA06.11 - Phase II Trial of Ensartinib for Advanced or Metastatic Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations**  
*Yang Xia, China*
- 12:08**     **MA06.12 - Updated Efficacy, Safety, and Biomarker Analysis in Patients with TRK Fusion Lung Cancer Treated with Larotrectinib**  
*Jessica Lin, USA*
- 12:13**     **MA06.13 - Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study**  
*Gregory Riely, USA*
- 12:18**     **Q&A**

**11:15 - 12:30 MA07 - Novel Targets to Overcome Resistance to Therapy**

**Track: Tumor Biology – Preclinical Biology**

**ROOM: 33ABC**

 NOT FOR CME CREDIT

*Chairs: Alice Berger, USA and Fabrizio Bianchi, Italy*

- 11:15**     **Welcome & Introduction**  
*Alice Berger, USA and Fabrizio Bianchi, Italy*
- 11:17**     **MA07.03 - Systematic Engineering of TROP2 CAR T Cell Therapy to Overcome Resistance Pathways in EGFR Mutant NSCLC**  
*Elliott Brea, USA (Early Career Education Award Winner)*
- 11:22**     **MA07.04 - Targeting CD24 Enhances the Response to Third-Generation Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer**  
*Jiaqi Liang, China*
- 11:27**     **MA07.05 - Unbiased Functional Genomics Screen Identifies Unique Therapeutic Vulnerabilities in Osimertinib-Resistant NSCLCs**

Alex Gooding, USA

- 11:32** **MA07.06 - Eradicating Drug Tolerant Persisters (DTPs) in EGFR-Mutated Non Small Cell Lung Cancer (NSCLC) by Targeting TROP2**  
*Simon Baldacci, USA*
- 11:37** **Q&A**
- 11:45** **MA07.08 - Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC**  
*Mei Mei Zheng, China*
- 11:50** **MA07.09 - Genome-Wide CRISPR Screen Identifies SFRP2 as a Novel Stromal Target to Enhance Abscopal Effect of Radioimmunotherapy**  
*Zhang Yanpei, China (Developing Country Education Award Winner)*
- 11:55** **Q&A**
- 12:03** **MA07.11 - AGRN-Positive Tumor Cells Promoting Immunotherapy Resistance in Lung Adenocarcinoma by Reshaping the Immune Microenvironment**  
*Huan Zhang, China*
- 12:08** **MA07.12 - Unleashing the Potential of the Probiotic F.prausnitzii to Optimize PD-1 Inhibitor Efficacy in NSCLC Treatment**  
*Long Jiang, China (Developing Country Education Award Winner)*
- 12:13** **MA07.13 - Neoadjuvant Chemotherapy Is Associated with Optimized Spatial Landscape of Tissue-Resident Memory T Cells in Non-Small Cell Lung Cancer**  
*Ligang Xing, China*
- 12:18** **Q&A**

## 11:15 - 12:30 MA08 - Pulmonary Nodes and Nodules

Track: Pulmonology and Staging

ROOM: 32AB

NOT FOR CME CREDIT

Chairs: Antoni Rosell, Spain and Dorith Shaham, Israel

- 11:15** **Welcome & Introduction**  
*Antoni Rosell, Spain and Dorith Shaham, Israel*
- 11:17** **MA08.03 - Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer**  
*Fangqiu Fu, China*
- 11:22** **MA08.04 - Exploration on the Prognostic Heterogeneity in Stage IIB (the 9th Edition of TNM Classification) NSCLC Patients with Different Nodal Statuses**  
*Jing-Sheng Cai, China*
- 11:27** **MA08.05 - Lung Cancer in Young Adults is Associated with Advanced Disease at Diagnosis and Increased Frequency of Targetable Mutations**  
*Filiz Oezkan, Germany*
- 11:32** **Q&A**
- 11:40** **MA08.07 - Transthoracic Versus Transbronchial Approaches for Diagnosis of Pulmonary Nodules Located in the Middle Lung Zone**  
*Tsukasa Ishiwata, Canada*
- 11:45** **MA08.08 - Association of FDG-PET/CT Findings with Sufficient Amount of Tissue Samples for Gene Panel Testing in TBB/TBNA**  
*Akiko Tamura, Japan*
- 11:50** **MA08.09 - Predictive CT Features of Visceral Pleural Invasion in Lung Cancer with Ground Glass Opacity**  
*Naohiro Hayashi, Japan*
- 11:55** **Q&A**
- 12:03** **MA08.11 - Incidental Lung Nodule Program: A New Approach for Early Detection**



**and Management of Lung Cancer**

*Javier J. Zulueta, USA*

**12:08 MA08.12 - Semi-Solid Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population**  
*Gavitt Woodard, USA*

**12:13 Q&A**

**11:15 - 12:30 MA09 - Beyond the Microscope: Predicting Benefit and Understanding Biology Through Biomarkers**

**Track: Pathology and Biomarkers**

**ROOM: 30DE**

 NOT FOR CME CREDIT

*Chairs: Yuchen Han, China and Guilherme Harada, Brazil*

**11:15 Welcome & Introduction**

*Zhe Wang, China and Guilherme Harada, Brazil*

**11:17 MA09.03 - Plasma Proteomics-based Models for Predicting Immunotherapy- and Chemotherapy-Related Toxicity in NSCLC Patients**

*Jarushka Naidoo, Ireland*

**11:22 MA09.04 - Differential CD8+FoxP3+ T Cell Infiltration Patterns Associate with Pathologic Response after Neoadjuvant Anti-PD-1 in NSCLC**

*Michael Fotheringham, Canada*

**11:27 MA09.05 - Circulating Protein Signatures and Immune Cells Are Predictive and Prognostic Markers for Patients with NSCLC in the SAKK 17/18 Trial**

*Angelica Rigutto, Switzerland*

**11:32 MA09.06 - Use of Biosimulation to Predict Chemotherapy Benefit in Patients with Metastatic NSCLC Being Treated with Immunotherapy**

*Mark Klein, USA*

**11:37 Q&A**

**11:45 MA09.08 - The Mechanical Change and Metastasis Promoting in Lung Adenocarcinoma Progression: From AIS, MIA to IAC**

*Ming Li, China (International Mentorship Program Participant)*

**11:50 MA09.09 - Genomic Mapping of Evolutionary from Pre-Invasive to Advanced Stage in Lung Adenocarcinoma**

*Yi-Duo Lin, China (Developing Country Education Award Winner)*

**11:55 MA09.10 - Spatial Transcriptomics and Next-Generation Sequencing Reveals the Gene Expression Andmolecular Immune Characteristics in LUAD**

*Yifei Liu, China*

**12:00 Q&A**

**12:08 MA09.12 - The Role of Different Lepidic Patterns for Determining Whether it is a Multiple Primary Pulmonary Adenocarcinoma**

*Junhong Guo, China*

**12:13 MA09.13 - Clinical Outcome of Bilateral Invasive Mucinous Adenocarcinoma (IMA) without Mediastinal Nodal Involvement from SEER Database**

*Jongwoo Kim, USA*

**12:18 Q&A**

**11:15 - 12:30 MA10 - Financial Toxicity, Clinical Communication, and the Needs of Patients and Caregivers**

**Track: Patient Advocacy**

**ROOM: 30A**

 NOT FOR CME CREDIT

*Chairs: Kim Norris, USA and Angeline Low, Australia*

- 11:15**     **Welcome & Introduction**  
*Kim Norris, USA and Angeline Low, Australia*
- 11:17**     **MA10.03 - Paying the Price: How Lung Cancer Care Impacts Wallets and Well-Being**  
*David Pottinger, USA*
- 11:22**     **MA10.04 - The Financial Toxicity of Lung Cancer Impacts All Spheres of Life**  
*Anne-Marie Baird, Switzerland*
- 11:27**     **MA10.05 - Characterization of the Basic Financial Needs of Those Living with Lung Cancer**  
*Brittney Nichols, USA*
- 11:32**     **Q&A**
- 11:40**     **MA10.07 - Understanding Symptom Burden in Young Adults with Lung Cancer Based on an Analysis from the E2C2 Pragmatic Clinical Trial**  
*Katherine Smith, USA*
- 11:45**     **MA10.08 - Unravelling the Impact: Understanding Caregivers in the Lung Cancer Community**  
*Bellinda King-Kallimanis, USA*
- 11:50**     **MA10.09 - Mapping of Patient-Reported Outcome Items to Symptomatic Adverse Events of Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer**  
*Emily Paton, USA*
- 11:55**     **Q&A**
- 12:03**     **MA10.11 - Patient-Reported Doctor Communication and Preference on Treatment Decision Making: Oligometastatic vs Metastatic Lung Cancer**  
*Tendai Chihuri, USA*
- 12:08**     **MA10.12 - Patient-Centered Communication and Knowledge and Preparedness in Treatment Decision-Making Among People with Lung Cancer**  
*Kara Doughtie, USA*
- 12:13**     **MA10.13 - TIME TOX Lung: Retrospectively Quantifying the Time Toxicity of Lung Cancer Clinical Trials**  
*Amanda Herrmann, USA*
- 12:18**     **Q&A**

**12:30 - 13:30     Lunch Break**

**EXHIBIT HALL**

 **LUNCH PROVIDED**

**12:30 - 13:30     DEI02 - Beyond Equity: Creating Understanding in Thoracic Oncology**

**ROOM: 22**

 **NOT FOR CME CREDIT**

 **LUNCH PROVIDED**

*Chairs: Narjust Florez, USA and Cecilia Pompili, UK*

- 12:30**     **Welcome & Introduction**  
*Narjust Florez, USA and Cecilia Pompili, UK*
- 12:32**     **DEI02.03 - An Update from the IASLC DEI Task Force**  
*Cecilia Pompili, UK*
- 12:42**     **DEI02.04 - Realistic Tips to Improve Inclusion in Clinical Trials**  
*William William Jr., Brazil*
- 12:52**     **DEI02.05 - Caring for Members of the LGBTQIA+ What You Should Know**  
*Charles Kamen-Mohn, USA*
- 13:02**     **DEI02.06 - Creating a Mutually Respectful Work Environment: How, When**

and Why?

*Misako Nagasaka, USA*

**13:12 DEI02.07 - Learning from Challenging Cases in DEI: Realistic Recommendations From Experts**

*Sue Crengle, New Zealand, Sabita Jiwnani, India, Raymond Osarogiagbon, USA, Ana Velazquez Manana, USA*

**13:25 Q&A**

**13:30 - 14:45 ES40 - Trial Design in the Early Stage Space: Concerns and Controversies**

**Track: Early-Stage Non-small Cell Lung Cancer**

**ROOM: 31ABC**

 ACCME ACCREDITED BY IASLC

*Chairs: Ayten Kayi Cangir, Turkey and Pamela Samson, USA*

**13:30 Welcome & Introduction**

*Ayten Kayi Cangir, Turkey and Pamela Samson, USA*

**13:32 ES40.03 - Designing Trials That Matter**

*Julie Brahmer, USA*

**13:43 ES40.04 - Issues in Trial Development from the Institutional to Cooperative Group Level**

*Noriko Kishi, Japan*

**13:55 ES40.05 - Completing Challenging Trials**

*Eric Lim, UK*

**14:07 ES40.06 - Approaching Patients With Early Stage Lung Cancer to Participate in Trials**

*Mary Duffy, Australia*

**14:19 Q&A**

**13:30 - 14:45 ES41 - Pulmonary & Pleural Complications in Pulmonary Malignancy**

**Track: Pulmonology and Staging**

**ROOM: 30BC**

 ACCME ACCREDITED BY IASLC

*Chairs: Douglas Arenberg, USA and David Feller-Kopman, USA*

**13:30 Welcome & Introduction**

*Douglas Arenberg, USA and David Feller-Kopman, USA*

**13:32 ES41.03 - Imaging of Complications of Lung Cancer Therapy: Targeted Therapy, Immunotherapy, Radiation Therapy**

*Mylene Truong, USA*

**13:44 ES41.04 - Management of Radiation Toxicities in the Era of Chemo Immunotherapy**

*Percy Lee, USA*

**13:56 ES41.05 - Managing Pneumonitis Secondary to Systemic Cancer Treatment**

*Willemijn Theelen, Netherlands*

**14:08 ES41.06 - Optimal Management of Malignant Pleural Effusion**

*Pyng Lee, Singapore*

**14:20 Q&A**

**13:30 - 14:45 ES42 - The Rest of the Pie: State of the Art for “Other” Targets**

**Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy**

**ROOM: 32AB**

 ACCME ACCREDITED BY IASLC

*Chairs: Ilit Turgeman, Israel and Chul Kim, USA*

- 13:30** **Welcome & Introduction**  
*Ilit Turgeman, Israel and Chul Kim, USA*
- 13:32** **ES42.03 - Exon 20: EGFR and HER2**  
*Susan Scott, USA*
- 13:44** **ES42.04 - RET cetera: RET, MET, and BRAF in 2024**  
*Giannis Mountzios, Greece*
- 13:56** **ES42.05 - KRAS G12C - Optimal Management**  
*Chunxia Su, China*
- 14:08** **ES42.06 - Targeted Therapies for NSCLC: The Patients' Perspective**  
*Korina Bell, Greece*
- 14:20** **Q&A**

## **13:30 - 14:45** **MA11 - Building on the Foundations of Current Immunotherapies**

**Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy**

**ROOM: 20BC**

 **NOT FOR CME CREDIT**

*Chairs: Antoinette Wozniak, USA and Alessandro Russo, Italy*

- 13:30** **Welcome & Introduction**  
*Antoinette Wozniak, USA and Alessandro Russo, Italy*
- 13:32** **MA11.03 - First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepithelioma-likecarcinoma: A Multicenter, Single-Arm, Phase II Trial**  
*Ni Sun, China*
- 13:37** **MA11.04 - First-in-Class PD-1/IL-2 Bispecific Antibody IBI363 In Patients with Advanced Non-Small Cell Lung Cancer in a Phase I Study**  
*Jianya Zhou, China*
- 13:42** **MA11.05 - Nivolumab + Ipilimumab vs Chemotherapy in Patients with Stage IVrecurrent NSCLC and PD-L1  $\geq$  in China: Checkmate 227 CHESS**  
*Yi-Long Wu, China*
- 13:47** **Q&A**
- 13:50** **MA11.07 - Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study**  
*Jhanelle Gray, USA*
- 13:55** **MA11.08 - Preliminary Efficacy and Safety of SHR-1701 Plus Fluzoparib as Maintenance Therapy for Patients with Advanced Lung Squamous Cell Carcinoma**  
*Yongchang Zhang, China*
- 14:00** **MA11.09 - Phase II Trial of Atezolizumab Plus Cobimetinib in PD-(L)1 Inhibitor Resistant NSCLC: NCI ETCTN Study 10166**  
*Andreas Saltos, USA*
- 14:10** **Q&A**
- 14:18** **MA11.11 - Benmelstobart, a PD-L1 Mab, Plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies: Phase II Results Update**  
*Meiqi Shi, China*
- 14:23** **MA11.12 - A Phase Ib Study of TQB2618 (Anti-TIM-3) in Combination with Penpulimab and Chemotherapy in Patients with Non-Small Cell Lung Cancer**  
*Yongsheng Wang, China*
- 14:28** **MA11.13 - Peripheral T-Cell Receptor Repertoire Differentiates a Typical Progression in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy**  
*Jiefei Han, China*
- 14:33** **Q&A**

**13:30 - 14:45 MA12 - Paving the Path to Precision Oncology: Targeting EGFR and HER2**

**Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy**

**ROOM: 20D**

 NOT FOR CME CREDIT

*Chairs: Christian Rolfo, USA and Fabiana Cecere, Italy*

- 13:30 Welcome & Introduction**  
*Christian Rolfo, USA and Fabiana Cecere, Italy*
- 13:32 MA12.03- FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed**  
*Jame CH Yang, Taiwan*
- 13:37 MA12.04 - FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFR-mutated Advanced NSCLC**  
*Natalia Valdiviezo, Peru*
- 13:42 Q&A**
- 13:50 MA12.06 - PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC**  
*Jonathan Goldman, USA*
- 13:55 MA12.07 - Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSA**  
*Danny Nguyen, USA*
- 14:00 MA12.08 - Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study**  
*Gilberto Lopes, USA*
- 14:05 Q&A**
- 14:13 MA12.10 - Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial**  
*Frans Opdam, Netherlands*
- 14:18 MA12.11 - Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI**  
*Fei Zhou, China*
- 14:23 Q&A**

**13:30 - 14:45 MA13 - Advancing Lung Cancer Prevention Through Understanding Risk Factors**

**Track: Risk Factors, Risk Reduction & Tobacco Control**

**ROOM: 30DE**

 NOT FOR CME CREDIT

*Chairs: Randi Williams, USA and Marcelo Corassa, Brazil*

- 13:30 Welcome & Introduction**  
*Randi Williams, USA and Marcelo Corassa, Brazil*
- 13:32 MA13.03 - Impact of a Tobacco Endgame Intervention on Lung Cancer Mortality in 185 Countries: A Population Birth Cohort Simulation Study**  
*Julia Rey Brandariz, Spain*
- 13:37 MA13.04 - A Comparison of Ever vs Never Smoking Surgically Treated Lung Cancer Patients**  
*Stephanie Tuminello, USA*
- 13:42 MA13.05 - The Impact of Tobacco Control on Lung Cancer Mortality Across 48 Countries**  
*Matthew Warkentin, Canada*
- 13:47 Q&A**

- 13:55**    **MA13.07 - Practical Implementation of Outdoor Air Pollution Exposure Measurement for Lung Cancer Risk Assessment**  
*Clinton Durney, Canada*
- 14:00**    **MA13.08 - PM2.5 Exposure Impact on Never-Smoking Lung Cancer Patients**  
*Yixian Chen, Canada*
- 14:05**    **MA13.09 - A World Map of Air Pollution and EGFR Prevalence**  
*Leonardo Rojas, Columbia*
- 14:10**    **Q&A**
- 14:18**    **MA13.11 - Glucagon-Like Peptide 1 Receptor Agonists Associated with Reduced Risk of Lung Cancer in Type 2 Diabetes Mellitus**  
*Tomasz Tabernacki, USA*
- 14:23**    **MA13.12 - Prevalence of Pathogenic or Likely Pathogenic Germline Variants in Cancer Predisposition Genes in Selected Lung Adenocarcinoma Patients**  
*Oscar Arrieta, Mexico*
- 14:28**    **Q&A**

**13:30 - 14:45      MA14 - Global Perspectives of Lung Cancer Across the Care Continuum**

**Track: Global Health, Health Services, and Health Economics**

**ROOM: 30A**

 **NOT FOR CME CREDIT**

*Chairs: Melody Qu, Canada and Ullas Batra, India*

- 13:30**    **Welcome & Introduction**  
*Melody Qu, Canada and Ullas Batra, India*
- 13:32**    **MA14.03 - Breathing Dangers: Unraveling Particulate Matter and Asbestos-Associated Lung Cancer Trends in the Top Ten Most Populous Countries**  
*Chinmay Jani, USA (Early Career Education Award Winner)*
- 13:37**    **MA14.04 - Global Burden and Trends of Asbestos-Related Thoracic Cancers and Their Associations with National Asbestos Ban Status: A Cross-Sectional Study**  
*Wang-Zhong Li, China*
- 13:42**    **Q&A**
- 13:50**    **MA14.06 - Cost-effectiveness Analysis of Entrectinib in the First-Line Treatment of ROS1+ Locally Advanced or Metastatic NSCLC in China**  
*Yan Xia, China*
- 13:55**    **MA14.07 - Access Disparities to Lung Cancer Radiotherapy Across Brazil: An Observational Analysis**  
*Andre Gouveia, Brazil*
- 14:00**    **MA14.08 - Revolutionizing Survival: The Real-World Impact of High-Cost Therapies on Advanced NSCLC**  
*Rossana Ruiz, Peru*
- 14:05**    **MA14.09 - Disparities in Outcomes of Hospitalized Unhoused Patients with Lung Cancer**  
*Fayaz Khan, USA*
- 14:10**    **Q&A**
- 14:18**    **MA14.11 - Duration of Intervals in the Care-Seeking Pathway of Lung Cancer in Nepal - Unraveling the Delays from Symptom Onset to Treatment Initiation**  
*Shama Pandey, Nepal (Developing Country Education Award Winner)*

**14:23** MA14.12 - Characterization of Sexual Dysfunction in Patients with Lung Cancer Undergoing Oncological Management: Results from the LUDICAS Study.

*Aylen Ospina Serrano, Spain*

**14:28** MA14.13 - Analysis of Lung Cancer-Specific Patient-Reported Outcome Measures (PROMs): Results from the PRO4All Project

*Alberto Servetto, Italy*

**14:33** Q&A

## 13:30 - 14:45 OA16 - Transforming Cancer Therapy: Biomarkers and Novel ADCs

**Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy**

**ROOM: 20A**

 ACCME ACCREDITED BY IASLC

*Chairs: Mihaela Aldea, France and Isabel Preeshagul, USA*

**13:30** Welcome & Introduction

*Mihaela Aldea, France and Isabel Preeshagul, USA*

**13:32** OA16.03 - Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY

*Hidehito Horinouchi, Japan*

**13:42** OA16.04 - Preliminary Results from a FIH Study of GQ1005, A Novel HER2-ADC, in Patients with Advanced HER2-Expressing Solid Tumors and HER2-Mutated NSCLC

*Anwen Xiong, China*

**13:52** OA16.05 - Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-Averexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1

*James C-H Yang, Taiwan*

**14:02** OA16.06 - Discussant

*Federico Cappuzzo, Italy*

**14:12** Q&A

## 13:30 - 14:45 OA17 - Increasing Access to Early Lung Cancer Detection

**Track: Screening and Early Detection**

**ROOM: 33ABC**

 ACCME ACCREDITED BY IASLC

*Chairs: Coral Olazagasti, USA and Rudolf Huber, Germany*

**13:30** Welcome & Introduction

*Coral Olazagasti, USA and Rudolf Huber, Germany*

**13:32** OA17.03 - Missed Opportunities for Early Lung Cancer Detection in a Multi-Disciplinary Thoracic Oncology Clinic Cohort

*Raymond Osarogiagbon, USA*

**13:42** OA17.04 - Implementation of a Natural Language Processing (NLP) Model to Detect Incidental Lung Nodules in a Nationwide Health Care Network

*Clarissa Baldotto, Brazil*

**13:52** OA17.05 - A Randomized Controlled Trial of a Digital Lung Health Intervention to Facilitate Smoking Cessation and Lung Cancer Screening

*Mary Cooley, USA*

**14:02** OA17.06 - Impact of Using Smoking Duration in Place of Pack-Years as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities

*Chloe Su, USA (Early Career Education Award Winner)*

**14:12**    **OA17.07 - Discussant**  
*Betty Tong, USA*

**14:22**    **Q&A**

**15:00 - 16:15**    **ES43 - Latest Advances in Unresectable Local-Regional NSCLC**

**Track: Local-Regional Non-small Cell Lung Cancer**

**ROOM: 31ABC**

 ACCME ACCREDITED BY IASLC

*Chairs: Aditya Juloori, USA and Qian Chu, China*

**15:00**    **Welcome & Introduction**

*Aditya Juloori, USA and Qian Chu, China*

**15:02**    **ES43.03 - Tobacco Awareness Moment - Smoking Cessation Improves Outcomes**  
*Joelle Fathi, USA*

**15:05**    **ES43.04 - Optimal Systemic Therapy During and After CRT**  
*Sanjay Popat, UK*

**15:17**    **ES43.05 - Redefining RT in the Context of Advances in Systemic Therapy**  
*Corinne Faivre-Finn, UK*

**15:29**    **ES43.06 - Monitoring Response and Relapse with PROM, Imaging and Circulating Biomarkers**  
*Josephine Feliciano, USA*

**15:41**    **ES43.07 - Supportive Care Before/During/After CRT**  
*Pablo Munoz-Schuffenegger, Chile*

**15:53**    **Q&A**

**15:00 - 16:15**    **ES44 - Updates on Lung Cancer Pathology 2024**

**Track: Pathology and Biomarkers**

**ROOM: 30DE**

 ACCME ACCREDITED BY IASLC

*Chairs: Paul Hofman, France and Tricia Cottrell, Canada*

**15:00**    **ES44.01 - Welcome & Introduction**

*Paul Hofman, France and Tricia Cottrell, Canada*

**15:02**    **ES44.03 - Common Differential Diagnostic Dilemmas in Lung Cancer Pathology and How to Deal with Them**  
*Yuko Minami, Japan*

**15:14**    **ES44.04 - Challenges of Delivering a Lung Cancer Pathology Service in Low and Middle Income Countries**  
*Fabio Tavoro, Brazil*

**15:26**    **ES44.05 - Assessment of MPR in Lung Cancer Resections: Where Are We in 2024?**  
*Annikka Weissferdt, USA*

**15:38**    **ES44.06 - Challenges in the Diagnosis of Neuroendocrine Tumours of the Lung**  
*Mauro Papotti, Italy*

**15:50**    **Q&A**

**15:00 - 16:15**    **ES45 - Intensifying Suboptimal Response to Targeted Therapy**

**Track: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy**

**ROOM: 32AB**

 ACCME ACCREDITED BY IASLC

*Chairs: Susan Scott, USA and Alfredo Addeo, Switzerland*

**15:00**    **Welcome & Introduction**

*Susan Scott, USA and Alfredo Addeo, Switzerland*



- 15:02** **ES45.03 - Addition of Cytotoxic Chemotherapy**  
*Bruna Pellini, USA*
- 15:14** **ES45.04 - Radiation Targeted Combinations**  
*Melina Marmarelis, USA*
- 15:26** **ES45.05 - Radiation to Residual Disease**  
*Henning Willers, USA*
- 15:38** **ES45.06 - Resecting Residual Disease**  
*Yi-Long Wu, China*
- 15:50** **Q&A**

## 15:00 - 16:15 **MA15 - Paradigm Shifts in Recurrence Assessment After Surgery**

**Track: Early-Stage Non-small Cell Lung Cancer**

**ROOM: 20A**

 NOT FOR CME CREDIT

*Chairs: Meera Ragavan, USA and Hari Keshava, USA*

- 15:00** **Welcome & Introduction**  
*Meera Ragavan, USA and Hari Keshava, USA*
- 15:02** **MA15.03 - Surveillance with [18F]FDG PET/CT of Lung Cancer after Curative Therapy; First Results of a Randomized Trial (SUPE\_R)**  
*Kasper Guldbrandsen, Denmark*
- 15:07** **MA15.04 - MRD Predicts Clinical Outcomes of Patients with Early-Stage EGFR-Mutant NSCLC: A Post-Hoc Biomarker Analyses of EVIDENCE**  
*Fei Zhou, China*
- 15:12** **MA15.05 - Follow-Up Update of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer**  
*Jia-Tao Zhang, China*
- 15:17** **Q&A**
- 15:25** **MA15.07 - Preliminary Analysis of Adjuvant Chemotherapy with Atezolizumab in Stage I-III Resected NSCLC and Clearance of ctDNA**  
*Rohan Maniar, USA*
- 15:30** **MA15.08 - Ultrasensitive Blood Test for Early Lung Cancer: Integrating Fragmentomics and Mutational Signatures in cfDNA**  
*Jianxing He, China*
- 15:35** **MA15.09 - LCMC3: Long-Term Disease-Free and Overall Survival and their Association with ctDNA after Neoadjuvant Atezolizumab for NSCLC**  
*Dwight Owen, USA*
- 15:40** **Q&A**
- 15:53** **MA15.11 - Aumolertinib as Adjuvant Therapy in Resectable I-III EGFR-Mutant NSCLC: Also Effective in Patients with High-Risk Relapse Factors**  
*Jian Yao, China*
- 15:58** **MA15.12 - Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations**  
*Ruixuan Geng, China*
- 16:03** **Q&A**

## 15:00 - 16:15 **MA16 - Strategies Beyond Current Immunotherapies**

**Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy**

**ROOM: 20BC**

 NOT FOR CME CREDIT

*Chairs: Merel Hennink, Netherlands and Fernando Santini, USA*

- 15:00** **Welcome & Introduction**  
*Merel Hennink, Netherlands and Fernando Santini, USA*

- 15:02** **MA16.03 - Survival Outcomes in Single Versus Double Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis**  
*Ben Ponvilawan, USA*
- 15:07** **MA16.04 - Radiomic Biomarkers Predict Response to Immunotherapy Rechallenge in Recurrent NSCLC after Chemoradiation and Durvalumab**  
*Lukas Delasos, USA*
- 15:12** **MA16.05 - PIEZO1+ Cancer-associated Fibroblasts Shape an Inert Microenvironment to Suppress Anticancer Immunity in Non-Small Cell Lung Cancer**  
*Mengzhu Zhou, China*
- 15:17** **Q&A**
- 15:30** **MA16.07 - A First in Human (FIH), Phase 1 Open Label, Dose Escalation and Expansion Study of CTM103, a LNP mRNA Encoding an IL2RB? Selective II-2v, As Monotherapy and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors**  
*Chengying Kong, China*
- 15:35** **MA16.08 - Impact of Site of CAN-2409 Injection Plus Continued Immune Checkpoint Inhibitor (ICI) In CI-resistant stage III/IV NSCLC**  
*Daniel Sterman, USA*
- 15:40** **Q&A**

**15:00 - 16:15** **MA17 - Limited-stage SCLC, Novel Immunotherapy Combinations and Biomarkers in SCLC**

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

**ROOM: 20D**

 NOT FOR CME CREDIT

*Chairs: Abraham Wu, USA and Sara Ramella, Italy*

- 15:00** **Welcome & Introduction**  
*Abraham Wu, USA and Sara Ramella, Italy*
- 15:02** **MA17.03 - 30 Years of International Real World Outcomes in Patients with Limited Disease Small Cell Lung Cancer**  
*Sam Khan, Canada*
- 15:07** **MA17.04 - Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC**  
*Silvia Novello, Italy*
- 15:12** **MA17.05 - Longitudinal MRD Monitoring Enhances Prognosis Prediction in 105 Patients with Limited-Stage SCLC Receiving Concurrent Chemoradiotherapy**  
*Yin Yang, China*
- 15:17** **Q&A**
- 15:25** **MA17.06 - Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial**  
*Baohui Han, China*
- 15:30** **MA17.07 - Safety and Efficacy of Tifcemalimab Combined with Toripalimab in Refractory Extensive Stage Small Cell Lung Cancer**  
*Liang Zhang, China*
- 15:35** **MA17.08 - Efficacy and Safety of Tislelizumab Plus Anlotinib and 2-Cycle Irinotecan as Second-Line Treatment for ES-Small Cell Lung Cancer(ESTAIL)**  
*Xian Chen, China*
- 15:40** **Q&A**
- 15:48** **MA17.10 - NOTCH1 Expression Is Associated with Overall Survival in Small Cell Lung Cancer Patients Treated with Atezolizumab in IMpower133**  
*Nitin Roper, USA*
- 15:53** **MA17.11 - Delineating the Mechanism of Resistance to Targeted Therapy via Cellular Transdifferentiation**  
*Priyanka Gopal, USA*

**15:58** MA17.12 - DLL3-targeted CAR-T Therapy of Small Cell Lung Cancer Utilizing Circular RNA  
*Mantang Qiu, China*

**16:03** Q&A

## 15:00 - 16:15 MA18 - New Paradigms in Lung Cancer Screening

**ROOM: 33ABC**

 NOT FOR CME CREDIT

*Chairs: Loretta Erhunmwunsee, USA and Long Jiang, China*

**15:00** Welcome & Introduction

*Loretta Erhunmwunsee, USA and Long Jiang, China*

**15:02** MA18.03 - Participant Eligibility for Lung Cancer Screening in Australia: An Analysis of Proposed Criteria

*Chellan Kumarasamy, Australia*

**15:07** MA18.04 - Evaluating Early-Stage Lung Cancer Survival Based on Age and Morbidity to Inform the Upper Age Limit for Screening

*Matthew Warkentin, Canada*

**15:12** MA18.05 - Effectiveness of NELSON vs PLCOm2012 Lung Cancer Screening Eligibility Criteria: Final Analysis of the Prospective German HANSE Study

*Jens Vogel-Clausen, Germany*

**15:17** Q&A

**15:25** MA18.07 - Missing Variables and the Utility of Lung Cancer and Lung Nodule Risk Calculators

*Matthew Smeltzer, USA*

**15:30** MA18.08 - Risk and Timing of Second Primary Lung Cancer Among Young Women with a History of Breast Cancer in the USA

*Alexandra Potter, USA (Early Career Education Award Winner)*

**15:35** MA18.09 - Comparing Efficient Lung Cancer Screening Strategies for Black and White Americans

*Sarah Skolnick, USA*

**15:40** Q&A

**15:48** MA18.11 - The Evolution of the Lung Screening Network: Uniting to Strengthen Community and Share Best Practices Among Navigators

*Sabrina Moffat, USA (Nurse & Allied Health Professionals Award Winner)*

**15:53** MA18.12 - Innovations in Lung Cancer Screening: Adoption of the Pink and Pearl Campaign

*Annie Lally, USA*

**15:58** MA18.13 - Comparison of Sybil with Brock and PLCOm2012 Models Among Screening Participants with Positive and Negative Baseline Screens

*Rafael Meza, Canada*

**16:03** Q&A

## 15:00 - 16:15 MA19 - Innovative Therapeutic Approaches and Molecular Insights in Lung Cancer

**Track: Tumor Biology – Translational Biology**

**ROOM: 30A**

 NOT FOR CME CREDIT

*Chairs: Sandra Ortiz-Cuaran, France and Hongbin Ji, China*

**15:00** Welcome & Introduction

*Sandra Ortiz-Cuaran, France and Hongbin Ji, China*

**15:02** MA19.03 - SMARCA4 Controls State Plasticity in SCLC Through Regulation of Neuroendocrine Transcription Factors and REST Splicing

*Esther Redin, USA (Early Career Education Award Winner)*

- 15:07** MA19.04 - Teriflunomide in Vitro or Leflunomide in Vivo Treatment Increases the Efficacy of Lurbinectedin in SCLC  
*Tamara Mirzapoiazova, USA*
- 15:12** MA19.05 - Dynamic Immune Profile of Peripheral Blood Predicts Immunotherapy Efficacy and Prognosis in Small Cell Lung Cancer  
*Lin Wu, China*
- 15:17** Q&A
- 15:25** MA19.07 - Targeting USP22 Suppressed Carcinogenesis and Enhanced Immune Response in KRAS-Induced Lung Cancer  
*Keqiang Zhang, USA*
- 15:30** MA19.08 - Transcriptomic Features of Circulating CX3CR1+CD8+ Temra Cells as a Predictor of Chemo-Immunotherapy Response in NSCLC Patients  
*Yichen Dong, China*
- 15:35** Q&A
- 15:43** MA19.10 - The Tracerx 421 Cohort Provides Insights to Key Pathological Features of Lung Squamous Cell Cancer  
*David Moore, UK*
- 15:48** MA19.11 - In Vivo CRISPR/Cas9 Library Screening for Target Genes of SCLC Brain Metastasis  
*Yiyun Wang, China*
- 15:53** MA19.12 - Identification of Novel Therapeutic Targets for SOX2 Driven Lung Squamous Cell Carcinoma  
*Roya Navab, Canada*
- 15:58** Q&A

**15:00 - 16:15** OA18 - Pleural, Mediastinal and Undifferentiated Thoracic Cancers

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

ROOM: 30BC

ACCME ACCREDITED BY IASLC

Chairs: Rebecca Heist, USA and Francesco Passiglia, Italy

- 15:00** Welcome & Introduction  
*Rebecca Heist, USA and Francesco Passiglia, Italy*
- 15:02** OA18.03 - Real-World Data on the Efficacy and Safety of Lenvatinib in Patients with Previously Treated Thymic Carcinoma  
*Nobuaki Mamesaya, Japan*
- 15:12** OA18.04 - Pembrolizumab Plus Lenvatinib in Second-Line Pleural Mesothelioma Patients: A Single Arm Phase II Study (PEMELA Cohort 2)  
*LiAnne Douma, Netherlands*
- 15:22** OA18.05 - Neoadjuvant Versus Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial  
*Yaoyao Zhu, China*
- 15:32** OA18.06 - Characteristics and Outcomes of Patients with SMARCA4-Deficient Undifferentiated Thoracic Tumors  
*Alissa Cooper, USA*
- 15:42** OA18.07 - Discussant  
*Prasad Adusumilli, USA*
- 15:52** Q&A

16:30 - 17:30

**PL07 - Closing Plenary: Breaking Barriers, Building Bridges: Advancing Patient Advocacy Worldwide****ROOM: 20A** **LIVESTREAMED** **ACCME ACCREDITED BY IASLC***Chairs and Panel Moderators: Jhanelle Gray, USA and Annabelle Gurwitch, USA***16:30 Welcome & Introduction***Jhanelle Gray, USA and Annabelle Gurwitch, USA***16:32 Panel Discussion: Overcoming Barriers to Patient Advocacy Worldwide***Yvonne Diaz, UK, Caleb Egwuenu, Nigeria, Lillian Leigh, Australia, Shani Shilo, Israel***16:52 Panel Discussion: Enhancing the Patient Physician Partnership***Timothy Monds, Canada, Isabelle Schmitt-Opitz, Switzerland, Paul Wheatley-Price, Canada***17:12 Discussion Closing Remarks***Annabelle Gurwitch, USA***17:17 Conference Closing Remarks***WCLC 2024 Conference Chairs: Narjust Florez, USA, Linda Martin, USA, Sandip Patel, USA, Fabio Ynoe de Moraes, Canada  
IASLC President: Paul Van Schil, Belgium***17:22 Invitation to WCLC 2025***WCLC 2025 Chairs: Umberto Malapelle, Italy, Jarushka Naidoo, Ireland, Noemi Reguart, Spain, Isabelle Schmitt-Opitz, Switzerland***05 / Conference Program****SCIENTIFIC PROGRAM / ON DEMAND****HOD03 - Highlights of the Day - Tuesday Abstracts****ON-DEMAND** **ACCME ACCREDITED BY IASLC****HOD03.01 - mNSCLC: Innovative Frontiers: Advances in mNSCLC Cytotoxic Therapy and ADCs, Immune Insights, and Targeted Treatment Paradigms***Ryan Gentzler, USA***HOD03.02 - Expanding the Boundaries in Mesothelioma, Thymoma, SCLC, and Early-Stage NSCLC***Young Tae Kim, Republic of Korea***HOD03.03 - Transforming Screening and Early Detection and Precision Diagnostics in Pulmonology and Staging***Antoni Rosell, Spain***HOD03.04 - Lab to Clinic and Back: Breakthroughs in Tumor Biology - Translational and Preclinical Research, Pathology, and Biomarkers***Sukhmani Padda, USA***HOD03.05 - Empowering Voices with Patient Advocacy, Mitigating Risks, and Global Perspectives in Health Services and Health Economics***Morten Quist, Denmark****Thank you for attending WCLC 2024 and celebrating 50 years of IASLC with us.******See you in Barcelona, Spain from September 6 - 9, 2025 for WCLC 2025.***



**SAVE THE DATE!**



European Lung  
Cancer Congress 2025

**PARIS FRANCE**  
**26-29 MARCH 2025**









# Order Your Copy of the IASLC 50th Anniversary History Book

*Advances in Thoracic Oncology Treatment &  
Research: Legacy of Impact, Future of Promise*

Secure your piece of history now! Order your 50th Anniversary edition of our exclusive history book today and cherish this momentous occasion for years to come.

Don't wait, order your copy now and be among the first to relive the memories!



Edited by Fred R. Hirsch, MD, PhD and Paul A. Dunn, Jr., MD



Scan the QR code or go to  
<https://bit.ly/IASLC50Book>  
to order your copy.







P1: Presenters in Attendance between **12:00 – 14:00**

P2: Presenters in Attendance between **18:15 – 19:45**

P1 Posters – Presenters in Attendance: **12:00 – 14:00**

## TRACK 01: RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

### POSTER SESSION P1.01A – SUB-THEME A: CLINICAL TRIALS IN PROGRESS

**P1.01A.01** The INHERIT Study - Investigating Hereditary Risk in Thoracic Cancers (NCT05587439)  
*Courtney Granville, USA*

**P1.01A.02** Monitoring Inflammatory Response Secondary to Air Pollution Exposure Through Volatile Organic Compounds  
*Renelle Myers, Canada*

**P1.01A.03** Can-Prevent-Lung Trial-Canakinumab for the Prevention of Lung Cancer: Updated Interim Clinical and Biomarker Analysis  
*Jianjun Zhang, USA*

**P1.01A.04** Point-of-care Nicotine Replacement for the Treatment of Nicotine Addiction in a Provincial Cancer System  
*Cheryl Colby, Canada*

### POSTER SESSION P1.01B - SUB-THEME B: DISEASE - PROFILE

**P1.01B.01** Derivation and Validation of Nomogram to Predict Outcomes of Patients with Simultaneous Multiple Primary Lung Cancer  
*Ying Liu, China*

**P1.01B.02** The Genomic Landscape of Lung Cancer in Never-Smokers from the Women's Health Initiative  
*Sitapriya Moorthi, USA*

**P1.01B.03** Risk Factors Associated with Venous Thromboembolism in Advanced ALK Rearranged Non-Small Cell Lung Cancer  
*Simon Ekman, Sweden*

**P1.01B.04** A Highly Unmet Need: Patterns of Lung Cancer Screening in Head and Neck Cancer Survivors Preceding a Lung Cancer Diagnosis  
*Coral Olazagasti, USA*

**P1.01B.05** Real-World Data on 3-Year Survival in Non-Small Cell Lung Cancer (NSCLC): Results from 3 French Nationwide Cohorts from 2000 To 2020  
*Didier Debieuvre, France*

### POSTER SESSION P1.01C - SUB-THEME C: TOBACCO

**P1.01C.01** Effectiveness of Health Education on Adolescent Tobacco Use Intention: Cluster RCT in Ibadan, Nigeria  
*Omotayo Fagbule, Nigeria*

**P1.01C.02** Tobacco Control and Smoking Cessation-related Content in Oncology Meetings: A Scoping Review  
*Sun Choi, Canada*

**P1.01C.03** The Influence of Smoking on Morbidity and Early Mortality after Anatomical Lung Resections for Stage I-IIIa NSCLC  
*Konstantinos Grapatsas, Germany*

**POSTER SESSIONS / SUNDAY, SEPTEMBER 8 (P1 + P2 POSTERS)**

- P1.01C.04** Key Stakeholder Priorities on Embedding Smoking Cessation into Lung Cancer Screening: National Australian Consensus Workshop  
*Nicole Rankin, Australia*
- P1.01C.05** Potential Impact of Tobacco Control Policies in Preventing Incident Lung Cancers in the Eastern Mediterranean Region  
*Saeed Nemati, France*

**TRACK 02: TUMOR BIOLOGY – PRECLINICAL BIOLOGY**

**POSTER SESSION P1.02A – SUB-THEME A: EARLY STAGE DISEASE/STEM CELLS**

- P1.02A.01** ADAR1 Regulates Tumorigenesis and Stem Cell Properties in Non-Small Cell Lung Carcinoma  
*Manish Patel, USA*

**POSTER SESSION P1.02B - SUB-THEME B: GENOMICS**

- P1.02B.01** Mirnome Functional Profiling of Non-Small Cell Lung Cancer Identified New Mechanisms of PD-L1 Regulation  
*Fabrizio Bianchi, Italy*
- P1.02B.02** Role of Chromosome 3 Aneuploidy in Basal Cell Differentiation and Lung Squamous Cell Carcinoma Initiation  
*Joan Castellano, USA*

**POSTER SESSION P1.02C - SUB-THEME C: IMMUNE MODULATION**

- P1.02C.01** Intrinsic STING of CD8+T Cells Regulates Self-Metabolic Reprogramming and Improves Anti-Tumor Effects  
*Qiuli Xu, China*
- P1.02C.02** NIR-II Mediates Cancer Nanocomposite Vaccines for Lymph Node Targeted Delivery and Enhanced Immunotherapy  
*Lintong Yao, China*
- P1.02C.03** A Novel IL-15 Superagonist SHR-1501 Promotes Immune Response in Lung Cancer via Modulating Tumor Microenvironment  
*Qian Zhang, China*

**POSTER SESSION P1.02D - SUB-THEME D: NOVEL MODELS/NOVEL TECHNOLOGIES**

- P1.02D.01** Exosome PAICS Enhances Radioresistance in NSCLC by Mitigating Radiation-Induced DNA Damage and Facilitating Immune Evasion  
*Xiaomei Gong, China*
- P1.02D.02** Tumor-Derived Exosomal tsRNA 3' tiRNA-AlaCGC Promotes Immune Tolerance by Inducing Fibroblast Senescence in LUAD  
*Yuchen Zhang, China*

**TRACK 03: TUMOR BIOLOGY – TRANSLATIONAL BIOLOGY**

**POSTER SESSION P1.03A – SUB-THEME A: BIOMARKERS**

- P1.03A.01** Identification of Disulfidptosis in ESCC Based on Single-Cell and Bulk RNA-seq Data to Predict Prognosis and Treatment Response  
*Maohui Chen, China*
- P1.03A.02** FBXO32 Promotes EMT and Regulates the Cell Cycle by Targeting PTEN for Proteasomal-Dependent Degradation in LUAD  
*Sida Qin, China*

**POSTER SESSION P1.03B - SUB-THEME B: EARLY STAGE/STEM CELLS**

- P1.03B.01** Multi-Omics Profiling Reveals the Genomic Origin and Adeno-Squamous Transdifferentiation Mechanism in Adenosquamous Carcinoma  
*Gen Lin, China*

**POSTER SESSION P1.03C - SUB-THEME C: GENOMICS**

- P1.03C.01** A Landscape of the Driver Alterations in 920 Brazilian Lung Cancer Patients.  
*Flávio Augusto Ferreira da Silva, Brazil*
- P1.03C.02** Different STK11 Mutation Status Defines Various TIME in NSCLC  
*Xiaohui Chen, China*

**POSTER SESSION P1.03D - SUB-THEME D: IMMUNE MODULATION**

- P1.03D.01** Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC)  
*Nan Wu, China*
- P1.03D.02** An Enhanced Immunotherapeutic Strategies for NSCLC via in Situ Tumor Nanovaccines and Activation of STING and TLR7/8 Pathways  
*Shaowei Wu, China*
- P1.03D.03** Artemisinin Enhances Anti-Tumor Immunity by Increasing FGL1 Ubiquitination Degradation via Activating TRIM21 In NSCLC  
*Yuchen Zhang, China*
- P1.03D.04** Circulating APOBEC Signature as a Non-Invasive Biomarker Delineating Potential Responder to Neoadjuvant Immunotherapy for IIIA-N2 NSCLC  
*Changbin Zhu, China*
- P1.03D.05** A Novel DNA Repair-Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients with EGFR-Mutant Non-Small Cell Lung Cancer  
*Fen Wang, China*
- P1.03D.06** Targeting IL-6 And Immune Checkpoint Interactions to Augment the Anti-Tumor Immune Response in Lung Carcinoma  
*Kayla Goliwas, USA*
- P1.03D.07** Overcoming Immunotherapy Resistance in Non-Small Cell Lung Cancer With a Triple Combination Therapy: Efficacy and Mechanisms  
*Yaping Xu, China*
- P1.03D.08** Padeliporphan VTP Reverts NSCLC Orthotopic Tumors in Animal Models into Highly Responsive to aPD1 Therapy  
*David Kain, Israel*
- P1.03D.09** Single Cell RNA Sequencing and Functional Monocyte Stimulation Reveals Phenotypic Predispositions to Developing Lung Cancer in Never Smokers  
*Venessa Chin, Australia*
- P1.03D.10** Uncovering the Molecular Pathways Associated with Immunotherapy-Induced Pneumonitis in Non-Small Cell Lung Cancer Patients  
*Jiayi Deng, China*
- P1.03D.11** Association Between Plasminogen Activator Inhibitor-1 & Tolerance Against Anti-PD-1 Antibody in Non-Small Cell Lung Cancer  
*Masahiko Sumii, Japan*

**POSTER SESSION P1.03E - SUB-THEME E: MICROBIOME**

- P1.03E.01** Effect of Gut Microbiota and Metabolites on the Efficacy of Immunotherapy Combined with Chemotherapy in Lung Squamous Cell Carcinoma Patients  
*Xu Han, China*

## POSTER SESSION P1.03F - SUB-THEME F: NOVEL MODELS/NOVEL TECHNOLOGIES

- P1.03F.01** Imaging the Nucleolus Using Two-Photon Microscopy to Distinguish Between Tumor Cells and Normal Cells  
*Jiani Gao, China*
- P1.03F.02** Establishment of EBUS-TBNA Sample Derived Lung Cancer Organoid and Xenograft and Utility for Development of Targeted Therapy  
*Takamasa Koga, Canada*
- P1.03F.03** Utility of Patient-Derived Xenograft and Xenograft-Derived Organoid Models with EGFR Mutation to Study EGFR-TKI Resistance  
*Nhu-An Pham, Canada*

## POSTER SESSION P1.03G - SUB-THEME G: SCLC

- P1.03G.01** Lurbinectedin Synergizes with Selinexor by Inhibiting DNA Damage Repair and Enhancing Immune Cell Infiltration in Neuroendocrine Lung Tumors  
*Esther Redin, USA*
- P1.03G.02** Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFR-Mutant Lung Cancers with SCLC Transformation  
*Jie Huang, China*
- P1.03G.03** Role of SMARCA4, Core SWI/SNF Complex Component, in Small Cell Lung Cancer Development  
*Nicole Kirk, USA*
- P1.03G.04** A Model of Human Small Cell Lung Cancer Metastasis Utilizing Orthotopic Transplantation of Patient-Derived Xenografts  
*James Kim, USA*

## TRACK 06: PATHOLOGY AND BIOMARKERS

## POSTER SESSION P1.06A - SUB-THEME A: AI

- P1.06A.01** Machine Learning Models Discriminate Independent Primaries with Metastatic in Non-Small-Cell Lung Cancer  
*Ning Liu, China*
- P1.06A.02** Discovery of Morphomolecular Neighbourhoods in Lung Adenocarcinoma Using Self-supervised Learning  
*Kai Rakovic, UK*
- P1.06A.03** Use of Biosimulation to Predict Concomitant Chemotherapy Benefit in NSCLC Patients with EGFR Mutations Being Treated with Osimertinib  
*Charu Aggarwal, USA*
- P1.06A.04** Deep Learning-based Whole Slide Image Analysis Predicts PD-L1 Status from H&E-Stained Histopathology Images in Lung Cancer  
*Yi-Fan Qi, China*
- P1.06A.05** Assessing Pathologic Response to Neoadjuvant Chemoimmunotherapy for NSCLC: Aligning Current Protocols with Artificial Intelligence  
*Fernando Lopez-Rios, Spain*
- P1.06A.06** Post-COVID-19 Tumor Microenvironment Features and AI-Based Evaluation in KRAS-Mutant NSCLC  
*Ziling Huang, China*
- P1.06A.07** Prognostic Gene Expression Profiling in Lung Adenocarcinoma Using Deep Learning Applied to Whole-Slide Images  
*Pierre Murchan, Ireland*

## POSTER SESSION P1.06B - SUB-THEME B: BIOMARKERS

- P1.06B.01** NSCLC in Patients with CTD-ILD: Apobec-Related Mutagenesis, Frequent TP53 Mutations and Paucity of Targetable Alterations  
*Igor Odintsov, USA*
- P1.06B.02** A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC  
*Ziling Huang, China*
- P1.06B.03** Genetic Profiles and Evolutionary Trajectory of Early-Stage Lung Adenocarcinoma (AAH, AIS, MIA and IA) Revealed by Multiplex Sequencing  
*Lin Lixuan, China*
- P1.06B.04** Exploring Circulating Tumor Antigens as a Faster and Lower Cost Alternative to Circulating Tumor DNA in IMpower150  
*Namrata Patil, USA*
- P1.06B.05** Utility of Molecular Tumor Board Driven by Precision Medicine Service and Cloud-Based Datamart for Therapy and Trial Matching  
*J. Hicks, USA*
- P1.06B.06** Analysis of Antibody-Drug Conjugate Target Expression Across Genomic Subsets of Non-Small Cell Lung Cancer  
*Jessica Lin, USA*
- P1.06B.07** Association of NEDD9 Expression and Survival of Patients with KRAS Mutant and STK11 Mutant Non-Small Cell Lung Cancer (KRASMUT/STK11MUT-NSCLC)  
*Julia Judd, USA*
- P1.06B.08** The Prognostic Value of Histidine-rich Glycoprotein in Patients with Bronchial Carcinoid  
*Dwayne Naves, Netherlands*
- P1.06B.09** Noninvasive Blood Biopsy of CRTAM-Type 3 Immune Axis Enables Dynamic Monitoring of Iraes Over the Course of Immunotherapy in Lung Cancer  
*Si-Cong Ma, China*
- P1.06B.10** Post-hoc Biomarker Analysis of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy as First-Line Therapy for ES-SCLC  
*Changbin Zhu, China*
- P1.06B.11** Plasma MicroRNAs Profiling to Monitor Immunotherapy Response in Advanced NSCLC Patients  
*Marta Brambilla, Italy*
- P1.06B.12** Racial and Socioeconomic Disparities in Molecular Diagnostics for NSCLC Patients  
*Stephanie Tuminello, USA*
- P1.06B.13** Blood-Based Loss of Heterozygosity in Human Leukocyte Antigen Class I Alleles Reveals Resistance to Immunotherapy in Non-Small Cell Lung Cancer  
*Yiting Dong, China*
- P1.06B.14** Optimal Cut-Off with NGS for Metamplification and Clinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer  
*Si-Yang Liu, China*
- P1.06B.15** The Role and Clinical Significance of the MICOS Family in Lung Adenocarcinoma: A Focus on MIC19  
*Xuanguang Li, China*
- P1.06B.16** HER3 Expression Across Genomic Subsets of NSCLC  
*Brinda Gupta, USA*
- P1.06B.17** Combing Circulating Tumor Cell Associated Liquid Biopsy and Radiomics to Predict the Pathology Grade of LUAD Patients  
*Wang Hongchang, China*
- P1.06B.18** Pathologic Response Assessment of Resected NSCLC Neoadjuvant Therapy Specimens with Tumor Size Larger Than 3cm by Different Sampling Methods  
*Guo JunHong, China*



**P1.06B.19** Effect of Gut Microbiota and Metabolites on Malignant Pleural Effusion of Lung Adenocarcinoma  
*Meixi Lin, China*

**POSTER SESSION P1.06C - SUB-THEME C: PATHOLOGY**

**P1.06C.01** Evaluation of Small Pulmonary Pathology Specimen Management in the Province of Quebec, Canada  
*Michael Maranda-Robitaille, Canada*

**P1.06C.02** Description of A Single Center Thoracic Rapid Tissue Donation Program Experience  
*Theresa Boyle, USA*

**P1.06C.03** Prediction of STAS by Intraoperative Frozen Section for cTINOMO Lung Adenocarcinoma: A Prospective, Multi-Center Clinical Trial (ECTOP-1016)  
*Yang Zhang, China*

**P1.06C.04** Low-Level Deletion of Chromosome 19p Genes May Be Sufficient to Drive Histology-Dependent Phenotypes in Lung Cancer  
*Brian Henick, USA*

**P1.06C.05** The Impact of Lymphovascular Invasion as Prognostic Factor on Long-Term Survival in More Than 3500 Resected NSCLC Patients  
*Fabian Doerr, Germany*

**P1.06C.06** The Prognostic Impacts of Three Invasive Patterns in Pulmonary Peripheral Squamous Cell Carcinoma  
*Hideto Iguchi, Japan*

**TRACK 08: LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER**

**POSTER SESSION P1.08A - SUB-THEME A: ADJUVANT THERAPY**

**P1.08A.01** Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Multicenter Study  
*Zeliang Ma, China*

**POSTER SESSION P1.08B - SUB-THEME B: BIOMARKERS FOR UNRESECTABLE NSCLC**

**P1.08B.01** Predicting Tumor Recurrence Risk in Locally Advanced NSCLC with Detectable ctDNA-Based Molecular Residual Disease: An Xgboost Model Analysis  
*Yi Pan, China*

**P1.08B.02** Circulating T-Cell Immunosenescence in Patients with Unresectable Locally Advanced NSCLC: Preliminary Results of the SENLOAD Study  
*Jose Benitez, France*

**POSTER SESSION P1.08C - SUB-THEME C: CLINICAL NEOADJUVANT**

**P1.08C.01** Targeted Therapy or Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIb EGFRm Lung Adenocarcinoma: A Study Between Four Cohorts  
*Fang-Liang Lu, China*

**P1.08C.02** Revisiting the ACS 3N2 + 1N1 Mandate: Should Old Data Define Today's Standard?  
*Shubham Gulati, USA*

**P1.08C.03** Updated Event-Free Survival of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for Stage IIB-IIIC NSCLC (Lungmark Study)  
*Yao-Bin Lin, China*

**P1.08C.04** Delineating the Prognosis Spectrum: Disentangling Primary Tumor and Lymph Node Responses in NSCLC Following Neoadjuvant Immunotherapy  
*Long Jiang, China*

## POSTERS / SUNDAY, SEPTEMBER 8 (P1 + P2 POSTERS)

- P1.08C.05** The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study  
*Ken Suzawa, Japan*

## POSTER SESSION P1.08D - SUB-THEME D: UNRESECTABLE NSCLC

- P1.08D.01** The Efficacy of Durvalumab after Concurrent Chemoradiotherapy for EGFR-Mutated Stage III Non-Small Cell Lung Cancer (NEJ063)  
*Gen Kida, Japan*
- P1.08D.02** Survival after Salvage Treatment Following Durvalumab Consolidation in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)  
*Margaret Stalker, USA*
- P1.08D.03** Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC)  
*Rachel Sanborn, USA*
- P1.08D.04** The Clinical Outcomes of Contralateral Esophagus Sparing IMRT in Concurrent Chemoradiotherapy for Stage III Lung Cancer  
*Yong Chan Ahn, Republic of Korea*

## TRACK 09: METASTATIC NON-SMALL CELL LUNG CANCER – LOCAL THERAPIES

## POSTER SESSION P1.09A – SUB-THEME A: RADIATION

- P1.09A.01** The Effectiveness of Split-course Stereotactic Body Radiation Therapy in Treating Large Thoracic Cancer  
*SiQi Tian, China*
- P1.09A.02** Pathologic Tumor Positivity vs Only Necrosis in Clinically Suspected Recurrent Brain Metastasis Post-Radiation  
*Rupesh Kotecha, USA*
- P1.09A.03** Concurrent Combination of EGFR-TKIs and Thoracic Radiation Therapy for Metastatic Non Small Cell Lung Cancer Patients  
*Masahiro Yoshida, Japan*

## POSTER SESSION P1.09B – SUB-THEME B: SURGERY

- P1.09B.01** Surgical Reduction at the Peak of Response Before Disease Progression in Patients with Metastatic EGFR-Mutated Lung Cancer  
*Daniil Stroyakovskiy, Russian Federation*
- P1.09B.02** Double Lung Transplantation in Patients with Metastatic Lung-limited Non-Small Cell Lung Carcinoma (NSCLC)  
*Young Chae, USA*
- P1.09B.03** Ex-Situ Lung Transplantation without Heparinization: A Novel Surgical Approach for Locally Advanced and Central Lung Carcinoma  
*Sijia Yang, China*
- P1.09B.04** Impact of BMI on TTFields in Patients with mNSCLC: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data  
*Christian Rolfo, USA*
- P1.09B.05** Improved Survival of Primary Tumor Resection for Metastatic Non Small Cell Lung Cancer: A Propensity Score-matched Analysis  
*Jiayan Wu, China*

## POSTER SESSION P1.09C – SUB-THEME C: CLINICAL TRIALS IN PROGRESS

- P1.09C.01** A Multicenter, Randomized, Phase II Trial of EGFR TKI with Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients  
*Pei-Hsing Chen, Taiwan*
- P1.09C.02** SICARIO: A Phase I/II Study of Split Course Adaptive Radioimmunotherapy for the Treatment of Oligometastatic Non-Small Cell Lung Cancer  
*Ryan Whitaker, USA*
- P1.09C.03** IMMUNOResist: Defining the Immunophenotype of Immunotherapy Resistance with PD-L1 and CD8 Novel Tracer PET  
*Fiona Hegi-Johnson, Australia*

## TRACK 12: METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY

## POSTER SESSION P1.12A – SUB-THEME A: EGFR

- P1.12A.01** Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm  
*Jorge Nieva, USA*
- P1.12A.02** Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with NSCLC Harboring EGFR Exon 19 Insertions: A Report from the LC-SCRUM-Asia  
*Yuji Uehara, Japan*
- P1.12A.03** Outcome and Transcriptomic Features of Dual EGFR and MET Blockade in NSCLC  
*David Lee, Malaysia*
- P1.12A.04** Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib  
*Matthew Lee, USA*
- P1.12A.05** Aumolertinib in Treatment-Naïve EGFR-Mutant NSCLC Patients with Brain Metastases: Efficacy and Safety Data from the ARTISTRY  
*Xiaojuan Zhang, China*
- P1.12A.06** A Phase II 80 Mg Osimertinib in Patients with Leptomeningeal Metastases Associated with EGFR Mutation-Positive NSCLC (BLOSSOM)  
*Jinyong Kim, Republic of Korea*
- P1.12A.07** A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation  
*Baohui Han, China*
- P1.12A.08** The Mechanism Study on a Novel CD3-EGFR Bispecific Antibody Combo Improves Osimertinib-Resistant NSCLC Tumor Environment  
*Haoyue Guo, China*
- P1.12A.09** A Phase 1b Study of the MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination with Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer  
*Conor Steuer, USA*
- P1.12A.10** Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC  
*Fangdi Sun, USA*
- P1.12A.11** Analysis of Uncommon EGFR Exon 19 Alterations Identified by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer (NSCLC)  
*Jason Porter, USA*
- P1.12A.12** Liquid Biopsy Based Risk Stratification and Intensification of Treatment in EGFR Mutant Advanced NSCLC (L-BRITE) Preliminary Analysis  
*Hemavathi Baskarane, India*
- P1.12A.13** When Targeted Therapy Targets the Heart: Osimertinib-related Cardiotoxicity in EGFR Mutated Non-Small Cell Lung Cancer  
*Francisco Martinez, USA*

## POSTER SESSION P1.12B - SUB-THEME B: FUSIONS: ALK / ROS1 / RET / NTRK

- P1.12B.01** Intracranial Efficacy of Lorlatinib via RANO-BM in ALK-Fusion NSCLC with CNS Metastases: A Retrospective, Multicenter Study  
*Juan Li, China*
- P1.12B.02** Mechanisms of Resistance to First-Line vs Later-Line Alectinib in ALK Fusion-Positive Non-Small Cell Lung Cancer  
*Sarah Waliqny, USA*
- P1.12B.03** Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK+ NSCLC from the ALTA-1L Trial  
*Myung-Ju Ahn, Republic of Korea*
- P1.12B.04** Central Nervous System (CNS) Progression on CNS Penetrable ALK TKI: Real-World Practice Patterns and Patient Outcomes  
*Surbhi Singhal, USA*
- P1.12B.05** Patient and Oncologist Preferences for ALK+ Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments  
*Hannah Le, USA*
- P1.12B.06** Deulorlatinib (TGRX-326) in Patients with ALK Fusion-Positive NSCLC: Update from the Phase 1 Trial  
*Hongyun Zhao, China*
- P1.12B.07** Iruplinalkib in Patients with ALK-Positive Crizotinib-Resistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 Trial  
*Yuankai Shi, China*
- P1.12B.08** Thrombotic Events at Diagnosis are Associated with Poorer First Line TKI Outcomes Among Metastatic ALK and ROS1 NSCLC Patients  
*Tejas Patil, USA*
- P1.12B.09** Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials  
*Ben Solomon, Australia*
- P1.12B.10** Dose Adjustments and Exposure-Response Associated with Selpercatinib in Patients with Advanced NSCLC  
*Keunchil Park, Republic of Korea*
- P1.12B.11** ALK Positive Lifestyle  
*K. Culver, USA*

## TRACK 13: SMALL CELL LUNG CANCER AND NEUROENDOCRINE TUMORS

## POSTER SESSION P1.13A - SUB-THEME A: CLINICAL TRIALS

- P1.13A.01** DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer  
*Afshin Dowlati, USA*
- P1.13A.02** Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial  
*Maurice Perol, France*
- P1.13A.03** MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC  
*Hirva Mamdani, USA*
- P1.13A.05** Preliminary Results of a Phase II Study of Camrelizumab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for LD-SCLC  
*Yaping Xu, China*

- P1.13A.06** Outcomes in LS SCLC Patients with Severe Acute Esophagitis During Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy  
*Miriam Grønberg, Norway*
- P1.13A.07** Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study  
*Changping Hu, China*
- P1.13A.08** Biomarker Analysis of Camrelizumab Plus Nab-paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer  
*Shengxiang Ren, China*
- P1.13A.09** RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer  
*Sonam Puri, USA*
- P1.13A.10** Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study  
*Balazs Halmos, USA*
- P1.13A.11** Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study  
*Rosario García-Campelo, Spain*
- P1.13A.12** Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (Ifinatamab Deruxtecan) in Extensive Stage SCLC Patients  
*Narasimha Midde, USA*
- P1.13A.13** ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study  
*Taofeek Owonikoko, USA*

#### POSTER SESSION P1.13B – SUB-THEME B: RELAPSED/REFRACTORY ES-SCLC

- P1.13B.01** Lurbinectedin vs. Platinum Rechallenge in Extensive Stage Small Cell Lung Cancer after Platinum Doublet, A Multicenter Retrospective Study  
*Michael Libre, USA*
- P1.13B.02** Radiation Necrosis in Small Cell Lung Cancer Patients  
*Oded Icht, Israel*

P2 Posters – Presenters in Attendance: **18:15 - 19:45**

## TRACK 02: SCREENING AND EARLY DETECTION

### POSTER SESSION P2.04A – SUB-THEME A: CLINICAL TRIALS IN PROGRESS

- P2.04A.01** FIRSTLUNG (L301): Cluster Randomized Trial Evaluating the Clinical Utility of DELFI's Blood-Based Lung Cancer Screening Test  
*Lindsey Cotton, USA*
- P2.04A.02** Using an AI Transformer Model to Identify Incidental Pulmonary Nodules (IPN) For Lung Cancer Early Detection  
*Renelle Myers, Canada*
- P2.04A.03** Enhancing Participation in Flemish Lung Cancer Screening: Strategies for Engaging the Hard-To-Reach  
*Charlotte Theuns, Belgium*
- P2.04A.04** The Lung Health Check Pilot: Ireland's Flagship Lung Cancer Screening Trial  
*David O Reilly, Ireland*
- P2.04A.05** Providing Tobacco Treatment to Patients Undergoing Lung Cancer Screening at a Large U.S. Health System: A Randomized Trial  
*Kathryn Taylor, USA*
- P2.04A.06** A Multilevel Approach to Address Disparities in Lung Cancer Screening: The PREP Trial  
*Randi Williams, USA*
- P2.04A.07** Improving IPN Management Through CAD and Virtual Nodule Clinics: A Prospective, Observational Multicenter Study (PINPOINT)  
*Bo Alexander Willems, Netherlands*

### POSTER SESSION P2.04B - SUB-THEME B: SCREENING IMPLEMENTATION AROUND THE WORLD

- P2.04B.01** Argentine Lung Cancer Screening Programs Collaborative Registry: The LuCaS.Ar Project  
*Iris Boyeras Navarro, Argentina*
- P2.04B.02** Eight Year Outcomes of a Multidisciplinary Lung Cancer Screening Program at a Large Community Centre in Canada  
*Marc Ossip, Canada*
- P2.04B.03** Low Cost Low Dose CT Scan for Lung Cancer Screening - Seven Year Experience at a Sub-urban Community Hospital  
*Deepankar Sharma, USA*
- P2.04B.04** Harnessing EHR/IT to Accelerate Lung Cancer Screening - An American Cancer Society National Lung Cancer Roundtable Initiative  
*Lauren Rosenthal, USA*
- P2.04B.05** Engaging Culturally and Linguistically Diverse Communities to Prepare for Lung Cancer Screening Implementation in Australia  
*Nicole Rankin, Australia*
- P2.04B.06** Lung Cancer Screening Program in Serbia: A 3-year- Results and Challenges  
*Darijo Bokan, Serbia*
- P2.04B.07** Impact of Primary Care Initiated Lung Cancer Screening Program: The VANCHCS Experience  
*Guneet Kaleka, USA*
- P2.04B.08** Terminology in Lung Cancer Screening and Early Detection - IASLC Early Detection and Screening Committee Recommendations  
*Rudolf Huber, Germany*

## POSTER SESSIONS SUNDAY, SEPTEMBER 8 (P1 + P2 POSTERS)

- P2.04B.09** A Qualitative Evaluation of the Critical Role of Lung Cancer Screening Program Navigators  
*Lucy Spalluto, USA*
- P2.04B.10** Leveraging High Mammography Screening Prevalence to Increase Lung Cancer Screening Among Women - A Geospatial Perspective  
*Liora Sahar, USA*
- P2.04B.11** Factors Associated with Early-Stage Lung Cancer Diagnosis (ESLCD) In Brazil - 2013 - 2019: A Multivariable Analysis  
*Isabel Emmerick, USA*
- P2.04B.12** Respiratory Function as a Prognostic Factor for Lung Cancer in Screening and General Populations  
*Kiera Murison, Canada*
- P2.04B.13** Time to Benefit: A Systematic Review and Meta-Analysis of Lung Cancer Screening Trials  
*Eliana Kim, USA*
- P2.04B.14** Barriers to Maximal Screening Impact in Persons Diagnosed with Lung Cancer in a Prospective Cohort  
*Osa Ogbeide, USA*
- P2.04B.15** Co-Design of Decision Support Tools for Lung Cancer Screening in Australia  
*Rachael Dodd, Australia*

## TRACK 05: PULMONOLOGY AND STAGING

## POSTER SESSION P2.05A – SUB-THEME A: CLINICAL COURSE

- P2.05A.01** Clinical Presentation, Outcomes, and Anticoagulant Strategies in Patients with Lung Cancer-Associated Isolated Distal Deep Vein Thrombosis  
*Delun Yang, China*
- P2.05A.02** Incidence of Pneumonitis in Asian Patients with Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis  
*Christine Pierce, USA*
- P2.05A.03** Regional Disparities in Distant Metastatic Lung Cancer Patients and Overall Survival in Norway: A Nationwide Population Study  
*Janna Berg, Norway*
- P2.05A.04** Does the Treating Physician's Specialty-Oncology or Pulmonology-Affect Clinical Outcomes and Survival in Lung Cancer Patients?  
*Janna Berg, Norway*

## POSTER SESSION P2.05B - SUB-THEME B: IMAGING

- P2.05B.01** How Reliable Is PET/CT in T1A and T1B Non-Small Cell Lung Cancer for Mediastinal Staging?  
*Akif Turna, Turkey*
- P2.05B.02** Automated Extraction of Key Entities from Thorax CT Reports Using NER with Prompt Engineering  
*Ozden Altundag, Turkey*
- P2.05B.03** A Novel Lung Nodule Localize Method: Topographic Map Dyeing Model for Target Vessel Watershed Boundary  
*Zihao Chen, China*
- P2.05B.04** Development of a CT Image-Based Virtual Atelectasis Simulation Model and Noninvasive Lung Nodule Localization System  
*Jinwook Hwang, Republic of Korea*

## POSTER SESSION P2.05C - SUB-THEME C: PATHOLOGY ASSESSMENT

- P2.05C.01** Pathologic Nodal Staging Reporting Quality: A Multi-Center Assessment of NSCLC Trends Over Time & Key Reporting Parameters  
*Haley Tupper, USA*
- P2.05C.02** Does the Proposed 9th TNM Offer Improved Prognostic Accuracy after Lung Carcinoma Resection? Preliminary Analysis Results  
*Piotr Kaluzynski, Poland*

## TRACK 07: EARLY-STAGE NON-SMALL CELL LUNG CANCER

## POSTER SESSION P2.07A – SUB-THEME A: DEVELOPMENTS IN EGFR MUTATED EARLY STAGE NSCLC

- P2.07A.01** Clinicopathological vs. Molecular Models in Predicting Adjuvant EGFR-TKI Benefit in Stage I NSCLC  
*Yu Jiang, China*
- P2.07A.02** The Effect of EGFR Mutation on Adjuvant Tegafur/Uracil for Patients with Non-Lymph Node Metastatic NSCLC (> 2 Cm)  
*Tomohiro Miyoshi, Japan*
- P2.07A.03** Prognostic Analysis of Completely Resected Lung Adenocarcinoma with Uncommon EGFR Mutations: CReGYT-01 EGFR Study  
*Kazuki Hayasaka, Japan*
- P2.07A.04** Clinical Relevance of PD-L1 Expression Levels in Surgically Resected EGFR-Mutant Lung Adenocarcinoma Patients (CReGYT-01 Study)  
*Fumihiko Kinoshita, Japan*
- P2.07A.05** Synchronous Super Multiple Primary Lung Cancers Prefer High-Frequency BRAF and Low-Frequency EGFR Mutations in MAPK Pathway  
*Haochen Li, China*

## POSTER SESSION P2.07B - SUB-THEME B: EVOLVING SURGICAL APPROACHES

- P2.07B.01** Single Versus Multiple Segmentectomies: A Comparison of Short- And Long-Term Outcomes  
*Fatemehsadat Pezeshkian, USA*
- P2.07B.02** Is Wedge Resection Really Enough for the Treatment of Patient with Stage I Non-Small Cell Lung Cancer? A SEER Database Analysis  
*Luigi Ventura, UK*
- P2.07B.03** Simultaneous Bilateral Video-Assisted Thoracic Surgery Is Safe and Feasible for Multiple Primary Lung Cancers  
*Libing Yang, China*
- P2.07B.04** Comparative Effectiveness of Sub-Lobar Resection vs Lobectomy for Medically Operable Stage I NSCLC: A VACCR Analysis  
*Michael Snider, USA*
- P2.07B.05** Prospective Comparative Study of Postoperative Respiratory Function after Lobectomy Versus Segmentectomy  
*Chihiro Takemura, Japan*
- P2.07B.06** Segmentectomy for cIA1-2 Lung Cancer in the Lower Lobe with Solid-Predominant Opacity: Impact on Recurrence and Survival Rates  
*Makoto Endo, Japan*
- P2.07B.07** Multi-Institutional Retrospective Analysis of Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer Larger Than 3 cm in Diameter  
*Yujin Kudo, Japan*



- P2.07B.08** Outcome Comparison Between Left Upper Lung Lobectomy and Split Lobe Segmentectomy for Clinical Stage I Lung Cancer  
*Tzu-Ning Kao, Taiwan*
- P2.07B.09** Real-World Validation for Impact of Sublobar Resection Over Lobectomy on Lung Cancer Survival and Frailty Using SEER-Medicare  
*Eunji Choi, USA*
- P2.07B.10** Should Lymph Node Dissection Be Routinely Undertaken for Patients with Small-Sized Solid-Dominant Non-Small-Cell Lung Cancer?  
*Naoyuki Oka, Japan*
- P2.07B.11** Delays to Lung Cancer Surgery by Biopsy Technique  
*Jeffrey Zhu, USA*

### POSTER SESSION P2.07C - SUB-THEME C: PERIOPERATIVE THERAPY FOR OPERABLE EARLY STAGE NSCLC

- P2.07C.01** LCMC3: Clinical Utility of Suvmax on Preoperative 18F-FDG PET-CT in Resectable NSCLC Treated with Neoadjuvant Atezolizumab  
*Robert Merritt, USA*
- P2.07C.02** Prognostic Impact of Adjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer Following Neoadjuvant Immunotherapy  
*Yichen Dong, China*
- P2.07C.03** Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting  
*Zhen-bin Qiu, China (International Mentorship Program Participant)*
- P2.07C.04** Surgical Complexity of Anatomical Lung Resections after Induction Immunotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer  
*Raphael Werner, Switzerland*
- P2.07C.05** Perioperative (Neoadjuvant Plus Adjuvant) Immunotherapies for Resectable NSCLC: A Systematic Review and Meta-Analysis of Phase 3 Trials  
*Hongxu Liu, China*

### TRACK 10: METASTATIC NON-SMALL CELL LUNG CANCER – CYTOTOXIC THERAPY

#### POSTER SESSION P2.10A – SUB-THEME A: CLINICAL TRIALS IN PROGRESS

- P2.10A.01** Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress)  
*Jonathan Riess, USA*
- P2.10A.02** Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors  
*Kellogg Parsons, USA*
- P2.10A.03** RESOLUTION: Phase II Study of Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in Patients with HER2 Alteration Advanced NSCLC  
*Jianing Chen, China*
- P2.10A.04** Valemetostat and Datopotamab Deruxtecan in Previously Treated, Advanced, Unresectable, or Metastatic Non-squamous NSCLC  
*Alexander Spira, USA*
- P2.10A.05** Ipat-Lung: A Multi-Center Phase 2 Study of Ipatasertib Plus Docetaxel in NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy  
*Jun Zhang, USA*
- P2.10A.06** Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations  
*Edward Garon, USA*

## POSTERS | SUNDAY, SEPTEMBER 8 (P1 + P2 POSTERS)

**P2.10A.07** Trofuse-009: Phase 3 Study of Sac-TNT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

*Natasha Leighl, Canada*

## POSTER SESSION P2.10B - SUB-THEME B: CYTOTOXIC CHEMOTHERAPY AND ADCS

**P2.10B.01** Exploratory Analyses of Tusamitamab Ravtansine vs Docetaxel in Previously Treated Non-squamous NSCLC Patients: CARMEN-LC03

*Byoung Chul Cho, Republic of Korea*

**P2.10B.02** Cutoff Determination for C-met Protein Overexpression by VENTANA MET (SP44) IHC to Determine Teliso-v Eligibility in NSCLC

*Nancy Zhang, USA*

**P2.10B.03** Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer After Progression on Osimertinib - A Prospective Cohort Study

*Saurav Verma, Canada*

**P2.10B.04** Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study

*Liyan Jiang, China*

**P2.10B.05** Renal Toxicity in Patients with Non-Small Cell Lung Cancer Receiving Maintenance Therapy with Pemetrexed and Pembrolizuma

*Urs Weber, USA*

**P2.10B.06** Improvements in Survival Outcomes of Large Cell Carcinoma Over Past Two Decades (2000-2020)

*Aditya Sood, USA*

**P2.10B.07** Chemotherapy in Combination with Anti-PD1 in PD-L1-Negative Non-Small Cell Lung Cancer Patients: A Single-Center Experience

*Silvia Sequero López, Spain*

**P2.10B.08** Opportunities for ADC Development in 2L NSCLC Leveraging Predictive Biomarkers

*Bruno Larvol, USA*

## TRACK 11: METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY

## POSTER SESSION P2.11A - SUB-THEME A: IMMUNOBIOLOGY

**P2.11A.01** Racial/ethnic Differences in Real-World Adverse Events and Survival Among Patients on Immunotherapy for Advanced NSCLC

*Gene Ho, USA*

**P2.11A.02** Proteomics-Based Target Identification for Optimizing Bispecific Antibody Use in NSCLC

*Atulya Khosla, USA*

**P2.11A.03** Association of LIPI with Patterns of Response, Resistance, and Survival in Patients with Metastatic NSCLC Treated with PD(L)-1 Blockade

*Enrique Caballe, Mexico (Developing Country Education Award Winner)*

**P2.11A.04** Exhaled Breath Biomarkers of Response to Immunotherapy in Advanced Non-Small Lung Cancer

*David O Reilly, Ireland*

**P2.11A.05** The Impact of Tumor Molecular Features and Smoking History on Survival with Chemo-Immunotherapy in EGFR-Mutant NSCLC

*J. Nicholas Bodor, USA*

**P2.11A.06** Tumor-Informed ctDNA Status Guiding 1st-line Immuno-Chemotherapy in Advanced NSCLC: CHOICE-01 Retrospective Analysis

*Zhijie Wang, China*

**P2.11A.07** Selected Shared Neoantigens for Personalized Tumor Neoantigen Peptide Vaccine in the Treatment of Advanced Tumors

*Yan Zhang, China*

- P2.11A.08** Molecular and Immunological Features Associated with Long-Term Benefit in Metastatic NSCLC Patients Undergoing Immune Checkpoint Blockade  
*Pedro Rocha, Spain*
- P2.11A.09** Survival Outcomes of Lung Adenocarcinoma with Intestinal Differentiation in the Era of Immunotherapy  
*Micah Tratt, USA*
- P2.11A.10** Impact of Baseline Glucocorticoid Use on the Efficacy of Immunoradiotherapy in NSCLC Patients with Brain Metastases  
*Yuan Peng, China*
- P2.11A.11** Impact of Proton Pump Inhibitor Use on Faecal Microbiome in Patients with NSCLC Treated with Immune Checkpoint Inhibitor  
*Yiqing Huang, Singapore*
- P2.11A.12** Machine Learning-Based Clinicogenomic Prediction of Response to PD-(L)1 Inhibition in KRAS Altered Non-Small Cell Lung Cancer  
*Natalie Vokes, USA*
- P2.11A.13** Cytokine Release Syndrome from Dual Immune Checkpoint Blockade in Non-Small Cell Lung Cancer: FAERS Analysis  
*Yu Fujiwara, USA*
- P2.11A.14** Research of the Predictive Role of Immune Cells and Intestinal Flora on Immune-related Adverse Event in Lung Cancer  
*Meixi Lin, China*
- P2.11A.15** Gut Metatranscriptomics Predict Survival in Anti-PD Immunotherapy Treated Advanced-Stage Non-Small Cell Lung Cancer  
*Zoltan Lohinai, Hungary*
- P2.11A.16** Categorizing Steroid-Response Types in Checkpoint Inhibitor-Related Pneumonitis  
*Yilin Yang, China*
- P2.11A.17** Impact of Mutation Class and Smoking Status in BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated with Immune Checkpoint Inhibitors (ICI)  
*Julian Marin-Acevedo, USA*
- P2.11A.19** Invasive Lymph Node Patterns and Prognosis in Lung Adenocarcinoma  
*Shen Lao, China*
- P2.11A.20** Metformin Enhances Immune Checkpoint Inhibitor Response in Overweight Lung Cancer Patients: A Retrospective Cohort Study  
*Akhil Pachimatla, USA*
- P2.11A.21** CCL4 Attenuated the Efficacy of Immunotherapy via Regulating the Phenotype and Function of Treg in EGFR-TKI Resistant NSCLC  
*Sangtian Liu, China*
- P2.11A.22** Higher Blood TMB/Tissue TMB Ratio as an Inferior Prognostic Biomarker for Survival in Advanced Stage NSCLC  
*Leeseul Kim, USA*
- P2.11A.23** Fecal Microbiota Transplantation Plus Rechallenging Immunotherapy in Patients with Advanced Non Small Cell Lung Cancer: An Exploratory Study  
*Mei Juan Huang, China*
- P2.11A.24** Characterization of Circulating Tumor-Associated and Immune Cells in Advanced-Stage NSCLC  
*Ken O'Byrne, Australia*
- P2.11A.25** Clinicogenomic Profile of Different Resistance Patterns to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer  
*Lingzhi Hong, USA*
- P2.11A.26** Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab  
*Rolando Acosta, USA*

- P2.11A.27** Generalizability of Radiomics Based Progression Risk Models in Immunotherapy Treated Mnscl Subjects  
*Jacob Gordon, USA*

#### POSTER SESSION P2.11B – SUB-THEME B: IMMUNORESISTANCE

- P2.11B.01** Deciphering Immunotherapy Resistance Mechanisms in Metastatic NSCLC, Insights from Plasma Proteomics Analysis  
*Itamar Sela, Israel*
- P2.11B.02** Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer  
*Arushi Saini, USA*
- P2.11B.03** Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy  
*Roberto Ferrara, Italy*
- P2.11B.04** Chemotherapy Increases Acquired Resistance to Immunotherapy in NSCLC: A Metanalysis of Aggregate and Individual Patient Data  
*Roberto Ferrara, Italy*
- P2.11B.05** Effect of Dysbiosis-Inducing Drugs on the Response to Immune Checkpoint Inhibitors in Patients with NSCLC  
*Celine Mascaux, France*
- P2.11B.06** BIRC5 Expression Correlated with Immunosuppressive Phenotype and Predicted Inferior Response to Immunotherapy in LUAD  
*Shuo Yang, China*

#### POSTER SESSION P2.11C - SUB-THEME C: IMMUNE ADVERSE EVENTS

- P2.11C.01** With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer  
*Lauren Kiel, USA*
- P2.11C.02** Incidence of Hematological Toxicity with Use of Immunotherapy and Chemotherapy in Advanced NSCLC: A Network Meta Analysis  
*Wenhai Fu, China*
- P2.11C.03** Immune-Related Adverse Events are Associated with Survival in Chinese Lung Cancer Patients Treated with Immunotherapy  
*Yongchang Zhang, China*
- P2.11C.04** Enhancing Multidisciplinary Clinicians' Ability in Identifying and Managing irAEs in the Emergency Setting Through Online CME  
*Michelle Worst, USA*
- P2.11C.05** Correlation Between Gut Microbiome and Immune-Related Adverse Reactions for Lung Cancer  
*Xu Han, China*

### TRACK 14: MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

#### POSTER SESSION P2.14A - SUB-THEME A: THYMUS AND OTHER CANCERS

- P2.14A.01** Clinicopathological Characteristics and Treatment Outcomes of Patients with Advanced SMARCA4-Deficient Non-Small Cell Lung Cancer  
*Hui Liu, China*
- P2.14A.02** Assessment of Immunohistochemical Panel Utilization in Thymic Carcinoma Diagnosis: Real World Experience Insights  
*Nilansh Kataria, USA*
- P2.14A.03** Prediction of Post-Surgical Recurrence of Thymic Epithelial Tumours Using Clinicopathological Parameters Incorporating TNM9 Classification  
*Yu Zhi Zhang, UK*

- P2.14A.04** Mapping the Distribution of Ectopic Thymus Through Flow Cytometry Analysis of CD3 Medium TCR  $\alpha\beta$  Medium CD4+CD8+ T Cells  
*Yongqiang Ao, China*
- P2.14A.05** Validity of Simple Thymectomy for Clinical Stage I Thymoma without Myasthenia Gravis: A Propensity Score-Matched Analysis  
*Tomoyuki Hishida, Japan*
- P2.14A.06** Diaphragmatic Plication in Surgery for Complex Mediastinal Tumor  
*Ye Yuan, China*
- P2.14A.07** Learning Curve Analysis of Near-Infrared Fluorescence-Guided Robotic-Assisted Minimally Invasive Esophagectomy with Indocyanine Green Dye  
*Yogita S. Patel, Canada*
- P2.14A.08** Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics  
*Andres Cardona, Colombia*
- P2.14A.09** Adaptive Reprogramming of Arginine Biosynthesis is an Attractive Target for Modulating the Response to WEE1 Inhibition in Pleural Mesothelioma  
*Duo Xu, China*
- P2.14A.10** Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma  
*Takanori Kondo, Japan*
- P2.14A.11** Real-World Immunotherapy Use in Pleural Mesothelioma: Insights & Immunological Landscape  
*Xiaoling Xu, China*
- P2.14A.12** Unveiling COL17A1 as a Novel Cell Surface Target in Thymic Epithelial Tumors: A Target Discovery Pipeline Approach  
*Fatemeh Ardeshir Larijani, USA*
- P2.14A.13** Discovery and Clinical Application of Potential Prognostic Genes for Clinical Outcome in Malignant Pleural Mesothelioma  
*Taketo Kato, Japan*
- P2.14A.14** A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma  
*Kaushal Parikh, USA*

### POSTER SESSION P2.14B – SUB-THEME B: CLINICAL TRIALS IN PROGRESS

- P2.14B.01** [DREAM] Double Lung Transplant Registry Aimed for Lung-limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers  
*Young Kwang Chae, USA*
- P2.14B.02** Application of Chemokine Receptor 4 Targeted 68Ga Pentixafor in Evaluation of Thymic Epithelial Tumors (TETs): A Prospective Study  
*Xuehan Gao, China*
- P2.14B.03** A Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients with Advanced Thymoma and Thymic Carcinoma  
*Jennifer Marks, USA*
- P2.14B.04** Tislelizumab Plus Standard Chemotherapy as First-Line Treatment in Advanced Thymic Epithelial Tumors (TETs): A Prospective, Single-Arm Trial  
*Wen Gao, China*
- P2.14B.05** eOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma  
*Arnaud Scherpereel, France*

## TRACK 16: PATIENT ADVOCACY

## POSTER SESSION P2.16A - SUB-THEME A: BIOMARKERS

**P2.16A.01** Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA

*Stefania Vallone, Italy*

**P2.16A.02** Improving Patients' Awareness of Biomarker Test Timing and Purpose with 4R Oncology Intervention

*Frank Weinberg, USA*

## POSTER SESSION P2.16B - SUB-THEME B: CLINICAL COMMUNICATION

**P2.16B.01** Attributes that Impact Patient and Physician Preferences for Maintenance Treatment in Advanced/metastatic NSCLC

*Umit Tapan, USA*

## POSTER SESSION P2.16C - SUB-THEME C: DISPARITIES

**P2.16C.01** Awareness, Stigma, and Fatalism Towards Cancer Clinical Trials Among Black Individuals Diagnosed with Lung Cancer

*Andrew Ciupek, USA*

**P2.16C.02** Development of a Framework to Address Lung Cancer Health Disparities: One Organization's Experience

*Shanada Monestime, USA*

## POSTER SESSION P2.16D - SUB-THEME D: LUNG CANCER EDUCATION

**P2.16D.01** Changes in Students' Perceptions of Cancer Through Cancer Education and Lectures by External Instructors with Cancer Experience

*Kazuo Hasegawa, Japan*

## POSTER SESSION P2.16E - SUB-THEME E: NEEDS OF PATIENTS AND CAREGIVERS

**P2.16E.01** Lung Cancer Patients' Support Preferences: Insights from a Global Patient Experience Survey

*Karen Clayton, UK*

**P2.16E.02** Emotional Support Resource Access and Utilization Among People with Lung Cancer

*Heather Law, USA*

## POSTER SESSION P2.16F - SUB-THEME F: PATIENT-RESEARCHER PARTNERSHIP

**P2.16F.01** Patient-Led Oncogene-Driven Lung Cancer Translational Research to Expedite Therapeutic Development

*Marc Muskavitch, USA*

**P2.16F.02** LIFE Project: Lung Cancer Patients' Involvement in Research Fostering Their Empowerment

*Bernard Gaspar, Spain*

**P2.16F.03** Development of a Patient-Friendly Lung Cancer Lexicon

*Jill Feldman, USA*

## POSTER SESSION P2.16G - SUB-THEME G: SCREENING

**P2.16G.01** Annual Lung Cancer Screening Day in the USA- Year Two

*Tiffany Gowen, USA*

**P2.16G.02** "It's Like A Donut!" - Veteran Perspectives of Lung Cancer Screening with Low Dose CT

*Camden Castagna-McLeod, USA*

TRACK 17: GLOBAL HEALTH, HEALTH SERVICES, AND HEALTH ECONOMICS

POSTER SESSION P2.17A – SUB-THEME A: CLINICAL MANAGEMENT

- P2.17A.01** Treatment Outcomes after Access to Broad Molecular Tests, Targeted Agents and Immunotherapy in NSCLC Patients from Brazil  
*Fillipe Visani, Brazil*
- P2.17A.02** Cost-Efficiency Modeling of Conversion to Biosimilar Bevacizumab-BVZR in Metastatic Non-Small Cell Lung Cancer in Medicare  
*Joshua Roth, USA*
- P2.17A.03** Preoperative Anxiety in Patients Undergoing Video-Assisted Thoracoscopic Surgery: Predictive Factors and Specific Concerns and Fears  
*Yizhou Huang, China*
- P2.17A.04** Cost Effectiveness of a System-Level Precision Medicine Intervention for Stage IV Non-Small Cell Lung Cancer Patients  
*Johnie Rose, USA*
- P2.17A.05** Racial and Gender Disparities in Immune-Related Adverse Effects: A Nationwide Inpatient Sample Database Analysis  
*Kanishka Uttam Chandani, USA*
- P2.17A.06** Impact of COVID-19 Diagnosis and Treatment for Lung Cancer in the US National Cancer Database (NCDB) from 2014 To 2021  
*Isabel Emmerick, USA*
- P2.17A.07** Impact of Preoperative Anxiety on Postoperative Outcomes in Patients Undergoing Minimally Invasive Thoracoscopic Surgery  
*Yizhou Huang, China*
- P2.17A.08** Trends in Pulmonary Embolism Outcomes Among Lung Cancer Patients: A Nationwide Analysis Across a Decade  
*Divya Solipuram, USA*
- P2.17A.09** Real-World Study of the Efficacy and Safety Analysis of Immunotherapy in Advanced Lung Cancer Under Internet-Based Full-course Management  
*Di Zheng, China*
- P2.17A.10** Major Cardiovascular and Cerebrovascular Events in Lung Cancer - A Nationwide Inpatient Sample Database Analysis.  
*Kanishka Uttam Chandani, USA*

POSTER SESSION P2.17B - SUB-THEME B: SCREENING

- P2.17B.01** The Construction and Application of a Novel Precise Health Management Model for Lung Nodule Population  
*Dahai Liu, China*
- P2.17B.02** Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols  
*Anne Fraser, New Zealand*
- P2.17B.03** Improving Lung Cancer Screening Utilization and Efficiency Through a Patient-Centered Pathway with Virtual Visits  
*Sara Ghandehari, USA*

P3: Presenters in Attendance between **12:00 – 14:00**

P4: Presenters in Attendance between **18:30 – 20:00**

P3 Posters – Presenters in Attendance: **12:00 – 14:00**

### TRACK 01: RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

#### POSTER SESSION P3.01D – SUB-THEME D: DISPARITIES, INEQUITIES & GEOGRAPHIC DIFFERENCES

- P3.01D.01** Racial Disparities Among Patients Diagnosed with Lung Cancer at a Young Age  
*Aysswarya Manoharan, USA*
- P3.01D.02** Lung Cancer Incidence Trends by Histology and Sociodemographic Characteristics in the US from 2000-2019  
*Jihyouon Jeon, USA*
- P3.01D.03** Evaluating Lung Cancer Disparities Among Transgender Populations: A Retrospective Cohort Analysis  
*Tomasz Tabernacki, USA*
- P3.01D.04** Disparities in Lung Cancer Risk Assessment for People Living with HIV  
*Savanah Hardcastle, USA*
- P3.01D.05** Gender Differences in Lung Cancer Incidence Among Patients Who Never Smoked Cigarettes: A Systematic Literature Review  
*Daniela Molena, USA*

#### POSTER SESSION P3.01E – SUB-THEME B: LUNG CANCER PREVENTION STRATEGIES

- P3.01E.01** Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk in Treatment-Naïve Type 2 Diabetes: Potential Impact of Obesity and Gender  
*Junmin Song, USA*
- P3.01E.02** Association Between Composite Dietary Antioxidant Index and Lung Cancer Risk in Former Smokers: A Large Prospective Cohort Study in UK Biobank  
*Yi Feng, China*

#### POSTER SESSION P3.01F – SUB-THEME F: RISK FACTORS BEYOND SMOKING

- P3.01F.01** Evaluating the Relationship Between Veteran Toxic Exposure Status and Lung Cancer Prevalence  
*Patrick Meyers, USA*
- P3.01F.02** Retrospective Characterization of Patients with Primary Lung Cancer Related to World Trade Center Disaster Exposure  
*Julia Lo Cascio, USA*

### TRACK 02: TUMOR BIOLOGY – PRECLINICAL BIOLOGY

#### POSTER SESSION P3.02F – SUB-THEME F: METASTASIS

- P3.02F.01** CD47 Promotes Migration and Metastasis in Non-Small Cell Lung Cancer  
*Kelsie Thu, Canada*
- P3.02F.02** Long Non-Coding RNA STEAP2-AS1 Promotes Non-Small-Cell Lung Cancer Cells Progression by Interacting with ARNTL2 To Upregulate DARS2  
*Huan Zhang, China*



## POSTERS / MONDAY, SEPTEMBER 9 (P3 + P4 POSTERS)

- P3.02F.04** Investigating the Role of Lactate Import and Metabolism in Non-Small Cell Lung Cancer  
*Robert Cameron, USA*
- P3.02F.05** A Genetic Engineering Approach to Interrogate Myosin 10 As a Driver of Non-Small Cell Lung Cancer Metastasis  
*Raaven Goffe, USA*
- P3.02F.06** Multi-Omics Reveals Effects of Gut Microbiome on Tumor Immune and Metabolism in Mouse Lewis Lung Carcinoma Model  
*Zixuan Hu, China*

## POSTER SESSION P3.02G – SUB-THEME G: TARGETED THERAPY/NOVEL THERAPY

- P3.02G.01** Therapeutic Targeting of Lung Cancer-Associated Fibroblasts Mitigates Mediastinal Lymphatic Dissemination in Non-Small Cell Lung Cancer  
*James HO, Hong Kong*
- P3.02G.02** Integrin-Linked Kinase Facilitates Drug Tolerant Persister Cell Survival and EMT in Response to EGFR Targeted Therapy  
*William Lockwood, Canada*
- P3.02G.03** High-Dose Ascorbic Acid Sensitizes Immunotherapy in LKB1-Deficient Lung Cancer by Promoting Tumor Cell Pyroptosis  
*Xiaoting Cai, China (Developing Country Education Award Winner)*
- P3.02G.04** JP11646-mediated PIM2 Inhibition Has Potent Antitumor Effects in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung  
*Katherine Minton, USA*

## TRACK 03: TUMOR BIOLOGY – TRANSLATIONAL BIOLOGY

## POSTER SESSION P3.03H – SUB-THEME H: METASTASIS/TUMOR PROGRESSION

- P3.03H.01** Tumour Educated Platelets Display A Distinct RNA Content Profile Across Metastatic Patterns in NSCLC  
*Anne-Marie Baird, Ireland*
- P3.03H.02** PMS2 Amplification Contributes Brain Metastasis from Lung Cancer  
*Jianing Chen, China*
- P3.03H.03** Feasibility of Metastatic Lymph Node-informed ctDNA Analysis in Surgically Resected NSCLC Patients  
*Shuta Ohara, Japan*
- P3.03H.04** Molecular and Clonal Evolution of Primary Lesions vs Brain Metastasis and Progressive Disease of EGFR Mutated Patients  
*Leonardo Rojas, Colombia*
- P3.03H.05** AKAP12 Deficiency Leads to Blood-Brain Barrier Disruption and Serves as a Crucial Diagnostic Marker for Brain Metastasis in Lung Adenocarcinoma  
*Xie Tian, China*

## POSTER SESSION P3.03I – SUB-THEME I: TARGETED THERAPY/NOVEL THERAPY

- P3.03I.01** Targeting RLIPT76 with a Novel Small Molecule for Lung Cancer Therapy  
*Soroush Shahrokh, USA*
- P3.03I.02** Co-Inhibition of MEK/RTK Pathways Induces High Therapeutic Efficacy in Pan-KRAS-Mutant Non-Small Cell Lung Cancer  
*Jun Lu, China*
- P3.03I.03** AptBCis1 - A Novel DNA Therapeutics for Lung Cancer Leptomeningeal Carcinomatosis  
*Emily Lin, Taiwan*

- P3.031.04** Annamycin: Opening New Doors for Organotropic Targeting of Primary and Metastatic Lung Cancer  
*Waldemar Priebe, USA*
- P3.031.05** DSTYK Inhibition as a Novel Strategy for Taxane-Based Chemotherapy Sensitization in Early and Advanced Lung Cancer  
*Luis Montuenga, Spain*
- P3.031.06** Neoadjuvant Gefitinib in EGFR Mutated NSCLC (a Phase 2 Window-Of-Opportunity Study): Deep Genomic and Transcriptomic Analysis  
*Aaron Tan, Singapore*
- P3.031.07** Comprehensive Pan-Cancer Analysis of Oncogenic MET Rearrangements with a Focus on Targetability in NSCLC  
*Morana Vojnic, USA*
- P3.031.08** Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations - An in Vitro Study  
*Hana Oiki, Japan*
- P3.031.09** Augmenting Post-Surgical Tumor Immune Response and Recurrence Prevention via Nanoparticle-Assisted Targeted Drug Delivery  
*Weijie Zhan, China*
- P3.031.10** RRAS and RRAS2 Mutations Are Oncogenic Drivers in Lung Cancer and are Sensitive to the Pan-RAS Inhibitor RMC-6236  
*Alexander Pfeil, USA*
- P3.031.11** The ATXN3-USP25-TRMT1 Axis Regulates tRNAm<sub>2,2G</sub> Modification and Promotes Osimertinib Resistance in Lung Cancer  
*Tianqing Chu, China*
- P3.031.12** Modulation of EMT Increases the Activity of Lurbinectedin in Small Cell Lung Cancer  
*Edurne Arriola, Spain*
- P3.031.13** High EGFR Expression Confers Acquired Resistance to Adagrasib - In Vitro Study Using KRASg12C Mutated Lung Cancer Cells  
*Akira Hamada, Japan*
- P3.031.14** Osalmid Inhibits the Progression of Lung Adenocarcinoma and Sensitizes It to EGFR-TKIs: A Preclinical and Translational Study  
*Lei-Lei Wu, China*
- P3.031.15** The Mechanisms and Impact of EGFR TKIs in Modulating Blood Immune Cells in Patients with Oncogene-Driven NSCLC  
*Tianhong Li, USA*
- P3.031.16** Treatment Outcomes in Patients who Received Bevacizumab Therapy for Radiation Induced Brain Necrosis  
*Jenoy Merchant, USA*
- P3.031.17** Exploring Autophagy Flux-Related Molecules to Overcome in Acquired Resistance to EGFR TKIs in NSCLC Patients Harboring EGFR Mutations  
*Jeong-Oh Kim, Republic of Korea*
- P3.031.18** Optimizing Delivery of Anti-Cancer Therapeutics in Lung Adenocarcinoma Using Ultrasound-Induced Cavitation of Microbubbles  
*Ryunosuke Hoshi, Canada*
- P3.031.19** The International Pregnancy and Lung Cancer Registry at Dana-Farber Cancer Institute  
*Narjust Florez, USA*

#### POSTER SESSION P3.03J - SUB-THEME J: TUMOR MICROENVIRONMENT

- P3.03J.01** Genomic and Spatial Characterization of Neoadjuvant Efficacy Differences in Non-Small Cell Lung Cancer  
*Yue He, China*

- P3.03J.02** Identification of CD200 as Potential Endothelia Target to Relieve the Immune Suppression in Precursor Lung Adenocarcinoma  
*Chao Zhang, China*
- P3.03J.03** Genetic Signature Derived from Single-Cell Defined Microenvironment Remodeling Correlate with Efficacy of Neoadjuvant Immunotherapy in LUSC  
*Xing Li, China*
- P3.03J.04** Single-Cell Landscape of Senescent Cells in the Lung Cancer Microenvironment Unveils Pivotal Roles of Senescent Cancer Cells  
*Jie Huang, China*
- P3.03J.05** Enhancement of Chemotherapy and Immunotherapy in LUSC Animal Models Through Tumor Microenvironment Remodeling by Losartan  
*Haiyu Zhou, China*
- P3.03J.06** The Co-Location of APOE+ Macrophages and MMP7+ Tumor Cells Contributed to Worse Immunotherapy Response in NSCLC  
*Guangyu Fan, China*

## TRACK 06: PATHOLOGY AND BIOMARKERS

## POSTER SESSION P3.06D – SUB-THEME D: ctDNA

- P3.06D.01** Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Treatment-Naive Patients with Advanced Lung Squamous Cancer  
*Fei Zhou, China*
- P3.06D.02** Dynamic ctDNA-MRD Indicates Pathological Benefits of Additional Neoadjuvant Chemoimmunotherapy Courses for Locally Advanced NSCLC  
*Dong Lin, China*
- P3.06D.03** Prognostic and Predictive ctDNA Signature for Patients on Targeted Therapy for Metastatic NSCLC: A Pathway-based Approach  
*David Qian, USA*
- P3.06D.04** Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer  
*Rodrigo Paredes de la Fuente, USA*
- P3.06D.05** Stratifying Risk in Oligoprogressive EGFR-Mutated Non-Small Cell Lung Cancer: The Role of ctDNA  
*Alberto Guijosa, Mexico*
- P3.06D.06** Incremental Value of Liquid Biopsy in the Initial Evaluation of Non-Small Cell Lung Cancer Patients Undergoing Tissue Based Molecular Testing  
*Benjamin Bleiberg, USA*
- P3.06D.07** Liquid Biopsy: Exploration of its Added Value in a Daily Practice  
*Alfredo Addeo, Switzerland*
- P3.06D.08** ctDNA-NGS Assay (Liquid Biopsy) for Non-Small Cell Lung Cancer: Utility of Plasma Cell-Free DNA and Tissue NGS in Detecting Genetic Mutations  
*Jason Agulnik, Canada*
- P3.06D.09** Reciprocal DNA Fusions and their Association with DNA Damage Response Genes in Patients with NSCLC Through cfDNA NGS  
*Laila Roisman, Israel*
- P3.06D.10** Concordance of Liquid Biopsy and Tissue Biopsy for the Detection of EGFR Mutation in Stage III NSCLC in the USA  
*Umberto Malapelle, Italy*
- P3.06D.11** Faster Treatment Decision-Making Using Liquid Biopsies NGS in Non-Small Cell Lung Cancer  
*Luis Raez, USA*

- P3.06D.12** Racial Differences in ALK Gene Alterations Detected by Tissue and Liquid Biopsy Across Patients with Lung Cancer  
*Fawzi Abu Rous, USA*
- P3.06D.13** Patterns of Tissue NGS Alterations are Associated with ctDNA Shedding in Non Small Cell Lung Cancer Tumors Harboring EGFR Mutations  
*Anna Di Lello, USA*
- P3.06D.14** Liquid Biopsy-Based Single T-Cell Dynamic Polyfunctionality Profiling as a NSCLC Immunotherapy Biomarker  
*Zuan-Fu Lim, USA*

**POSTER SESSION P3.06E – SUB-THEME E: IO**

- P3.06E.01** Evaluation of the Immune Landscape of Patients with Adenosquamous NSCLC (LUAS)  
*Matthew Lee, USA*
- P3.06E.02** Serum NY-ESO-1 And XAGE1 Antibodies Are Diagnostic and Cancer-Specific Immunomonitoring Markers in NSCLC  
*Mikio Oka, Japan*
- P3.06E.03** Anlotinib Mediated Inflammation Response Through NFKB/TNFRSF11A Cascade in Lung Cancer  
*Yidan Chen, China*
- P3.06E.04** Genetic and Immunological Backgrounds in Advanced NSCLC Patients Treated with Immunotherapy - NGS and Flow Cytometry Analysis  
*Paweł Krawczyk, Poland*
- P3.06E.05** The Inflammation Induced by Neoadjuvant Immunotherapy Facilitated Favorable Clinical Outcomes  
*Xinying Xue, China*
- P3.06E.06** Angiogenesis and Immune-Related Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors  
*Konstantinos Syrigos, Greece*

**POSTER SESSION P3.06F - SUB-THEME F: PROFILING**

- P3.06F.01** Proteomic Profiling Reveals Distinct Biological Characteristics of EGFR L858R Mutation and a Prognostic Model in Lung Adenocarcinoma  
*Jie Huang, China*
- P3.06F.02** Role of GOLT1B and PTGES3 In Suppressing Lung Adenocarcinoma Progression  
*Jiayue Ye, China*
- P3.06F.03** Unbiased Proteomics and Multi-Omics Discovery of a Peripheral Blood-Based Classifier for Early Lung Cancer Detection  
*Brian Koh, USA*
- P3.06F.04** Multi-Omics Analysis of SMARCA4-Deficient Tumors  
*Yiting Dong, China*
- P3.06F.05** Spatial Profiling of the Tumor Microenvironment of SMARCA4-Mutant NSCLCs Using Whole-Slide Multiplex Fluorescence Imaging  
*Andréanne Gagné, USA*
- P3.06F.06** Spatial Transcriptomic Profiling Reveals Molecular Patterns Associated with Poor Prognosis in ALK-Rearranged NSCLC Patients  
*Warisa Khatoon, India (Developing Country Education Award Winner)*
- P3.06F.07** Effect of Neoadjuvant Chemotherapy on the Spatial Landscape of Regulatory T Cells in Non-Small Cell Lung Cancer Patients  
*Ligang Xing, China*

## TRACK 08: LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER

## POSTER SESSION P3.08E – SUB-THEME E: BIOMARKERS FOR NEOADJUVANT

- P3.08E.01** Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival  
*Marta Molina-Alejandre, Spain (Early Career Education Award Winner)*
- P3.08E.02** An Artificial Intelligence Driven Approach to Predict Pathological Response to Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer  
*Yang Xia, China*
- P3.08E.03** Dynamics of Peripheral Blood Inflammatory Index Predict Response of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer  
*Wenyu Zhai, China*
- P3.08E.04** TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials  
*Cristina Martínez-Toledo, Spain*

## POSTER SESSION P3.08F - SUB-THEME F: CLINICAL TRIALS IN PROGRESS

- P3.08F.01** Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)  
*Wen-Zhao Zhong, China*
- P3.08F.02** MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)  
*Qing Zhou, China*
- P3.08F.03** NRG LU008: Phase III Randomized Trial of Primary Tumor SBRT Followed by Concurrent Mediastinal Chemoradiation for LA-NSCLC  
*John Heinzerling, USA*
- P3.08F.04** Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer: An Update on the VIGILANCE Study  
*Ashley Horne, UK*
- P3.08F.05** Four-Cycle Compared with Two-Cycle Neoadjuvant Chemoimmunotherapy Achieved a Higher Rate of pCR: Preliminary Results of a Phase III Trial  
*Dong Lin, China*
- P3.08F.06** PLATINUM Trial: Preliminary Analysis of Lazertinib Therapy in Locally Advanced, Unresectable, EGFR Mutation(+) NSCLC Following CCRT  
*Sung Yong Lee, Republic of Korea*
- P3.08F.07** Efficacy and Safety of Envalofolimab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB NSCLC  
*Hongyu Zhang, China*
- P3.08F.08** NEOLA: Phase II Study of Osimertinib Treatment Before and after Chemoradiotherapy in Unresectable Stage III EGFRm NSCLC  
*Heather Wakelee, USA*

## TRACK 12: METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY

## POSTER SESSION P3.12C - SUB-THEME C: BRAF/ HER2 / MET / NOVEL TARGETS

- P3.12C.01** BRAF Mutation Diversity and Impact on Clinical Outcomes in Non-Small Cell Lung Cancer  
*Kevin Lu, USA*
- P3.12C.02** MET Fusions in NSCLC: Prevalence, Oncogenicity, and Resistance Mechanism  
*Seshiru Nakazawa, USA*

- P3.12C.03** Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma  
*Noboru Yamamoto, Japan*
- P3.12C.04** Seribantumab Results in Robust and Durable Responses in NRG1 Fusion-Positive Non-Small Cell Lung Cancer: A Multi-Center Case Series  
*Chelsea Lau, USA*
- P3.12C.05** Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC  
*Mihaela Aldea, USA*
- P3.12C.06** Clinical Characteristics and Outcomes in Patients with Leptomeningeal Disease (LMD) from Non-Small Cell Lung Cancer  
*Kelsey Pan, USA*
- P3.12C.07** Breaking New Ground: Selecting the Best Treatment for Non-Small Cell Lung Cancer According to Mutational Status  
*Jean Henri Maselli Schoueri, Brazil*

#### POSTER SESSION P3.12D - SUB-THEME D: CLINICAL TRIALS IN PROGRESS

- P3.12D.01** A Phase Ib Study of Osimertinib and Tegavivint as First-Line Therapy in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)  
*Regan Memmott, USA*
- P3.12D.02** Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)  
*Sun Min Lim, Republic of Korea*
- P3.12D.03** A Study to Investigate Safety, PK, and Anti-Tumor Activity of TRX-221 In EGFR Mutant NSCLC: TRX-221-001 In Progress  
*Sumin Lim, Republic of Korea*
- P3.12D.04** Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study  
*Byoung Chul Cho, Republic of Korea*
- P3.12D.05** Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups  
*Hualin Chen, China*
- P3.12D.06** Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations  
*Yi-Long Wu, China*
- P3.12D.07** Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)  
*Shirish Gadgeel, USA*
- P3.12D.08** DCC-3116 In Combination with Sotorasib in Advanced or Metastatic KRASG12C-Mutant Cancers: First-in-human Phase 1/2 Study  
*Frederic Reu, USA*
- P3.12D.09** Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer  
*Alejandro Mas Fernandez, Singapore*
- P3.12D.10** Phase 1b Study of AMG 193, An MTA-Cooperative PRMT5i, Alone and in Combination with Other Therapies in MTAP-deleted NSCLC  
*Alexander Spira, USA*
- P3.12D.11** Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC  
*Adrian Sacher, Canada*

## POSTER SESSION P3.12E - SUB-THEME E: KRAS

- P3.12E.02** MEK Inhibitor Combined with RTK Inhibitor (Trametinib Plus Anlotinib) In Non-g12c KRAS-Mutant Non-Small Cell Lung Cancer: A New Strategy  
*Hua Zhong, China*
- P3.12E.03** Anti-Tumor Efficacy of HRS-4642 and its Potential Combination with Proteasome Inhibition in KRAS G12D-Mutant Cancer  
*Shengxiang Ren, China*
- P3.12E.04** Long-Term Outcomes with Sotorasib in KRAS G12c-Mutated Advanced NSCLC from the Global Expanded Access Program (EAP) Study-436  
*Silvia Novello, Italy*
- P3.12E.05** Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC  
*Melissa Johnson, USA*

## TRACK 13: SMALL CELL LUNG CANCER AND ENDOCRINE TUMORS

## POSTER SESSION P3.13C – SUB-THEME C: BIOMARKERS AND DISEASE MONITORING

- P3.13C.02** A Plasma Proteomics-Based Model for Clinical Benefit Prediction in Small Cell Lung Cancer Patients Receiving Immunotherapy  
*David Gandara, USA*
- P3.13C.03** Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC  
*Margarita Majem, Spain*
- P3.13C.04** Assessing ctDNA using a Methylation-informed Molecular Response Algorithm in Extensive-Stage Small Cell Lung Cancer Patients  
*Jinesh Gheeya, USA*
- P3.13C.05** Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC  
*Matthew Lu, USA*
- P3.13C.06** Artificial Intelligence Meets SCLC - Integrating Clinicopathological and Whole-Slide Image Data for Prognostic Prediction in SCLC.  
*Pedro Rocha, Spain*
- P3.13C.07** Novel Nomogram Integrating Clinical, Radiomics and Genomics for Prediction of Radiation Pneumonitis in Limited-Stage Small Cell Lung Cancer  
*Shuanghu Yuan, China*
- P3.13C.08** Optimal Treatment Strategies for Older Adults with Clinical Stage IA Small Cell Lung Cancer  
*Margaret Yang, USA*
- P3.13C.09** First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC): Insights from a Global Clinico-Genomic Study  
*Amin Nassar, USA*

## POSTER SESSION P3.13D - SUB-THEME D: MOLECULAR PROFILING AND MOLECULAR TARGETS

- P3.13D.01** Proteomic Characterization of Antibody Drug Conjugate Target Expression Profiles in Small Cell Lung Cancer (SCLC)  
*Edwin Lin, USA*
- P3.13D.02** DLL3 Expression in Early-Stage SCLC: Comparative Analysis of IHC and mRNA ISH in Tumor and Lymph Nodes  
*May-Lucie Meyer, USA*
- P3.13D.03** Inhibition of LSD1 Prevented Tumor Progression and Recurrence to Radioimmunotherapy in Small Cell Lung Cancer  
*Feifei Na, China*

- P3.13D.04** Extrachromosomal MYC-Paralogs Amplification Defines Immunosuppressive Microenvironment with Metastatic Potential in Small Cell Lung Cancer  
*Jingwei Zhang, China*
- P3.13D.05** Genomics and Immune Infiltration Biomarkers for Short-term and Long-Term ES-SCLC Survivors with First-Line Chemoimmunotherapy  
*Ping Zhan, China*
- P3.13D.06** Distinct Single-Cell Transcriptomic Characteristics and Responses to the Front-Line Therapy in Patients with Central or Peripheral ES-SCLC  
*Libo Luo, China*
- P3.13D.07** Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade  
*Anne Chiang, USA*
- P3.13D.08** MYCNOS Epigenetically Regulated by Super-Enhancer is a Potential Predictor to NOTCH Inhibitor in Chemoresistance SCLC  
*Linlang Guo, China*
- P3.13D.09** Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer  
*Song Wang, USA*
- P3.13D.10** Clinical Outcomes of Transformed Small-Cell Lung Cancer Versus Extensive Primary Small-Cell Lung Cancer  
*Lina Chen, China (Developing Country Education Award Winner)*
- P3.13D.11** SEZ6 Expression in Neuroendocrine Tumors  
*Jennifer Marks, USA*

#### POSTER SESSION P3.13E - SUB-THEME E: NEUROENDOCRINE TUMORS: LCNEC, CARCINOID, TRANSFORMED SCLC

- P3.13E.01** Is Systematic Lymphadenectomy Pivotal for Bronchial Carcinoid Surgical Treatment? A TNM 9th Classification Validation Pilot Study  
*Leonardo Valentini, Italy*
- P3.13E.02** Adjuvant Chemotherapy in cT1N0M0 Large-Cell Neuroendocrine Cancer with or without Pathological Upstaging  
*Yota Suzuki, USA*



P4 Posters - Presenters in Attendance: 18:30 – 20:00

**TRACK 04: SCREENING AND EARLY DETECTION**

**POSTER SESSION P4.04C – SUB-THEME C: INNOVATIVE SCREENING TECHNOLOGY**

- P4.04C.01** Incidental Pulmonary Nodule Management Using Computer Assisted Detection and Patient Tracking: PINPOINT Project, Pilot Data  
*Asabi Leliveld, Netherlands*
- P4.04C.02** Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosomal DNA Methylation Profile  
*In Ae Kim, Republic of Korea*
- P4.04C.03** Nodule Type Classification for Lung Cancer Screening with CT  
*Doohyun Park, Republic of Korea*
- P4.04C.04** Epidemiological Characteristics of Incidental Pulmonary Nodules and in China: A Prospective Multicenter Trial of 10,560 Cases  
*Jian-Bing Fan, China*
- P4.04C.05** AI-Assisted CXR Analysis in the Detection of Lung Nodules and Incidental Lung Cancers  
*Se Hyun Kwak, Republic of Korea*
- P4.04C.06** DNA Methylation Analysis in Plasma for Early Diagnosis In Lung Adenocarcinoma  
*Jin Yulin, China*
- P4.04C.07** Improving the Efficiency of Lung Cancer Screening Through a Blood-based Lung Cancer Screening Test Prior to Low-Dose CT  
*Lindsey Cotton, USA*
- P4.04C.08** Sensitivity of Artificial Intelligence in Low-dose Computed Tomography Screening for Lung Cancer  
*Albin Mahovkic, Norway*
- P4.04C.09** Exhaled VOC Detection in Lung Cancer Screening: A Comprehensive Meta-Analysis  
*Xianzhe Fan, China*
- P4.04C.10** Validation of LungFlag™ Prediction Model Using Electronic Medical Records (EMR) On Taiwan Data  
*Eran Netanel Choman, Israel*
- P4.04C.11** Pixel-Wise Pulmonary Nodule Growth Prediction on Low-Dose Computed Tomography with 3D-ConvLSTM Deep Neural Network  
*Xing Lu, China*

**POSTER SESSION P4.04D - SUB-THEME D: REVISING LUNG CANCER SCREENING ELIGIBILITY**

- P4.04D.01** Gender Disparities in Lung Cancer Screening: A Systematic Literature Review  
*Elaine Shum, USA*
- P4.04D.02** Lung Cancer in Never Smokers and Individuals with a Family History of Lung Cancer: Missed Opportunities for Screening  
*Rowena Yip, USA*
- P4.04D.03** Lung Cancer in Those Who Never Smoked Study (luCNeSS) - Preliminary Analysis  
*Mostafa Aglan, USA*
- P4.04D.04** Efficiency of the Annual CT Screening Interval for Those at a Lower Risk of Lung Cancer - A CISNET Comparative Modelling Study  
*Kevin ten Haaf, Netherlands*
- P4.04D.05** Family History is an Independent Predictor of Lung Cancer Detection in Women in a Predominantly Caucasian Screening Cohort  
*Emily Stone, Australia*

- P4.04D.06** Improving Lung Cancer Risk Prediction in Asbestos Exposed Individuals: An Ensemble Approach  
*Chellan Kumarasamy, Australia*
- P4.04D.07** Lung Cancer Biomarkers in Nonsmokers: Diagnostic and Prognostic Use of Liquid Biopsy for Metabolites Found in the Urine  
*Bhavik Dalal, USA*
- P4.04D.08** Natural History Model for Second Primary Lung Cancer Among Lung Cancer Survivors: Utilizing the U.S. SEER Cancer Registries  
*Eunji Choi, USA*
- P4.04D.09** Assessing the Risk of Second Primary Lung Cancer in Women after Previous Breast Cancer  
*Jasmine Huang, USA*
- P4.04D.10** Risk-Based LDCT Screening for Non-smokers in Taoyuan, Taiwan  
*Yi-ching YU, Taiwan*

### TRACK 07: EARLY-STAGE NON-SMALL CELL LUNG CANCER

#### POSTER SESSION P4.07D – SUB-THEME D: CLINICAL TRIALS IN PROGRESS

- P4.07D.01** Neoadjuvant Osimertinib Followed by Radiation And/or Surgery in Stage III EGFR-Mutant NSCLC: An Open-Label, Single-Arm, Phase 2 Study  
*Laila Roisman, Israel*
- P4.07D.02** Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC with High-Risk Pathological Factors  
*Xiao-Long Li, China*
- P4.07D.03** Phase 2 Peri-Operative Study of Fianlimab+Cemiplimab+Chemotherapy vs Cemiplimab+Chemotherapy in Resectable Early-Stage NSCLC  
*Luis Paz-Ares, Spain*
- P4.07D.04** Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC  
*Jay Lee, USA*

#### POSTER SESSION P4.07E - SUB-THEME E: DEVELOPMENTS IN SURGICAL PATHOLOGY AND MICROENVIRONMENT

- P4.07E.00** The Impact of PD-1/PD-L1 Inhibitor on GGN Lesion: An Exploratory and Retrospective Study  
*Fang Wu, China*
- P4.07E.01** A Revised International Association for the Study of Lung Cancer Grading System: The Inclusion of Invasive Mucinous Adenocarcinomas  
*Hanyue Li, China*
- P4.07E.02** Genomic Profiling of Pre-invasive and Early-Stage Lung Adenocarcinoma Delineates Gene Signatures of Different Adenocarcinoma Subtypes  
*Yung-Hung Luo, Taiwan*
- P4.07E.03** Real-World Data on Early Lung Cancer in Never-Smokers and Light Smokers-Prevalence, Family History, and Molecular Alterations  
*Louis Gros, USA*
- P4.07E.04** Pathological Grading of Early-Stage Lung Cancers Through CT-to-PET Translation and Co-Learning Model  
*Haiyu Zhou, China*
- P4.07E.05** Insights from Molecular Profiling after Second Lung Surgeries in Early-Stage NSCLC - Recurrence or New Primary Tumor?  
*Louis Gros, USA*
- P4.07E.06** Distinct Genomic and Immune Microenvironment Features of Solid or Micropapillary Predominant Subtype in Stage I Lung Adenocarcinomas  
*Lincheng Zhang, China*

## POSTERS MONDAY, SEPTEMBER 9 (P3 + P4 POSTERS)

- P4.07E.07** Spatial Memory B Cells Activation by CXCL13+ Th Cells via the MIF(CD74-CXCR4) Axis may Improve Immunotherapy Efficacy in HER2 Mutant NSCLC  
*Huizhao Hong, China*
- P4.07E.08** Single-Cell TCR Barcoding and RNA Sequencing Illuminate Distinct Tumor-Draining Lymph Node T Cell Responses to Neoadjuvant PD-1 Blockade  
*Rachel Honigsberg, USA*

## POSTER SESSION P4.07F - SUB-THEME F: PROFILING FOR RECURRENCE

- P4.07F.01** Real World Characteristics and Distant Metastasis Free Survival of Patients with Early NSCLC Treated with Chemoimmunotherapy  
*Karen Schwed, USA*
- P4.07F.02** Invasiveness Diagnosis by Intraoperative Frozen Section Guides Resection Strategy Among  $\leq 2$ cm Non-Small-Cell Lung Cancer  
*Jianfu Li, China*
- P4.07F.03** A Cost-Effective Tumor-Informed ctDNA Analysis for MRD Detection in Resected NSCLC With Common Driver Genes  
*Ran Zhong, China*
- P4.07F.04** Ground Glass Nodules with Scattered or Eccentric Island-Shaped Consolidations may have Poor Outcomes  
*Ming Li, China*
- P4.07F.05** Low OLFM1/BMP6 Expression Identifies High-Risk Stage I Non-Squamous Non-Small Cell Lung Cancer after Pulmonary Resection  
*Kenichi Suda, Japan*
- P4.07F.06** CT-Based Deep Learning Model for Predicting Visceral Pleural Invasion in NSCLCs with Tumor Diameter Less Than 3cm  
*Mong-Wei Lin, Taiwan*

## POSTER SESSION P4.07G - SUB-THEME G: UNDERSTANDING LONG-TERM OUTCOMES

- P4.07G.01** Incidence of and Outcomes of Second Primary Lung Cancer after Resection for Screen-Detected Lung Cancer  
*Quiana Guo, USA*
- P4.07G.02** Prediction of Relapse-free Survival of NSCLC Patients Through Multimodal Data Fusion Using Deep Learning Model  
*Kyongmin Beck, Republic of Korea*
- P4.07G.03** Real-World Clinical Outcomes and the Association Between EFS and OS in Early-Stage NSCLC Treated with Primary SBRT  
*Megan Daly, USA*
- P4.07G.04** BML is Associated with Potential Survival Advantages in Patients with Solid-Dominant Stage I NSCLC  
*Weidong Wang, China*
- P4.07G.05** Prediction of Quality-of-Life Results after Lung Stereotactic Body Radiotherapy Using Functional Mapping on Gallium-68 Perfusion PET/CT  
*François Lucia, France*

## TRACK 11: METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY

## POSTER SESSION P4.11D – SUB-THEME D: CLINICAL TRIALS IN PROGRESS

- P4.11D.01** TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations  
*Stephen Liu, USA*

- P4.11D.011** Evaluating the Impact of Performance Status on Outcomes in Advanced Lung Cancer: A Phase II Clinical Trial  
*Martin Porebski, USA*
- P4.11D.02** Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS  $\geq 50\%$   
*Ana Nunes, USA*
- P4.11D.03** Trial in Progress: Phase 1/2 Study of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Solid Tumors  
*Adam Schoenfeld, USA*
- P4.11D.04** A Phase 1/2 Study of REGN7075 (EGFR $\Delta$ -CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update  
*Melissa Johnson, USA*
- P4.11D.05** EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy  
*Lifeng Wang, China*
- P4.11D.06** A Phase II Trial of Restorative Microbiota Therapy with Chemoimmunotherapy in Metastatic Non-Small Cell Lung Cancer  
*Amit Kulkarni, USA*
- P4.11D.07** A Single Arm, Exploratory Study of Tislelizumab Intrapleural Therapy in NSCLC Patients with Malignant Pleural Effusion  
*Cheng Chen, China*
- P4.11D.08** Tislelizumab in Combination with Anlotinib as First-Line Treatment for Advanced Pulmonary Sarcomatoid Carcinoma: A Phase II Study  
*Zhimin Zeng, China*
- P4.11D.09** Fianlimab-Based Combination Therapies in Patients with Advanced Non-Small Cell Lung Cancer: Trials in Progress Updates  
*Ana Baramidze, Georgia*
- P4.11D.10** A Phase II Trial of Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab in Non-Squamous NSCLC and Brain Metastases  
*Benjamin Schluger, USA*
- P4.11D.12** Phase 3 Trial of OSE2101 Versus Docetaxel in Patients with Non-Small Cell Lung Cancer & Secondary Resistance to Immunotherapy  
*Stephen Liu, USA*

#### POSTER SESSION P4.11E - SUB-THEME E: IMMUNOTHERAPY UTILIZATION

- P4.11E.01** Real-World First-Line Maintenance Immunotherapy for Nonsquamous Advanced/Metastatic NSCLC without Targetable Mutations  
*Manasee Shah, USA*
- P4.11E.02** Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study  
*Yoshihito Kogure, Japan*
- P4.11E.03** Safety and Efficacy of AL2846 Combined with TQB2450 In NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)  
*Liuchun Wang, China*
- P4.11E.05** A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC  
*Yongsheng Wang, China*
- P4.11E.06** Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC  
*Lian Liu, China*

- P4.11E.07** Envafolelimab Combined with Recombinant Human Endostatin and Chemotherapy for NSCLC  
*Chuanwang Miao, China*
- P4.11E.08** Integrated PK/PD Modeling for Uliedlimab, an Anti-CD73 Monoclonal Antibody, in Non-Small Cell Lung Cancer Patients  
*Jaime Yanez, USA*
- P4.11E.09** The Efficacy of PD-1/PD-L1 Inhibitors Combined with Chemotherapy and Anti-Angiogenesis Therapy in Driver Gene-Negative NSCLC Brain Metastases  
*Yali Yi, China*
- P4.11E.10** Safety and Efficacy of Sintilimab Combined with Anlotinib in Patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer  
*Fen Wang, China*
- P4.11E.11** Dosing Regimen for Acasunlimab (DuoBody-PD-L1x4-1BB) In Combination with Pembrolizumab  
*Gaurav Bajaj, USA*
- P4.11E.12** First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial  
*Yang-Si Li, China*
- P4.11E.13** Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US  
*Divyan Chopra, USA*
- P4.11E.14** Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated with PD-1/PD-L1 Inhibitors  
*Huijuan Wang, China*
- P4.11E.15** Risk Factors for Ir-AEs in Patients with NSCLC Receiving Chemotherapy Combined with a PD-1/PD-L1 Inhibitor or Nivolumab and Ipilimumab  
*Akio Nomura, Japan*
- P4.11E.16** Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs  
*Hai-Yan Tu, China*
- P4.11E.17** Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade  
*Biagio Ricciuti, USA*
- P4.11E.18** Impact of Prophylactic use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancer: A Cohort Study  
*Cheng Han, China*
- P4.11E.19** The Effect of COVID-19 On Treatment Outcomes in Non-Small Cell Lung Cancer Patients: A Propensity Score Matched Analysis  
*Wint Yan Aung, USA*
- P4.11E.20** Immune Checkpoint Inhibitors Plus Chemotherapy as First-Line Treatment in Patients with Advanced Pulmonary Sarcomatoid Carcinoma  
*Fengying Wu, China*
- P4.11E.21** Predictive Value of Longitudinal Systemic Inflammatory Markers for Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable NSCLC  
*Qian Zhang, China*
- P4.11E.22** Treatment-Free Survival in Advanced NSCLC Patients who Terminated Immune-Checkpoint Inhibitors  
*Takahiro Nagai, Japan*
- P4.11E.23** Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)  
*Silvia Masini, Spain*

## POSTERS MONDAY, SEPTEMBER 9 (P3 + P4 POSTERS)

- P4.11E.24** Clinical Features of Long-Term Response (LTR) to Immune Checkpoint Inhibitors (ICIs) in Patients with Advanced or Recurrent NSCLC  
*Waka Dohi, Japan*
- P4.11E.25** NSCLC Immune Hemogram Index (NIHX) A Predictive Score for Immunotherapy Response in PD-L1 Negative Advanced NSCLC  
*Carlos Picón, Argentina (International Mentorship Program Participant)*
- P4.11E.26** A Multicenter Retrospective Study Reveals High MET Expression Associated with Superior Benefit from Immunotherapy in Advanced NSCLC Patients  
*Hui Li, USA*
- P4.11E.27** Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study  
*Akito Miyazaki, Japan*
- P4.11E.28** Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA  
*Tanay Samant, USA*

## TRACK 14: MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

## POSTER SESSION P4.14C - SUB-THEME C: MESOTHELIOMA

- P4.14C.01** Trends of Asbestos Lung Content in the General Population  
*Emanuela Taioli, USA*
- P4.14C.02** Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single Center Retrospective Study  
*Tomoki Higashiyama, Japan*
- P4.14C.03** Real-World Prognostic & Predictive Implications of EORTC & MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)  
*Florence Wu, Canada*
- P4.14C.04** Exhaled Breath Analysis for the Early Diagnosis of Malignant Pleural Mesothelioma and the Surveillance of Asbestos-Exposed At-Risk Subjects  
*Domenico Galetta, Italy*
- P4.14C.05** Incidence of Pseudoprogression and Hyperprogression in Patients with Pleural Mesothelioma Treated with Ipilimumab and Nivolumab  
*Owen Mitchell, USA*
- P4.14C.06** Effect of Cytotoxic Chemotherapy Following Ipilimumab Puls Nivolumab Combination Therapy for Malignant Pleural Mesothelioma  
*Koji Mikami, Japan*
- P4.14C.07** A Combination of Routine and Novel Immunohistochemical Markers to Improve the Histological Diagnosis of Mesothelioma in Challenging Biopsies  
*Patrizia Viola, UK*
- P4.14C.08** HIT-MESO: Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma. UK National Proton Radiotherapy Study  
*Crispin Hiley, UK*

## TRACK 15: MULTIDISCIPLINARY CARE: NURSING, ALLIED HEALTH AND PALLIATIVE CARE

- P4.15A.01** Efficacy of Digital Therapeutics for the Perioperative Management in Patients with Lung Cancer: A Randomized Controlled Trial  
*Jinming Xu, China*

## POSTER SESSION P4.15B – SUB-THEME B: EXERCISE

- P4.15B.01** Remote Exercise Program for Patients with Lung Cancer on Immune Checkpoint Inhibitors  
*Paulo Bergerot, Brazil*
- P4.15B.02** Cardiopulmonary Rehabilitation Exercises Effectively Improve the Radiation-Induced Cardiopulmonary and Patients' Life Quality  
*Qingwei Meng, China*
- P4.15B.03** Effects of Tai Chi and Qigong Interventions in Lung Cancer Patients: A Systematic Review  
*Tindara Franchina, Italy*

## POSTER SESSION P4.15C - SUB-THEME C: MULTIDISCIPLINARY CARE DELIVERY

- P4.15C.01** Improving Care Coordination to Address Healthcare Inequities in Lung Cancer  
*Lilly Meier, USA*
- P4.15C.02** Palliative Care Impact on Time Toxicity Among Patients with Advanced Lung Cancer at the End of Life  
*Ali Duffens, USA*
- P4.15C.03** Successful Implementation of a Lung Cancer Navigator Workshop: A Cancer Site-Specific Training Program by GO2 For Lung Cancer  
*Marie Fay, USA*

## POSTER SESSION P4.15D - SUB-THEME D: SURVIVORSHIP

- P4.15D.01** Beyond Survival: A Pilot Study Analyzing Physician and Patient Perspectives on Lung Cancer Survivorship Care at Weill Cornell Medicine  
*Christine Garcia, USA*
- P4.15D.02** Risk of Osteoporosis and Bone Fracture by Systemic Therapy in Lung Cancer Survivors  
*Melinda Hsu, USA*
- P4.15D.03** The Lung Cancer Stigma Communications Assessment Tool: Supporting Engagement with the Lung Cancer Community  
*Jamie Studts, USA*
- P4.15D.04** Association Between Emotional Distress and Immunotherapy Response in Advanced NSCLC (STRESS-LUNG-1): Biomarkers Exploratory Analyses  
*Fang Wu, China*

## POSTER SESSION P4.15E - SUB-THEME E: SYMPTOM MONITORING AND MANAGEMENT

- P4.15E.01** Association Between Dynamic Patient-Reported Outcome-Based Symptom Exacerbation and Postoperative Complication in Lung Cancer  
*Shujie Huang, China (Developing Country Education Award Winner)*
- P4.15E.02** Acceptability and Feasibility of Integrating A Chatbot into Routine Lung Cancer Care: Patient and Clinician Perspectives  
*Jocelyn Wainwright, USA*
- P4.15E.03** Assessing the Utilization of Palliative Care in Advanced NSCLC Patients with Brain Metastases  
*Abhinav Vyas, USA*

## TRACK 17: GLOBAL HEALTH, HEALTH SERVICES, AND HEALTH ECONOMICS

## POSTER SESSION P4.17C – SUB-THEME C: DISPARITIES

- P4.17C.01** Clinical Trial Enrollment at a Thoracic Oncology Program at a Single-Academic Institution Serving Primarily Underrepresented Patients  
*Frank Weinberg, USA*

## POSTER SESSION P4.17D - SUB-THEME D: EPIDEMIOLOGY

- P4.17D.01** Incidence Correlation Between Different Diseases and Lung Cancer: A Global Cross-Sectional and Time-series Study  
*Jianfu Li, China*
- P4.17D.02** Global Trends in Lung Cancer Survival by Morphology: Analysis from 61 Countries During 2000-2014 (CONCORD-3)  
*Hongcheng Zhu, China (International Mentorship Program Participant)*
- P4.17D.03** Analysis of Lung Cancer Mortality Trends and Factors Impacting Years of Life Lost: A 20-Year Hospital-Based Cohort Study in São Paulo, Brazil.  
*André Marcheti, Brazil*
- P4.17D.04** Insights into Lung Cancer During Pregnancy: Analysis of the National Inpatient Database (NIS)  
*Nehemias Guevara Rodriguez, USA*
- P4.17D.05** Squamous Cell Lung Cancer Still Remains the Most Common Histological Subtype of Lung Cancer in Rural India  
*Jahanvi Grover, India*
- P4.17D.06** Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System  
*Sara Kuruvilla, Canada*
- P4.17D.07** Temporal Improvements in Overall Survival in Metastatic Non-Small Cell Lung Cancer in the USA Since 2004  
*Yong Yuan, USA*

## POSTER SESSION P4.17E - SUB-THEME E: HEALTH ECONOMICS

- P4.17E.01** Navigating from Target to Treatment: Early Impact of the Lung Precision Oncology Navigation Program (LPOP)  
*Nadia Ghazali, Canada*

## POSTER SESSION P4.17F - SUB-THEME F: HEALTH SYSTEM

- P4.17F.01** Effective EGFR Testing Rates in Advanced Stage NSCLC Patients Treated in Community Oncology Practices: Impact of a Decision Support Program  
*Ray Page, USA*
- P4.17F.02** Sociodemographic and Clinical Predictors of Diagnosis of Lung Cancer in the Emergency Department in a Large, Integrated Health System  
*Meera Ragavan, USA*
- P4.17F.03** Utilizing AI for Automated Data Entry and Analysis to Pre-Screen Lung Cancer Clinical Trial Candidates  
*Mihaela Aldea, France*
- P4.17F.04** Feasibility of Comprehensive Genomic Profiling for Advanced NSCLC in Public Healthcare System - The Hong Kong Experience  
*Ka Man Cheung, Hong Kong*
- P4.17F.05** Adherence to Clinical Practice Guideline - Analysis of 89 Multidisciplinary Team Discussed Patients with Stage III Lung Cancer  
*Jia-Tao Zhang, China*
- P4.17F.06** Review of State Legislation Mandating Biomarker Coverage in Cancer Care  
*Goetz Kloecker, USA*





# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

# VISIT THE IASLC BOOTH TODAY!

## Exhibit Hall Booth #1610



Visit us in the  
exhibit hall for  
all your IASLC  
needs...

Membership  
Resources | Journals  
Wellness Challenge

Only IASLC Members  
receive the **NEW** 9th Edition  
of the TNM Classification  
of Thoracic Malignancies  
Staging Cards on-site

**Renew or  
Join Today!**

<https://bit.ly/IASLCmembership>



IASLC 2024 WORLD CONFERENCE ON LUNG CANCER • SEPTEMBER 7-10, 2024 • SAN DIEGO, CALIFORNIA

# MEET THE EDITORS

Journal of  
Thoracic  
Oncology

JTO   
CLINICAL AND  
RESEARCH  
REPORTS

September 9 | 14:00 - 15:00 | Room 26B

Join JTO Editor-in-Chief Alex A. Adjei, MD, PhD, FACP and JTO CRR Editor-in-Chief Emily Stone, MBBS, PhD, FRACP, for a Meet-the-Editor session during WCLC 2024. This session is open to all WCLC attendees.

Also plan to visit the IASLC booth in the exhibit hall to learn more about the journals, including how to become a reviewer.



**Alex A. Adjei, MD, PhD, FACP**  
Chairman  
Taussig Cancer Institute,  
Cleveland Clinic  
Ohio, USA



**Emily Stone, MBBS, PhD, FRACP**  
Conjoint Professor, Faculty of  
Medicine, UNSW Medicine &  
Health,  
St Vincent's Healthcare  
Clinical Campus  
Sydney, Australia

IASLC



Conquering Lung & Thoracic Cancers Worldwide in the 21st Century

INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER



[jto.org](http://jto.org) | [jtocrr.org](http://jtocrr.org)











- EP.04A.09** The Impetus, Formation and Initial Strategic Aims of the UCLCC Screening and Prevention Task Force  
*Ashley Prosper, USA*
- EP.04A.10** Creating Safe Connections: Usability Testing of an Intervention Co-designed to Increase Equitable Access to Lung Cancer Screening  
*Ambreen Sayani, Canada*
- EP.04A.11** Patients Reported Outcomes in Short- And Long-Term Lung Cancer Survivors Who Were Diagnosed via Chest Low-Dose CT Screening  
*Kexin Tan, USA*
- EP.04A.12** Exploring Rural Appalachian Community Perceptions and Practices on Health and Lung Cancer to Inform Screening Interventions  
*Michael Gieske, USA*
- EP.04A.13** Necessity for Early Detection and Screening Initiatives: Evidence from Indonesia  
*Andika Putra, Indonesia*
- EP.04A.14** Community Outreach for Lung Cancer Awareness: Utilizing the ‘Cancer Challenge’ to Educate the Public  
*Dusty Donaldson, USA*
- EP.04A.15** Recruitment Strategies in a Lung Cancer Screening Program for Asian Women with No Smoking History  
*Elaine Shum, USA*
- EP.04A.16** Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study  
*Pianpian Cao, USA*
- EP.04A.17** Screening for Lung Cancer in Indonesia: Are All the Variables Valid for Determining These Factors?  
*Elisna Syahrudin, Indonesia*

**POSTER SESSION EP.04B - SUB-THEME B: NODULE IDENTIFICATION AND MANAGEMENT**

- EP.04B.01** Evidence Based Communication on Lung Cancer Screening to Political Decision Makers  
*Sebastian Schmidt, Germany*
- EP.04B.02** Identification of Circulating MicroRNAs Associated with Lung Cancer Diagnosis and Progression  
*Joji Samejima, Japan*
- EP.04B.03** The Diagnostic Efficacy of Seven Lung Cancer Autoantibodies in Early Detection of Pulmonary Ground-Glass Nodules  
*Hua Guo, China*
- EP.04B.04** Defining A Positive CT Screening for Lung Cancer Using Different Nodule Sizes: Implications from a Prospective Cohort Study in China  
*Jie He, China*
- EP.04B.05** Discordance Between Nodule and Lung Cancer Location in Early Lung Cancer Detection Cohorts  
*Osarenren Ogbeide, USA*
- EP.04B.06** High-Resolution CT with 1024-Matrix for AI-Assisted Diagnosis System in the Evaluation of Pulmonary Nodules  
*Qinling Jiang, China*

**POSTER SESSION EP.04C - SUB-THEME C: EXPANDING ACCESS TO EARLY LUNG CANCER DETECTION**

- EP.04C.01** The Value of Ultrahigh Frequency Ultrasound in Localizing Small Pulmonary Ground Glass Opacity Intraoperatively: A Prospective Study  
*Xuehan Gao, China*
- EP.04C.02** Estimation of Numbers of Healthcare Providers Eligible for National Lung Cancer Screening in South Korea  
*Chang Kyun Choi, Republic of Korea*





- EP.04E.05** Prevalence and Characterization of MET Overexpression in Chinese NSCLC Patients: A Retrospective Real-World Analysis  
*Li Yang, China*
- EP.04E.06** The Prediction of Spread Through Air Spaces with Preoperative 18F-FDG PET/CT in Clinical Stage I Lung Cancer  
*Yusuf Kahya, Turkey*
- EP.04E.07** Lung Cancer Patient Reported Experiences with Biomarker Testing  
*Dianna Cronin, USA*
- EP.04E.08** Rapid in House Next Generation Sequencing and Impact on Treatment Decisions and Initiation in Advanced NSCLC  
*Ravnoor Kang, Canada*

#### **POSTER SESSION EP.04F - SUB-THEME F: CLINICAL TRIALS IN PROGRESS**

- EP.04F.01** Challenges in Recruiting for a Randomized Controlled Intervention to Increase Lung Cancer Screening  
*Lucy Rios, USA*

### **TRACK 05: PULMONOLOGY AND STAGING**

#### **POSTER SESSION EP.05A - SUB-THEME A: ENDOSCOPIC EVALUATION**

- EP.05A.01** Efficacy and Safety of Midazolam with Fentanyl for Sedation During EBUS-TBNA: A Randomized, Double-Blind, Phase III Study  
*Jun Yamada, Japan*
- EP.05A.02** Timing of PET-CT has no Significant Impact on Staging EBUS Results in Mediastinal Staging and Diagnosis of Lung Cancer  
*Vytis Dudzevicius, UK*
- EP.05A.03** The Accuracy of EBUS, EUS, EBUS Plus EUS, and Mediastinoscopy for Mediastinal Staging in NSCLC - A Systematic Review and Meta-Analysis  
*Ana Gelatti, Brazil*
- EP.05A.04** Risk Factors for the Development of Pulmonary Infection after Bronchoscopy in Patients with Lung Cancer - A Centre in Greece  
*Vasileios Papavasileiou, Greece*
- EP.05A.05** Brazilian Single-Center Experience in the Staging of Thoracic Neoplasms Using Endosonographic Methods (EUS/EBUS)  
*João Victor Assef, Brazil*
- EP.05A.06** Timing of Thoracentesis in Hospitalized Patients with Malignant Pleural Effusion: A Study of the US National Inpatient Sample  
*Aditya Sood, USA*
- EP.05A.07** Feasibility and Safety of Nasal Access for EBUS-TBNA in the Korean Population: A Single Center Experience  
*Jick Hwan Ha, Republic of Korea*
- EP.05A.08** The Accuracy of Bronchoscopy and Transthoracic Needle Biopsy for Diagnosing Lung Cancer - A Systematic Review  
*Eldsamira Mascarenhas, Brazil*
- EP.05A.09** The Accuracy of CT, 18FDG-PET/CT, and Mediastinoscopy for Staging in NSCLC - A Systematic Review and Meta-Analysis  
*Vladmir Cordeiro de Lima, Brazil*

#### **POSTER SESSION EP.05B - SUB-THEME B: CLINICAL COURSE**

- EP.05B.01** Characterization of Patients with Primary Lung Cancer who Attended a Pulmonology Clinic in Bogotá, Colombia  
*Lucia Silva Cala, Colombia*

- EP.05B.02** Mucinous Adenocarcinoma of the Lung in a Brazilian Population: Clinical, Pathological, Molecular Features and Outcomes  
*Caio Leite, Brazil*
- EP.05B.03** Evaluating the Risk of Pneumonitis from G-CSF in Thoracic Cancer Patients with Pre-Existing ILD  
*Arisa Komatsu, Japan*
- EP.05B.04** Correlation Between Radiologic Feature and Spread Through Air Space in Lung Solid Adenocarcinoma 30.0 mm or Less in Maximum Diameter  
*Pengfei Li, China*
- EP.05B.05** Integrative Prediction Model for Radiation Pneumonitis: Genetic and Clinical-Pathological Factors Utilizing Machine Learning  
*Hong In Yoon, Republic of Korea*

## TRACK 06: PATHOLOGY AND BIOMARKERS

### POSTER SESSION EP.06A - SUB-THEME A: ARTIFICIAL INTELLIGENCE

- EP.06A.01** Computational Linguistic Analysis for the Isolation of Propitious miRNA Biomarkers in Lung Cancer  
*Di Ge, China*

### POSTER SESSION EP.06B - SUB-THEME B: BIOMARKER

- EP.06B.01** The Actual Status of Biomarker Testing and Prognosis in Postoperative Recurrent NSCLC: Subgroup Analyses of WJOG15421L (REVEAL)  
*Takayuki Takahama, Japan*
- EP.06B.03** Performance of a Prognostic OTP, CD44, Ki-67 Biomarker Panel for Relapse in Paired Biopsies and Resections of Pulmonary Carcinoids  
*Jules Derks, Netherlands*
- EP.06B.04** Aging Alteration of Biomarkers and Its Prognostic Role in Elderly Lung Cancer Patients Treated with Adjuvant S-1 Chemotherapy  
*Junichi Soh, Japan*
- EP.06B.05** Ultra-Stat Idylla EGFR Testing for Non-Small Cell Lung Carcinomas: Patient Selection and Impact on Clinical Outcomes  
*Kate Fitzsimmons, Canada*
- EP.06B.06** A Meta-Analysis of Advanced Lung Index (ALI) in Advanced Lung Cancer Patients  
*Kok Hoe Chan, USA*
- EP.06B.07** CARE: Developing a Clinical Composite Score for mNSCLC and Co-Design Solutions to Bridge the Metropolitan vs Regional Gap  
*Dan Stout, Australia*
- EP.06B.08** Biomarker-Guided Treatment Selection in NSCLC: A Quality Improvement Initiative to Strengthen Multidisciplinary Care  
*Benjamin Levy, USA*
- EP.06B.09** The Role of Cytokines in Predicting the Efficacy of Immunotherapy in Advanced NSCLC Patient  
*Wei Wang, China*
- EP.06B.10** Clinical Feasibility of Multiplex Digital PCR for Major Mutation Detection in NSCLC Patients: The Droplex NSCLC Panel Test  
*Kyung A Kim, Republic of Korea*
- EP.06B.11** Construction of a Prognostic Model for Lung Adenocarcinoma Based on Disulfidptosis-related LncRNAs  
*Man Sun, China*
- EP.06B.12** A Knowledge-Based Database on 1100 Non-Small Cell Lung Cancer from Italian Clinical Experience: The Biomarkers ATLAS  
*Umberto Malapelle, Italy*
- EP.06B.13** Prognostic Impact of Serum CA125 Level in Patients with cN0 Non-Small Cell Lung Cancer  
*Yuki Yazaki, Japan*

- EP.06B.14** Differential Expression in Potential Therapeutic Target Protein by Treatment in Small Cell Lung Cancer with and without Transformation  
*Saori Murata, Japan*
- EP.06B.15** Targetable Genetic Alterations Associated with Non-Small Cell Lung Cancer Mortality  
*Haley Tupper, USA*
- EP.06B.16** Latin-American Non-Small Cell Lung Cancer Patient's Tumors Harbor Many Novels Potentially Actionable/driver Mutations.  
*Ricardo Armisen, Chile*
- EP.06B.17** Detection of EGFR Mutations T790M and L858R for Therapeutic Guidance of NSCLC  
*Shima Asil, USA*
- EP.06B.18** Biomarker Landscape of Antibody-Drug Conjugates and Bispecific Antibodies in Clinical Trials for Lung Cancer  
*Madhan Srinivasan Kumar, USA*
- EP.06B.19** WNT/ $\beta$ -Catenin Signalling Pathway in Non-Small Cell Lung Cancer: Study of Immuno-expression GSK-3 $\beta$ ,  $\beta$ -Catenin, And CD44.  
*Erna Kristiani, Indonesia*
- EP.06B.20** Prognostic Impact of Nectin-like Molecule-5 (CD155) Expression in Non-Small Cell Lung Cancer  
*Enrique Caballé-Pérez, Mexico*

### POSTER SESSION EP.06C - SUB-THEME C: COHORT

- EP.06C.01** KRAS Q61H Mutation Defines a Distinct Clinicopathological Entity of Lung Adenocarcinomas in East Asian Patients  
*Hyo Sup Shim, Republic of Korea*
- EP.06C.02** Clinical Features and Survival Outcome of Lung Invasive Mucinous Adenocarcinoma: A Real-World Analysis of 387,197 Patients  
*Wongi Woo, USA*
- EP.06C.03** Clinicopathological Analysis of Each EGFR Status in Surgically Resected Lung Adenocarcinoma: A Real-World Study (CReGYT-01 EGFR)  
*Hironobu Hoshino, Japan*
- EP.06C.04** Impact of TP53/EGFR Mutations in Advanced-Stage NSCLC: LATAM Population  
*Thanya Runciman, Peru*
- EP.06C.05** Impact of TP53 Mutation in Advanced NSCLC in LATAM  
*Thanya Runciman, Peru*
- EP.06C.06** Outcome and Clinical Profile of Common and Uncommon EGFR Mutations in NSCLC: Retrospective Analysis from an Argentinean Cancer Center  
*Mónica Castro, Argentina*
- EP.06C.07** Impact of a Diagnostic Bronchoscopy Service with Embedded Reflex Molecular Testing Within an Oncology Centre in Patients with Lung Cancer.  
*Haris Charalambous, Cyprus*
- EP.06C.08** Presentations and Outcomes of Pulmonary Carcinosarcoma: Results of Comparing Pulmonary Carcinosarcoma and Primary Lung Sarcoma  
*Jing-Sheng Cai, China*

### POSTER SESSION EP.06D - SUB-THEME D: CTDNA

- EP.06D.01** Prognostic Evaluation by Using ctDNA in Patients with EGFR Mutated Resectable Lung Cancer  
*Yuya Murase, Japan*
- EP.06D.02** Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated with Osimertinib  
*Anthonie van der Wekken, Netherlands*
- EP.06D.03** Concurrent Liquid and Tissue Biopsy from Same Laboratory Increases On-Label Alteration Detection with Faster Turnaround Time  
*Sean Gordon, USA*

**EP.06D.04** Prognostic Value of Variant Allele Frequency in Circulating Tumor DNA for Survival Outcomes in Metastatic Non-Small Cell Lung Cancer

*Ariel Peleg, USA*

**EP.06D.05** The Prognostic Role of the Dynamic Changes in the Plasma ctDNA Levels in Advanced NSCLC after IO Initiation: A Meta-Analysis

*Konstantinos Syrigos, Greece*

## **POSTER SESSION EP.06E – SUB-THEME E: IO**

**EP.06E.01** Preexisting CD153+CD4+ T Cells Cause Lung Specific Toxicity via Type 3 Immunity without Kidnapping Efficacy in Immunotherapy

*Zi-Xuan Rong, China*

**EP.06E.02** Integrated Analysis of Prognosis and Immune Characterization of COMMD3 In Lung Squamous Cell Carcinoma

*Jingjun Wu, China*

**EP.06E.03** Body Composition and Inflammation Index-Based Nomograms to Assess the Outcomes of Patients with NSCLC Receiving Chemoimmunotherapy

*Qiyu Fang, China*

**EP.06E.04** Insight Into the Significance of CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma

*Kazu Shiomi, Japan*

**EP.06E.05** Is Diffusion-Weighted Imaging Able to Indicate Pathological Response in NSCLC after Neo-Adjuvant Immuno-Chemotherapy?

*Daria Kifjak, Austria*

**EP.06E.06** Elucidating the Interplay Between Oncogenic Fusions and the Tumor Immune Microenvironment in Lung Adenocarcinoma

*Xuezhong Chen, China*

**EP.06E.07** Geospatial and Molecular Characterization of Tumor Immune Cell Infiltration in NSCLC

*Tyler Faith, USA*

**EP.06E.08** Clinical Significance of JPH4 and Correlation with the Immune Microenvironment of Lung Adenocarcinoma

*Jia Feng, China*

**EP.06E.09** Spatial Multiomics Analysis Reveals AT2 Cells Inhibit B Cells of TLS in Pre-invasive Lung Adenocarcinoma after Neoadjuvant Immunotherapy

*Wenxiang Wang, China*

## **POSTER SESSION EP.06F - SUB-THEME F: NGS**

**EP.06F.01** Survival Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination

*Po-Hsin Lee, Taiwan*

**EP.06F.02** Enhancing Clinical Utility: Oncomine Dx Target Test Augments Biomarker Detection in Advanced Non-Small-Cell Lung Cancer

*Tae-Jung Kim, Republic of Korea*

**EP.06F.03** Analysis of Copy Number Variations of MET, EGFR and ERBB2 Genes in a Lung Cancer Patient Series: Comparison of FISH with NGS

*Simonetta Buglioni, Italy*

**EP.06F.04** The Characteristics of Plasma Sample NGS Analysis in the Detection of Lung Cancer Driver Genes

*Ken Uchibori, Japan*

**EP.06F.05** External Quality Assessment Results of Third-party NGS Laboratories in China for the Detection of Rare Mutations in Lung Cancer

*Qianlan Yao, China*

**EP.06F.06** Concurrent DNA and RNA NGS Testing to Characterize Rare Fusions in Advanced NSCLC Patients

*Josephine Feliciano, USA*

- EP.06F.07** Comparison Between EGFR PCR Alone and NGS with Gene Fusion PCR for Detecting Oncogenic Driver Alteration in Thai NSCLC Patients  
*Boonyasit Ngamvirocharoen, Thailand*
- EP.06F.08** Cancer Evolution Analysis for Lung Carcinomas with Multiple Driver Mutations  
*Katsutoshi Seto, Japan*
- EP.06F.09** Epidemiological Profile of Patients with Non-Small Cell Lung Cancer Treated at Oncologia D' or Bahia from January 2018 to December 2022.  
*Marília Loula, Brazil*

## **POSTER SESSION EP.06G - SUB-THEME G: PATHOLOGY**

- EP.06G.01** Prognostic Significance of Purinergic Receptor- and Ectonucleotidase- Expression in NSCLC Tumor Cells and Stroma  
*Sophie Prozmann, Germany*
- EP.06G.02** Profiling the Metastatic Potential of Non-Small Cell Lung Cancer Patients Based on TP53 Classification  
*Jun Lu, China*
- EP.06G.03** Newly WHO Reporting System for Lung Cytopathology: Reproducibility Test of the Diagnosis  
*Yuko Minami, Japan*
- EP.06G.04** Clinicopathological Differences between EGFR Mutated and EGFR Wild-Type Lung Adenocarcinoma with Papillary Predominant Pattern  
*Eisuke Goto, Japan*
- EP.06G.05** Molecular Characteristics of Pulmonary Lymphoepithelioma-Like Carcinoma in the Chinese Population  
*Wenyan Yu, China*
- EP.06G.06** Molecular Profiling of Separate Primary Non Small Cell Lung Cancers  
*Giselle Dutcher, USA*
- EP.06G.08** Clinicopathologic and Molecular Features of SWI/SNF-Deficient Thoracic Tumors  
*Jia Feng, China*
- EP.06G.09** Harnessing Real-World Data for Translational Research in Lung Cancer: MD Anderson Thoracic GEMINI Program  
*Jianjun Zhang, USA*
- EP.06G.10** Comprehensive Analysis of the Clinicopathological Features, Targetable Profile, and Prognosis of Mucinous Adenocarcinoma of the Lung  
*Daisuke Ueda, Japan*
- EP.06G.11** Effects of Gut Microbiota and Metabolites on Peritoneal Metastasis of Non-Small Cell Lung Cancer  
*Meixi Lin, China*
- EP.06G.12** The Fibrosis Around the Pulmonary Artery Is Associated with Difficulty in Dissection During Surgery after Systemic Therapy  
*Mitsue Kawahara, Japan*
- EP.06G.13** TP53 Somatic Mutation and its Association with Clinicopathological Parameters and Long-Term Clinical Outcome in Non-Squamous NSCLC Patients  
*João Pedro Apolinário, Brazil*
- EP.06G.14** Discovery of Immune-Related Long Noncoding RNA Signatures in Lung Adenocarcinoma  
*David Hu, USA*
- EP.06G.15** Rapid Immunohistochemistry of Microsatellite Instability Using Non-Contact Alternating Current Electric Field Mixing  
*Kazuhiro Imai, Japan*
- EP.06G.16** Pleural Fluid EGFR Mutation Testing in 10 Patients with Advanced Lung Adenocarcinoma with Pleural Effusion  
*Yu Jin Hong, Republic of Korea*
- EP.06G.17** A Clinical Conundrum: Lung Cancer in the Breast  
*Jonathan Nakata, USA*



- EP.07A.15** Prognosis after Surgical Treatment of Lung Cancer with Multifocal Ground-Glass Nodules: The Effect of Nodule Characteristics  
*In Kyu Park, Republic of Korea*
- EP.07A.16** The Prognostic Disparities Between the T3 Descriptors in Surgically Resected Primary Lung Cancer  
*Ayumi Suzuki, Japan*
- EP.07A.17** One-Stage Versus Two-Stage Thoracoscopic Surgery for Synchronous Bilateral Pulmonary Nodules: A Propensity Score-Matched Analysis  
*Yu Han, China*
- EP.07A.18** Do Excessive Delays Affect Pathologic Upstaging for Early Lung Cancer?  
*Jeffrey Zhu, USA*
- EP.07A.19** Impact of Preoperative Pulmonary Function on Survival Following Lobectomy for Stage I and II Lung Cancer  
*Konstantinos Grapatsas, Germany*
- EP.07A.20** Intraoperative Near-infrared Fluorescence Visualization of the Pulmonary Bronchus with Indocyanine Green Inhalation  
*Jian Zhou, China*
- EP.07A.21** Tubeless Strategy after Thoracoscopic Pulmonary Wedge Resection: A Better Choice for Specific Patients  
*You Wu, China*
- EP.07A.22** The Optimal Surgical Procedure Based on the Risk of Recurrence in Clinical Stage 0 or IA Lung Adenocarcinoma  
*Tomoyoshi Takenaka, Japan*
- EP.07A.23** Initial Experience of Robotic Assisted Pulmonary Resection Using a Novel Surgical Robot with Haptic Feedback Function  
*Yuichiro Ueda, Japan*
- EP.07A.24** European Experience of Early-Stage NSCLC Patients with Any Prior Cancer History Following Lobectomy or Segmentectomy  
*Lukadi Joseph Lula, Romania*
- EP.07A.25** Portable Cone Beam CT for Intraoperative Marking of Small Pulmonary Nodules; Anywhere, Anytime!  
*Nagiko Mitsuoka, Japan*
- EP.07A.26** A Novel Four-Hook Puncture Needle for Accurate Localization of Small Pulmonary Nodules in VATS: A Single-Center Retrospective Study  
*Baolei liang, China*

## **POSTER SESSION EP.07B - SUB-THEME B: RADIOTHERAPY OUTCOMES**

- EP.07B.01** Definitions of Local Control after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer Reported in the Literature  
*Drew Moghanaki, USA*
- EP.07B.02** Comparative Outcomes of Surgery and SBRT for Stage I Lung Cancer in Koreans: A Propensity Matched Multidisciplinary Cohort Study  
*Eunhye Lee, Republic of Korea*
- EP.07B.03** Analysis of 30- And 90-day Mortality after Lung SBRT as an Indicator for Its Appropriateness  
*Gregory Videtic, USA*
- EP.07B.04** Two-Stage Bilateral Video-Assisted Thoracic Surgery Combined with Gefitinib for Bilateral Primary Lung Cancer: A Case Report  
*Baolei liang, China*
- EP.07B.05** Comparison of Image-Guided Thermal Ablation or Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer  
*John Nikitas, USA*
- EP.07B.06** Transplant Patients with Medically Inoperable Early-Stage Lung Cancer Have Worse Outcomes When Treated with SBRT  
*Gregory Videtic, USA*









**POSTER SESSION EP.08A – SUB-THEME A: ADJUVANT THERAPY**

- EP.08A.01** Impact of Locoregional Recurrence Versus Distant Metastasis on Survival in Patients with NSCLC after Surgery: A Secondary Analysis of PORT-C RCT  
*Zeliang Ma, China*
- EP.08A.02** Adherence to Adjuvant Immunotherapy and Target Therapy Protocols in Patients with Resected NSCLC: A Meta Analysis  
*Pietro Bertoglio, Italy*
- EP.08A.03** Real World Outcomes of Adjuvant Atezolizumab in NSCLC: A Single Institution Study  
*Xena Zheng, USA*

**POSTER SESSION EP.08B - SUB-THEME B: BIOMARKERS FOR NEOADJUVANT**

- EP.08B.01** Heterogeneity of Peripheral Blood Cell Dynamics and Oncologic Outcomes Between LUAD and LUSC Receiving Neoadjuvant Immunochemotherapy  
*Shaowei Wu, China*
- EP.08B.02** The Impact of C-Met Expression on the Immune Microenvironment and Survival in Locally Advanced Non-Small Cell Lung Cancer  
*Yaping Xu, China*
- EP.08B.03** Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.  
*Andre Gouveia, Canada*

**POSTER SESSION EP.08C - SUB-THEME C: BIOMARKERS IN UNRESECTABLE NSCLC**

- EP.08C.02** Impact of Non-Coplanar Radiation Beam Geometry on Effective Dose to Immune Cells (EDIC) In Stage III NSCLC  
*Benjamin Hopkins, USA*
- EP.08C.03** To Construct Multi-Omics Model for Predicting Prognosis of Definitive Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer  
*Li Li, China*

**POSTER SESSION EP.08D - SUB-THEME D: CLINICAL NEOADJUVANT**

- EP.08D.01** Neoadjuvant Chemoimmunotherapy for Potentially Resectable IIIA/IIIB NSCLC (Neo-Pre-IC): Survival Updates and Predictive Effect of MRD  
*Kewei Ma, China*
- EP.08D.02** Adjuvant Treatment Options after Neoadjuvant Chemotherapy Combined with Immunotherapy and Surgery in Patients with Non-Small Cell Lung Cancer  
*Junfeng Zhao, China*
- EP.08D.03** Efficacy of Neoadjuvant Immunochemotherapy in the Treatment of Stage III Non-Small-Cell Lung Cancer with Cancer-driven Gene Mutations  
*Jiacong Liu, China*
- EP.08D.04** Association of Lymph Node Metastatic Patterns and Neoadjuvant Immunochemotherapy Effectiveness in Resectable Non-Small Cell Lung Cancer  
*Yuheng Zhou, China*
- EP.08D.05** Long Term Follow-up of Two Decades Experience with Neoadjuvant Chemotherapy in Resectable Non Small Cell Lung Cancer  
*Monica Antoñanzas, Spain*
- EP.08D.06** Neoadjuvant Chemoimmunotherapy Does Not Increase Postoperative Morbidity of Pneumonectomy in NSCLC Patients: A Multi-Center PSM Analysis  
*Zhixin Li, China*
- EP.08D.07** Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC  
*Ting Wang, China*
- EP.08D.08** Aumolertinib as Neoadjuvant Therapy for EGFR M+ NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated  
*Wen Fang, China*

- EP.08D.09** Efficacy and Safety of Neoadjuvant Tislelizumab Plus Chemotherapy for the Treatment of Non-Small Cell Lung Cancer: a Pooled Analysis  
*Yao-Bin Lin, China*
- EP.08D.10** Outcome after Preoperative Chemoradiotherapy for Non-Small Cell Lung Cancer with Chest Wall Invasion  
*Yutaro Koike, Japan*
- EP.08D.11** Redefining Prognosis in NSCLC after Neoadjuvant Immunotherapy: The Predictive Power of Pathologic Response and Lymph Node Status  
*Yuan Xu, China*
- EP.08D.12** Comparison of Neoadjuvant Chemoimmunotherapy and Chemotherapy for Potentially Resectable Stage IIIA/B NSCLC  
*Kewei Ma, China*
- EP.08D.13** Macrophage Polarization States Predicting the Efficacy of Neoadjuvant Chemoimmunotherapy in Resectable or Potentially Resectable NSCLC  
*Ziyi Xu, China*
- EP.08D.14** Long-Term Prognosis of Patients Undergoing Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer  
*Kazuhiro Okada, Japan*
- EP.08D.15** Radical Surgery after Induction Therapy for Initially Unresectable Stage III Non-Small Cell Lung Cancer  
*Yan Yan, China*
- EP.08D.16** Neoadjuvant Chemoimmunotherapy in the Treatment of Stage III Non-Small Cell Lung Cancer: A Single-Center Initial Results.  
*Parvin Akhmedov, Russian Federation*
- EP.08D.17** Long-Term Survival Outcomes of Surgery after Neoadjuvant TKI for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutations  
*Masaya Aoki, Japan*
- POSTER SESSION EP.08E – SUB-THEME E: CLINICAL SURGICAL**
- EP.08E.01** Comparison of CT Findings Between Staple Line Granuloma and Recurrent Tumor after Sub-Lobar Resection for Lung Cancer and Pulmonary Metastasis.  
*Taein An, Republic of Korea*
- EP.08E.02** Long Term Impact of IASLC Uncertain Resection (Run) Definition in Surgically Resected pN2 Non-Small Cell Lung Cancer  
*Pietro Bertoglio, Italy*
- EP.08E.03** Clinical Characteristics and Outcomes in Resectable Stage III ALK-Positive Non-Small Cell Lung Cancer: A Multicenter Real-World Cohort Study  
*Fengwei Tan, China*
- EP.08E.04** Not all pN1 Are the Same: Stations 12-14 Involvement, an Independent Prognostic Factor of Better Survival  
*Sara Ricciardi, Italy*
- EP.08E.05** The Presence of NSCLC Results in Diminished Ventilation in the Affected Lung  
*Kai Yu, China*
- EP.08E.06** The Peripheral Bronchial Occlusion or Stenosis after Dumon Y-stenting is Prognostic Factor in Patients with Advanced Lung Cancer  
*Tomohiko Higashiyama, Japan*
- EP.08E.07** Optimal Surveillance Interval and Prediction Models of Short-term Mortality Risk for Elderly Patients ( $\geq 70$ ) after Lung Cancer Surgery  
*Nan Wu, China*
- EP.08E.08** Local Advanced Lung Cancer: Artificial Intelligence, Complex System Analysis, Simulation of Alive Supersystems for Optimal Management  
*Oleg Kshivets, Russian Federation*
- EP08E.09** Safety and Feasibility of Uniportal Robotic Lung Resection  
*Shengcheng Lin, China*

**POSTER SESSION EP.08F - SUB-THEME F: UNRESECTABLE NSCLC**

- EP.08F.01** Predicting Radiation Pneumonitis with Baseline Pulmonary Function Tests in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)  
*Sooyun Tavalacci, USA*
- EP.08F.02** Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors  
*Guang Han, China*
- EP.08F.03** Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study  
*Xiangjiao Meng, China*
- EP.08F.04** Development of Learning-Based Predictive Models for Radiation-Induced Atrial Fibrillation in Non-Small Cell Lung Cancer  
*Hong In Yoon, Republic of Korea*
- EP.08F.05** Real World Evidence of Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: AYAME Study  
*Nobuyuki Yamamoto, Japan*
- EP.08F.06** Concurrent Chemoradiotherapy Followed by Durvalumab for Elderly Patients  
*Atsuhiko Yatani, Japan*
- EP.08F.07** Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Patients with Stage III Non-Small Cell Lung Cancer  
*Shuohan Zheng, China*
- EP.08F.08** Safety and Efficacy of Durvalumab Consolidation Therapy after Chemoradiotherapy in NSCLC Patients Positive for Antinuclear Antibodies  
*Akihiro Tsukaguchi, Japan*
- EP.08F.10** Semi-Automated NSCLC Segmentation and RECIST Measurement: Bridging the Gap Between Speed and Radiologist-Level Accuracy  
*Kai Zhang, USA*
- EP.08F.11** Development of Clinical Prediction Model Using Digital Device for ILD in the Stage III NSCLC Patients Treated with Durvalumab  
*Hirotsugu Kenmotsu, Japan*
- EP.08F.12** Toxicity and Outcomes by Radio-Sensitizing Chemotherapy Regimen for Unresectable Stage III NSCLC in British Columbia, Canada  
*Marie-Frédérique Damours, Canada*
- EP.08F.13** Machine Learning Analysis of Cardiac Sub-Structure Dose and Overall Survival of NSCLC Pts Treated with Concurrent Definitive Chemoradiotherapy  
*Thomas Dilling, USA*
- EP.08F.14** Outcomes of Durvalumab Consolidation Treatment in Stage III Unresectable NSCLC: A Retrospective Real-World Study  
*Marko Jakopovic, Croatia*
- EP.08F.15** A Retrospective Study of Tislelizumab Combined with Chemotherapy in Patients with Locally Advanced Lung Cancer  
*Jiarong Zhang, China*
- EP.08F.16** Re-Irradiation with Chemotherapy with/without Immunotherapy for In-Field Local Recurrence Among Lung Cancer Patients  
*Soth Vannhong, China*
- EP.08F.17** An Exploratory Study of Induction Chemoimmunotherapy Followed by Definitive Radiotherapy in Unresectable Stage III NSCLC  
*Xia Gan, China*
- EP.08F.18** Survival and Incidence Trends of Non-Small Cell Lung Cancer in Elderly Patients (>75 Years): Insights from SEER Database  
*Nikhila Aimalla, USA*
- EP.08F.19** Dosimetric Benefits in Adaptive Intensity Modulated Radiotherapy with Sib for Lung Cancer: An Indian Regional Cancer Centers' Early Experience  
*Souvik Das, India*
- EP.08F.20** Stage IIIA Non-Small Cell Lung Cancer (NSCLC): Outcomes by Treatment Strategy  
*William Carroway, USA*



- EP.11A.03** Anti-PD-1 Therapy Plus Denosumab in Advanced Non-Small Cell Lung Cancer with Bone Metastases: A Single-Centre, Retrospective Study in China  
*Jianya Zhou, China*
- EP.11A.04** Patterns of Failure and Subsequent Treatment after Progression on First-Line Immunotherapy Monotherapy in Advanced NSCLC  
*Jia-Yi Deng, China*
- EP.11A.05** Use of Immune Checkpoint Inhibitors in Advanced NSCLC Cases with Very Poor ECOG-PS: A Real World Experience  
*Pawan Singh, India*
- EP.11A.06** Somatic Gene Changes Associated with Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer  
*Akhil Goud Pachimatla, USA*
- EP.11A.07** Immunotherapy in Metastatic Pulmonary Lymphoepithelioma-Like Carcinoma  
*Chun Yee Ryan Ho, Hong Kong*
- EP.11A.08** Real-World Comparative Effectiveness in Advanced NSCLC and High PD-L1 with 1L Immune Checkpoint Inhibitors ± Chemotherapy  
*Melinda Hsu, USA*
- EP.11A.09** Predictive Role of BMI and Inflammation Markers in Immunotherapy (ICI) For HIV Associated Lung Cancer  
*Ayse Ece Cali Daylan, USA*
- EP.11A.10** Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer  
*Guillermo Suay, Spain*
- EP.11A.11** Application of Circulating Tumor Cell (CTC) PD-L1 Detection in the Evaluation of Therapeutic Efficacy in Advanced NSCLC: A Retrospective Study  
*Youjun Deng, China*
- EP.11A.12** Real-World Treatment Patterns and Clinical Outcomes Following Chemotherapy and Anti-PD-(L)1 In Non-Small Cell Lung Cancer  
*Vamsidhar Velcheti, USA*
- EP.11A.13** Efficacy and Safety of Immune-Checkpoint Inhibitors in Advanced NSCLC Patients with Rare Mutation after Developing Targeted Therapy Resistance  
*Wei Zhang, China*
- EP.11A.14** Impact of Immune-Related Adverse Event Severity on Overall Survival in Patients Receiving PD-1/L1 Therapy, with a Focus on Combination Regimens  
*Mayu Sugai, Japan*
- EP.11A.15** NSCLC-ClustOpt: A Semi-Supervised Optimized Clustering to Stratify Patients with NSCLC on Immune Checkpoint Blockers Therapy  
*Francesco Paoloni, Italy*
- EP.11A.16** Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study  
*Ryuta Tagawa, Japan*
- EP.11A.17** Efficacy and Influencing Clinical Factors of Tislelizumab Combined with Chemotherapy Plus Bone-Targeted Agents for NSCLC Bone Metastasis  
*Yina Wang, China*
- EP.11A.18** LUMINATE 101-Maccabi: Real-World Study of Treatment Patterns and Clinical Outcomes in Patients with mNSCLC in an Israeli HMO  
*Hasan Alhasani, USA*
- EP.11A.19** Efficacy and Outcomes of Immunotherapy-Based Treatments in EGFR-Mutant Non-Small Cell Lung Cancer  
*Yung-Hung Luo, Taiwan*
- EP.11A.20** Incidence and Outcomes of Adrenal Oligoprogression in Metastatic Lung Cancer During Immunotherapy  
*Beatriz Miyamura, Brazil*
- EP.11A.21** Target Switching as an Effective Second-Line Strategy for Refractory Metastatic NSCLC  
*Wint Yan Aung, USA*



- EP.11A.22** Comparing Outcomes and Adverse Events in Lung Cancer Immunotherapy: The Impact of Smoking Status  
*Maha Zafar, USA*
- EP.11A.23** REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC - A Multicenter Cohort Study in Argentina  
*Carlos Picón, Argentina*
- EP.11A.24** Clinical Prognostic Index for Immunochemotherapy in Lung Cancer (CLIP1-LC)- A Prognostic Score for Advanced Non-Small-Cell Lung Cancer  
*Magdalena Knetki-Wróblewska, Poland*
- EP.11A.25** Consensus on Maintenance Therapy after a First-Line Pembrolizumab-Containing Regimen in Advanced/Metastatic NSCLC  
*Umit Tapan, USA*
- EP.11A.26** Evaluating Efficacy and Safety of Nivolumab in Pretreated NSCLC Patients: Insights from Real-World Data  
*Marko Jakopovic, Croatia*
- EP.11A.27** Real-Life Study of Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Followed by Durvalumab.  
*Matias Tuller, Argentina*
- EP.11A.28** Efficacy and Safety of Penpulimab-Containing Regimens for Advanced Malignant Solid Tumors That Have Failed Immunotherapy: A Real World Study.  
*Juying Zhou, China*
- EP.11A.29** C-Reactive Protein's Impact on Immune Adverse Events in Non Small Cell Lung Cancer Patients Undergoing Immunotherapy: Meta-Analysis  
*Sakditad Saowapa, USA*

#### POSTER SESSION EP.11B - SUB-THEME B: IMMUNOBIOLOGY

- EP.11B.01** Machine Learning-Based Clinical Model for Predicting Thromboembolism in Lung Cancer after Immunotherapy  
*Mengmeng Zhao, China*
- EP.11B.02** Correlation Analysis of Peripheral Blood Cell Immune Phenotype with Prognosis of Immunotherapy in Advanced Non-Small Cell Lung Cancer  
*Xia Song, China*
- EP.11B.03** Body Mass Index and Genetic Association in Durable Responders to Immunotherapy in Metastatic Non-Small Cell Lung Cancer  
*Shuai Wang, USA*
- EP.11B.04** Differential Durable Responses in Intrathoracic Versus Overall Lesions of Non-Small Cell Lung Cancer Treated with Immunotherapy  
*Young Kwang Chae, USA*
- EP.11B.05** The Differential Effect of Radiation, IL39, and the Combination on Expression of HLA Molecules  
*Erin Kaser, USA*
- EP.11B.06** The Impact of Body Mass Index on Immune-Related Adverse Events and Outcomes in Patients with Lung Cancer: A Real-World Study  
*Xiao Hu, USA*

#### POSTER SESSION EP.11C - SUB-THEME C: IMMUNORESISTANCE

- EP.11C.01** Treatment Options for Tumor Progression after Initial Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study  
*Junfeng Zhao, China*
- EP.11C.02** Role of Immune-Related Adverse Events (irAEs) and Albumin in Non-Small-Cell Lung Cancer (NSCLC)  
*Sawyer Bawek, USA*
- EP.11C.03** Anlotinib Combined with Immune Checkpoint Inhibitor May Benefit Advanced Smarca4-Deficient Thoracic Tumor Patients in First Line  
*Wei Zhang, China*



- EP.12A.08** **Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study**  
*Ning Yan, China*
- EP.12A.09** **Oligoprogression and Osimertinib Continuation Post-progression in Patients with EGFR-Mutations**  
*Geoffrey Liu, Canada*
- EP.12A.10** **Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients**  
*Per Hydbring, Sweden*
- EP.12A.11** **Effect of Antibiotic Exposure on the Efficacy of EGFR TKIs in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)**  
*Naiyarat Prasongsook, Thailand*
- EP.12A.12** **Lazertinib as Second-Line or Greater Treatment is More Effective in Patients Who Showed Extended Response to Prior TKI in Advanced NSCLC**  
*Chang Dong Yeo, Republic of Korea*
- EP.12A.13** **CRISPR with Double Mismatch Guide RNA Enhances Detection EGFR Mutation in Circulating Cell-Free DNA of Lung Cancer Patients**  
*Boksoon Chang, Republic of Korea*
- EP.12A.14** **Multicentered Real-World Evidence of Osimertinib Treatment in EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) In Thailand**  
*Thanaporn Thamrongjirapat, Thailand*
- EP.12A.15** **ACTN4 as a Predictive Biomarker for Osimertinib Efficacy in EGFR Mutant Non-Small Cell Lung Cancer**  
*Takehiro Tozuka, Japan*
- EP.12A.16** **High-Dose Aumolertinib Combined Intrathecal Chemotherapy for the Treatment of EGFR-Mutated NSCLC with Leptomeningeal Metastasis**  
*Wei Wang, China*
- EP.12A.17** **Impact of Osimertinib and Cranial Therapy on EGFR-Mutated Lung Cancer with Brain Metastasis: A Single-institution Retrospective Study**  
*Christine Garcia, USA*
- EP.12A.18** **Afatinib vs. Osimertinib as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations**  
*Thu Hoang, Vietnam*
- EP.12A.19** **Race May Affect Survival in 1L Patients with Metastatic Non-Small Cell Lung Cancer (mNSLC) Oneqfr-Targeted Therapy**  
*Melina Marmarelis, USA*
- EP.12A.20** **EGFR Inhibitors Combined with Intrathoracic Perfusion Manages Malignant Pleural Effusion in EGFR-Mutated Metastatic Lung Adenocarcinoma**  
*Weijia Huang, China*
- EP.12A.21** **Nimotuzumab Plus Chemotherapy in the Posterior Line Therapy of EGFR-TKIs Resistant Lung Adenocarcinoma: A Case Series Study**  
*Kaihua Lu, China*
- EP.12A.22** **Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study**  
*Jiali Xu, China*
- EP.12A.23** **PD-L1 Induced Resistance to EGFR-TKIs in Lung Adenocarcinoma**  
*Guangming Yi, China*
- EP.12A.24** **Prognostic Value of Functional Subtype Classification of Co-Occurring TP53 Mutations in Patients with EGFR-Mutant NSCLC Treated with TKI**  
*Divya Chukkalore, USA*
- EP.12A.25** **Concurrent RB1/TP53 Alterations in Targetable EGFR-Mutant Lung Adenocarcinoma Imply Aggressive Treatment**  
*Yan Li, China*
- EP.12A.26** **Overall Survival of Advanced Non-Small Cell Lung Cancer Treated with First-Line Afatinib: A Multicenter Real-World Study in Vietnam**  
*Hoa Nguyen, Vietnam*

- EP.12A.27** Targeting DDR Pathway Activates the TBK1-NF $\kappa$ B P65 Axis and Enhances the Killing Effect of CD8<sup>+</sup> T Cells  
*Guo Li, China*
- EP.12A.28** Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment  
*Ying Liu, USA*
- EP.12A.29** Characteristics of Osimertinib Non-Responders vs Responders in EGFR Mutated Lung Cancer  
*Amanda Reyes, USA*
- EP.12A.30** Landscape of EGFR Mutations and Real-World Experience of Therapeutic Interventions - A Community Oncology Study  
*Kshitij Joshi, India*
- EP.12A.31** Clinical Characteristics and Outcomes of EGFR-Positive Non-Small Cell Lung Cancer with Acquired RET Fusions  
*Takayuki Kobayashi, Japan*
- EP.12A.32** Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities  
*Peng Huang, China*
- EP.12A.33** A Comparative Analysis of Outcomes in Patients with Single EGFR Mutations for Concurrent Gene Alterations  
*Linh Le, Vietnam*
- EP.12A.34** Chemotherapy and/or Immunotherapy after Progression on Tyrosine Kinase Inhibitors in EGFR Mutant Non-Small Cell Lung Cancer Patients.  
*Maxwell Okunrobo, USA*
- EP.12A.35** A Phase I Open-label Study Ofnimotuzumab with Nivolumab in Advanced Non-Small Cell Lung Cancer or Head and Neck Squamous Cell Cancer  
*Ather Hussain Syed, USA*
- EP.12A.36** Early Experience with the FLAURA2 Regimen in Patients with NSCLC and EGFR Mutations in Latin America  
*Andres Cardona, Colombia*
- EP.12A.37** Erlotinib: A Beacon of Hope in EGFR TKI-Progressed Lung Cancer, A Real-World Experience from a Tertiary Care Cancer Centre in South India  
*Pragadeesh Thamarai Selvan, India*
- EP.12A.38** Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series  
*Jianwei Liu, China*
- EP.12A.39** MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review  
*Vanya Aggarwal, USA*
- EP.12A.40** Savolitinib Plus Osimertinib for Previously Untreated NSCLC Patients with EGFR Mutations and Met-Amplification: A Case Series  
*Kui Xiao, China*
- EP.12A.41** First-Line Treatment of EGFR-Mutant NSCLC: TKI Alone or Combinations - What I Use Today and Why in the Latin America vs the World  
*Victor dos Santos, Brazil*
- EP.12A.42** Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor  
*Yong Mao, China*
- EP.12A.43** Savolitinib and Third-Generation EGFR-TKI Therapy in EGFRm, MET-Altered NSCLC Patients: A Case Series  
*Xixi Lai, China*
- EP.12A.44** Short-course Immunotherapy Prior to Targeted Therapy in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: A Retrospective Study  
*Peiling Chen, China*

























# Journal of Thoracic Oncology

**Official Journal of the  
International Association for  
the Study of Lung Cancer**

Editor-in-Chief: **Alex A. Adjei**,  
MD, PhD, Taussig Cancer  
Institute, Cleveland Clinic,  
Cleveland, OH, USA



**2023 Journal  
Impact Factor\***

**21.0**

\*Journal Citation Reports®  
(Clarivate Analytics, 2024)

ISSN: 1556-0864

A subscription to **JTO** is a benefit of membership in the IASLC. To join, visit [www.IASLC.org](http://www.IASLC.org).

The **Journal of Thoracic Oncology (JTO)**, the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.



**jto.org**



# Applications Open Now!



**Submit your LOI for the “2024 Career Advancement Grant: Bridging the Gap to Independent Research” by October 1st, 2024!**

The IASLC’s Career Advancement Grant aims to support and facilitate the career advancement of mid-career professionals within the thoracic oncology field by bridging the gap between early-career funding opportunities and more advanced support mechanisms.



For more information visit:  
<https://bit.ly/IASLCgrantprogram>  
or scan the QR code







# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

# GET SOCIAL

Remember to use  
the official hashtag:

**#WCLC24**

-  /IASLC
-  @IASLC
-  iaslungcancer
-  IASLC
-  IASLC
-  IASLC

# JOIN THE CONVERSATION



# 07 / GENERAL INFORMATION

GENERAL INFORMATION GENERAL INFORMATION GENERAL INFORMATION



Conference Supporters

Diamond Level



Gold Level



Silver Level



Bronze Level



IASLC 50th Anniversary Celebration  
Presenting Supporter:



Virtual Platform Supporter:



Welcome Networking Reception  
Supporter:



Faculty Networking Dinner  
Supporter:



Wellness Challenge Supporter:



Water Stations Supporter:



Lung Cancer Considered Podcast  
Studio Supporter:



Exhibit Information Booth Supporter:



GENERAL INFORMATION / EXHIBIT AND SUPPORTER INFORMATION



EXHIBIT HALL FEATURES

- ✓ Delegate Lounges
- ✓ Exhibit Showcase Theater
- ✓ Podcast Studio
- ✓ Exhibitor Help Desk
- ✓ Meeting Pods
- ✓ Exhibitor Lounge
- ✓ Charging Lounge
- ✓ Food & Beverage (F&B)
- ✓ ePoster Lounge

Exhibitors By Name

AbbVie	1618	Boehringer Ingelheim	2318
Akeso, Inc.	3300	Bristol Myers Squibb	3003
ALCMI	Tabletop #7	Burning Rock Dx	2501
American Association For Cancer Research	508	Caris Life Sciences	408
Amgen	1010	Catalyst	1421
Amoy Diagnostics	1320	Catalyst	2721
Association of Cancer Care Centers	Tabletop #1	Conexiant	3305
AstraZeneca	1000	CyPath Lung	409
Bayer	908	Daiichi Sankyo	2408
Biocartis	1020	DAVA Oncology	509
Biofidelity	1319	Dejavi Innovation	3303
BioNTech	2820	EMD Serono	418

## GENERAL INFORMATION / EXHIBIT AND SUPPORTER INFORMATION

Exact Sciences	1318
Flatiron Health	3302
Fosun Pharma USA	609
Foundation Medicine	2801
Genentech	1008
Genmab	3013
Gilead	514
Global Lung Cancer Coalition	Tabletop #2
GSK	608
Guardant Health	2718
IASLC Booth	1610
IASLC Member Lounge	1810
IASLC Patient Advocacy Lounge	1311
Jazz Pharmaceuticals	1018
Jazz Pharmaceuticals	1121
Johnson & Johnson	1800
Kras Kickers	Tabletop #4
Lambda Biologics	3304
Lilly	913
LiveLung	Tabletop #3
Lung Cancer Research Foundation	Tabletop #5
Median Technologies	2601

Merck	1818
MeVis Medical Solutions	1021
Natera	2800
Novartis	1418
Novocure	2908
OncoHost	2500
Oncology Advocates United for Climate and Health International	Tabletop #6
Optomedic, Inc.	1120
Pfizer Oncology	604
Predicine	1420
Qure.ai	709
Regeneron	2412
Rigel Pharmaceuticals	2720
Scanlan International, Inc.	2600
Summit Therapeutics Inc.	2900
Takeda Oncology	2503
Tempus Labs	911
The 23andMe Lung Cancer Genetics Study	Tabletop #8
Thermo Fisher Scientific	2818

## Exhibitors By Booth Number

Caris Life Sciences	408
CyPath Lung	409
EMD Serono	418
American Association For Cancer Research	508
DAVA Oncology	509
Gilead	514
Pfizer Oncology	604
GSK	608
Fosun Pharma USA	609
Qure.ai	709
Bayer	908
Tempus Labs	911
Lilly	913
AstraZeneca	1000
Genentech	1008
Amgen	1010
Jazz Pharmaceuticals	1018
Biocartis	1020
MeVis Medical Solutions	1021
Optomedic, Inc.	1120
Jazz Pharmaceuticals	1121
IASLC Patient Advocacy Lounge	1311
Exact Sciences	1318
Biofidelity	1319
Amoy Diagnostics	1320
Novartis	1418
Predicine	1420
Catalyst	1421
IASLC Booth	1610
AbbVie	1618
Johnson & Johnson	1800
IASLC Member Lounge	1810
Merck	1818
Boehringer Ingelheim	2318

Daiichi Sankyo	2408
Regeneron	2412
OncoHost	2500
Burning Rock Dx	2501
Takeda Oncology	2503
Scanlan International, Inc.	2600
Median Technologies	2601
Guardant Health	2718
Rigel Pharmaceuticals	2720
Catalyst	2721
Natera	2800
Foundation Medicine	2801
Thermo Fisher Scientific	2818
BioNTech	2820
Summit Therapeutics Inc.	2900
Novocure	2908
Bristol Myers Squibb	3003
Genmab	3013
Akeso, Inc.	3300
Flatiron Health	3302
Dejavi Innovation	3303
Lambda Biologics	3304
Conexiant	3305
Association of Cancer Care Centers	Tabletop #1
Global Lung Cancer Coalition	Tabletop #2
LiveLung	Tabletop #3
Kras Kickers	Tabletop #4
Lung Cancer Research Foundation	Tabletop #5
Oncology Advocates United for Climate and Health International	Tabletop #6
ALCMI	Tabletop #7
The 23andMe Lung Cancer Genetics Study	Tabletop #8

## GENERAL INFORMATION / EXHIBITOR DESCRIPTIONS



American Association  
for Cancer Research

FINDING CURES TOGETHER™

BOOTH 508

The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through: Research, Education, Communication, Collaboration, Science Policy and Advocacy, and Funding for Cancer Research. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

[www.aacr.org](http://www.aacr.org)



BOOTH 1618

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at [www.abbvie.com](http://www.abbvie.com). Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

[www.abbvie.com](http://www.abbvie.com)



BOOTH 3300

Akeso, Inc. (9926.HK), established in 2012, is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease, and other major therapeutic areas. Akeso has successfully promoted the commercialization of three innovative biological drugs (one out-licensed drug).

[www.akesobio.com](http://www.akesobio.com)



TABLETOP #7

ALCMI is a nonprofit international consortium comprised of 25 of the world's premier oncology research institutions. We partner with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated trials. We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects.

[www.alcmi.org](http://www.alcmi.org)



ASSOCIATION OF CANCER CARE CENTERS™

TABLETOP #1

The Association of Cancer Care Centers (ACCC) provides education and advocacy for the cancer care community. Founded in 1974, ACCC is a powerful network of more than 40,000 multidisciplinary practitioners from over 1,700 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team.

[www.accc-cancer.org](http://www.accc-cancer.org)





BOOTH 1000

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

[www.astrazeneca.com](http://www.astrazeneca.com)



BOOTH 1010

Amgen harnesses the best of biology and technology to make people's lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what's known today. With roots in the biotech revolution, we are one of the world's leading independent biotech companies.

[www.amgen.com](http://www.amgen.com)



BOOTH 1320

Amoy Diagnostics Co., Ltd. is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe.

[www.amoydiagnostics.com](http://www.amoydiagnostics.com)



BOOTH 908

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The company has the passion and determination to develop innovative medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes marketed products across various indications and several compounds in different stages of clinical development. We have built an early pipeline in tumor intrinsic pathways, next-generation immuno-oncology, and targeted alpha therapies. Bayer focuses its research activities on expanding the druggable target pool, developing efficacious and "kinder", better tolerated medicines, as well as addressing drug resistance.

[www.bayer.com](http://www.bayer.com)



BOOTH 1020

Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary Idylla platform. The Idylla platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting. With Idylla, labs can produce molecular testing results within 90 - 180 minutes and only 2 minutes hands-on-time directly from FFPE tissue. Idylla test kits cover a wide variety of important oncology biomarkers.

[www.biocartis.com](http://www.biocartis.com)

## Biofidelity.

BOOTH 1319

Biofidelity is a revolutionary genomic technology company dedicated to removing the noise from genomic analysis to unleash its potential to transform human health. Our platform technology can be used on existing instrumentation in laboratories around the world, making genomic data far more accessible, far lower cost, and bringing the benefits of precision medicine to far more patients. Founded in 2019, Biofidelity is a rapidly growing company of scientists, engineers, physicians and commercial experts dedicated to making genomics globally accessible, and to becoming the dominant provider of reagent-based solutions in oncology. Connect with us on LinkedIn and Twitter. For media inquiries please reach out to [media@biofidelity.com](mailto:media@biofidelity.com).

[biofidelity.com](http://biofidelity.com)



BOOTH 2820

BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer & other serious diseases. We exploit a wide array of computational discovery & therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our diversified oncology portfolio of product candidates includes individualized & off-the-shelf mRNA cancer vaccines, targeted therapies comprising chimeric antigen receptor T cells & antibody-drug conjugate & novel immunomodulators.

[www.biontech.com](http://www.biontech.com)



Boehringer  
Ingelheim

BOOTH 2318

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed & immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent & broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today & for generations.

[www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)



**BOOTH 3003**

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our people work for millions of patients around the world in disease areas such as oncology, hematology, immunology, cardiovascular and neuroscience. Our employees around the world work every day to transform patients' lives through science.

[www.bms.com](http://www.bms.com)



**BOOTH 2501**

Burning Rock Dx (NASDAQ: BNR and LSE: BNR) is committed to providing NGS-based testing for late-stage cancer patients, global biomarker detection & companion diagnostic development services to pharmaceutical partners & NGS-based multi-cancer early detection testing. We focus on providing multi-dimensional tumor genomic data solutions, multi-modal clinical trial solutions, integrated CDx development & commercialization, and precision patient recruitment for pharmaceutical companies, thereby efficiently facilitating the entire process of anti-cancer drug development.

[us.brbiotech.com](http://us.brbiotech.com)



**BOOTH 408**

Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company & precision medicine pioneer actively developing & delivering innovative solutions to revolutionize healthcare & improve the human condition. Through comprehensive molecular profiling (DNA, RNA and proteins) & the application of AI & machine learning algorithms, Caris has created the large-scale, clinico-genomic database & computing capability needed to analyze & unravel the molecular complexity of disease. This provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection & drug development.

[www.carislifesciences.com](http://www.carislifesciences.com)



**BOOTH 1421 + 2721**

Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases.

[catalystpharma.com](http://catalystpharma.com)



**BOOTH 409**

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung. Its flagship product, CyPath® Lung, is a noninvasive test using advanced flow cytometry and AI to improve diagnosis of early-stage lung cancer. CyPath® Lung has shown 92% sensitivity, 87% specificity and 88% accuracy in identifying malignancy in the lung in patients with pulmonary nodules less than 20 mm. Physicians order CyPath® Lung for their patients who collect sputum at home and overnight the sample to our laboratory in pre-paid packaging.

[www.cypathlung.com](http://www.cypathlung.com)



BOOTH 2408

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

[www.daiichisankyo.com](http://www.daiichisankyo.com)



BOOTH 509

DAVA’s trial acceleration services optimize the recruitment and retention of patients in cancer clinical trials using physician-focused approaches including education workshops, medical feasibility assessment, site ID, site motivation, and referral outreach. DAVA conducts non-CME, oncology-focused meetings under the Oncology Meeting Innovations name. There are three types of meetings: global summits, regional summits, and expert forums. The goal of these programs is to improve the dissemination of knowledge between researchers, innovators, and implementers in the treatment of cancer. Leveraging the clinical and biopharmaceutical expertise of our MD team, the ONE oncology business unit offers consultative services and tools to the biopharmaceutical industry. Services include, but are not limited to, syndicated competitive intelligence tools, MD-led training, e-learning modules and qualitative market research.

[davaonc.com](http://davaonc.com)

BOOTH 3303

In Dejavi innovation we are passionate about providing you with the best natural and safe solution for your overall health. After years of working in the health and beauty industry we gathered the best collection of medical devices and body treatments to accommodate your most specific needs.



BOOTH 418

EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, is a science-led organization dedicated to making a meaningful difference in the lives of people affected by cancer. Our oncology research aims to leverage our synergistic portfolio to tackle challenging tumor types, as we work to illuminate a path to scientific breakthroughs to transform patient outcomes.

[www.merckgrouponcology.com](http://www.merckgrouponcology.com)



BOOTH 1318

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. Follow Exact Sciences on X (formerly Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

[www.exactsciences.com](http://www.exactsciences.com)

## FOSUN PHARMA USA INC

BOOTH 609

Fosun Pharma USA is a fast-growing, Delaware-incorporated, New Jersey-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun), a patient-centered, global pharmaceutical company. Fosun and Fosun Pharma USA are committed to delivering world-class science to advance care for cancer patients globally.

[www.fosunpharmausa.com](http://www.fosunpharmausa.com)

## flatiron.

BOOTH 3302

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @ FlatironHealth

[www.flatiron.com](http://www.flatiron.com)

## FOUNDATION MEDICINE®

BOOTH 2801

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action as we work to transform cancer care.

[www.foundationmedicine.com](http://www.foundationmedicine.com)

## Genentech *A Member of the Roche Group*

BOOTH 1008

For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.

[www.gene.com](http://www.gene.com)

## Genmab

BOOTH 3013

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. To help develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit [Genmab.com](http://Genmab.com) and follow us on [Twitter.com/Genmab](https://twitter.com/Genmab).

[www.genmab.com](http://www.genmab.com)



Oncology

BOOTH 514

Gilead is creating the future of oncology to help bring more life to people with cancer. Making bold strides against cancer requires a strategy built on the power of partnerships, groundbreaking technologies, and unexpected clinical combinations. From antibody-drug conjugates to small molecules our research and development programs are creating possibilities for people with overlooked, underserved, and difficult-to-treat cancers.

[www.gilead.com](http://www.gilead.com)



TABLETOP #2

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

[www.lungcancercoalition.org](http://www.lungcancercoalition.org)



BOOTH 608

GSK is focused on maximising patient survival through transformational medicines. Our goal is to achieve a sustainable flow of new treatments in immuno-oncology, tumour cell targeting therapies and synthetic lethality.

[www.gsk.com](http://www.gsk.com)



BOOTH 2718

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information follow the company on LinkedIn, X (Twitter) and Facebook.

[www.guardanthealth.com](http://www.guardanthealth.com)



BOOTH 1018 + 1121

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries.

[www.jazzpharma.com](http://www.jazzpharma.com)

## Johnson & Johnson

BOOTH 1800

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

[www.jnj.com](http://www.jnj.com)



TABLETOP #4

At KRAS Kickers, we firmly believe that Knowledge + Research + Advocacy = Survivorship. Our mission is to empower patients and caregivers with knowledge, connect them to current KRAS oncogene research, ensure advocacy resources are available, and ultimately create a community for them to share stories of hope and survivorship. We are committed to ensuring that patients and caregivers are equipped with the best treatment strategy from the very beginning and throughout their path toward survivorship. Our work spans the cancer network, and our programs and events are well-attended and always free to patients, advocates, and care partners.

[www.kraskickers.org](http://www.kraskickers.org)



BOOTH 913

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe.

[www.lilly.com](http://www.lilly.com)



TABLETOP #3

LiveLung is on a mission to improve health outcomes by advancing lung cancer education, early detection, and compassion for people impacted by lung cancer. We do this by hosting a network of monthly educational community lung cancer patient groups. We provide resource bags to dozens of cancer centers where nurse navigators give them to newly diagnosed lung cancer patients. We are a 501(c)(3) nonprofit organization, here to serve the lung cancer community. While we gratefully accept donations, we never solicit donations from lung cancer patients or caregivers.

[www.livelung.org](http://www.livelung.org)



TABLETOP #5

The mission of the Lung Cancer Research Foundation (LCRF) is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer. LCRF is committed to improving lung cancer patients' quality of life and survival rates through advancing the best new research in the field. To accomplish this, LCRF has begun implementing strategies toward its goals for the next three years and intends to have funded a total of \$45 million in direct lung cancer research through 444 grants by 2024.

[www.lungcancerresearchfoundation.org](http://www.lungcancerresearchfoundation.org)



BOOTH 2601

Median Technologies is helping conquer cancer by extracting invaluable clinical insights from patients' medical images. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs. With eyonis, our AI/ML tech-based suite of software as medical devices (SaMD), and iCRO our solution for medical image analysis and management in oncology trials, we transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients.

[mediantechnologies.com](http://mediantechnologies.com)



BOOTH 1818

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

[www.merck.com](http://www.merck.com)



BOOTH 1021

MeVis Medical Solutions AG develops software for the analysis and processing of medical imaging data. Focus is the image-based early detection of cancer. Its AI-aided workflow solutions support the image-based early detection of lung cancer.

[www.mevis.de](http://www.mevis.de)



BOOTH 2800

Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer. Monitoring ctDNA with Signatera™ across the Lung cancer treatment journey can answer important clinical questions and inform treatment decisions.

- Identify High Risk Patients
- Detect Recurrence Earlier
- Monitor Immunotherapy Treatment Response

[www.natera.com](http://www.natera.com)



BOOTH 1418

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at [novartis.com](http://novartis.com) and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

[www.novartis.com](http://www.novartis.com)



Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, non-small cell lung cancer, pancreatic cancer. Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel.

[www.novocure.com](http://www.novocure.com)

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Its proprietary platform, PROphet®, is a plasma-based proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. PROphet® NSCLC provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

[www.oncohost.com](http://www.oncohost.com)

Climate change is associated with increased cancer risk through a variety of mechanisms, including increased ultraviolet exposure, risk of exposure to air pollution and toxic chemicals, heat, and reduced access to cancer screening, and most notably through disruption in cancer care itself. (Climate Change & Cancer Care: A Policy Statement from ASCO, 2023). The mission of Oncology Advocates United for Climate and Health – International is to advance awareness, actions, and policies that mitigate the effects of climate change and cancer care. Our goals are to educate stakeholders (oncology health care professionals, patients, advocates, health systems, policy makers) on the link between climate change and cancer and advocate for sustainable cancer care.

[www.ouchforclimate.org](http://www.ouchforclimate.org)



**BOOTH 1120**

Guangdong OptoMedic Technologies, Inc. is a high-tech company committed to providing high-performance medical devices and services utilizing cutting-edge optical and bio-optical technologies in the medical field.

OptoMedic was founded in July 2013 by a coalition of multi-disciplinary experts in medical, biomedical, engineering, quality assurance as well as regulatory affairs. Dedicated to technological innovations, we provide our customers with an array of high-end medical devices, among which the intraoperative endoscopic fluorescence navigation system has become a global leader and been widely used across many departments in general surgery. Our latest innovation Stellar is the first Fluorescence Endoscopy Platform combining 4k, 3D and Multi-Fluorescence all over the world.

[www.optomedic.com](http://www.optomedic.com)



**BOOTH 604**

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients' lives.

[www.pfizer.com](http://www.pfizer.com)



**BOOTH 1420**

Predicine is a leading molecular insights company committed to advancing precision medicine in oncology. Predicine has developed a proprietary cell-free DNA and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The Predicine portfolio comprises state-of-the-art blood, urine, and tissue-based Next-Generation Sequencing (NGS) assays designed for harmonized global use in research, clinical development, companion diagnostic (CDx) development, and patient testing. With operational hubs in Silicon Valley, Houston, Chicago, and Shanghai, Predicine collaborates with leading biopharma companies, institutions, and governments in personalized healthcare on a global scale.

[www.predicine.com](http://www.predicine.com)

# quire.ai

BOOTH 709

Qure.ai is a global innovator of AI for healthcare. Its lung cancer care suite include CE & FDA cleared solutions for rapid detection, reporting & precise quantification or monitoring of lung nodules. This helps to plug gaps in healthcare provision & propel developments in the pharma industry.

[www.quire.ai](http://www.quire.ai)

# REGENERON®

BOOTH 2412

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center.

[www.regeneron.com](http://www.regeneron.com)



BOOTH 2720

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.

Rigel has 3 FDA approved products:

- TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit [www.TAVALISSEhcp.com](http://www.TAVALISSEhcp.com) to see the Full Prescribing Information to learn more.
- GAVRETO® (pralsetinib) capsules was approved in 2020. Please visit [www.GAVRETO-hcp.com](http://www.GAVRETO-hcp.com) to see the Full Prescribing Information to learn more
- REZLIDHIA® (olutasidenib) capsules was approved in 2022. Please visit [www.REZLIDHIAhcp.com](http://www.REZLIDHIAhcp.com) to see the Full Prescribing Information, including Boxed WARNING to learn more.

[www.rigel.com](http://www.rigel.com)



BOOTH 2600

Since 1921, the Scanlan family has been dedicated to hand-crafting the highest quality surgical instruments. Explore our Scanlan® LEGACY Needle Holders and Forceps, showcasing the revolutionary Scan-II™ handle design. Our comprehensive range includes Scanlan® VATS instruments such as D'Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps, and Khan Decortication Grasper. Join us on our continued journey of excellence in surgical solutions.

[www.scanlaninternational.com](http://www.scanlaninternational.com)



BOOTH 2900

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Our lead investigational product, ivonescimab, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF.

[www.smmmtx.com](http://www.smmmtx.com)



BOOTH 2503

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our therapies for hematologic cancers and solid tumors have helped transform the treatment landscape for previously underserved patients. Building on this leadership, we are advancing a pipeline focused on the power of innate immunity. Our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so more patients can benefit from innovative medicines.

[www.takedaoncology.com](http://www.takedaoncology.com)

# TEMPUS

BOOTH 911

AI-enabled precision medicine. Bringing the power of data and artificial intelligence to healthcare.

[www.tempus.com](http://www.tempus.com)



Thermo Fisher  
SCIENTIFIC

BOOTH 2818

Thermo Fisher Scientific is the world leader in serving science. We provide a comprehensive suite of solutions for precision oncology, spanning early development through commercial strategy, encompassing companion diagnostics. Our leading clinical research services enable customers to accelerate innovation and increase development productivity. Our advanced next-generation sequencing technology, OncoPrint™ Solutions, enables laboratories everywhere to deliver genomic profiling from solid tumors and hematological cancers in as little as one day.

[www.thermofisher.com](http://www.thermofisher.com)



The 23andMe  
Lung Cancer  
Genetics Study

BOOTH 3305

23andMe and more than 20 advocacy organizations are collaborating on a new study to help advance research in lung cancer. The focus of the Lung Cancer Genetics Study is to better understand the genetics of people diagnosed with lung cancer in order to improve detection, risk reduction, and care. Ultimately, we want to help advance research toward finding a cure. Your participation is vital in helping us reach this important goal. To learn more visit our exhibit table.

[www.23andme.com/lung-cancer](http://www.23andme.com/lung-cancer)



## INDUSTRY SPONSORED SYMPOSIA

## Saturday, September 7, 2024

**12:00 - 13:00** **IS01: Industry Sponsored Symposium by Johnson & Johnson: Join us to hear thought leaders discuss a newly approved combination therapy that includes RYBREVANT® (amivantamab-vmjw)**

ROOM: 20BC

LUNCH PROVIDED

NOT FOR CME CREDIT

Chair: Alexander Spira, USA

**12:00** **Panel Discussion**  
Alexander Spira, USA, Misako Nagasaka, USA, David Waterhouse, USA

**12:00 - 13:00** **IS02: Industry Sponsored Symposium by Amgen: Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**

ROOM: 33ABC

LUNCH PROVIDED

NOT FOR CME CREDIT

**12:00** **Welcome and Introduction**  
James Inglis, USA

**12:05** **Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**  
Martin Dietrich, USA

**12:50** **Discussion and Audience Q&A**

**13:15 - 14:15** **IS04: Industry Sponsored Symposium by Merck & Co., Inc. : A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)**

ROOM: 20D

LUNCH PROVIDED

NOT FOR CME CREDIT

**12:00** **A Treatment Option for Certain Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)**  
Eric Vallieres, USA

**15:45 - 16:45** **IS07: Industry Sponsored Symposium by Boehringer Ingelheim: Emerging Therapies in Clinical Practice: What are the Patient Perspectives?**

ROOM: 30DE

NOT FOR CME CREDIT

Chair: Ernest Nadal, Spain

**15:45** **Chair's Welcome and Introduction**  
Ernest Nadal, Spain

**15:50** **Unmet Needs and Future Perspectives for Treatment of Lung Cancer**  
Christine Lovly, USA

**16:00** **Emerging Targeted Therapies in Lung Cancers of Neuroendocrine Origin: DLL3**  
Solange Peters, Switzerland

**16:15** **Selectively Targeting HER2 in NSCLC***John Heymach, USA***16:30** **Panel Discussion and Q&A: What Will Be the Impact of These Emerging Therapies for Patients with Lung Cancer****16:40** **Chair's Closing Remarks***Ernest Nadal, Spain***15:45 - 16:45** **IS08: Industry Sponsored Symposium by Daiichi Sankyo and AstraZeneca: New Treatment Approach for HER2+ (IHC3+) Metastatic Solid Tumors After Prior Systemic Treatment****ROOM: 20A** **REFRESHMENTS PROVIDED** **LIVESTREAMED** **NOT FOR CME CREDIT***Chair: Tarek Mekhail, USA***15:45** **Welcome and Introduction***Tarek Mekhail, USA***15:50** **New Treatment Approach for HER2+ (IHC3+) Metastatic Solid Tumors After Prior Systemic Treatment***Tarek Mekhail, USA***16:30** **Summary and Audience Q&A**

## Saturday, September 7, 2024

**14:30 - 15:30**     **IS05: Satellite EBAC/CME Symposium by PeerView supported by Janssen Biotech Inc.: Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management**

**ROOM: 33ABC**

 LUNCH PROVIDED

 ACCME ACCREDITED BY OTHER PROVIDER

*Chair: Natasha B. Leigh, Canada*

**14:30**     **Welcome, Introductions, and Educational Goals**

*Natasha B. Leigh, Canada*

**14:35**     **Best Practices for Biomarker Testing to Precisely Identify All EGFR Mutation Subtypes**

*Natasha B. Leigh, Canada*

**14:45**     **Considerations for Selection and Sequencing of EGFR-Targeted Therapies Throughout the Advanced EGFR-Mutated NSCLC Disease Continuum**

*Luis Paz-Ares, Spain*

**15:05**     **Making the Most of the Latest Treatment Progress in Advanced NSCLC With EGFR Exon 20 Insertion Mutations**

*Joshua Sabari, USA*

**15:20**     **Discussion and Audience Q&A**

**14:30 - 15:30**     **IS06: Satellite CME Symposium by Physicians' Education Resource supported by AstraZeneca & Boehringer Ingelheim Pharmaceuticals, Inc: Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real World Settings, What's Next for Emerging Novel Strategies**

**ROOM: 20BC**

 LIVESTREAMED

 LUNCH PROVIDED

 ACCME ACCREDITED BY OTHER PROVIDER

*Chair: Anne Chiang, USA*

**14:30**     **Welcome, Introductions, and Pre-session Survey**

*Anne Chiang, USA*

**14:35**     **Integrating Multiple Therapeutic Modalities in Curative Settings for Limited-Stage SCLC**

*Anne Chiang, USA, Jonathan Wesley Riess, USA, Misty Dawn Shields, USA*

**14:55**     **Extensive-Stage SCLC First-line and Subsequent Therapies: Best Practices and Updates on Novel Strategies**

*Anne Chiang, USA, Jonathan Wesley Riess, USA, Misty Dawn Shields, USA*

**15:20**     **Post-session Survey**

*Anne Chiang, USA*

**15:25**     **Question and Answer Session**



**15:45 - 16:45**

**IS09: Satellite EBAC/CME Symposium by PeerView supported by AstraZeneca: Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC**

**ROOM: 20D**

 **LUNCH PROVIDED**

 **ACCME ACCREDITED BY OTHER PROVIDER**

*Chair: Suresh S. Ramalingam, USA*

**15:45 Welcome, Introductions, and Educational Goals**

*Suresh S. Ramalingam, USA*

**15:50 Multidisciplinary Patient Evaluation and the Role of Chemoradiotherapy in Unresectable Stage III NSCLC**

*Kristin Higgins, USA*

**16:05 Making the Most of Immunotherapy in Unresectable Stage III NSCLC**

*Jarushka Naidoo, Ireland*

**16:20 Assessing the Potential of EGFR-Targeted Therapy in Unresectable Stage III NSCLC**

*Suresh S. Ramalingam, USA*

**16:35 Discussion, Future Directions, and Audience Q&A**

## INDUSTRY SPONSORED SYMPOSIA

Sunday, September 8, 2024

**12:30 - 13:30** **IS10: Industry Sponsored Symposium by Pfizer Oncology: LORBRENA® (lorlatinib): Overview of CROWN Trial Efficacy and Safety Data**

**ROOM: 20BC**

LUNCH PROVIDED



LIVESTREAMED



NOT FOR CME CREDIT

Chair: Todd M. Bauer, USA

**12:30** **Introduction and Key Considerations for LORBRENA**  
Todd M. Bauer, USA

**12:45** **Overview of CROWN Trial Clinical Data**  
Todd M. Bauer, USA

**13:00** **Dosing and Administration With LORBRENA**  
Todd M. Bauer, USA, Mary Grizzard, USA

**13:15** **Therapy Management Strategies to Address Some of the Adverse Reactions with LORBRENA**  
Todd M. Bauer, USA, Mary Grizzard, USA

**12:30 - 13:30** **IS11: Industry Sponsored Symposium by Abbvie: Un-Met Needs in NSCLC: The Emerging Potential Role of ADCs Targeting c-Met**

**ROOM: 33ABC**

LUNCH PROVIDED



LIVESTREAMED



NOT FOR CME CREDIT

Chair: Hossein Borghaei, USA

**12:30** **Welcome and Introduction**  
Hossein Borghaei, USA

**12:40** **All MET Aberrations Are Not Created Equal**  
Quincy Chu, Canada

**12:55** **Exploring Antibody-Drug Conjugates Targeting C-Met**  
Hidehito Horinouchi, Japan

**13:15** **Panel Discussion, Q&A, and Closing**

**18:30 - 19:30** **IS13: Industry Sponsored Symposium by Thermo Fisher Scientific: Accelerating Treatment Initiation with Next-Day NGS: Insights From a Multidisciplinary Collaboration Program in Precision Oncology**

**ROOM: 33ABC**

REFRESHMENTS PROVIDED



NOT FOR CME CREDIT

Chair: Fernando Lopez-Rios, Spain

**18:30** **Welcome and Introductions**  
Fernando Lopez-Rios, Spain

**18:35** **Molecular Testing in NSCLC: Importance of Expedited Testing**  
Ibiayi Dagogo-Jack, USA

**18:55** **Molecular Testing in NSCLC: Rapid Tissue-Based NGS**  
Charlotte Wang, USA

**19:15** **Q&A and Panel Discussion**

**19:28** **Closing Remarks**  
Fernando Lopez-Rios, Spain

## Sunday, September 8, 2024

**12:30 - 13:30**      **IS12: Satellite CME Symposium by Physicians' Education Resource supported by AstraZeneca: What's Next for HER2- and Trop2-Directed ADCs in Lung Cancer: How Emerging Trial Data Will Impact Our Clinics Today and Tomorrow**

**ROOM: 20D**

 **LIVESTREAMED**

 **LUNCH PROVIDED**

 **ACCME ACCREDITED BY OTHER PROVIDER**

*Chair: Jacob Sands, USA*

**12:30**      **Welcome, Introduction, and Housekeeping Notes**

*Jacob Sands, USA*

**12:35**      **ADCs in Lung Cancer Module #1: HER2-Directed Therapies**

*Jacob Sands, USA, Aaron Lisberg, USA, Myung-Ju Ahn, Republic of Korea*

**13:00**      **ADCs in Lung Cancer #2: TROP2-Directed Therapies**

*Jacob Sands, USA, Aaron Lisberg, USA, Myung-Ju Ahn, Republic of Korea*

**13:20**      **What's Next in ADCs for Lung Cancer? Highlights from the 2024 WCLC**

*Jacob Sands, USA*

**13:25**      **Q&A, Post-test Adjourn**



INDUSTRY SPONSORED SYMPOSIA

Monday, September 9, 2024

12:30 - 13:30 **IS16: Industry Sponsored Symposium by Roche Diagnostics: Actionable Biomarkers in Early-Stage NSCLC**

**ROOM: 33ABC**

 LUNCH PROVIDED

 LIVESTREAMED

 NOT FOR CME CREDIT

Chair: *Beatrice Wegrzyniak, USA*

- 12:30** **Welcome and Introduction**  
*Beatrice Wegrzyniak, USA*
- 12:35** **The Role of Targeted Therapies in Early-Stage NSCLC**  
*Jamie E. Chافت, USA*
- 13:00** **Biomarker Testing in Early-Stage NSCLC**  
*Soo-Ryum Yang, USA*
- 13:25** **Closing Remarks**  
*Beatrice Wegrzyniak, USA*

## Monday, September 9, 2024

**12:30 - 13:30**      **IS14: Satellite EBAC/CME/MOC Symposium by PeerView supported by AstraZeneca: Elevating Care in Resectable Stage I-III NSCLC: Targeted Therapy and Immunotherapy at the Forefront of Multimodal Treatment Strategies**

**ROOM: 20D** LUNCH PROVIDED ACCME ACCREDITED BY OTHER PROVIDER*Chair: Roy S. Herbst, USA***12:30**      **Welcome, Introductions, and Educational Goals***Roy S. Herbst, USA***12:35**      **Gaps and Opportunities for Improvement in Multidisciplinary Patient Evaluation and Treatment Planning in Stage I-III NSCLC***Tetsuya Mitsudomi, Japan***12:50**      **Mastering the Integration of Targeted Therapy in Resectable Stage I-III NSCLC***Roy S. Herbst, USA***13:05**      **Navigating Decisions About Neoadjuvant, Adjuvant, or Perioperative Immunotherapy in Resectable Stage I-III NSCLC***Tina Cascone, USA***13:20**      **Discussion and Audience Q&A**

**12:30 - 13:30**      **IS15: Satellite EBAC/CME Symposium by PeerView supported by Daiichi Sankyo, Inc.: Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects**

**ROOM: 20A** LUNCH PROVIDED ACCME ACCREDITED BY OTHER PROVIDER*Chair: Stephen V. Liu, USA***12:30**      **Welcome, Introduction, and Goal Setting***Stephen V. Liu, USA***12:35**      **Targeting HER2: The First ADC to Enter the Lung Cancer Treatment Arsenal***David Planchard, France***12:50**      **Targeting HER3: ADC Approach in Addressing Unmet Needs in EGFR-Mutated Lung Cancer***Melissa L. Johnson, USA***13:00**      **Targeting TROP2: Evolving Evidence on ADCs in Different Treatment Settings and Patient Populations***David Planchard, France***13:10**      **Other ADCs on the Horizon for Lung Cancer***Melissa L. Johnson, USA***13:15**      **Case Discussion and Audience Q&A**

**18:45 – 19:45** **IS17: Satellite CME Symposium by Physicians' Education Resource supported by Novartis Pharmaceuticals Corporation & Rigel Pharmaceuticals, Inc: Lung Cancer Tumor Board®: Enhancing Precision Medicine Through Advancements in Molecular Testing and Optimal Therapy Selection in MET, RET, and KRAS-altered NSCLC**

**ROOM: 30DE**  **LIVESTREAMED**  **LUNCH PROVIDED**  **ACCME ACCREDITED BY OTHER PROVIDER**

*Chair: Charu Aggarwal, USA*

- 18:45** **Welcome, Intro, and Pre-test**  
*Charu Aggarwal, USA*
- 18:50** **Comprehensive Molecular Testing in NSCLC**  
*Charu Aggarwal, USA*
- 18:55** **Managing NSCLC with MET Mutations**  
*Charu Aggarwal, USA, Karen L. Reckamp, USA, Christine Bestvina, USA, Hatim Husain, USA*
- 19:10** **RET Fusion Targeted Therapy for NSCLC**  
*Charu Aggarwal, USA, Karen L. Reckamp, USA, Christine Bestvina, USA, Hatim Husain, USA*
- 19:25** **Targeting KRAS Mutations in NSCLC**  
*Charu Aggarwal, USA, Karen L. Reckamp, USA, Christine Bestvina, USA, Hatim Husain, USA*
- 19:35** **Conclusions, Q&A, and Post-test**

## EXHIBIT SHOWCASE

## Sunday, September 8, 2024

10:10 – 10:40

**EXH1: Exhibit Showcase by Flatiron Health: Global Perspectives: Unlocking Real-World Evidence for Biomarker-Defined Lung Cancer Cohorts**

## EXHIBIT SHOWCASE THEATER, EXHIBIT HALL

*Presenter: Emily Castellanos, USA*

Lung cancer research has entered an exciting new phase with over 30 novel therapy approvals over the past two decades. Much of this innovation centers on our evolving understanding of biomarkers as both predictive and prognostic, which has led to many important innovations across clinical research, drug commercialization and patient care. Real-world evidence unlocks insights critical to the research, helps us better understand biomarker-defined cohorts across disease settings and geographies. Join Emily Castellanos, MD, MPH, Senior Medical Director at Flatiron Health for her discussion on how Flatiron partners across the oncology ecosystem to turn data into practice-changing evidence.

12:30 – 13:30

**EXH2: Exhibit Showcase by BMS Foundation: Beyond Screening: Ensuring Continuity of Care in Lung Cancer Management**

## EXHIBIT SHOWCASE THEATER, EXHIBIT HALL

*Moderator: Roy S. Herbst, USA*

*Panelists: Wonda Bekele, Ethiopia, Ricardo Sales dos Santos, USA, Mellisa Wheeler, USA, David Yankelevitz, USA*

The panel will explore the multi-faceted needs of patients with lung cancer and their families, as well as delivering care in mixed resource settings. Panelists will discuss ways to bring lung cancer screening and care to patients where they are and the innovative approaches to building lung cancer screening capacity.

10:10 – 10:50

**EXH03. Exhibit Showcase Supported by 23andMe: Fireside Chat: Building an Open Access Genetics Research Database for Lung Cancer**

## EXHIBIT SHOWCASE THEATER, EXHIBIT HALL

*Presenters: Joyce Tung, USA and Sandip Patel, USA*





# 2024 World Conference on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

## IASLC Congratulates the 2024 IASLC Patient Advocate Education Award Winners



**Adela Ayensa Alonso**  
*Mexico*

**Alison Bolton**  
*Australia*

**Occhiena Carlotta**  
*Italy*

**Lee-Anne Currie**  
*Australia*

**Blessing Erinwusi**  
*Nigeria*

**James Hiter**  
*USA*

**Patricia Mondragon**  
*Mexico*

**Ravi Prakash**  
*India*

**Prakaitip Susilparat**  
*Thailand*

# The JTO Clinical and Research Reports 2023 Impact Factor is...

# 3.0

**#142** OF 322 JOURNALS  
IN ONCOLOGY

**#37** OF 100 JOURNALS IN  
RESPIRATORY SYSTEM

**JTO**  
CLINICAL AND  
RESEARCH  
REPORTS



INTERNATIONAL  
ASSOCIATION  
FOR THE STUDY  
OF LUNG CANCER

**FIRST  
IMPACT  
FACTOR!**





# 2024 Latin America Conference on Lung Cancer

NOVEMBER 14-16, 2024 | BOGOTA, COLOMBIA

# REGISTER NOW!



#LALCA24




<https://bit.ly/LALCA24>



# Cancer Pain Management Bundle

This cancer pain educational bundle covers a wide range of pain management topics to help clinicians that manage patients with cancer. The bundle has three different accredited CME activities and a patient toolkit.

This certified CE/CME activity is designed for physicians, nurses, physician assistants, and nurse practitioners who treat cancer patients, as well as patients and caregivers.



This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.

*Accredited for CME and CNE. Certificate of Attendance also available.*

## Components of the Bundle:

- ▶ **The Basics of Pain Management for Cancer Patients from Diagnosis to Palliative Care: A Comprehensive Overview**  
<https://education.iaslc.org/URL/CancerPainMgmtCourse>  
This is a comprehensive, interactive online course.
- ▶ **KOL Knockout™: Cancer Pain Management Edition**  
<https://education.iaslc.org/URL/KOLKnockoutCancerPainMgmt>  
This is an interactive KOL challenge to diagnose and manage patient case studies.
- ▶ **The Basics of Pain Management for Cancer Patients from Diagnosis to Palliative Care – Thoracic Cancer Edition Course**  
<https://education.iaslc.org/URL/CancerPainMgmt>  
This is a virtual symposium recording.
- ▶ **Cancer Pain Management: Patient Toolkit**  
<https://education.iaslc.org/URL/CancerPainPatientToolkit>  
Includes a series of resource and tools.

Sponsored by

  
evolve  
medical education



Scan the QR  
Code for More  
Information





2024 World Conference  
on Lung Cancer

SEPTEMBER 7-10, 2024 | SAN DIEGO, CA USA

# FREE WIFI

## GET CONNECTED!

We are delighted to offer FREE WIFI for all WCLC 2024 delegates!

Network Name: **WCLC2024**

Password: **WCLC2024**



 TAIHO ONCOLOGY  
Making the human connection.

# Collaborative Dynamic

## Patient-Centered

At Taiho Oncology, our mission is to improve the lives of patients with cancer, their families, and their caregivers.

Taiho continues to deliver innovative products to the U.S. and global marketplace. The oncology patient, and their support systems, are at the center of our every activity.

## Hours of Operation:

### REGISTRATION DELEGATE HELP DESK VIRTUAL PLATFORM HELP DESK

📍 Outside Halls F+G, Ground Floor

Friday, September 6: **15:00 – 19:00**

Saturday, September 7: **07:00 – 20:30**

Sunday, September 8: **07:00 – 17:00**

Monday, September 9: **07:00 – 17:00**

Tuesday, September 10: **07:00 – 15:30**

### SPEAKER LOUNGE

📍 27AB, Upper Level

Friday, September 6: **15:00 – 19:00**

Saturday, September 7: **07:00 – 20:30**

Sunday, September 8: **07:00 – 17:00**

Monday, September 9: **07:00 – 17:00**

Tuesday, September 10: **07:00 – 15:30**

### IASLC 50TH ANNIVERSARY MERCHANDISE STORE

📍 Outside Hall F, Ground Floor

Saturday, September 7: **08:00 – 16:45**

Sunday, September 8: **10:00 – 16:45**

Monday, September 9: **10:00 – 16:45**

Tuesday, September 10: **11:15 – 16:15**

### IASLC AWARD CEREMONY

📍 33ABC, Upper Level

Saturday, September 7: **17:00 – 18:00**

### IASLC BUSINESS MEETING

📍 20A, Upper Level

Tuesday, September 10: **10:30 – 11:15**

### PRESS & MEDIA WORK ROOM

📍 26A, Upper Level

Saturday, September 7: **08:00 – 18:00**

Sunday, September 8: **08:00 – 18:00**

Monday, September 9: **08:00 – 18:00**

Tuesday, September 10: **08:00 – 16:00**

### PRESS CONFERENCE SCHEDULE

📍 26B, Upper Level

Saturday, September 7: **08:30 – 09:30**

Sunday, September 8: **10:05 – 11:05**

Monday, September 9: **10:05 – 11:05**

Tuesday, September 10: **10:35 – 11:35**

### EXHIBIT HALL

📍 Halls F+G, Ground Floor

Saturday, September 7: **20:00 – 21:30**

Sunday, September 8: **09:45 – 19:45**

Monday, September 9: **09:45 – 20:00**

Tuesday, September 10: **10:15 – 14:15**

### POSTER DISPLAY

📍 Exhibit Hall, Ground Floor

Sunday, September 8:

**P1 + P2: 09:45 – 19:45**

Monday, September 9:

**P3 + P4: 09:45 – 20:00**

### POSTER PRESENTERS IN ATTENDANCE

📍 Exhibit Hall, Ground Floor

Sunday, September 8:

**P1: 12:00 – 14:00 | P2: 18:15 – 19:45**

Monday, September 9:

**P3: 12:00 – 14:00 | P4: 18:30 – 20:00**

#### NURSING MOTHER'S LOUNGE

A nursing mother's lounge is available in the restroom near Hall E, next to Starbucks. The room is equipped with comfortable furniture and private areas for nursing mothers.

#### PRAYER ROOM

A prayer area is available in the lobby of Hall H, just around the corner from the main Hall H entrance.



#### FIRST AID

A First Aid Station, exclusively for WCLC 2024 attendees, is located in the lobby of Hall H, just behind the escalators in front of the main Hall H entrance.

#### FIRST RESPONDER CONTACTS:

San Diego Police: **619.531.2000**

San Diego Fire/Rescue: **619.533.4300**

Emergency: **911**

#### WHAT TO DO IN THE EVENT THAT THE FIRE ALARM ACTIVATES

1. Do not evacuate unless there are obvious signs of danger or fire.
2. Listen for an announcement that the alarm is being investigated.
3. A follow-up announcement will be made to advise that the alarm has been cleared, and you may continue your activities.
4. If evacuation is needed, leave the building through the nearest exit and follow staff to one of the three assembly areas.

#### CONTINUING MEDICAL EDUCATION (CME) & CERTIFICATE OF ATTENDANCE

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the "other activity" (a live conference offered in a hybrid format including recorded virtual participation) format for this educational activity for a maximum of 107.5 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Visit <https://wclc2024.iaslc.org/cme-information/> for more information on how to obtain CME credits and your Certificate of Attendance.

#### FEDEX OFFICE BUSINESS CENTER

A FedEx Office Business Center is available in Lobby D, offering printing, shipping and other services.



For more information on presenter resources please visit:  
[wclc2024.iaslc.org/presenter-resources](https://wclc2024.iaslc.org/presenter-resources)



For more information on press and media policies please visit:  
[wclc2024.iaslc.org/press-media](https://wclc2024.iaslc.org/press-media)

Download the free official WCLC 2024 Virtual Platform for a convenient way to stay up-to-date on the latest Conference information. The platform is available for desktop and mobile devices.

All sessions will be audio recorded and made available along with the presentation slides on the Virtual Platform within 24 hours after the session. Abstracts as well as all posters are also accessible via the Virtual Platform.

Log-in details were sent to your registered email. If you need assistance, you can visit the Virtual Platform Help Desk in the registration area or send an email to: [wclc2024-registration@icsevents.com](mailto:wclc2024-registration@icsevents.com)



### Virtual Platform Features:

- 🕒 Full Scientific Schedule
- 📖 Abstract Book, Program Book
- 🗺️ Venue and Exhibit Floor Plan
- 📺 Presentation Slides and Recordings (Within 24 Hours)
- 📅 Opportunity to Create Personalized Schedule
- 👤 Networking Features to Connect with Delegates and Faculty
- 🔔 Notification Alerts
- 📺 Livestream of Plenary Sessions and IASLC Award Ceremony

### Download the WCLC 2024 App



### WALKTHROUGH VIDEO:

Check out our Virtual Platform Info Video for more information and useful tips.





# LUNG CANCER CONSIDERED



with **Dr. Stephen Liu** and **Dr. Narjust Florez**  
an IASLC Podcast

The podcast was ranked in the Top 5% of Global Podcasts by Listen Notes in 2023 and in 2024 exceeded more than 250,000 listens.

Join us in listening to our award winning content on your favorite app.




Find new podcast episodes here.



Lung Cancer Considered is funded in part by:  
**AstraZeneca,**  
**Daiichi-Sankyo**  
& **Takeda**




### Upper Level (West)




ON THIS LEVEL: ■ Corporate Offices

### Mezzanine Level (West)



ON THIS LEVEL: ■ Corporate Offices

### Ground Level (West)



IASLC



**2025 Pan-Africa  
Conference on  
Lung Cancer**

JANUARY 31-FEBRUARY 1, 2025 | ACCRA, GHANA

**SAVE THE  
DATE!**

**#PACLC25**



<https://bit.ly/PACLC25>

# IASLC 2024-2025

## MEETINGS SCHEDULE

### 2024 Asia Conference on Lung Cancer

October 17-19, 2024 | Hong Kong, China | #ACLC24

### 2024 Latin America Conference on Lung Cancer

November 14-16, 2024 | Bogotá, Colombia | #LALCA24

### 2024 Hot Topic Meeting: Tolerance and Resistance to Targeted Therapy in NSCLC

December 13-15, 2024 | Washington, DC, USA | #HTTR24

### 2025 Pan-Africa Conference on Lung Cancer

January 31-February 1, 2025 | Accra, Ghana | #PACLC25

### 2025 Targeted Therapies of Lung Cancer

February 19-22, 2025 | Huntington Beach, CA, USA | #TTL25

### 2025 European Lung Cancer Congress

March 26-29, 2025 | Paris, France | #ELCC25

### 2025 Hot Topic in Basic & Translational Science: Small Cell Lung Cancer

Spring 2025 | New York, NY, USA | #SCLC25

### 2025 World Conference on Lung Cancer

September 6-9, 2025 | Barcelona, Spain | #WCLC25



*IASLC Members  
receive discounted  
registration for  
our meetings.*


[iaslc.org/meetings-webinars](https://iaslc.org/meetings-webinars)

\* Location and dates subject to change



# JTO

## CLINICAL AND RESEARCH REPORTS



**Editor-in-Chief:** Emily Stone, MBBS, PhD, FRACP,  
St. Vincent's Hospital, Sydney and School of  
Clinical Medicine, UNSW, Sydney, Australia.



*JTO Clinical and Research Reports* is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the *Journal of Thoracic Oncology* by offering authors a gold open access publication option and publishing of the following article types in particular:

- Phase I trials
- Well-performed single-arm phase II trials
- Small to moderate-sized randomized phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports



[jtocr.org](http://jtocr.org)

# WEBINARS



## Explore IASLC Webinars!

Webinars are an important part of IASLC's offerings, providing education and insight to the thoracic cancer community—representing multiple specialties, geographical regions, and key stakeholders.



1974–2024

Conquering Lung & Thoracic Cancers  
Worldwide in the 21st Century

Learn More!

[iaslc.org/meetings-webinars](https://iaslc.org/meetings-webinars)



# IASLC Education Center: Lung Cancer 360

## YOUR NEW GO-TO DESTINATION FOR ONLINE MULTIDISCIPLINARY EDUCATION

THE IASLC EDUCATION CENTER



LUNG  
CANCER  
360

NOW ONLINE!



- Online courses and simulations
- Microlearning modules
- IASLC conference materials
- Webinar recordings
- Patient Advocacy resources
- JTO, JTO CRR, & ILCN

The screenshots display the user interface of the IASLC Education Center Lung Cancer 360 platform. The top navigation bar includes the IASLC logo and the text 'INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER'. The main content area features several course listings, each with a title, a star rating, and a 'Summary' button. The courses shown include:

- The Amazing Case Race Microlearning: Case Study 1 - Navigating into the Deep of Molecular Profiling of NSCLC** (5 stars)
- KOL Knockout TM: Cancer Pain Management Edition** (5 stars)
- 2023 North America Conference on Lung Cancer (NACLC) - Live/Hybrid Attendee Access** (5 stars)

Each course listing includes a 'Summary' button and a 'Create Account' button. The interface is clean and professional, with a blue and white color scheme.





# 2024 Asia Conference on Lung Cancer

OCTOBER 17-19, 2024  HONG KONG, CHINA

The background image shows a panoramic view of the Hong Kong skyline across the water. In the foreground, several traditional wooden boats with large red sails are on the water. The modern skyscrapers of the city are visible in the background under a clear blue sky.

# REGISTER NOW!

<https://bit.ly/ACLC24> | #ACLC24





IASLC 50 YEAR  
ANNIVERSARY

# Celebration

**Sunday, September 8, 2024**

**20:00 - 23:00**

\*Outdoor events end at 22:00

*This event is limited to ages 21 and up*



**GASLAMP QUARTER**

Entrance is located at the Intersection of  
K Street and Fifth Ave  
(by the Old Spaghetti Factory)

**DRESS TO  
IMPRESS!**

Join us in your favorite outfits from the 70s, 80s  
and 90s as we commemorate 50 years of IASLC!



IASLC



**2025 World Conference  
on Lung Cancer**

SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN

# SAVE THE DATE!

Mark your calendars and prepare for an unforgettable experience in Barcelona.

**We look forward to welcoming you to  
WCLC 2025!**

[wclc.iaslc.org](https://wclc.iaslc.org)



**#WCLC25**

# IVONESCIMAB

## HARMONI-2<sup>\*,1</sup>

Phase 3 randomized monotherapy  
1L SQ + NSQ NSCLC PD-L1 TPS  $\geq$  1%

**ivonescimab vs. pembrolizumab**

\*HARMONI-2 Trial Conducted in China, Sponsored by Akeso.



First-in-class<sup>+</sup>  
PD-1/VEGF  
Bispecific  
Antibody in Clinical  
Development

Cooperative<sup>2</sup>  
Binding  
Increased:  
Avidity in TME  
Activity of T cells

**Presented at #WCLC24**

Summit is currently enrolling two Phase 3 trials with ivonescimab in NSCLC<sup>3,4</sup>  
(HARMONI and HARMONI-3)

**Learn more at WCLC Booth #2900**

Ivonescimab is an investigational therapy not approved by any regulatory authority  
other than China's National Medical Products Administration (NMPA)

+There are no known PD-1-based bispecific antibodies approved by the U.S. Food  
and Drug Administration ("FDA") or the European Medicines Agency ("EMA")

Abbreviations: 1L=first-line; NSQ=non-squamous; NSCLC=non-small cell lung cancer; PD-1= programmed cell death protein 1;  
TME=tumor microenvironment; TPS=tumor proportion score; VEGF= vascular endothelial growth factor; SQ=squamous.

## THE COMMENCEMENT OF A NEW ERA

References: 1. HARMONI-2 ClinicalTrials.gov identifier: NCT05499390.; 2. Zhong T, et al.  
AACR-NCI-EORTC International Conference 2023. Poster #B123, Abstract #35333,  
Boston, MA, USA; 3. HARMONI ClinicalTrials.gov identifier: NCT06396065.  
4. HARMONI-3 ClinicalTrials.gov identifier: NCT05899608. MAT-SMT112-0078

[smmmtx.com](http://smmmtx.com) • [medinfo@smmmtx.com](mailto:medinfo@smmmtx.com) • [investors@smmmtx.com](mailto:investors@smmmtx.com)



Summit Therapeutics and the Summit Therapeutics logo are trademarks of  
Summit Therapeutics, Inc. Copyright 2024, Summit Therapeutics, Inc. All Rights Reserved



By use of the QR Code you agree  
to Summit's privacy notice  
located at [smmmtx.com](http://smmmtx.com)